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Abstract 
Schizophrenia, bipolar disorder and major depressive disorder are devastating 
psychiatric conditions with a complex, overlapping genetic and environmental 
architecture. Previously, a family has been reported where a balanced chromosomal 
translocation between chromosomes 1 and 11 [t(1;11)] shows significant linkage to 
these disorders. This translocation transects three genes: Disrupted in schizophrenia-
1 (DISC1) on chromosome 1, a non-coding RNA, Disrupted in schizophrenia-2 
(DISC2) antisense to DISC1, and a non-coding transcript, DISC1 fusion partner-1 
(DISC1FP1) on chromosome 11, all of which could result in pathogenic properties in 
the context of the translocation. This thesis focuses on the genome-wide effects of the 
t(1;11) translocation, primarily examining differences in gene expression and DNA 
methylation, using various biological samples from the t(1;11) family. 
 
To assess the genome-wide effects of the t(1;11) translocation on methylation, DNA 
methylation was profiled in whole-blood from 41 family members using the Infinium 
HumanMethylation450 BeadChip. Significant differential methylation was observed 
within the translocation breakpoint regions on chromosomes 1 and 11. Downstream 
analysis identified additional regions of differential methylation outwith these 
chromosomes, while pathway analysis showed terms related to psychiatric disorders 
and neurodevelopment were enriched amongst differentially methylated genes, in 
addition to more general terms pertaining to cellular function. Using induced 
pluripotent stem cell (iPSC) technology, neuronal samples were developed from 
fibroblasts in a subset of individuals profiled for genome-wide methylation in whole 
blood (N = 6) with an aim to replicate the significant findings around the breakpoint 
regions. Here, methylation was profiled using the Infinium HumanMethylation450 
BeadChip’s successor: the Infinium MethylationEPIC BeadChip. The results from the 
blood-based study failed to replicate in the neuronal samples, which could be attributed 
to low statistical power or tissue-specific factors such as methylation quantitative trait 
loci. The differences in methylation in the most significantly differentially methylated 
loci were found to be driven by a single individual, rendering further interpretation of 
the findings from this analysis difficult without additional samples. Cross-tissue 
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analyses of DNA methylation were performed on blood and neuronal DNA from these 
six individuals, revealing little correlation between cell types. 
DISC1 is central to a network of interacting protein partners, including the 
transcription factor ATF4, and PDE4; both of which are associated with the cAMP 
signalling pathway. Haploinsufficiency of DISC1 due to the translocation may 
therefore be disruptive to cAMP-mediated gene expression. In order to identify 
transcriptomic effects which may be related to the t(1;11) translocation, genome-wide 
expression profiling was performed in lymphoblastoid cell line RNA from 13 family 
members. No transcripts were found to be differentially expressed at the genome-wide 
significant level. A post-hoc power analysis suggested that more samples would be 
required in order to detect genome-wide significant differential expression. However, 
imposing a fold-change cut-off to the data identified a number of candidate genes for 
follow-up analysis, including SORL1: a member of the brain-expressed Sortilin gene 
family. Sortilin genes have been linked to multiple psychiatric disorders including 
schizophrenia, bipolar disorder and Alzheimer’s disease. Follow-up analyses of 
Sortilin family members were performed in a Disc1 mouse model of schizophrenia, 
containing an amino acid substitution (L100P). Here, developmental gene expression 
profiling was performed with an additional aim to optimise and validate work 
performed by others using this mouse model. However, results from these experiments 
were variable between two independent batches mice tested. Additional investigation 
of Sortilin family genes was performed using GWAS data from human samples, using 
machine learning techniques to identify epistatic interactions linked to depression and 
brain function, revealing no statistically significant interactions. 
 
The results presented in this thesis suggest a potential mechanism for differential DNA 
methylation in the context of chromosomal translocations, and suggests mechanisms 
whereby increased risk of illness is conferred upon translocation carriers through 
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Lay Abstract 
Schizophrenia, bipolar disorder and major depression are common psychiatric 
conditions with both genetic and environmental risk factors. A genetic risk factor for 
these disorders has been identified in a large Scottish family in the form of a 
chromosomal rearrangement whereby three genes are disrupted. One of these genes, 
DISC1, has been shown to play multiple roles in brain function and development. The 
work presented in this thesis aims to investigate widespread effects of this 
chromosomal rearrangement in the family. 
 
Disease can occur through genetic (sequence-based) and epigenetic (non-sequence-
based) mechanisms. One such epigenetic mechanism, DNA methylation, was 
examined in blood-derived DNA, comparing 17 family members with the above-
mentioned chromosomal rearrangement to 24 of those without. Significant differences 
in DNA methylation were observed on chromosomes 1 and 11, within the regions at 
which the chromosomal rearrangement occurs. Furthermore, regions containing genes 
with previously reported functions in the brain and psychiatric illness showed 
differences in DNA methylation between carriers of the rearrangement compared to 
those without. 
 
DNA methylation was also examined in stem cell-derived neuronal material from a 
subset of these individuals, consisting of three carriers of the chromosomal 
rearrangement to three without. Differences in methylation at nine of the top ten sites 
were found to be largely driven by a single individual. Unlike the findings observed in 
blood DNA, there were no differences observed in the regions of the rearrangement in 
these samples. This may be attributed to differences in sample size or the cell type 
studied. DNA methylation differences were also studied within individuals, comparing 
these levels across blood and brain-like cells. 
 
The DISC1 protein has several interacting partners, including proteins involved in the 
control of gene expression. Individuals with the chromosomal rearrangement have 
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previously been reported to display half the normal levels of DISC1. This may have 
downstream effects on the levels of gene expression through the reduced interaction 
between DISC1 and its partners. To test this, gene expression levels were examined, 
comparing carriers of the chromosomal rearrangement to those without. Although no 
significant changes were observed, there was suggestive evidence for a number of 
genes with disrupted expression. One of these genes, SORL1, is a member of the 
Sortilin gene family. Members of this gene family are abundantly expressed in the 
brain and have been linked to schizophrenia, bipolar disorder and Alzheimer’s disease.  
 
Exploratory work was performed to investigate a relationship between DISC1 and 
Sortilin family members. Levels of Sortilin family gene expression were assessed in a 
mouse containing a mutation in the Disc1 gene, which had previously been shown to 
display schizophrenic-like behaviours. Additional work was performed to investigate 
a genetic interaction between DISC1 and Sortilin family members in relation to 
psychiatric illness and brain function. However, no significant findings were observed 
in either of these analyses. 
 
The work presented in this thesis identifies a relationship between DNA methylation 
and chromosomal rearrangements, and provides support for genes previously 
implicated in psychiatric disorders. 
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1 Introduction 
1.1 Overview of major mental illness 
Schizophrenia, bipolar disorder and major depressive disorder (MDD) are severe 
psychiatric disorders with a prevalence between approximately 1 and 4% for 
schizophrenia and bipolar disorder, and approximately 15% for MDD (McGrath et al., 
2008; Craddock and Sklar, 2009; Ferrari et al., 2013; Smoller et al., 2013). These 
disorders are complex with both environmental and genetic risk factors, and contribute 
to a significant social and economic burden. In England alone, mental illness incurs an 
estimated annual economic cost of £105 billion, including the cost of care and services, 
reduced quality of life, and lost productivity at work (Centre for Mental Health, 2010). 
 
1.1.1 Schizophrenia 
Schizophrenia is a psychotic disorder characterised by positive symptoms, negative 
symptoms and cognitive dysfunction. Positive symptoms refer to increases in normal 
functions and include auditory and visual hallucinations, irrational beliefs 
(delusions), thought disorder and motor dysfunction. Negative symptoms refer to 
reductions in normal functions and can include anhedonia (the inability to experience 
pleasure) and self-neglect. The cognitive effects associated with schizophrenia 
include impairments in working memory, attention deficits and reduced decision-
making abilities (i.e. deficits in executive functioning).  
 
The current edition of the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-V) defines a diagnosis of schizophrenia as presentation for at least one month 
with two or more symptoms, of which one must be either hallucinations, delusions 
or disorganised speech. Additional symptoms that can incur a diagnosis include 
negative symptoms and disorganised or catatonic behaviour (American Psychiatric 
Association, 2013). Prior to DSM-V, the symptomatic heterogeneity of 
schizophrenia was addressed by dividing the disorder into clinical subtypes: 
disorganised, catatonic, paranoid and undifferentiated schizophrenia. However, due 
to their limited reliability and validity (Korver-Nieberg et al., 2011), subtypes have 
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been removed and replaced by the introduction of psychopathological dimensions in 
the current manual. Cognitive dysfunction has not been included as a criterion for a 
diagnosis of schizophrenia, despite being a common symptom of the disorder 
(O’Carroll, 2000). The reason for this exclusion was that cognitive deficits are not 
sufficient as a diagnostic marker for distinguishing between schizophrenia and other 
psychiatric disorders (Barch et al., 2013). Treatment of schizophrenia involves 
management of symptoms and prevention of relapse through pharmacological and 
psychotherapeutic intervention. This can be through antipsychotic administration 
alone or in conjunction with cognitive, individual, and/or group therapy (Patel et al., 
2014). However, recurrence of episodes is common and patients can develop 
resistance to treatments (Hasan et al., 2012; Elmsley et al., 2013). 
 
1.1.2 Bipolar disorder 
Bipolar disorder is characterised by recurrent episodes of elevated mood (mania) and 
depression. Bipolar disorder is divided into two subtypes: bipolar I and bipolar II. 
According to DSM-V criteria, a diagnosis of the former type requires presentation of 
at least one manic episode. The latter type is characterised by presentation of both a 
depressive and a hypomanic episode, without escalating to a manic episode. The 
prevalence of bipolar disorder I is equal between males and females. However, 
gender differences have been reported in bipolar disorder II, with a greater incidence 
among females (Nivoli et al., 2011). Furthermore, rapid cycling (i.e. four or more 
episodes in 12 months) is displayed more frequently in females (Lebenluft, 1996). 
Approximately 75% of patients with an acute manic episode co-present with 
psychosis (Goodwin and Jamison, 2007). Treatment for bipolar disorder is dependent 
on the degree of mania or depression presented. Lithium is a well-established 
treatment for bipolar disorder, functioning as a mood stabiliser. Antipsychotics are 
also effective in the treatment of mania (Cipriani et al., 2011). In the case of bipolar 
depression (i.e. depression with a history of mania or hypomania), identification of 
effective treatments has been more challenging (Geddes and Miklowitz, 2013).  
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1.1.3 Major depressive disorder 
Major depressive disorder (MDD) is a mood disorder characterised by depressive 
episodes in the absence of mania or hypomania. MDD is more prevalent in females 
(Piccinelli and Wilkinson, 2000), and has been ranked as the 4th leading cause of 
disability worldwide by the World Health Organisation (WHO; Murray and Lopez, 
1996). Symptoms of MDD include weight changes, sleep disturbances, abnormal 
motor function, fatigue, feelings of worthlessness or guilt, cognitive deficits, suicidal 
ideation, a depressed mood, and anhedonia. DSM-V criteria state that to incur a 
diagnosis of MDD, a patient must present with five or more of these symptoms 
including at least one of the latter two, almost every day for at least two weeks. This 
renders MDD a highly heterogeneous disorder in terms of clinical presentation. There 
are 227 possible combinations of symptoms that can incur a diagnosis of MDD, with 
some more commonly presented than others (Zimmerman et al., 2015). Recurrence 
of the disorder is common: at least 50% of patients present with a subsequent episode 
in their lifetime (American Psychiatric Association, 2000). Treatment of MDD 
usually involves pharmacological intervention with antidepressant medications, 
psychotherapy, or a combination of both approaches. However, challenges remain in 
identifying the most efficient treatments to target a given MDD subtype (Miller and 
O’Callaghan, 2013) 
 
1.2 Mechanisms of major mental illness 
Pharmacological, post-mortem, and brain-imaging studies have been key for 
investigating the mechanisms by which the above disorders might occur. There is 
strong evidence for aberrant neurotransmission as well as brain structural 
abnormalities in psychiatric illness which are likely to be involved in its 
pathophysiology. While post-mortem brains are a useful resource for investigating the 
pathophysiology of psychiatric disorders, they can be subject to numerous potential 
confounding factors. Tissue quality, medication status, diagnosis, age of death, cause 
of death and post-mortem interval are some of the factors which must be considered to 
generate robust data from such studies. Nonetheless, these studies have provided 
valuable insights into the neuropathology of psychiatric illness. 
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1.2.1 Neurotransmitter dysfunction in major mental illness 
Pharmacological intervention of psychiatric disorders is primarily targeted towards 
neurotransmitter systems in the brain. Neurochemical signaling pathways such as the 
N-Methyl-ᴅ-Aspartate (NMDA), dopaminergic, and serotonergic systems have all 
been implicated in the pathophysiology of schizophrenia, bipolar disorder and MDD. 
Moreover, current treatments for these illnesses act directly upon these pathways to 
relieve symptoms. 
 
Early suggestions of neurotransmitter abnormalities in psychiatric illness emerged 
with the dopamine hypothesis of schizophrenia, which initially arose from the 
observation that antipsychotic drugs resulted in increased dopamine metabolism in 
mice (Carlsson and Lindqvist, 1963). It was later noted that antipsychotic drugs 
directly interacted with dopamine receptors (Creese et al., 1976). Furthermore, the 
effectiveness of these drugs at relieving symptoms was found to be correlated with 
their affinity to these receptors (Seeman et al., 1975; Creese et al., 1976). A 
pathogenic mechanism was suggested whereby psychosis occurred as a result of 
excess dopamine transmission (Matthysse, 1973). Subsequent research led to a 
modified hypothesis by Davis et al. (1991), who proposed that differential regional 
distributions of dopamine activity could account for positive and negative symptoms 
of schizophrenia. Like the original hypothesis, this was narrowly focused on 
dopamine dysfunction, with no description of the origins of these abnormalities. 
However, advances in research in the years since then have been able to utilise 
imaging and genetic studies to provide a higher-resolution representation of 
dopamine dysfunction in schizophrenia. Howes and Kapur (2009) proposed a new 
hypothesis whereby dopamine dysfunction results from the interaction of both 
genetic and environmental factors. This version of the dopamine hypothesis suggests 
multiple genetic and environmental factors act to cause presynaptic 
hyperdopaminergia, thus giving rise to psychotic symptoms rather than 
schizophrenia itself, through aberrantly salient ideas and perceptions stimulated by a 
normal environment (i.e. delusions and hallucinations). While current antipsychotic 
drugs act postsynaptically, at the level of the dopamine receptor (Jones and Pilowsky, 
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2002), normalisation of presynaptic dopamine levels has been suggested as an 
alternative treatment mechanism based on the current hypothesis (Howes et al., 2012; 
Bonoldi and Howes, 2014). 
 
Another major class of receptor in the brain is the NMDA receptor. NMDA receptors 
play essential roles in cellular homeostasis and neurotransmission through their 
activation by glutamate or glycine (Lakhan et al., 2013). An initial hypothesis of 
NMDA hypofunction in schizophrenia emerged from the observation that 
schizophrenia patients had low levels of glutamate in cerebrospinal fluid (Kim et al., 
1980). This hypothesis of NMDA hypofunction has been supported by reports of the 
induction of positive, negative and cognitive symptoms through the antagonism of 
NMDA receptors using ketamine (Krystal et al., 1994; Gilmour et al., 2012). There 
is also evidence to suggest a function for NMDA receptors in mood disorders. 
Ketamine has been shown to relieve symptoms of depression (Zarate et al., 2006) 
while Michael et al. (2003) reported an increase in glutamate levels in the brains of 
bipolar patients during acute manic episodes. Several mechanisms have been 
suggested for the role of NMDA receptors in mood disorders. Increased activity of 
the neurotrophic mammalian target of rapamycin (mTOR) signaling pathway has 
been reported in rats following administration of ketamine, resulting in increased 
levels of synaptogenesis (Li et al., 2010). Others have shown that ketamine-mediated 
blocking of NMDA receptors results in an increased interaction between glutamate 
and α–amino-3-hydroxy-5-methyl-4-isoxazoleproponionic acid (AMPA) receptors, 
proposing a mechanism for its antidepressant effects (Andreasen et al., 2013).   
 
In addition to glutamate and dopamine signaling, there is strong evidence for the role 
of 5-hydroxytryptophan (5-HT; also known as serotonin) in psychiatric illness – 
particularly in mood disorders. Serotonin is synthesised from tryptophan by action 
of tryptophan hydroxylase (TPH; Fitzpatrick, 1999). Early reports of a link between 
serotonin and mood were provided by Coppen (1965), who proposed that deficits in 
serotonin levels in the brain led to depressive symptoms. Young et al. (1985) later 
observed a lowering of mood in males suffering from acute tryphtophan depletion 
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(ATD), proposing a pathogenic mechanism for depression via the lowering of 
serotonin. A widely-used treatment for depression and bipolar depression is the 
administration of selective serotonin reuptake inhibitors (SSRIs). These work to 
increase extracellular serotonin levels by preventing their reabsorption into the 
presynaptic cell (Albert and Benkelfat, 2013; Geddes and Miklowitz, 2013). 
 
There is clear evidence for dysfunction of neurotransmitter systems in psychiatric 
illness. While current treatments show some promise by targeting individual 
pathways to alleviate symptoms, a greater understanding of the interactions between 
the above pathways is likely to be necessary in order to develop more efficient 
treatment options for these disorders. Furthermore, knowledge of the pathways 
disrupted in a given patient will be required in order to provide the most efficient 
treatment. 
   
1.2.2 Brain structural abnormalities 
The first image-based reports of brain abnormalities in schizophrenia were by 
Johnstone et al. (1976), who, using computerised tomography (CT) scanning, 
observed enlarged ventricles in patients. Reduced volumes of frontal and temporal 
lobes have also been observed in schizophrenia (Turetsky et al., 1995). It has been 
suggested that the reductions in frontal lobe volume observed in schizophrenia may 
be related to symptoms of apathy in patients (Roth et al., 2004).  
 
Imaging studies have also reported structural abnormalities in patients with bipolar 
disorder and MDD (Kempton et al., 2011). Reduced grey matter volumes have been 
observed in both MDD and bipolar disorder (Lim et al., 1999; Tang et al., 2007). 
However, treatment with mood stabilisers such as lithium have been shown to affect 
grey matter volume, rendering the findings for bipolar disorder more difficult to 
interpret (Moore et al., 2000; Hafeman et al., 2012). A meta-analysis of 20 studies 
by Lai (2013) reported reduced grey matter volumes in the anterior cingulate cortex 
(ACC) of MDD patients, while a meta-analysis of schizophrenia brain imaging 
studies by Glahn et al. (2008) identified grey matter abnormalities in multiple brain 
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regions. Network analysis of the regions containing grey-matter differences revealed 
four discrete networks, each potentially associated with pathological hallmarks of 
schizophrenia, such as cognitive deficits. Deficits in white matter volume have also 
been associated with illness: MRI studies have shown reduced white matter density 
in both schizophrenia and bipolar disorder (McIntosh et al., 2005), while post-
mortem studies have revealed increased neuronal density in white matter in both 
schizophrenia and bipolar disorder (Connor et al., 2009, Connor et al., 2011). These 
results may suggest that the above disorders are, at least in part, a result of disrupted 
connectivity in the brain. 
 
Abnormalities in the caudate nucleus have also been reported in schizophrenia. The 
caudate nucleus is highly innervated by the dopamine system and functions in 
learning, memory and executive functioning (Grahn et al., 2008). Jernigan et al. 
(1991) reported enlargements of the caudate nucleus in schizophrenia while later 
studies revealed that this could be modulated by treatment with antipsychotics 
(Chakos et al., 1994). Enlargement of the caudate nucleus has also been observed in 
bipolar I (Maller et al., 2014), along with differences in size and shape between 
affected and unaffected individuals (Ong et al., 2012). 
 
The presence of such structural abnormalities in illness strongly points to a 
neurodevelopmental origin of these disorders. The neurodevelopmental hypothesis 
of schizophrenia was first proposed by Weinberger (1987), who suggested the 
disorder may occur as a result of perturbed brain development. Observations in 
support of this come from brain imaging, behavioural and animal studies. Structural 
abnormalities have been reported in the absence of gliosis, suggesting these are not 
neurodegenerative but rather neurodevelopmental (Harrison, 2000), while cognitive 
deficits have been observed in individuals who later went on to develop 
schizophrenia (Fuller et al., 2002). Moreover, illness-associated genetic variation is 
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1.3 Evidence for a genetic contribution to psychiatric disorders 
Family, twin and adoption studies have been useful tools to demonstrate the 
heritability of psychiatric disorders (Shih et al., 2004). There is a correlation between 
the risk of schizophrenia and the degree of genetic relatedness between individuals 
(Figure 1.1; Gottesman, 1991). This risk correlates with the degree of genetic sharing 
between affected and unaffected individuals: individuals with an affected first degree 
relative (approximately 50% genetics shared) have a tenfold higher risk of developing 
the disorder compared to the general population. This risk is decreased to double that 
of the general population in individuals with an affected cousin (approximately 12.5% 
genetics shared). This section will summarise the methods utilised in psychiatric 
research to elucidate the genetic architecture of major mental illness, along with key 
findings, beginning with evidence from early approaches such as linkage and 
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Figure 1.1: Risks for developing schizophrenia.  
Figure summarises the relative lifetime risk of schizophrenia in percent (x-axis) with each bar 
corresponding to the general population and individuals with various degrees of genetic 
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1.3.1 Linkage studies 
Genetic linkage analysis is a commonly used method in epidemiology to identify 
genomic regions that may be inherited or “linked” with a disease or trait among 
related individuals separated by a low number of meiotic events. Linkage studies 
have proven useful in identifying the genes underlying disorders with Mendelian 
patterns of inheritance, such as Huntington’s disease (Gusella et al., 1983), but less 
so for complex psychiatric disorders. Several studies have reported evidence for 
linkage, but these have generally failed to define specific gene loci and have been 
largely unsuccessful in yielding replicable results. 
 
1.3.1.1 Linkage studies of schizophrenia 
More than 30 genome-wide linkage scans have been performed for schizophrenia as 
well as several meta-analyses. However, many of the results from these studies have 
been inconsistent. A meta-analysis of 18 studies by Badner and Gershon (2002) 
reported significant linkage with schizophrenia in regions of chromosomes 8p, 13q 
and 22q. In a meta-analysis of 20 genome-wide linkage studies, Lewis et al. (2003) 
identified genome-wide significant evidence for linkage on chromosome 2q, with 
nominally significant results observed at 8p and 22q, among several other regions. A 
more recent meta-analysis by Ng et al. (2009) consisting of 32 independent studies 
also reported genome-wide significant linkage at chromosome 2q, with additional 
regions at chromosomes 5q and 2q showing suggestive evidence for linkage with 
schizophrenia. When they considered studies of European ancestry only, suggestive 
evidence for linkage was also observed on chromosome 8p. 
 
1.3.1.2 Linkage studies of bipolar disorder 
Badner and Gershon (2002) performed a meta-analysis of 11 genome-wide linkage 
scans of bipolar disorder, finding evidence for susceptibility regions at 13q and 22q. 
In a meta-analysis of 18 studies, Seguardo et al. (2003) failed to find genome-wide 
significant evidence for linkage to bipolar disorder. A more recent meta-analysis by 
McQueen et al. (2005) was successful in identifying genome-wide significant regions 
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of susceptibility at chromosomes 6q and 8q, using the original genotype data from 11 
studies, unlike the former meta-analyses which used summary statistics. A review by 
Seretti and Mandelli (2008) provided a comprehensive overview of linkage studies of 
bipolar disorder performed up to December 2007, reporting susceptibility regions on 
all autosomes along with the X chromosome. The majority of regions reported had 
been derived from single studies, but some regions have been implicated in multiple 
studies (e.g. 6q21; Ewald et al., 2002; Park et al., 2004), while for others there are 
reports of both positive and negative findings (e.g. 1q31: Detera-Wadleigh et al., 1999; 
Ekholm et al., 2003). 
 
Positive findings by linkage analysis depends upon two factors, the existence of loci 
of major effect in a given family; and either a family of sufficient size to generate a 
significant finding in itself, or more than one family that are segregating a major effect 
risk allele at the same locus. The equivocal findings from linkage studies, balanced 
against the strong evidence for twin and family studies for a strong genetic component 
implies a high degree of genetic heterogeneity and multiple genetic risk loci.  
 
1.3.2 Association studies 
In contrast to linkage studies, which look for evidence of consistent meiotic 
segregation of a given trait with a specific chromosomal region, association studies 
look for evidence of allelic distortion between cases and controls in candidate genes, 
or more commonly now in the era of gene chips, genome-wide. By design and 
practice, association studies provide higher resolution mapping than linkage analysis 
for identifying putative risk loci. A further advantage of association studies is the 
power to detect smaller effect sizes, which may be masked in linkage studies. 
Association studies depend on comparing a group of unrelated individuals with a 
phenotype (trait or diagnosis) of interest (cases) with a matched set of individuals 
without the phenotype (controls). Association is determined based on whether a 
given variant is present at a statistically significant level in one phenotypic group 
over another (case vs. control). Such studies can be hypothesis-driven (i.e. candidate 
gene association studies) or hypothesis-free (i.e. GWAS).  
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1.3.2.1 Candidate gene association studies 
Prior to the GWAS era (defined as 2008 or earlier), candidate gene studies tended to 
be performed on the basis on evidence obtained from linkage and cytogenetic analyses.  
 
A review by Farrell et al. (2015) assessed the current status of 25 candidate genes for 
schizophrenia, based on the number of pre-GWAS era studies as reported by the 
SZGene database (Allen et al., 2008), or their appearance in four selected reviews on 
the genetics of schizophrenia (Lohmueller et al., 2003; Owen et al., 2005; Sullivan et 
al., 2005; Harrison and Weinberger, 2005). The authors reported COMT as the gene 
of interest in the most published candidate gene association studies for schizophrenia 
(81 publications). COMT functions in the degradation of dopamine and maps to 
chromosome 22q11, a region implicated in schizophrenia by linkage and cytogenetic 
analyses. A non-synonymous Val108/158Met polymorphism in COMT has been 
reported to be associated with a two to four-fold variation COMT enzyme activity 
(Lachman et al., 1996; Chen et al., 2003). Harrison and Weinberger (2005) reviewed 
several studies in which association with schizophrenia was reported for the Val-
COMT allele (conferring high enzyme activity). Considering the current hypothesis of 
hyperdopaminergia in schizophrenia (Howes and Kapur, 2009), this finding may 
appear contradictory. However, a study by Egan et al. (2001) reported a negative 
correlation between Val-COMT allele dosage (high activity enzyme) and cognitive 
function, as well as fMRI evidence for a negative correlation between the Val-COMT 
allele and efficiency of physiological response in the prefrontal cortex during working 
memory tasks, independent of psychiatric diagnosis. They proposed a mechanism 
whereby the high activity allele leads to reduced synaptic dopamine in the prefrontal 
cortex, resulting in deficits in prefrontal function: a neuropathological characteristic of 
schizophrenia (Weinberger et al., 2001). 
A meta-analysis by Seifuddin et al. (2012) examining 487 candidate gene association 
studies on bipolar disorder failed to find significant association with the disorder 
among 362 genes after correction for multiple testing. However, nominally significant 
associations (p < 0.05) were observed for polymorphisms within four genes: Brain 
derived neurotrophic factor (BDNF), Dopamine receptor D4 (DRD4), D-amino acid 
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oxidase activator (DAOA), and Tryptophan hydroxylase 1 (TPH1). Several analyses 
and meta-analyses have been performed on these genes, reporting mixed results. 
 
The BDNF protein plays multiple roles in neural development, maintenance and 
function (reviewed by Huang and Reichardt, 2001). Upregulation of BDNF has been 
observed in response to treatment with mood stabilisers, as well as anti-depressant 
medications, rendering it an attractive functional candidate for bipolar disorder 
(Fukumoto et al., 2001; Watanabe et al., 2010). However, results from association 
studies have been inconsistent: several studies have examined association between a 
non-synonymous variant in BDNF (rs6265 - Val66Met) and bipolar disorder, yielding 
both positive and negative findings (Neves-Pereira et al., 2002; Lohoff et al., 2005; 
Kunugi et al., 2004). A recent meta-analysis by Gonzáles-Castro et al. (2015) failed 
to find association between bipolar disorder and the Val66Met polymorphism in over 
16,000 individuals. 
 
DRD4 encodes a dopamine receptor and is located on chromosome 11p15.5, a region 
with both positive and negative findings for linkage to bipolar disorder (Serretti and 
Mandelli, 2008). Due to their roles in neurotransmission, dopamine receptor genes are 
strong functional candidates for psychiatric disorders (section 1.2.1). A family-based 
analysis of tandem repeat alleles in exon 3 of DRD4 reported that the excess 
transmission of a 4-repeat allele conferred an increased risk of bipolar disorder while 
the excess non-transmission of a 2-repeat allele conferred a protective effect (Muglia 
et al., 2002). A meta-analysis of candidate gene association studies of DRD4 reported 
significant association between the same 48 bp repeat polymorphism and mood 
disorders (unipolar and bipolar disorders) among 12 independent samples (López León 
et al., 2005). Findings for DRD4 are inconsistent, however. Using a family-based 
approach, Serretti et al. (2002) failed to find significant association between the same 
48 bp DRD4 repeat polymorphism and mood disorders. 
 
DAOA is located on chromosome 13q within the G72/G30 gene complex. Its protein 
product may be involved in glutamate signaling via the activation of D-amino acid 
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oxidase (DAAO; Boks et al., 2007). Multiple variants within this gene have been 
associated with schizophrenia and bipolar disorder in independent studies. Hattori et 
al. (2003), reported a haplotype within DAOA that was significantly overtransmitted 
to individuals with bipolar disorder. Prata et al. (2008) also reported a 2 SNP haplotype 
within DAOA showing significant association with bipolar disorder. Williams et al. 
(2006) investigated association between nine tag SNPs at the DAOA/G30 locus, 
reporting significant association between three variants and bipolar disorder in a 
British population. The same study reported no significant association between the 
same variants and schizophrenia. A meta-analysis performed by Shi et al. (2008) 
examined association studies of DAOA/G30 and bipolar disorder and schizophrenia 
performed before April 2007, and found no significant association between 
DAOA/G30 and bipolar disorder. However, they reported significant association 
between schizophrenia and genotype of two variants (rs947267 and rs778293) in an 
Asian population. A more recent study failed to replicate this finding in a family-based 
sample, examining these and three additional variants at the DAOA/G30 locus (Müller 
et al., 2011). However, significant association was reported between rs1935062 and 
bipolar disorder. In the same study, a meta-analysis was performed and, consistent 
with Shi et al. (2008), reported significant association between DAOA and 
schizophrenia in Asians at rs2391191 (albeit not the same locus as the previously-
associated polymorphism), but failed to find significant association between DAOA 
and bipolar disorder. 
 
TPH1 functions in the synthesis of serotonin, rendering it strong candidate gene for 
mood disorders. It is located on chromosome 11p15.3-14, a region with both positive 
and negative findings for linkage with bipolar disorder. An A > C intronic variant 
(A218C, rs1800532) has been the subject of several association studies between TPH1 
and mood disorders (e.g. Bellivier et al., 1998; Viikki et al., 2010). Mandelli et al. 
(2011) reported a nominally significant association between bipolar disorder and a 
two-marker haplotype containing rs1800532 and rs7933505. However, this did not 
survive correction for multiple testing. Although there have been also been negative 
reports for association between this gene and mood disorders (Furlong et al., 1998), a 
more recent meta-analysis found a significant association between the risk of 
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developing bipolar disorder and AA homozygosity at rs1800532 in a Caucasian 
population (Chen et al., 2012).  
 
Candidate gene studies have reported variable results in psychiatric research. These 
issues with replication may be attributable to factors such as illness heterogeneity or 
population stratification (Sher, 2001). Furthermore, differences in study designs may 
also be a contributing factor to discordant findings (Haslam, 2006). The last decade 
has seen a move from these hypothesis-driven studies to hypothesis-free approaches, 
examining samples at the genome-wide level to identify putative risk factors for 
complex disorders. 
 
1.3.2.2 Genome-wide association studies (GWAS) 
The development of high-throughput genotyping technologies has permitted genome-
wide screening of variation which may be associated with complex traits through 
GWAS. This section will focus on GWAS findings performed to date for 
schizophrenia, bipolar disorder and MDD, summarising the key findings. 
 
1.3.2.2.1 GWAS findings for schizophrenia 
The first GWAS performed on schizophrenia involved 25,000 markers genotyped in 
325 schizophrenia cases and 320 matched controls (Mah et al., 2006). This study 
identified plexin A2 (PLXNA2) as a susceptibility gene, although the findings were not 
significant at the later-suggested level of genome-wide significance to account for the 
multiple testing burden in GWAS (p ≤ 5 x 10-8 as suggested by Pe’er et al., 2008; 
Barsh et al., 2012). PLXNA2 is located on chromosome 1q32, within a region 
previously implicated in schizophrenia by linkage (Gurling et al., 2001). Subsequent 
GWASs of schizophrenia have generally involved the analysis of >300,000 markers. 
A study by Sullivan et al. (2008) was unable to identify genome-wide significant 
association with schizophrenia after interrogating genotype at over 490,000 markers 
across the genome. Failure to detect genome-wide significant association in these early 
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attempts may well have been an issue of small sample size resulting in low statistical 
power. O’Donovan et al. (2008) analysed a primary sample of schizophrenia cases 
versus controls as well as two replication samples finding the strongest evidence for 
association at zinc finger protein 804A (ZNF804A; meta-analysis p = 1.61 x 10-7). 
Although not significant at the genome-wide level, when including bipolar disorder in 
the affected phenotype, genome-wide significant association was attained (p = 9.96 x 
10-9). This marked the first study to identify a genome-wide significant variant 
associated with psychotic illness. A meta-analysis performed by Williams et al. (2011) 
reported genome-wide significant association between this gene and schizophrenia 
alone, as well as schizophrenia and bipolar disorder combined. ZNF804A is a brain-
expressed gene of unknown function. Walters et al. (2010) reported reduced 
association between the illness-associated variant and reduced cognitive performance 
in schizophrenia patients, but not controls. Furthermore, imaging studies have reported 
association between this variant and brain structural abnormalities (reviewed in 
Gurung and Prata, 2015). 
 
Shi et al. (2009), Steffanson et al. (2009) and the International Schizophrenia 
Consortium (ISC; Purcell et al., 2009) concurrently reported an association between 
the extended major histocompatibility complex (MHC) and schizophrenia, supporting 
previous reports of a link between immune system dysfunction and schizophrenia 
(reviewed in Upthegroves and Barnes, 2014). In their study, Steffanson et al. (2009) 
also reported association between a marker upstream of neurogranin (NRGN), at 
chromosome 11q, as well as a marker within transcription factor 4 (TCF4), on 
chromosome 18q. Both of these genes, along with the MHC region were again 
implicated in schizophrenia by Steinberg et al., (2011), with the addition of vaccinia 
related kinase 2 (VRK2), and a second variant approximately 400 kb from the 
previously-reported TCF4 risk variant. 
 
The establishment of the psychiatric genomics consortium (PGC) in 2007 brought 
together over 800 researchers from 36 countries with an aim to identify genetic risk 
factors in schizophrenia, affective disorders, ADHD and autism. In 2011, the 
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schizophrenia working group of the PGC published their first GWAS on schizophrenia 
implicating five new genes (Ripke et al., 2011). This was followed by the identification 
of a further 14 novel risk loci for schizophrenia by Ripke et al. (2013a). Here, among 
22 genome-wide significant loci, eight had previously been implicated in 
schizophrenia and/or bipolar disorder by earlier GWASs, supporting previous reports 
of a genetic overlap between the two disorders (Lichtenstein et al., 2009). The most 
recent and largest GWAS of the PGC’s schizophrenia working group was published 
in 2014, in which 83 novel loci among 108 were identified with genome-wide 
significant association with schizophrenia, (Ripke et al., 2014). Within these loci were 
128 independent sites of association. The top hit in this study was a broad region within 
the MHC (p = 3.48 x 10-31), adding to growing evidence of a relationship between the 
immune system and schizophrenia. Furthermore, the associated SNPs were found to 
be significantly enriched for sites that act as enhancers in immune-related tissues. 
Recently, the relationship between immune function and schizophrenia has been 
partially explained by variation at the complement component 4 (C4) genes. The C4 
locus consists of two isotypes located in tandem at the MHC: C4A and C4B, both of 
which are present in either a long and/or short form. Sekar et al. (2016) reported that 
variation at the C4 locus was associated with differential gene expression levels of 
C4A and C4B across multiple brain regions. Furthermore, they reported an increased 
risk of schizophrenia associated with common C4 structural variants as well as C4A 
expression levels. Of these common structural variants, the short form of C4B posed 
the lowest risk, while carrying tandem copies of the long form of C4A was associated 
with the greatest risk of the disorder. Upon examining post-mortem brains, Sekar et al. 
(2016) observed co-localisation of C4 and pre- and postsynaptic markers. 
Furthermore, they showed that C4 expression led to synapse elimination in-vivo. 
Complement receptors are expressed in the brain by microglia – this study proposed a 
pathogenic mechanism whereby interaction between neurons and microglia through 
C4 result in aberrant synaptic pruning, resulting in the reduction in grey matter and 
synaptic structures observed in schizophrenia (Cannon et al., 2002; Garey et al., 1998). 
 
1.3.2.2.2 GWAS findings for bipolar disorder 
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Significant associations have also been identified by GWAS for bipolar disorder but, 
to date, fewer loci have attained genome-wide significant association with the disorder 
than have been identified in schizophrenia. The first studies performed on bipolar 
disorder failed to find significant associations at the genome-wide level, with the most 
significant region of association occurring at chromosome 16p12 (WTCCC, 2007). 
The following year, Baum et al. (2008) reported genome-wide significant association 
with the disorder at diacylglycerol kinase eta (DGKH) while Sklar et al. (2008) failed 
to report genome-wide significant findings, identifying myosin 5B (MYO5B) as their 
top hit. A meta-analysis of Sklar et al. (2008) and the WTCCC study by Ferreira et al. 
(2008) reported genome-wide significant associations with bipolar disorder at two 
genes: calcium channel, voltage-dependent, L-type, alpha 1C subunit (CACNA1C) and 
ankyrin 3 (ANK3). Associations have subsequently been identified between 
CACNA1C and schizophrenia and recurrent major depressive disorder (Green et al., 
2010). The bipolar disorder working group of the PGC reported association between 
bipolar disorder and a novel variant in an intronic region of protein odd oz/ten-m 
homolog 4 (ODZ4), as well as supporting Ferrerira et al.’s (2008) finding of 
association with CACNA1C (Sklar et al., 2011). A study by Cichon et al. (2011) 
identified significant association between bipolar disorder and the neurocan (NCAN) 
gene, in the MooDS consortium. Although not significant at the genome-wide level, 
they also identified an intronic SNP within the cell cycle-related gene mitotic spindle 
assembly checkpoint protein MAD1 (MAD1L1) as the next most significant hit. 
Significant association has since been reported between MAD1L1 and schizophrenia 
in the PGC’s most recent GWAS (Ripke et al., 2014). Furthermore, Ruderfer et al. 
(2014) reported genome-wide significant association between MAD1L1 and 
schizophrenia and bipolar disorder combined. Recently, Hu et al. (2016) reported 
genome-wide significant association between MAD1L1 and bipolar disorder alone. A 
meta-analysis by Chen  et al. (2013) found support for association between ANK3 and 
bipolar disorder along with significant association with tetratricopeptide repeat and 
ankyrin repeat containing 1 (TRANK1). Using a combined population from the PGC 
bipolar disorder working group and the MooDS consortium, Mühleisen et al. (2014)  
reported association between bipolar disorder two novel loci: adenylyl cyclase type 2 
(ADCY2), and a region between microRNA 2113 (MIR2113) and POU class 3 
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homeobox 2 (POU3F2). The same study also supported previous findings, reporting 
association between bipolar disorder and ANK3, ODZ4 and TRANK1. The most recent 
genome-wide significant findings in bipolar disorder have come from Hou et al. 
(2016). Here, they identified six genome-wide significant loci, of which two were 
novel: an intergenic region on chromosome 9, and a region within erb-b2 receptor 
tyrosine kinase 2 (ERBB2). However, limitations to this study include a small sample 
size and unscreened controls, presenting potential issues with power. The authors also 
cautioned that the identification of previously-associated loci should not be considered 
replications, as many of the cases analysed had been included in previous studies. 
 
1.3.2.2.3 GWAS findings for MDD 
Unlike schizophrenia and bipolar disorder, which have generally been successful in 
identifying genome-wide significant results by GWAS; it was not until 2015 that 
genome-wide significant associations were identified for MDD. The CONVERGE 
consortium reported two loci attaining genome-wide significant association with 
MDD: one upstream of the chromosome 10 gene sirtuin 1 (SIRT1), and the other in an 
intronic region of phospholysine phosphohistidine inorganic pyrophosphate 
phosphatase (LHPP; Cai et al., 2015). The authors credited their success to the 
homogeneity of their sample, restricting their analysis to females of Han Chinese 
ethnicity with severe (hospitalised) recurrent MDD. As mentioned in section 1.1.3, 
MDD is a highly heterogeneous disorder in terms of clinical presentation. Any 
combination of five out of nine symptoms are required to incur a diagnosis, according 
to current DSM-V criteria (i.e. 227 possible combinations). Such heterogeneity may 
be responsible for noise and a reduction in the statistical power to dissect the 
underlying genetic architecture of the disorder. Therefore, stratification by gender and 
clinical presentation, for example, may be the key to identifying more genome-wide 
significant associations for MDD. More recently, Hyde et al. (2016) reported 
significant association with MDD in a population of European ancestry. Here, they 
availed of genotype data from over 450,000 consumers of 23andMe and self-reported 
phenotypes. Upon meta-analysis of 23andMe data and PGC data (Ripke et al., 2013), 
the authors reported 15 significantly associated loci. While Cai et al. (2016) were 
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successful in identifying genetic associations with MDD through reducing 
heterogeneity, the success of Hyde et al. (2016) was likely attributable to the size of 
the cohort studied.  
 
As well as individual successes in GWAS, a substantial degree of genetic overlap 
between these disorders has also been reported. This is best reflected in a GWAS 
performed by the PGC cross-disorder working group in which four genome-wide 
significant associations were identified between MDD, bipolar disorder, 
schizophrenia, ADHD and autism spectrum disorder combined (Smoller et al., 2013). 
Two of their associations were within calcium-channel genes: the previously-reported 
gene CACNA1C, as well as calcium voltage-gated channel auxiliary subunit beta 2 
(CACNB2). The top hit occurred on chromosome 3p and overlapped with findings of 
a combined bipolar and schizophrenia study (ITIH3; Ripke et al., 2011). A fourth 
region on chromosome 10 overlapped multiple genes, with the strongest signal 
mapping to an intronic site in arsenite methyltransferase (AS3MT).  
 
1.3.2.3 Evidence for a polygenic basis for psychiatric illness 
Associations from GWAS consist of common alleles, each of small effects. It is likely 
that such alleles, when inherited together, contribute to a polygenic burden of risk of 
illness. Gottesman and Shields (1967) had previously proposed a polygenic model for 
the risk of schizophrenia. More recently, polygenic scoring has been useful in 
assessing the collective effects of risk genes. Purcell et al. (2009) demonstrated the 
first successful application of polygenic scoring to psychiatric GWAS data, calculating 
polygenic risks for schizophrenia. They reported that although few markers were 
significantly associated with illness at the individual level, when taken collectively to 
calculate risk scores, these scores were significantly higher in schizophrenia cases 
compared to controls. This was also observed in bipolar disorder using polygenic risk 
scores calculated from schizophrenia GWAS data, indicative of a shared genetic 
component between the two disorders. More recently, Purcell et al. (2014) showed 
association between rare, deleterious coding variants and schizophrenia. Here, while 
no individual gene was associated with the disorder, a greater burden of these variants 
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was observed in cases compared to controls. Although there are limited findings of 
single gene associations for MDD, polygenic approaches have had some success. 
Using polygenic risk scores for psychiatric traits from PGC data (Ripke et al., 2013; 
Sklar et al., 2011; Ripke et al., 2014), Milaneschi et al. (2016) reported a significant 
association between typical MDD and schizophrenia polygenic risk scores in a cohort 
of 3230 Dutch patients. These findings are consistent with reports of genetic overlap 
between psychiatric disorders (Smoller et al., 2013). Polygenic scoring has also proven 
useful in the dissection of the overlapping genetic architecture between psychiatric 
disorders: Ruderfer et al. (2014) created a polygenic risk score capable of significantly 
discriminating between bipolar disorder and schizophrenia. 
 
Over 90% of disease-associated GWAS variants are located in non-coding regions 
such as intronic or intergenic regions (Maurano et al., 2012). This may point to an 
important role for regulatory variants in the pathology of psychiatric disorders. A 
summary of genome-wide significant association findings to date for schizophrenia, 
bipolar disorder and MDD is presented in Table 1.1. It is likely that the majority of 
findings from these studies are not the causal variants but are instead tagging the 
variant or variants of interest – an important factor to consider in downstream analyses 
based on these data. Furthermore, it is important to note that the heritability of these 
disorders will be further explained by rare genetic variation, gene-gene interactions 
(epistasis), and gene-environment interactions.  
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Study Disease(s) of Interest Findings 
Baum et al. 2008a Bipolar disorder 
Reported genome-wide significant association 
between bipolar disorder and DGHK in two 
independent samples. 
O’Donovan et al., 2008 
Schizophrenia and schizophrenia and bipolar 
disorder combined 
Reported strong evidence for association 
between ZNF804A and schizophrenia, attaining 
genome-wide significance when both 
schizophrenia and bipolar disorder were 
considered. 
Ferreira et al., 2008 Bipolar disorder 
First study to report genome-wide significant 
associations with bipolar disorder implicating 
CACNA1C and ANK3. 
Steffanson et al., 2009 Schizophrenia 
Reported genome-wide significant association 
with schizophrenia at loci in the major 











Study Disease(s) of Interest Findings 
Rietschel et al., 2011 Schizophrenia 
Reported genome-wide significant association 
between schizophrenia and four SNPs in 
AMBRA1, on chromosome 11. 
Shi et al., 2011 Schizophrenia 
Two schizophrenia-associated loci identified: 
one on chromosome 1q24 (BRP44) and another 
on chromosome 8p12 (LSM1/WHSC1L1) 
Steinberg et al., 2011 Schizophrenia 
Found evidence in support of association 
between schizophrenia and NRGN and TCF4. 
Identified two novel loci associated with 
schizophrenia at CCDC68 and VRK2 
Cichon et al., 2011 Bipolar disorder 
Reported genome-wide association between 
bipolar disorder and NCAN.  
 





Study Disease(s) of Interest Findings 
PGC (Ripke et al., 2011) 
Schizophrenia and schizophrenia and bipolar 
disorder combined 
Seven schizophrenia-associated loci identified, 
five of which were novel and mapped to six 
genes (MIR137, PCGEM1, CSMD1, MMP16, 
CNNM2 and NT5C2). Confirmed association 
between schizophrenia and TRIM26 and 
CCDC68. Also reported association between 
schizophrenia and bipolar disorder and 
CACNA1C, ANK3 and ITIH3-ITIH4, all 
previously associated with bipolar disorder. 
PGC (Sklar et al., 2011) 
Bipolar disorder and schizophrenia and bipolar 
disorder combined 
Confirmed evidence for association between 
bipolar disorder and CACNA1C. Identified a 
novel susceptibility locus at ODZ4. Reported 
association between schizophrenia and bipolar 
disorder combined and NEK4, CACNA1C and a 
multi-gene region spanning ITIH-1, -3 and -4. 
 




Study Disease(s) of Interest Findings 
PGC (Smoller et al., 2013) 
Autism spectrum disorder, attention deficit-
hyperactivity disorder, bipolar disorder, major 
depressive disorder and schizophrenia 
Four genome-wide significant loci identified 
across all disorders (ITIH3, AS3MT, CACNA1C 
and CACNB2), two of these had previously 
been associated with schizophrenia and/or 
bipolar disorder (ITIH3, CACNA1C). 
Chen et al. (2013) Bipolar disorder 
Genome wide significant association with 
bipolar disorder reported near TRANK1, 
LMAN2L and PTGFR. Also provided support 
for association with ANK3. 
Ripke et al. (2013) Schizophrenia 
13 novel loci identified among 22. The nine 
remaining loci had previously been associated 
with schizophrenia and/or bipolar disorder. 
Ruderfer et al. (2014) Bipolar disorder and schizophrenia 
Identified a novel association between both 
disorders and (PIK3C2A), as well as five 
previously-identified loci (TRANK1, MHC, 
MAD1L1, and CACNA1C) 
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Study Disease(s) of Interest Findings 
PGC (Ripke et al., 2014) Schizophrenia 
108 genome-wide significant loci consisting of 
intergenic regions, single genes and multiple 
genes. The top hit was a broad 400 kb region on 
chromosome 6, within the MHC 
Mühleisen et al., 2014 Bipolar disorder 
Five genome-wide significant loci were 
identified, two of which were novel (ADCY2 
and MIR2113-POU3F2). Also confirmed 
association between bipolar disorder and ANK3, 
ODZ4 and TRANK1. 
CONVERGE Consortium (Cai et al., 2015) MDD 
First report of genome-wide significant 
association in MDD. Two genome-wide 
significant loci identified on chromosome 10 
located 5’ of SIRT1 and within an intron of 
LHPP. 
Hou et al., 2016 Bipolar disorder 
Two novel genome-wide significant loci were 
identified: ERBB2 and an intergenic region on 
chromosome 9.  Reported the first association 
between MAD1L1 and bipolar disorder only. 
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Table 1.1: Summary of genome-wide significant findings for schizophrenia, bipolar disorder and MDD identified by GWAS (2008-
2016). 
Table summarises GWAS of psychiatric disorders in which genome-wide significant results have been reported based on a p-value threshold of 5 x 10-8 
(as suggested by Pe'er et al., 2008). “Study” column provides the references to each study, column labelled “Disease(s) of Interest” refers to the disease 
or diseases under investigation in each study while the column labelled “Findings” summarises the genome-wide significant disease-associated findings 
of each study. 
Study Disease(s) of Interest Findings 
Hyde et al., 2016 MDD 
15 novel genome-wide significant loci were 
identified in a meta-analysis of a previous 
GWAS of MDD by the PGC (Ripke et al., 2013) 
and consumer genomic data from 23andMe.  
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1.3.3 Chromosomal structural abnormalities 
Chromosomal abnormalities such as inversions, duplications, deletions and 
translocations have been linked to several disorders, including neuropsychiatric 
disorders (reviewed in Muir et al., 2006, Brand et al., 2014). A relatively frequent 
deletion at chromosome 22q11 is associated with velocardiofacial and DiGeorge 
syndromes and occurs in approximately 1 in 4,000 individuals, yielding variable 
phenotypes (Ou et al., 2008).  The most common psychiatric disorder associated with 
22q11 deletion syndrome is schizophrenia (Bassett et al., 2005). Among the genes 
within the affected region is COMT, a previously-described risk factor for 
schizophrenia (section 1.3.2.1).  
 
Xu et al. (2009) examined de novo CNVs in 359 trios from an Afrikaner population, 
reporting that sporadic cases of schizophrenia had approximately eight times more 
de novo CNVs than unaffected controls (p = 0.0008). A similar observation was made 
by Walsh et al. (2008), in that CNVs were present at a significantly higher rate in 
schizophrenia cases (22/150; p = 0.0008) - particularly early-onset cases (15/76; p = 
0.0001) than in unaffected controls (13/268). Pathway analysis showed these 
schizophrenia-specific CNV genes were significantly over-represented in 
neurodevelopmental processes while no significant over-representations were 
observed for the CNV genes identified in controls.  
 
The role for CNVs in bipolar disorder has been less clear. As previously observed in 
schizophrenia, Malhotra et al. (2009) reported a significantly higher rate of de novo 
CNVs in bipolar cases (8/185) compared to unaffected controls (4/426; p = 0.009). 
Grozeva et al. (2010) examined large (>100 kb), rare (frequency < 0.01) CNVs 
among bipolar disorder cases in the WTCCC finding no significant difference in the 
burden of CNVs between cases and unaffected controls. They compared their 
findings to those of Kirov et al. (2009) and found that the burden of CNVs in bipolar 
disorder was significantly less than that observed in schizophrenia. A meta-analysis 
by Malhotra and Sebat (2012) reported few overlaps between CNVs that contribute 
to schizophrenia and those that contribute to bipolar disorder and recurrent MDD. 
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Green et al. (2016) examined CNVs among the Bipolar Disorder Research Network 
sample and found significant evidence for association between bipolar disorder and 
a CNV at 16p11.2: a region also associated with schizophrenia through CNV analysis 
(Rees et al., 2014). Similar to Grozeva et al. (2010), Green et al. (2016) reported 
lesser association between large CNVs and bipolar disorder compared to the 
association observed between large CNVs and schizophrenia (Kirov et al., 2009).  
 
Along with inversions, duplications and deletions, there have been multiple reports 
of chromosomal translocations linked to psychiatric illness. Overhauser et al. (1997) 
reported a female with schizoaffective disorder possessing a balanced translocation 
between chromosomes 14 and 18 t(14;18)(q11.2;q21.1). The affected region of 
chromosome 18 contains the gene MYO5B. Suggestive association with this gene 
was reported by Sklar et al. (2008) as the top hit in a GWAS of bipolar disorder 
though it was not genome-wide significant (p = 1.66 x 10-7). Rajkumar et al. (2015) 
cross-referenced the Danish psychiatric case register with the Danish cytogenetic 
case register leading to the identification of an individual with both bipolar disorder 
and a translocation between chromosomes 9 and 17 t(9;17)(q33.2;q25.3). Four genes 
are present at the chromosome 17 breakpoint region of this translocation: raptor 
(RPTOR), endonuclease V (ENDOV), neuronal pentraxin I (NPTX1) and ring finger 
protein 213 (RNF213). The same study examined whether these genes were 
associated with the disorder in the PGC GWAS of bipolar disorder (Sklar et al., 
2011). Nominally significant associations were reported for RPTOR and NPTX1. 
Following Bonferroni correction, only NPTX1 remained significant.  
 
A balanced translocation between chromosomes 1 and 11 t(1;11)(q42.1;q14.3) has 
been linked to schizophrenia, bipolar disorder and recurrent major depressive 
disorder in a large Scottish pedigree (St. Clair et al., 1990; Blackwood et al., 2001). 
This translocation is the main focus of the work presented in this thesis and is 
described in greater detail in section 1.4.  
Challenges remain in identifying the susceptibility factor(s) associated with 
structural abnormalities implicated in psychiatric illness. It is possible that a 
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phenotype may be linked to a single gene disrupted by a structural variant, while 
others may be linked to a multitude of genes within a CNV or chromosomal 
rearrangement. Investigation of downstream consequences such as expression or 
epigenetic changes may be useful in identifying a mechanism whereby structural 
variants confer increased risk for illness. Moreover, variants in the DNA sequence 
surrounding such structural abnormalities may play an important role in 
pathogenesis, should these structural variants be co-inherited with flanking regions 
containing risk factors.  
 
1.4 The t(1;11) translocation and disrupted in schizophrenia-1 
1.4.1 Overview 
As discussed in the previous section, there is a range of evidence linking 
chromosomal structural abnormalities to the risk of developing psychiatric illness. A 
further example of such structural variation in psychiatric illness is the 
t(1;11)(q42.1;q14.3) translocation. This was first identified in a single individual 
through a cytogenetic survey of males in young offenders’ institutions (Jacobs et al., 
1970). Upon further investigation across four generations of the proband’s family, 
34 members out of 77 tested were found to carry the translocation. Of these 34 
translocation carriers, 16 also had a psychiatric diagnosis in contrast to five 
translocation non-carriers with a diagnosis (St Clair et al., 1990). The regions 
surrounding the translocation breakpoints were subsequently cloned, identifying two 
novel genes on chromosome 1: a large protein-coding gene on the sense strand, and 
a non-coding RNA on the antisense strand. These were termed disrupted in 
schizophrenia-1 and -2, respectively (DISC1 and DISC2; Millar et al., 2000). In 
addition, the translocation also disrupts a non-coding transcript on chromosome 11, 
termed boymaw, or DISC1 fusion partner-1 (DISC1FP1; Zhou et al., 2010; 
Eykelenboom et al., 2012). Further follow-up was performed by linkage analysis on 
the family in which additional members were karyotyped and diagnoses ascertained 
using DSM-IV criteria (Blackwood et al., 2001). Significant linkage was observed 
between schizophrenia and the translocation with a LOD score of 3.6 between 37 
t(1;11) carriers and 50 non-carriers. When considering an affected phenotype to 
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include schizophrenia, bipolar disorder and recurrent MDD, a maximum LOD score 
of 7.1 was obtained. The same study also observed significant reductions in P300 
event-related potential (ERP) in t(1;11) carriers compared to non-carrying controls: 
an endophenotype of schizophrenia associated with cognitive function. A recent 
follow-up of the family sought to confirm linkage between the translocation and 
illness following recruitment of additional members. Significant linkage was 
observed between the translocation and a clinical phenotype including schizophrenia, 
schizoaffective disorder, bipolar disorder and recurrent MDD (LOD = 6.1; Thomson 
et al., 2016). 
 
1.4.2 DISC1 interactions 
A potential mechanism for the role of DISC1 in psychiatric illness was proposed by 
Millar et al. (2005), who identified an interaction between the DISC1 protein and a 
key regulator of the cAMP signalling pathway, phosphodiesterase 4B (PDE4B). 
Here, they observed a reduction in this DISC1-PDE4B interaction following 
induction of cAMP signalling in SH-SY5Y cells. The authors suggested that DISC1 
plays a regulatory role in cAMP signalling by releasing PDE4B in the presence of 
cAMP activity. The same study also reported haploinsufficiency of DISC1 in t(1;11) 
carriers in patient-derived lymphoblastoid cell lines (LCLs). This might disrupt 
levels of DISC1-PDE4B interaction resulting in subsequent dysregulation of the 
cAMP signalling cascade: a pathway implicated in learning, memory and mood 
(Bauman et al., 2003). 
 
Along with PDE4B, evidence has emerged for several protein-protein interactions 
involving DISC1. Millar et al. (2003) identified several DISC1 protein interactors 
through a yeast-2-hybrid (Y2H) screen, including activating transcription factor 4 
(ATF4). Malavasi et al. (2012) later demonstrated ATF4-mediated gene expression 
was affected by missense variants in DISC1 (R37W and L607F). The DISC1-ATF4 
complex was reported by Soda et al. (2013) to suppress transcription of PDE4D9. 
Furthermore, they reported dopamine receptor activation resulted in PDE4D9 
upregulation: a process which coincided with DISC1 dissociating from the PDE4D9 
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locus. These findings suggest a role for DISC1 in dopaminergic signalling: a pathway 
heavily implicated in psychiatric disorders as described in section 1.2.1.  
 
A yeast-2-hybrid study performed by Camargo et al. (2007) identified a network of 
protein interactions centred on DISC1: the DISC1 interactome. This interactome 
comprised a network of 127 proteins and 158 interactions. Ontology analysis 
revealed terms relating to intracellular transport, cell cycle and division, and 
regulation and organisation of the cytoskeleton were over-represented in this network 
(Camargo et al., 2007).  
 
Several of DISC1’s protein interactors have themselves been implicated in 
psychiatric illness and have neurodevelopmental and synaptic functions (Brandon 
and Sawa, 2011). For example, DISC1 interacts with nuclear distribution element 1 
(NDE1) and its orthologue NDE-like 1 (NDEL1; Ozeki et al., 2003; Morris et al., 
2003). NDE1 is located on chromosome 16p, a region in which CNVs have been 
implicated in several neuropsychiatric disorders, including schizophrenia 
(Ramalingam et al., 2011; Ingason et al., 2011). NDE1 and NDEL1 form a complex 
with lissencephaly 1 (LIS1) to which the DISC1-PDE4B complex binds, mediating 
phosphorylation of NDE1 at threonine residue 131 (T131; Bradshaw et al., 2011). 
Bradshaw et al. (2011) also demonstrated that T131 phosphorylation affects neurite 
outgrowth in-vitro, supporting a neurodevelopmental role for DISC1.  
 
1.4.3 DISC1 and neurodevelopment 
There are several lines of evidence linking the neurodevelopmental theory of 
schizophrenia and DISC1. Callicott et al. (2005) reported significant association 
between a three SNP haplotype in DISC1 and schizophrenia. Of the three SNPs
 




making up this haplotype, a non-synonymous variant (Ser704Cys; rs821616) 
displayed the strongest evidence for association and was selected for investigation for 
association with hippocampal formation (HF) structure and function. A significant 
association was observed between Ser704Cys and HF grey matter volume, with 
reduced volume observed in Cys homozygotes. Kamiya et al. (2005) observed 
disrupted neuronal migration in the developing cortex when Disc1 was knocked down 
by RNAi in mouse embryos. A similar phenotype in embryonic mouse brains was 
observed when overexpressing a C-terminal truncated form of Disc1 to model the 
effects of the t(1;11) translocation on Disc1. The same study additionally showed that 
knockdown of DISC1 and expression of the truncated form each led in impaired 
neurite outgrowth in-vitro. Duan et al. (2007) examined the role of DISC1 in adult 
hippocampal neurogenesis noting an increase in the speed of neuronal integration 
following DISC1 knockdown, and, consequently, altered dendritic development and 
positioning in adult-born neurons. DISC1 has also been shown to play a key role in 
the proliferation of neural progenitor cells (NPCs). Mao et al. (2009) reported reduced 
proliferation and migration of adult hippocampal progenitors following DISC1 knock-
down, as well as premature differentiation. These deficiencies in proliferation were 
found to occur through the Wnt signalling pathway, mediated by a direct interaction 
between DISC1 and GSK3β. This inhibitory interaction is similar to that between 
lithium chloride - a widely-used treatment for bipolar disorder – and GSK3β. However, 
whether or not the inhibitory mechanisms of DISC1 and lithium are similar has yet to 
be determined. Ishizuka et al. (2011) proposed a mechanism whereby DISC1 mediates 
a transition between neuronal migration and proliferation through phosphorylation at 
serine 710 (S710) of DISC1. Here, they observed an increase in the interaction 
between DISC1 and Bardet-Biedle syndrome proteins (BBS1 and BBS4) was 
correlated with DISC1 S710 phosphorylation. They also demonstrated that the 
unphosphorylated S710 residue results in a greater affinity between DISC1 and 
GSK3β, thereby regulating proliferation. Phosphorylation of this residue was shown 
to result a decreased interaction between DISC1 and GSK3β, coinciding with DISC1-
BBS1 interaction and initiation of neuronal migration. Interaction between DISC1 and 
BBS1 in corticogenesis has previously been demonstrated by Kamiya et al. (2008).  
 
 




1.4.4 DISC1 and synaptic function 
In addition to evidence for a neurodevelopmental role of DISC1, multiple lines of 
evidence exist linking DISC1 to synaptic function, which is hypothesised to be 
altered in major mental illness (van Spronsen and Hoogenraad, 2010). A study by 
Cannon et al. (2005) reported reduced grey matter density in the prefrontal cortex in 
carriers of haplotypes within DISC1 and translin-associated factor X (TSNAX), 
which lies upstream of DISC1. Post-mortem analyses have demonstrated that DISC1 
localises to synapses (Kirkpatrick et al., 2006), while analysis of rat brain subcellular 
fractions has shown DISC1 to be present in the postsynaptic density (PSD), where it 
interacts with Traf2 and Nck-interacting kinase (TNIK) to regulate the levels of PSD 
proteins (Wang et al., 2011). Additional roles for DISC1 have been identified in 
regulating the structure of synapses. Following RNAi-mediated knock-down of 
DISC1, Hayashi-Takagi et al. (2010) reported an increase in size and number of 
dendritic spines. This was found to be related to the interaction between DISC1 and 
Kalirin-7 (Kal-7), a protein with a well-established role in synaptic development and 
neurological disorders (Mandela and Ma, 2012). Interaction between Kal-7 and 
Neuroligin 1 (NL1), a postsynaptic cell adhesion molecule (CAM), was later 
demonstrated to be regulated by DISC1, with reduced Kal-7-NL1 binding observed 
in the presence of DISC1 (Owczarek et al., 2015).  
 
1.4.5 DISC1 and mitochondrial trafficking 
More recently, DISC1 has been implicated in mitochondrial trafficking, through its 
interaction with Trafficking Protein, Kinesin Binding 1 (TRAK1; Ogawa et al., 
2014). NDE1 and GSK3β have also been shown to interact with TRAK1 in neuronal 
mitochondrial trafficking complexes (Ogawa et al., 2016). Efficient transport of 
mitochondria is essential in neurons in order to meet the high-energy requirements 
of processes such as neurotransmission (Vos et al., 2010). Disruption of 
mitochondrial trafficking and localisation may therefore be a contributory 
mechanism for psychiatric disorders (Manji et al., 2012). 
 
 




1.4.6 The Disc1 L100P mouse 
Additional support for the role of DISC1 in psychiatric illness comes from animal 
studies. Several studies have been published on mutant Disc1 mouse models, 
reporting behavioural and neurodevelopmental phenotypes suggestive of psychiatric 
illness. A study by Clapcote et al. (2007) reported two mouse models with missense 
mutations in Disc1 (Q31L and L100P). These mice have reduced brain volumes 
compared to wild-type, supporting a neurodevelopmental role for Disc1. Behavioural 
characterisation of these mice revealed endophenotypes of schizophrenia, including 
deficits in latent inhibition and acoustic startle response (Geyer and Ellenbroek, 
2003). The 31L mutants were found to display depressive-like behaviours, with 
increased durations of immobility observed in these mice during the forced swim test 
(David et al., 2003). The schizophrenic-like behaviours were reversed following 
antipsychotic treatments while depressive behaviours were altered by the 
antidepressant bupropion. Shoji et al. (2012), however, failed to observe these 
findings in the same model. These inconsistencies may have been due to variable 
laboratory environments and mixed genetic backgrounds of the mice: both of which 
are common limitations of animal studies.  
 
Lipina et al. (2012) reported rescue of schizophrenic-like behaviours in 100P mice 
following administration of valproic acid, an anticonvulsant used in the treatment of 
bipolar disorder. Furthermore, the same study reported a rescuing effect of valproic 
acid on 13/61 100P-associated gene expression changes in the hippocampus, 
suggesting these genes might be related to illness through the disruption of Disc1. 
Others have also reported gene dysregulation in the 100P mouse. Brown et al. (2011) 
reported misexpression of presynaptic CAMs Neurexin-1 and -3 (Nrxn1 and Nrxn3) 
at various stages of brain development in the mouse, supporting a role for Disc1 in 
synaptic function. Multiple independent studies have observed hyperlocomotor 
activity in the 100P mouse (Clapcote et al., 2007; Lipina et al., 2010; Shoji et al., 
2012). This phenotype is significantly enhanced by amphetamine in L100P mice 
compared to wild-type, and is reduced following antipsychotic treatment, suggestive 
of increased dopamine receptor sensitivity (Lipina et al., 2010). Dopamine 
dysfunction has also been observed in a Disc1 mouse model expressing a dominant 
 




negative C-terminal truncated form of human DISC1. Jaaro-Peled et al. (2013) 
reported a reduction in extracellular dopamine levels along with an increase in 
dopamine receptors in the brains of these mice, compared to wild-type. Structural 
abnormalities have also been reported in these mice, with mutants possessing 
enlarged ventricles – a well-established endophenotype of schizophrenia (Hikida et 
al., 2007; Johnstone et al., 1976). Taken together, the findings from current Disc1 
mouse models provide support for the gene’s role in neurodevelopment and 
signalling. 
 
1.4.7  DISC1 and psychiatric illness 
Numerous functional and genetic studies provide support a role for DISC1 in 
psychiatric illness. As well as the t(1;11) family, a second family has been reported 
with a mutation in DISC1 linked to psychiatric illness. Here, three siblings carrying 
a 4 bp deletion in DISC1 were reported as suffering from either schizophrenia or 
schizoaffective disorder, while their mutation-carrying father was reported as 
unaffected (Sachs et al., 2005). However, the same mutation was not detected in 655 
individuals, but was present in two non-psychiatrically screened controls out of 694 
(Green et al., 2006). 
 
To date, DISC1 has not been associated with any psychiatric disorders through 
GWAS. This has been a source of criticism by some, who have questioned its validity 
as a risk factor for major mental illness (Sullivan, 2013). Porteous et al. (2014) have 
argued that the lack of genome-wide significant association between DISC1 and its 
related disorders is in keeping with the ‘common disease; rare variant’ hypothesis, 
citing well-established Alzheimer’s disease risk factors amyloid precursor protein 
(APP), and presenelin-1 and -2 (PSEN1, PSEN2) as examples - all genes that have 
to date not been implicated in the disease by GWAS, despite the high penetrance of 
their mutated forms in the disorder (Van Cauwenberghe et al., 2015). An additional 
point of debate has been provided by Niculescu (2014), who suggested that the 
greater genetic diversity observed in biologically important genes (such as DISC1) 
calls for whole gene-based experimental approaches in order to produce replicable 
 




results, rather than SNP-level approaches as seen in GWAS. Furthermore, Thomson 
et al. (2014) have reported additional evidence for common and rare variants in 
DISC1 associated with recurrent MDD. Of the variants reported, R37W is of 
particular note as it was among five variants present only in affected individuals. The 
R37W mutation occurs within a PDE4B binding site (Murdoch et al., 2007) and has 
been reported to impair DISC1-mediated anterograde mitochondrial trafficking in 
neurons (Ogawa et al., 2014).  A summary of DI SC1 structure, variants and binding 
sites is presented in Figure 1.2. 
 
1.4.8 The t(1;11) translocation 
Due to its status as a protein coding gene with important roles in brain development 
and function, DISC1 has been an attractive candidate to explain the pathogenic 
properties of the t(1;11) translocation. However, it is important to note that DISC1 is 
not the only genetic element perturbed by the translocation. It is possible that the 
psychiatric phenotype in the t(1;11) family occurs not just through disruption of 
DISC1, but through DISC2, DISCFP1/Boymaw, generation of fusion transcripts, 
and/or the co-inheritance of functional or regulatory elements in linkage 
disequilibrium with the translocation.  
 
The translocation generates fusion transcripts consisting of the 5’ region of DISC1 
and the 3’ region of DISC1FP1. These transcripts encode fusion proteins which 
localise to mitochondria in t(1;11) family LCLs, with potentially deleterious effects 
(Eykelenboom et al., 2012). Zhou et al. (2010) had previously reported that such 
transcripts generated insoluble fusion proteins in HEK293 cells. Eykelenboom et al. 
(2012) observed similar insolubility of fusion proteins in COS7 cells. Insolubility of 
DISC1 may be a pathological mechanism for psychiatric disorders: others have 
reported DISC1 protein aggregates in post-mortem brains of bipolar disorder and 
schizophrenia patients (Leliveld et al., 2008). Expression of these fusion transcripts 
has been found to affect protein translation, with reduced levels of synaptic proteins 
 
 





Figure 1.2: DISC1 structure, mutations and binding sites  
Figure summarises the genetic and protein structure of DISC1, including known mutations 
and sequence conservation (a), along with binding sites for various DISC1 protein interactors 
(b; Soares et al., 2011) 
 
 




observed both in-vivo and in-vitro (Baohu et al., 2014). Taken together, these 
findings might indicate a pathogenic role for fusion proteins in t(1;11) carriers. 
 
1.4.9 Recent and ongoing work on the t(1;11) family 
Analysis of the t(1;11) family is ongoing. Additional family members have been 
recruited and have been the subject of linkage, imaging and methylation analyses. 
Imaging analyses have recently been performed identifying brain structural 
abnormalities in t(1;11) carriers. Doyle et al. (2015) reported reduced cortical 
thickness in t(1;11) carriers, resembling the phenotypes observed schizophrenia 
patients. The same study demonstrated a t(1;11) status classification accuracy of 
73%, using cortical thickness measures. Furthermore, Whalley et al. (2015) reported 
a reduction in white matter integrity in t(1;11) carriers compared to non-carriers: a 
phenotype also observed in a group of individuals with psychotic illness compared 
to healthy controls. In addition to the updated linkage analysis, Thomson et al. (2016) 
reported reduced cortical thickness and gyral folding in t(1;11) carriers. These 
findings suggest the translocation might impact upon neurodevelopment, conferring 
an increased risk of illness in t(1;11) carriers. Thomson et al. (2016) also reported a 
reduction in glutamate levels in the dorsolateral prefrontal cortex of t(1;11) carriers: 
a phenotype also seen in patients with mood disorders (Yüksel and Öngür, 2010). 
 
Study materials from the family include whole blood-derived DNA, LCL-derived 
RNA, and induced pluripotent stem cell (iPSC)-derived neurons. These have been 
subjected to expression, methylation and functional studies, some of which will be 
described further in this thesis. 
 
1.5 The Sortilin gene family 
The Sortilin gene family consists of five members: Sortilin-1, Sortilin-related 
receptor, LDLR class A repeats, and Sortilin related VPS10 domain containing 
receptor 1-3 (SORT1, SORL1, and SORCS1-3, respectively). These genes are 
 




expressed in the developing and mature central nervous system where they play a 
regulatory role in neuronal viability and function (Nykjaer and Willnow, 2012).  
 
1.5.1 Sortilin genes and psychiatric disorders 
Several lines of evidence exist linking Sortilin genes to psychiatric disorders 
including Alzheimer’s disease, schizophrenia, bipolar disorder and MDD. SORCS2 
is located within a region of chromosome 4p, which has been implicated in bipolar 
disorder through linkage studies (Blackwood et al., 1996; Christoforou et al., 2007). 
Furthermore, in a GWAS of bipolar disorder, Baum et al. (2008a) reported significant 
association between SORCS2 and the disorder. In a meta-analysis of bipolar disorder 
GWAS by Baum et al., (2008a) and the WTCCC (2007), a trend towards significance 
was reported for SORCS2 (p = 0.054 Baum et al., 2008b) Ollila et al. (2009) 
attempted to replicate findings by the three GWASs of bipolar disorder performed to 
date (WTCCC, 2007; Baum et al., 2008a; Sklar et al., 2008), reporting significant 
association between SORCS2 and bipolar disorder in a Finnish bipolar family cohort. 
Furthermore, an analysis by Christoforou et al., 2011 showed significant association 
between SORCS2 and bipolar disorder comparing 506 bipolar disorder patients to 
633 healthy controls in a Scottish population. SORCS3 has recently been implicated 
in MDD by GWAS (Hyde et al., 2016) in a European sample from the customer base 
of 23andMe, as well as in a combined 23andMe and PGC sample. 
 
SORL1 has been implicated in Alzheimer’s disease through GWAS at the genome-
wide significant level, as well as through candidate gene approaches (Lambert et al., 
2013; Rogaeva et al., 2007). A neuropathological feature of Alzheimer’s disease is 
the presence of β-amyloid plaques arising from the amyloidogenic processing of 
APP. SORL1 has been shown to regulate processing of APP, suggesting a potential 
mechanism for the gene in Alzheimer’s disease pathology (Gustafsen et al., 2013). 
SORL1 has also been implicated in schizophrenia through an analysis of DNA 
methylation by Montano et al. (2016). Here, hypomethylation was reported in SORL1 
in schizophrenia cases compared to healthy controls. Although Alzheimer’s disease 
and schizophrenia are pathologically distinct, there is a symptomatic overlap between 
 




the two disorders, such as psychosis and cognitive dysfunction. In addition to SORL1, 
a regulatory role for SORCS1 in APP processing and trafficking has been reported 
by Reitz et al. (2011). Based on these findings, Reitz et al. (2013) investigated 
epistatic interactions amongst Sortilin genes in Alzheimer’s disease. Here, they 
reported interactions between SORCS1 and SORCS3, SORCS2 and SORCS3, and 
SORCS1 and SORCS2 were associated with increased risk of Alzheimer’s disease (p 
≤ 0.0001).  
 
Gene expression differences have also been observed in Sortilin family members in 
psychiatric illness. Buttenschøn et al. (2015) reported increased SORT1 expression 
in depressed individuals when comparing 152 cases to 216 non-depressed controls. 
Stelzhammer et al. (2013) had previously reported downregulation of SORT1 in the 
serum of MDD patients following electroconvulsive therapy, along with BDNF. In 
mice, Sort1 has been linked to APP processing, with a positive correlation observed 
between Sort1 expression and non-amyloidogenic processing of APP (Gustafsen et 
al., 2013). In addition to the analysis of genetic interactions in Alzheimer’s disease, 
Reitz et al. (2011) examined expression of Sortilin genes in post-mortem brains of 
Alzheimer’s disease patients compared to healthy controls. Here, they observed 
reduced levels of SORCS3 in post-mortem brains of Alzheimer’s disease patients. 
Previously, Reitz et al. (2011) reported reduced levels of SORCS1 post-mortem 
brains of Alzheimer’s disease patients while reduced expression of SORL1 have also 
been observed in post-mortem brains of Alzheimer’s disease patients (Rogaeva et al., 
2007). 
 
Mouse models have been generated with knock-out mutations in Sort1, Sorl1, 
SorCS2 and SorCS3. Glerup et al. (2013) reported dysfunctional dopaminergic 
activity in Sorl1-deficient mice, along with reduced anxiety: a behavioural phenotype 
related to ADHD. In contrast, Sort1 knock-out mice have been shown to display 
anxiety-like behaviour (Ruan et al., 2016). Deficits in synaptic plasticity relating to 
long term depression have been reported in SorCS3 null mice, along with deficits in 
learning and fear memory modulation: features suggestive of anxiety-related brain 
 




activity (Breiderhoff et al., 2013). SorCS2 knock-out mice display similar deficits in 
learning and memory (Glerup et al., 2016). Furthermore, behavioural phenotypes 
reminscient of ADHD and bipolar disorder were observed in these mice, such as 
hyperactivity and increased risk taking, respectively (Glerup et al., 2014; Glerup et 
al., 2016).  
 
Suggestive evidence exists for a regulatory relationship between DISC1 and Sortilin 
genes. A study by Wen et al. (2014) profiled gene expression in stem cell-derived 
neurons from individuals with a 4bp DISC1 frameshift mutation and reported 
misexpression of SORCS1, SORCS2, and SORCS3 in mutant cells compared to wild-
type cells. Furthermore, a study of gene expression in the developing brains of 100P 
Disc1 mutant mice showed dysregulation of Sort1 and SorCS2 (Brown et al., 
unpublished data). A common function between DISC1 and a subset of Sortilin 
family members is APP processing: Shahani et al., (2015) reported a regulatory 
relationship between DISC1 and APP processing, as has previously been reported for 
SORCS1, SORT1 and SORL1 (Reitz et al., 2011; Gustafsen et al., 2012). 
 
Taken together, evidence from genetic studies of animal models suggest the Sortilin 
gene family have brain-related functions which, when disrupted, may result in a 
psychiatric phenotype. 
 
1.6 Environmental factors associated with psychiatric disorders 
As well as their use in demonstrating the heritability of psychiatric illness; twin and 
adoption studies have been useful tools for investigating the role of environmental 
contributors to these disorders. Evidence for an environmental component to 
psychiatric illness can perhaps best be seen in monozygotic twins discordant for 
schizophrenia. Despite being genetically identical, the risk of illness in the co-twin of 
an affected individual is approximately 50% (Gottesman, 1991; Figure 1.1). Further 
evidence for an environmental component for psychiatric disorders can be illustrated 
by the increased risk associated with factors such as stress, degree of urbanisation of 
 




birth, and season of birth (Sullivan, 2005). A commonly-studied mechanism of how 
the environment may interact with a biological system is DNA methylation: a 
fundamental epigenetic mark. 
 
DNA methylation typically occurs at the 5-position of a cytosine (C) base when 
present in the context of a cytosine-guanine dinucleotide (CpG), by action of DNA 
methyltransferase (DNMT) enzymes (Klose and Bird, 2006). DNA methylation is 
essential for normal developmental processes such as cell fate specification, X-
chromosome inactivation and genomic imprinting, and is also observed in disease 
(Gopalakrishnan et al., 2008). Disorders such as Russel-Silver syndrome, Prader-Willi 
syndrome, and Angelman syndrome occur as a result of defective genomic imprinting 
(Lim and Maher, 2009), whilst Rett syndrome is associated with dysfunction of Methyl 
CpG-binding protein 2 (MECP2) – a gene whose protein product regulates 
transcription through binding to methylated DNA (Amir et al., 1999). DNA 
methylation can be influenced by external factors such as diet, smoking, medication 
and stress (Lim and Song, 2012; Meaney et al., 2005; Klengel et al., 2014), as well as 
genetic factors such as sequence variation. Such genetic variants are termed 
methylation quantitative trait loci (meQTLs) and are associated with both cis- and 
trans-effects on methylation at local and independent loci, respectively, acting both in 
tissue-dependent, and tissue-independent manners (Lemire et al., 2015; Smith et al, 
2014; Hannon et al., 2015). 
 
A widely-used method in the detection of DNA methylation is bisulphite sequencing. 
This process involves treatment of DNA with sodium bisulphite, whereby all 
unmethylated C bases are deaminated to uracil (U), while all methylated C bases 
remain unchanged. This is followed by amplification by polymerase chain reaction 
(PCR), resulting in conversion of U bases to thymine (T). Analysis of the DNA 
sequence is then performed to identify the extent of methylated loci based on the 
resulting CpG (methylated) and TpG (unmethylated) dinucleotides. In recent years, 
the development of next-generation sequencing and array-based technologies have 
allowed researchers to quantify DNA methylation at the genome-wide level. This has 
 




permitted the assessment of the relationship between DNA methylation and various 
traits and conditions, through epigenome-wide association studies (EWAS).  
 
The greatest advantage of whole-genome bisulphite sequencing (WGBS) is its 
coverage of all CpG loci. However, the costs associated with this technology have 
posed a limitation to widespread application of the method (Ziller et al., 2015). A more 
affordable alternative to WGBS has been array-based technology, whereby 
methylation levels are assessed by probes targeting bisulphite-converted DNA at loci 
throughout the genome. The development of array-based options has provided 
progressively greater coverage of the genome, allowing for an economical alternative 
to next-generation sequencing methods.  
 
1.6.1 DNA methylation in psychiatric disorders 
Several lines of evidence link differential DNA methylation to psychotic illness, 
mood disorders and stress-related disorders. Monozygotic twin studies have been 
particularly illustrative of environmental effects as genotype, sex, age and maternal 
environment are matched between samples (Bell and Spector, 2011).  A twin-based 
EWAS by Dempster et al. (2014) examined methylation in buccal cell-derived DNA 
from individuals with adolescent depression. Although no single site showed 
differential methylation at the genome-wide significant level, the authors presented 
a ranked list based on p–values and methylation differences between groups. Their 
top-ranking site mapped to serine/threonine kinase 32C (STK32C) on chromosome 
10, a brain-expressed kinase. Methylation differences at this site were validated by 
targeted pyrosequencing in DNA derived from buccal cells, and by microarray 
analysis of post-mortem cerebellum DNA from MDD patients. A study by Numata 
et al. (2015) compared methylation in blood-derived DNA between MDD patients 
and healthy controls, identifying 363 genome-wide significant loci (false discovery 
rate q ≤ 0.05). Of the top 100 loci, 84 were nominally significant for differential 
methylation in an independent sample. Among these sites was GSK3β, whose 
expression was also found to be inversely correlated with methylation in these 
individuals.   
 





Using blood-derived DNA, Dempster et al. (2011) interrogated genome-wide 
methylation in monozygotic twin pairs that were discordant for either schizophrenia 
or bipolar disorder. Here, they identified DNA methylation differences associated 
with both disorders separately and combined, using a weighted t-test approach. Of 
their top 100 ranked loci for differential methylation in psychosis, five genes 
overlapped with those identified in a study by Mill et al. (2008) in which post-mortem 
brain was used as a study tissue. Kinoshita et al. (2013) reported 10,747 differentially 
methylated loci comparing blood-derived DNA from schizophrenia patients to 
healthy controls (q ≤ 0.05). A replication sample consisting of three schizophrenia-
discordant twin pairs yielded 234 differentially methylated loci in common with the 
discovery sample, based on unadjusted paired t-test p-values. Nishioka et al. (2013) 
examined methylation differences in blood between patients with first-episode 
schizophrenia and age-matched healthy controls identifying 603 sites with significant 
differential methylation in 589 genes. Ontology analysis showed nucleotide binding 
and transcription factor binding genes were significantly enriched amongst these 
results. When comparing their findings with those of Kinoshita et al. (2013) and 
Dempster et al. (2011), little overlap was observed. The authors suggested sample 
size and disease heterogeneity may have contributed to this lack of overlap. A recent 
large-scale EWAS of schizophrenia by Montano et al. (2016) identified 172 sites 
with differential methylation in both discovery and replication cohorts, including loci 
within genes previously implicated in schizophrenia through GWAS (Ripke et al., 
2014). However, the authors imposed a comparatively liberal q-value cut-off of 0.2, 
increasing the probability of the incidence of type-I errors among these findings, 
compared to other studies. 
 
The lack of agreement between the studies described here may be attributed to several 
factors including disease heterogeneity and methodological approaches (Teroganova 
et al., 2016). Moreover, the use of blood in these studies may also be linked to mixed 
results. Due to its accessibility, whole blood-derived DNA has been widely-used in 
EWAS. However, a limitation with the use these samples is their associated cellular 
 




heterogeneity. However, cell compositions can be estimated based on known 
methylation profiles of cell subtypes from flow-sorted blood (Houseman et al., 2012; 
Jaffe and Irizarry, 2014). Such estimates can be considered in downstream analyses 
of differential methylation to reduce or eliminate the confounding effects of tissue 
heterogeneity.  
 
A major shortcoming in the majority of psychiatry-based EWAS has been the limited 
access to the primary tissue of interest (i.e. brain tissue). Varying degrees of 
correlation have been reported between methylation in whole blood and methylation 
in various brain regions. Hannon et al. (2015) reported distinct methylation profiles 
between blood, cortex and cerebellum, suggesting the use of whole blood-derived 
DNA in psychiatry-related EWAS may not be a suitable proxy tissue for the brain. 
A study by Walton et al. (2015) reported significant correlation between blood and 
brain among 4.1% of CpG sites assayed by the Illumina Infinium 
HumanMethylation450 array - a widely-used platform for EWAS in recent years 
(Bibikova et al., 2011). However, the authors noted the following limitations to their 
study: the comparison was made between whole blood and temporal lobe samples 
biopsied from epilepsy patients, which may not be representative of the healthy brain, 
or of alternative brain regions. In contrast, others have reported that meQTLs are 
consistently detected across blood and brain (Smith et al., 2014). Here, they reported 
overlap of 254/724 SNP-CpG associations in both blood and frontal cortex. Analysis 
of such meQTL-associated sites in blood may therefore be useful in identifying 
biologically meaningful results when brain tissue is unavailable for psychiatry-
related DNA methylation studies.  
 
Although studies of DNA methylation in psychiatry have generally been performed 
on blood-derived DNA, there have been a number of reports using brain-derived 
material (Pidsley and Mill, 2011). A study of DNA methylation in post-mortem 
frontal cortex by Mill et al. (2008) reported psychosis-associated differences in DNA 
methylation among genes enriched in processes pertaining to brain development, 
stress response and mitochondrial function. Examination of candidate genes for 
 




psychosis showed the BDNF Val66Met polymorphism described in section 1.3.2.1 
was also associated with DNA methylation levels in these samples. Wockner et al. 
(2014) profiled genome-wide methylation in post-mortem prefrontal cortex of 
schizophrenic patients and healthy controls, identifying 4641 differentially 
methylated sites in 2929 genes after adjusting for age and post-mortem interval (q ≤ 
0.05). Of these genes, 99 were found to be common between this study and a blood-
based analysis of DNA methylation in schizophrenia by Nishioka et al. (2013). 
Rather than adjusting for gender in their study, Wockner et al. (2014) opted to 
exclude probes mapping to the sex chromosomes. As sex-specific differences in 
methylation have been reported at numerous autosomal sites (Hall et al., 2014), the 
probe-filtering strategy alone may not have eliminated the effects of gender on their 
results. A study by Numata et al. (2014) reported differential DNA methylation at 
107 sites in the dorsolateral prefrontal cortex of patients with schizophrenia. Upon 
analysis of meQTLs in these samples, they reported a number of significant meQTLs 
at SNPs previously implicated in schizophrenia by GWAS and candidate gene 
association studies. 
 
Other studies performed on brain tissue have made links between DNA methylation 
and the neurodevelopmental origin of schizophrenia. A study by Pidsley et al. (2014) 
examined methylation differences in prefrontal cortex and cerebellum samples 
between schizophrenia patients and healthy controls. Network analysis showed 
enrichment for neurodevelopmental pathways amongst the genes that were 
differentially methylated in schizophrenia. Furthermore, the schizophrenia-
associated sites in the prefrontal cortex were found to be significantly associated with 
age in the developing foetal brain. Hannon et al. (2015) reported that mQTLs in foetal 
brain tissue were enriched among loci implicated in schizophrenia by Ripke et al. 
(2014), proposing a potential mechanism relating DNA methylation to the 
neurodevelopmental hypothesis of schizophrenia. 
 
Disruption of DNA methylation is an attractive hypothesis to explain the 
environmental component of complex disorders such as psychiatric illness. Although 
 




technologies are ever-improving to detect DNA methylation differences, access to 
relevant tissue remains a challenge. To this end, animal and cellular models may 
prove useful in compensating for this shortcoming. 
 
1.7 Cellular models of major mental illness 
Although there are well-established protocols for assessing behavioural and 
physiological characteristics in animal models of psychiatric illness, a limitation is 
their inability to recapitulate the genetic complexity of these disorders in humans. An 
alternative approach has been the use of patient-derived cellular models. Due to the 
scarcity of high quality patient-derived post-mortem brain tissue, human-derived in-
vitro models of major mental illness have been valuable resources for psychiatric 
researchers. The development of iPSC technology (Takahashi et al., 2007) has been a 
significant step in modelling neuropsychiatric disorders, among several others 
(Sterneckert et al., 2014). Psychiatric disorders are generally characterised by 
symptoms presented by the patient, as there are no established biomarkers that can be 
used in their diagnosis. Generation of neuronal material derived from patient iPSCs 
have permitted greater insights into deficits in human neurodevelopment and neuronal 
function that may be contributing factors in psychiatric disorders.  
 
1.7.1 iPSC models of schizophrenia 
Brennand et al. (2011) presented one of the earliest iPSC models of schizophrenia. 
Here, they compared iPSC-derived neurons from four schizophrenia patients to those 
derived from five healthy controls. They reported decreased connectivity and neurite 
counts, as well as misexpression of schizophrenia-associated genes in patient 
samples compared to controls (e.g. ANK1). Furthermore, subsets of patient samples 
of showed dysregulation of schizophrenia candidate genes including DISC1 and 
ZNF804A when compared to controls. Lack of consistency across schizophrenia-
derived samples may be attributed to the small, heterogeneous sample and small 
number of individuals in this study. Developmental differences have also been 
observed in neuronal precursor cells (NPCs) derived from patient iPSCs, in support 
of a neurodevelopmental origin for schizophrenia. A study by Brennand et al. (2015) 
 




examined gene and protein expression in NPCs from four schizophrenia patients. 
Here, network analysis revealed disruption of cell adhesion pathways at the levels of 
both gene and protein expression while neuronal maturation pathway disruptions 
were reported at the gene expression level. These findings may indicate that both of 
these pathways are perturbed during neurodevelopment in patients with 
schizophrenia.  
 
Others have developed DISC1-based models of iPSC-derived neurons. Wen et al. 
(2014) reported synaptic deficits, reduced DISC1 expression and morphological 
differences in iPSC-derived neurons from an American family with a 4 bp frameshift 
mutation in DISC1, described in section 1.4.7 (Sachs et al., 2005). Genome editing-
mediated repair of the DISC1 mutation rescued these expression and synaptic 
deficits. Expression analysis by RNA-seq showed genome-wide transcriptional 
dysregulation in these neurons. However, an important limitation of this study was 
the small sample size, which consisted of just one control and two mutant lines. 
Srikanth et al. (2015) also used a gene-editing approach, this time to induce DISC1 
mutations in iPSC-derived neurons. They introduced frameshift mutations in either 
exon 2 of DISC1 (an exon common to all DISC1 isoforms), or in exon 8, within 10 
codons of the intron containing the chromosome 1 translocation breakpoint. In the 
exon 8 mutants, they observed decreased DISC1 expression, due to nonsense 
mediated decay of the mutant transcripts. Both mutant forms of DISC1 displayed 
defects in Wnt-signalling in NPCs, but not iPSCs. The Wnt pathway has previously 
been implicated in the pathology of psychiatric disorders (Freyberg et al., 2010). 
Furthermore, Singh et al. (2011) have reported defective Wnt signalling and 
disrupted neurodevelopment in mice and zebrafish expressing mutant forms of 
DISC1. 
 
1.7.2 iPSC models of bipolar disorder 
More recently, iPSC-based studies of bipolar studies have emerged. Chen et al. 
(2014) compared iPSC-derived neurons from three bipolar disorder patients to three 
controls. They reported significant transcriptional differences between groups at the 
 




neuronal level, but not at the iPSC stage. In addition, positional identity differences 
were observed between groups: while control neurons expressed transcription factors 
involved in the regulation of dorsal telencephalic fate, patient cells expressed ventral-
associated genes, suggesting illness may relate to disrupted neuronal differentiation 
during development. Pathway analysis of differentially expressed transcripts in 
iPSCs revealed an enrichment of genes involved in calcium signalling, in keeping 
with GWAS findings in bipolar disorder. Moreover, comparison of gene expression 
data between iPSC-derived neurons from bipolar disorder patients and bipolar 
disorder patients’ post-mortem brain samples revealed common dysregulation of 
transcripts involved in calcium signalling, neurotransmission and cell migration.  
 
A study by Madison et al. (2015) compared iPSC-derived neurons from related 
individuals: two brothers with bipolar disorder and their unaffected parents. Here, 
proliferation deficits and transcriptional dysregulation were observed in bipolar 
disorder NPCs. Network analysis of the dysregulated genes suggested disrupted Wnt 
signalling in the NPCs: a regulatory pathway during NPC proliferation (Valvezan 
and Klein, 2012). Upon treatment of the bipolar disorder NPCs with a GSK3 
inhibitor, the proliferation deficits were rescued. Bavamian et al. (2015) assessed the 
link between bipolar disorder and miR-34a using iPSC-derived neurons. This 
microRNA is predicted to target genes related to bipolar disorder and its expression 
has been shown to be modulated by mood stabilising drugs (Hunsberger et al., 2013). 
Dysregulated microRNA expression has been reported in both schizophrenia and 
bipolar disorder as well as among individuals at high risk of developing bipolar 
disorder (Moreau et al., 2011; Walker et al., 2015), while miR-137 has been 
associated with schizophrenia through GWAS (Ripke et al., 2011). Using a case and 
control from the study by Madison et al. (2015), Bavamian et al. (2015) examined 
miR-34a expression during neuronal differentiation finding significant 
overexpression in the bipolar case, compared to the unaffected control sample. 
Overexpression of miR-34a was shown to downregulate two of its predicted bipolar 
disorder-associated targets, ANK3 and CACNB3. Furthermore, overexpression of 
miR-34a in developing neurons also resulted in downregulation of pre- and 
postsynaptic proteins SYP, SYN1 and PSD95. Expression levels of miR-34a were 
 




found to be linked to dendritic morphology, with overexpression resulting in 
increased dendritic length, and inhibition resulting in increased branch numbers. 
Agostini et al. (2011) previously reported a similar phenotype in mice in response to 
miR-34a expression levels.  
 
Cellular models such as those described in this section have provided valuable 
insights into human neurodevelopment and brain function in the context of major 
mental illness. However, current limitations posed by iPSC-derived models of 
neuropsychiatric disorders include small sample sizes, variable culturing conditions 
and genetic heterogeneity, rendering useful comparisons between studies difficult. 
Through addressing these issues it is likely that iPSC-derived models will be an 

















Schizophrenia and affective disorders are devastating illnesses that contribute to a 
significant social and economic burden, with limited efficient treatment options 
available. It is evident that these are complex, heterogeneous disorders associated with 
genetic factors and environmental factors, as well as their interactions. Although it is 
unlikely that a single causal gene is responsible for these disorders, risk factors are 
being identified at a growing rate thanks to ever-increasing sample sizes and the 
development of high-throughput technologies, as well as identification of rare 
instances of genomic disruption. Moreover, the development of animal and cellular 
models for these illnesses are likely to be fruitful in identifying disrupted processes, 
genes and pathways related to these disorders. The work described in this chapter 
should form the basis of future studies into the biological mechanisms of these 
disorders in order to understand their associated cellular and molecular dysfunctions, 
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2 Materials and methods 
The experiments detailed in this thesis availed of three tissue types obtained from the 
t(1;11) family: lymphoblastoid cell lines (LCLs), whole blood, and induced pluripotent 
stem cell (iPSC)-derived neurons. A summary of sample demographics, including tissue 
type, gender, and translocation carrier status is detailed in Table 2.1. A detailed 
description of the study was given to all individuals and all participants gave written 
informed consent. Ethical approval was obtained from the Scotland A Research Ethics 
committee. 
 
2.1 Polymerase chain reaction (PCR) 
A master mix was prepared containing 1X PCR buffer containing 15 mM MgCl2 (Sigma-
Aldrich), 0.6 μM dNTPs, 20 μM forward and reverse primer mix, Taq DNA polymerase 
(Sigma-Aldrich), 1 μl DNA sample, and dH2O to make a total reaction volume of 20 μl. 
Reactions were placed on a thermocycler and run on the “TD55” program: 
   
TD55 PCR program:  
93°C for 1 minute  
93°C for 20 seconds  
    10 cycles 65°C for 30 seconds (-1°C per cycle)  
72°C for 1 minute 
93°C for 20 seconds  
    30 cycles 55°C for 30 seconds 
72°C for 1 minute 
72°C for 10 minutes  
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Samples were run on a 1-2% (w/v) Agarose/TBE gel and imaged on an ultraviolet 






Gender LCL Blood Neuron ID 
t(1;11) 
Status 
Gender LCL Blood Neuron 
18 T M  ● ● 80 N F  ●  
19 T M  ● ● 82 N F  ●  
24 T F  ● ● 85 N M  ●  
28 N F  ● ● 87 N M  ●  
29 N F  ● ● 88 N M  ●  
30 N F  ● ● 89 N M  ●  
40 N M ● ●  91 N F  ●  
50 T F ● ●  92 N M  ●  
52 N F ● ●  94 N M  ●  
61 T F ● ●  96 N F  ●  
72 T M ● ●  97 N M  ●  
9 T M  ●  99 N M  ●  
15 T F  ●  100 N F  ●  
26 T F  ●  104 T M  ●  
27 T F  ●  106 N F  ●  
32 T M  ●  107 N M  ●  
41 T F  ●  11 T M ●   
44 N F  ●  13 T F ●   
47 N M  ●  16 N M ●   
49 T F  ●  78 N M ●   
53 T M  ●  35 T M ●   
54 N M  ●  39 T F ●   
55 T M  ●  70 T F ●   
62 N F  ●  34 N F ●   
 





Gender LCL Blood Neuron       
67 T F  ●        
49 T F  ●        
53 T M  ●        
Table 2.1: Summary of t(1;11) family samples 
Shown is the linkage ID for each individual, t(1;11) status, where T = translocation carrier and 
N = non-carrier, sample gender and bullet points summarising whether or not a given 
individual is present in the lymphoblastoid, blood or iPSC-derived neuronal samples.. 
 
2.2 DNA sequencing 
2.2.1 Clean-up of PCR products 
In order to remove dNTPs and primers, 1 μl of each PCR product with were treated with 
3 μl ExoSAP-IT (Affymetrix), adding 1 μl dH2O for a total reaction volume of 5 μl. 
Reactions were set up in a 96 well plate and placed on a thermocycler and run under the 
following conditions: 
 
ExoSAP-IT PCR program: 
37°C for 60 minutes 
80°C for 20 minutes 
 
2.2.2 Sequencing reaction 
To each cleaned PCR product, 1 μl 5X BigDye® sequencing buffer (Applied 
Biosystems) was added, along with 1 μl BigDye® v3.1 and 1 μl forward primer at a 
concentration of 3.2 μM. Sequencing reactions were made up to 10 μl by adding 2 μl 
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Seq3-1 PCR Program:  
96°C for 1 minute  
96°C for 10 seconds  
    30 cycles 50°C  for 5 seconds 
60°C for 4 minutes 
 
2.2.3 EDTA/ethanol precipitation 
Following the reaction, DNA was precipitated by adding 2.5 μl 125 mM EDTA 
followed by 30 μl 95 % ethanol. The plate was inverted four times and left on the bench 
at room temperature for 15 minutes. Samples were centrifuged at 3000 RPM for 30 
minutes at 8°C. The supernatant was removed by inverting the plate and tapping it on a 
paper towel. The plate was then briefly centrifuged at 1000 RPM while inverted on a 
paper towel to remove any remaining liquid. 30 μl 70 % ethanol was added to each well 
and samples were centrifuged at 3000 RPM for 15 minutes at 8°C. The supernatant was 
removed as above and DNA pellets were left to dry at room temperature, loosely 
covering the plate with a paper towel. Samples were sent to Agnes Gallagher at the 
MRC Human Genetics Unit for sequencing. 
 
2.3 Lymphoblastoid cell culture 
EBV-transformed LCLs derived from t(1;11) family members were cultured in RPMI 
1640 media (Invitrogen) supplemented with 10 % foetal bovine serum (Invitrogen). Cells 
were fed by replacing the media on Mondays, Wednesdays and Fridays. Cells were grown 
in 75 cm3 flasks for RNA preparation. 
 
2.4 Harvesting of LCLs for RNA extraction 
After reaching sufficient confluency in a 75 cm3 flask, cells were fed for three consecutive 
days before harvesting. Prior to harvesting, cell counts were obtained by diluting a sample 
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taken directly from a flask by a factor of 10. Diluted samples were counted on a 
haemocytometer and, using this count, 107 cells were removed from the flask and 
transferred to a 15 ml tube. Cells were centrifuged at 1200 rpm for 5 minutes and the 
supernatant was removed using an aspirator vacuum pump. The cell pellet was 
resuspended in 4 ml PBS (Invitrogen) and spun again at 1200 rpm for 5 minutes and the 
supernatant was removed as above. The cell pellet was resuspended in 600 μl RLT lysis 
buffer containing β-mercaptoethanol (Qiagen) and transferred to a 1.5 ml RNase-free 
tube. Harvested cells were stored at -80°C for RNA extraction at a later date. 
 
2.5 RNA extraction from cultured cells 
An equal volume of 70 % ethanol (600 μl) was added to each sample and mixed by 
pipetting. The sample mixture was transferred to an RNeasy spin column (Qiagen) placed 
in a 2 ml collection tube. Samples were centrifuged at full speed for 15 seconds to bind 
the RNA to the spin column. The flow through was discarded and 350 μl buffer RW1 
wash buffer was added to each spin column. DNase I incubation mix was prepared by 
adding 10 μl DNase I to 70 μl Buffer RDD (Qiagen). The mix was added directly onto 
the membrane of each tube and left at room temperature for 15 minutes. Again, 350 μl 
buffer RW1 was added to the column and samples were centrifuged at full speed for 15 
seconds to wash the spin column membrane-bound RNA, discarding the flow-through. 
500 μl buffer RPE was added to each spin column and centrifuged for 15 seconds at full 
speed to wash the RNA. The flow-through was discarded and this wash step was repeated 
a final time, centrifuging for 2 minutes to dry the spin column. The spin column was 
placed in an RNase-free collection tube and 50 μl RNase free water was added to the 
membrane to elute the RNA. Samples were centrifuged at full speed for 1 minute. This 
step was repeated adding 30 μl RNase free water for a total eluate of 80 μl. RNA samples 
were stored at -80°C to await downstream sample preparation procedures. To minimise 
DNA contamination, the eluate underwent a second DNase treatment using the Ambion® 
DNA-freeTM kit (Applied Biosystems). To each sample, 8 μl 10X DNase I buffer was 
added along with 1 μl rDNase I. Samples were incubated at 37°C for 30 minutes. DNase 
inactivation reagent was resuspended by gently flicking the tube and 9 μl was added to 
each reaction. Samples were incubated for 2 minutes at room temperature followed by 
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centrifugation at full speed for 90 seconds. The RNA-containing supernatant was 
transferred to a fresh tube with care not to disturb the pelleted inactivation reagent. 
 
2.6 Quality control of RNA 
To assess the concentration and quality of extracted RNA, 5 μl of RNA eluate was set 
aside to be measured on an Agilent 2100 Bioanalyzer (Agilent) at the Wellcome Trust 
Clinical Research Facility (WTCRF), Western General Hospital, Edinburgh. 
Measurements of RNA integrity numbers (RIN scores) and concentration in ng/μl were 
obtained. A RIN threshold of 7.0 was set as the minimum acceptable quality to continue 
with downstream procedures (Thompson et al., 2007).  
 
2.7 Synthesis of cDNA 
Reverse transcription of RNA samples was performed to synthesis cDNA using the 
Applied Biosystems cDNA synthesis kit (Applied Biosystems). For each sample a 
reaction was set up containing 4.4 μl MgCl2, 2 μl PCR buffer, 1 μl dNTPs, 0.4 μl RNase 
inhibitors, 0.5 μl MultiScribeTM reverse transcriptase enzyme and 2 μl random hexamers. 
RNA was denatured by heating to 65°C for 10 minutes prior to addition to the reactions. 
The required volume for 500 ng RNA was determined using the concentrations obtained 
from the Agilent 2100 Bioanalyzer. 500 ng RNA was added to each reaction. RNase-free 
water was added to make a final reaction volume of 20 μl. Reverse transcriptase-free and 
sample-free negative control reactions were prepared as above, excluding MultiScribeTM 
reverse transcriptase and RNA respectively. Reactions were placed on a thermocycler and 
was incubated for 10 minutes at 25°C, followed by 30 minutes at 48°C, and 5 minutes at 
95°C. Samples were then stored at -20°C. To determine whether genomic DNA 
contamination was present in human samples, 1 μl  cDNA samples and the negative 
controls from the cDNA synthesis reaction underwent PCR using primers spanning exons 
7-8 of WDR1, alongside a genomic DNA positive control sample. This amplifies a 590 
bp region in genomic DNA and a 238 bp region in cDNA. For mouse samples, a primer 
pair amplifying exons 24 to 25 of SorCS2 was used, alongside a genomic DNA positive 
control. This amplifies a 628 bp region in genomic DNA, and a 156 bp region in cDNA. 
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2.8 Quantitative real-time PCR (qRT-PCR) 
qRT-PCR was performed on the ABI 7900-HT system (Applied Biosystems) at the 
Wellcome Trust Clinical Research Facility, and the Human Genetics Unit, MRC IGMM, 
Edinburgh.  
 
2.8.1 Reference gene selection: 
Reference genes were selected from a panel of ubiquitously-expressed housekeeping 
gene assays. From this panel, the most stably expressed genes across all samples were 
selected by GeNorm analysis using Biogazelle qBase+ software. Selections were made 
based on the GeNorm M- and GeNorm V- results. The GeNorm M result is a plot of the 
reference gene expression stability across all samples. The GeNorm M - value is derived 
by a stepwise process, determining the most stable reference genes to use based on the 
average pairwise variation between each individual gene and all other reference genes, 
eliminating the worst-performing gene at each step until just two remain. GeNorm-V 
determines the minimum optimal number of reference genes to use by comparing 
normalisation factors derived from n versus n+1 reference genes among samples 
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Table 2.2: Reference genes used in qRT-PCR experiments. 
Table summarises each reference gene, including gene name, catalogue number, species and 
manufacturer. 
 
2.8.2 Experimental setup: 
Each reaction consisted of 5 μl master mix (Applied Biosystems), 0.5 μl probe and 4.5 
μl cDNA. Samples were loaded in triplicate on a 384-well PCR plate which was sealed 
with an adhesive plastic sheet and run on the ABI 7900-HT. For each probe, a standard 






Catalogue no. Gene (Symbol) Species Manufacturer 
ge-DD-6 ATP Synthase, H
+
 Transporting, Mitochondrial 
F1 Complex (ATP5B) Human Primerdesign 
ge-DD-7 Ubiquitin C (UBC) Human Primerdesign 
ge-DD-8 TATA Box Binding Protein (TBP) Human Primerdesign 
ge-DD-9 
Nuclear Cap Binding Protein Subunit 2, 20kDa 
(NCBP2) Human Primerdesign 
ge-DD-10 
Glyceraldehyde-3-Phosphate Dehydrogenase 
(GAPDH) Human Primerdesign 
ge-DD-11 Cytochrome C-1 (CYC1) Human Primerdesign 
HK-DD-hu-300 Succinate Dehydrogenase Complex, Subunit A, 
Flavoprotein (SDHA) Human Primerdesign 
4333761T Ribosomal Protein, Large, P0 (RPLP0) Human Applied Biosystems 
Mm00446968_m1 Hypoxanthine Phosphoribosyltransferase 1 
(Hprt) Mouse Applied Biosystems 
Mm01143545_m1 Hydroxymethylbilane Synthase (Hmbs) Mouse Applied Biosystems 
HK-DD-mo-600 Succinate Dehydrogenase Complex, Subunit A, 
Flavoprotein (Sdha) Mouse Primerdesign 
HK-DD-mo-600 Ribosomal Protein, Large, P0 (Rplp0) Mouse Primerdesign 
DD-mo-600 Peptidylprolyl Isomerase D (Ppid) Mouse Primerdesign 
HK-DD-mo-600 Ubiquitin C (Ubc) Mouse Primerdesign 
qRT-PCR Program:  
96°C for 10 seconds 
    40 cycles 
60°C for 4 minutes 
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2.8.3 Data analysis: 
Raw data were exported from SDS v2.3 software (Applied Biosystems) to Microsoft 
Office® Excel for downstream analysis. Outlying triplicates were defined as those 
outwith 1 cycle threshold (Ct) value of the remaining two triplicates. Outliers were 
removed and log quantity means were calculated from raw Ct values based on the 
standard curve for the probe being analysed.  
 
Log quantities were obtained by subtracting the y-axis intercept from each Ct value and 
dividing the result from the slope of the standard curve (x coefficient). The antilog of 
the resulting log quantity was calculated by raising 10 to the power of the log quantity 
for each cell. Sample quantity means and standard deviations were calculated for each 
triplicate to compare gene expression between groups.  
 
For each sample, a normalisation factor was obtained by calculating the geometric mean 
of the reference genes tested for each sample. Aw data for the genes of interest were 
normalised by dividing the quantity mean of each sample by its corresponding 
normalisation factor. Means and standard errors were calculated for each group for 
comparison.  
 
2.8.4 Statistical analysis 
Normality was assessed using a Shapiro-Wilk test. Normally distributed data were 
compared using an unpaired student’s t-test. In cases where data were non-normal but 
showed homogenous variance as determined by a Levene’s test, a Mann-Whitney U 
test was performed on rank-transformed data. 
 
2.9 Microarray-based gene expression analysis of LCL RNA 
RNA samples prepared from t(1;11) family LCLs were hybridised to the Human HT-12 
v4 Expression BeadChip (Illumina, San Diego, CA) at the Wellcome Trust Clinical 
Research Facility, Edinburgh. Samples from 13 individuals were included on the 
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microarrays: eight t(1;11) carriers and five non-carrying controls. Samples were labelled 
and amplified by Helen Torrance. Microarray expression data were preprocessed and 
analysed in R (R Core Team ,2012). 
 
2.9.1 Raw data input and quality control 
Raw microarray data were loaded into an R environment using the lumiR() function 
available in the package lumi. Samples were spread across two slides. To control for 
technical variation, a within-slide technical replicate was present along with a between-
slide replicate (KK108). Reproducibility of data from these replicates was determined 
using the Pearson’s correlation coefficient by means of the cor.test() function, within 
the pre-loaded stats package in R.  
 
2.9.2 Data transformation, normalisation and filtering 
As one of the prerequisites for data undergoing linear regression is homoscedasticity, or 
equal variance across samples, raw data were transformed by variance stabilizing 
transformation (VST) prior to normalisation. This was performed using the lumiT() 
function in limma. In order to minimize systematic variation which may affect measured 
expression levels, normalisation was carried out. Data were normalised by robust spline 
normalisation (RSN), using limma’s lumiN() function. Probes with a detection p-value 
of ≥ 0.05 were removed from the dataset. This ensured only probes with a high signal-
to-background ratio were used in the final analysis, with the additional aim to reduce 
the burden of multiple tests. 
 
Chapter 2  65 
 
2.9.3 Data analysis 
2.9.3.1  Identification of differentially expressed transcripts 
Differential gene expression between t(1;11) carriers and non-carriers was identified by 
linear regression of the normalised, filtered dataset. Surrogate variables were identified 
in using the sva package in R, which were used alongside sample gender as covariates. 
Linear regression was performed using the limma’s lmFit() function. The output of this 
function was used to calculate t-statistics, F-statistics and log of odds for each probe using 
the eBayes() function in limma. A transcript was defined as differentially expressed if it 
was associated with an unadjusted p-value of ≤ 0.05 combined with an absolute fold-
change (FC) of ≥ 1.2. 
 
2.9.3.2  Gene ontology analysis 
Gene ontology (GO) analysis was performed using GOrilla (Gene Ontology enRIchment 
anaLysis and visuaLisAtion tool; Eden et al., 2009). GOrilla identifies significant 
enrichment for GO terms using a minimal hypergeometric score (mHG), assigning 
significance to pathways enriched for genes present towards the top of a p-value ranked 
list (Eden et al., 2007). All transcripts tested for differential expression were ranked by 
p-value and submitted to GOrilla for analysis. In the case of multiple probes per gene, the 
lowest p-value associated with that gene was submitted. 
 
2.10 Methylation analysis in whole blood and iPSC-derived neuronal 
DNA 
500 ng genomic DNA was treated with sodium bisulphite using the EZ-96 DNA 
Methylation Kit (Zymo Research, Irvine, California), following the manufacturer’s 
instructions at the WTCRF, Western General Hospital, Edinburgh. Blood-derived 
samples were analysed using the Infinium HumanMethylation450 BeadChip and iPSC-
derived samples were analysed using the Infinium HumanMethylationEPIC BeadChip 
(Illumina Inc., San Diego, CA). Both chips were run at the WTCRF.  
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During preprocessing, data were analysed in the form of β-values (calculated by dividing 
the methylated signal by the sum of the methylated and unmethylated signal plus an offset 
of 100 for each probe), which occur as a value between 0-1, with 1 representing 100 % 
methylation at that site. β-values were Logit transformed to M-values for analysis of 
differential methylation as recommended by Du et al. (2010).  
 
2.10.1 Sample information 
The whole-blood-based study consisted of 41 individuals: 17 t(1;11) carriers and 24 
non-carrying relatives spread across six slides of the Infinium HumanMethylation450k 
platform. The iPS-derivative-based study consisted of three differentiations each from 
six individuals: three t(1;11) carriers and three non-carrying controls. Samples were 
spread across three slides. Samples were assigned to slides such that, as far as possible, 
group and gender were counter-balanced across slides.  
 
2.10.2 Identification of potentially cross-hybridising on the Illumina 
Infinium HumanMethylationEPIC BeadChip 
Using a protocol described by Chen et al. (2013), all possible probe sequences on the 
array were aligned to four bisulphite-converted reference genomes representing a 
forward methylated sequence, reverse methylated sequence, forward unmethylated 
sequence and reverse unmethylated sequence. These were obtained through modifying 
the hg19 human genome sequence downloaded on 11th January 2016. To generate the 
methylated genomes, all non-CpG cytosines were converted to thymines (T). To 
generate the unmethylated genomes, all C bases were converted to T bases. 
  
Several Infinium Type II assays contain “R” nucleotides, representing adenine or 
guanine depending on whether an underlying cytosine is methylated or unmethylated in 
bisulphite-converted DNA. All possible Type II probe sequences were generated and 
added to a list of Type I probe sequences. This list constituted the query sequences to 
undergo alignment to a four reference genomes using the BLAST-like alignment tool 
(BLAT; Kent, 2002). Probes with an off-target match of ≥ 47 bp, along with a match at 
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the signal-generating end base were deemed potentially cross-hybridising based on the 
criteria of Chen et al. (2013). 
 
2.10.3 Quality control assessments of methylation data 
Raw intensity (.idat) files were read into R using the minfi package (Aryee et al., 2014), 
which was used to perform initial quality control assessments. Filtering of poor-
performing samples and sites was performed. Samples were removed from the dataset 
if ≥ 1% sites had a detection p-value of  ≥ 0.05. Probes were removed from the dataset 
if: (i) the CpG site (and/or the site of single base extension, at the base before the 
cytosine, for Type I probes) overlapped a single nucleotide polymorphism (SNP) 
present in any individual based on whole-genome sequence data from the individuals 
tested; (ii) they were predicted to cross-hybridise (Chen et al., 2013; McCartney et al., 
2016); (iii) they had more than five samples with a beadcount of less than 3; or (iv) ≥ 1 
samples had a detection p-value of ≥ 0.05 (Schalkwyk et al., 2013; Pidsley et al., 2013).  
 
2.10.4 Normalisation of the methylation data 
Data normalised by 14 normalisation methods were compared with the raw data to 
assess each method’s performance at reducing technical variation between arrays. This 
technique was first described by Pidsley et al. (2013) and all required functions are 
available in the wateRmelon and minfi packages in R (Schalkwyk et al., 2013; Aryee et 
al., 2014; Table 2.3). Three performance metrics were used to assess each method’s 
ability to reduce technical variation: differentially methylated region standard error 
(DMRSE), genotype combined standard error (GCOSE), and Seabird.  
 
The DMRSE metric is obtained by calculating the standard deviation of methylation at 
known imprinting differentially methylated regions (iDMRs). The array contains 220 
probes which provide a measure for this metric where methylation levels are expected 
to be around 50% (β = 0.5). The dmrse_row function was used to call the between-
sample standard error of β - values for all 220 probes. Lower values for the DMRSE 
metric indicate better performance of a given normalisation strategy. 
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The GCOSE method takes advantage of 65 probes present on the array which detect 
highly polymorphic CpG target sites. At these positions, β-values are expected to follow 
a tri-modal distribution corresponding to allele A homozygotes (e.g. CG/CG), AB 
heterozygotes (e.g. CG/CX) and BB homozygotes (e.g. CX/CX) representing high, 
medium and low methylation levels corresponding to each genotype, respectively. Peak 
width at each genotype is positively correlated with technical variability. The GCOSE 
metric is calculated by k-means clustering to define each genotype, noting sum of 
squares and the number of samples per cluster for 65 probes. In the absence of technical 
variation, the sum of squares should be zero.  Sums of squares for each cluster were 
summed across 65 probes and divided by the sum of samples. To obtain a standard-error 
like metric, these three values were divided by the square root of the total number of 
samples and averaged to obtain a single metric. As with the DMRSE metric, lower 
values are indicative of better performance of a given normalisation method.  
 
The Seabird metric estimates X-chromosome probes based on the expected methylation 
levels observed in female individuals (approximately 50 %) by means of a receiver 
operator characteristic (ROC) analysis. Normalisation methods associated with an area 
under the curve (AUC) closer to 1 are deemed to perform better. The metric of 1-AUC 
was used to remain in keeping with the “lower is better” scoring system of the DMRSE 
and GCOSE metrics. 
 
To determine the best-performing normalisation method, each metric was ranked and 
the mean rank was obtained. The mean rank was then ranked to obtain a final score for 
each normalisation strategy (rank of ranks). The method with the lowest rank of ranks 
was selected to normalise the raw data for downstream analysis. 
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Table 2.3: Summary of normalisation strategies compared in the genome-wide DNA methylation analyses. 
Table summarises the normalisation methods tested, including the function for the normalisation method and its corresponding R package, a brief 




preprocessSWAN():minfi Subset within array normalisation Maksimovic et al., 2012 
preprocessNoob():minfI Background correction method with dye-bias normalisation Triche et al., 2013 
betaqn():wateRmelon Beta mixture quantile normalisation Teschendorff et al., 2013; 
dasen():wateRmelon Same as nasen but type I and type II backgrounds are equalised first 
Schalkwyk et al., 2013; Pidsley 
et al., 2013 
nasen():wateRmelon 
Quantile normalises methylated and unmethylated intensites separately each for type I and type II probes, 
then calculates betas 
nanet():wateRmelon Quantile normalises methylated and unmethylated intensities together, then calculates betas 
naten():wateRmelon Quantile normalises methylated and unmethylated intensities separately, then calculates betas 
nanes():wateRmelon 
quantile normalises methylated and unmethylated intensities separately for type I probes, and together for 
type II probes 
danes():wateRmelon 
Background equalisation of type I and type II probes, quantile normalisation of methylated and unmethylated 
intensities separately 
danet():wateRmelon 
Background equalisation of type I and type II probes, quantile normalisation of methylated and unmethylated 
intensities together, followed by calculation of betas 
danen():wateRmelon Background equalisation only, no normalisation 
daten1():wateRmelon 
Type I and type II background are 
equalised first (smoothed only for methylated), quantile normalises methylated and unmethylated intensities 
separately, then calculates betas. 
daten2():wateRmelon 
Type I and type II background are 
equalised first (smoothed for methylated and unmethylated), quantile normalises methylated and 
unmethylated intensities separately, then calculates betas. 
fuks():wateRmelon Peak-based correction Dedeurwaerder et al., 2011 
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2.10.5 Estimation of cell proportions in whole blood 
Estimated cell counts for B-lymphocytes, granulocytes, monocytes, natural killer 
cells, CD4+ T-lymphocytes and CD8+ T-lymphocytes were generated using the 
estimateCellCounts() function in minfi. This function implements Jaffe and Irizarry’s 
modified version of Houseman’s algorithm (Jaffe and Irizarry, 2014, Houseman et 
al., 2012). Between-group differences in cell composition were assessed using an 
unpaired Student’s t-test. A p-value of ≤ 0.05 was deemed to represent a significant 
between-group difference. 
 
2.10.6 Data Analysis 
Methylation data were analysed at both the probe level (differentially methylated 
positions) and the regional level, consisting of multiple probes with correlated 
methylation signal (differentially methylated regions). Gene ontology analysis was 
performed on the single probe data to identify ontological terms enriched for 
differentially methylated genes. 
 
2.10.6.1 Identification of differentially methylated positions 
Linear regression was performed on the data to identify differentially methylated 
positions (DMPs) between groups using limma’s lmFit() function. For each probe, a t-
statistic, F-statistic and log-odd of differential methylation was determined using 
limma’s eBayes() function. Multiple testing correction was implemented controlling 
for the false discovery rate (FDR; Benjamini and Hochberg, 1995). DMPs were 
deemed significant if they had an associated FDR q - value of ≤ 0.05. 
 
2.10.6.2 Identification of differentially methylated regions 
The probe lasso algorithm was used to determine differentially methylated regions 
(DMRs) in the DNA methylation data (Butcher and Beck, 2015). This function is 
available in the R package ChAMP (Morris et al., 2014). Probe lasso identifies a DMR 
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if it detects three probes with differential methylation within a maximum user-defined 
“lasso radius”, set by default at 2000 bp.  
 
2.10.6.3 Gene ontology analysis 
GOrilla was used to identify to identify functions and pathways enriched for 
differentially methylated genes in each study. As multiple probes on the array are 
annotated to a single gene ID, the lowest p-value observed for a probe in each gene 
associated with that gene for GO analysis. 
 
2.10.6.4 DNA Methylation age calculation 
Using the DNA methylation age calculator (http://dnamage.genetics.ucla.edu/; 
Horvath, 2013), β-values methylation data were uploaded for all individuals profiled. 
From these data, DNA methylation age was calculated based on levels at 353 probes. 
 
2.11 Culturing of iPS-derivatives 
Frozen lines of neuronal precursor cells (NPCs), previously generated by Dr. Ellen 
Grunewald from iPS cells derived from fibroblast biopsies from the t(1;11) family 
were used in this study. Reagents and recipes for cell culture media used at the various 
stages of growth and differentiation are detailed in Table 2.4. Cell culture was 
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 RosV2F10 Default 
Default + 
Forskolin 
Default + BDNF  + 
GDNF 
PSF 500 μl 500 μl 500 μl 500 μl 
Glutamax 500 μl 250 μl 250 μl 250 μl 
N2 500 μl 250 μl 250 μl 250 μl 
B27 50 μl 100 μl 100 μl 100 μl 
FGF 25 μl    
Heparin  50 μl 50 μl 50 μl 
Forskolin   50 μl  
BDNF    25 μl 
GDNF    25 μl 
Advanced DMEM F12 To 50 ml To 50 ml To 50 ml To 50 ml 
Table 2.4: Media recipes for NPC and neuronal culturing. 
Table summarises the relative volumes of reagents required to make media for use in NPC 
culture and subsequent neuronal differentiation. 
 
2.11.1 Maintenance of neuronal precursor cells 
NPCs were seeded in a single well of a 6-well plate containing 3 ml RosV2F10F10 
media. Prior to seeding, each well of a 6-well plate was pre-coated with 1 ml 
RosV2F10 containing 10 μl Matrigel and incubated at 4°C for a minimum of 12 hours 
and a maximum of 7 days. Cells were fed every Monday, Wednesday and Friday by 
removing 1.5 ml media and replacing with 1.5 ml fresh media. Cells were passaged 
at a 1:2 split ratio when 100 % confluency was reached. When passaging, media was 
removed and set aside (conditioned media). Cell dissociation was initiated by adding 
1ml Accutase dissociation reagent. After 30 seconds 1 ml conditioned media was 
reintroduced to the well to neutralise the dissociation reagent. Cells were dissociated 
by flushing the wells with the neutralised Accutase using a P1000 pipette. Cells were 
transferred to a falcon tube and centrifuged at 1200 rpm for 3 minutes. While 
spinning, media was removed from the Matrigel-coated plates using an aspirator 
vacuum pump and 1 ml fresh RosV2F10 was added to each well. Following 
centrifugation, the supernatant was removed and the cell pellet was suspended in 
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conditioned media at a volume of 1 ml per well. To each well, 1 ml of resuspended 
cells was added. 
 
2.11.2 Neuronal differentiation and maintenance 
When 100 % confluency was reached in at least 8 wells across two 6-well plates, 
neuronal differentiation was initiated in 12-well plates. Neurons underwent 
differentiation for five weeks prior to harvesting. 
 
2.11.2.1 Initiation of neuronal differentiation 
Two 12-well plates were coated with 500 μl Default media containing 5 μl Matrigel 
and incubated at 4°C for a minimum of 12 hours. At least 2 hours prior to seeding, the 
contents of the wells were removed and replaced with 500 μl Default media containing 
5 μl Laminin and incubated at 37°C (or 4°C for long-term storage up to 7 days). NPCs 
were dissociated and pelleted as above. The pellet was resuspended in 10 ml Default 
media and cells were counted. The appropriate volume containing 24 x 106 cells was 
taken from the cell suspension and transferred to a 50 ml falcon tube. Default media 
was added to make a total volume of 12 ml. Media was removed from the two pre-
coated 12-well plates with an aspirator vacuum pump and 500 μl fresh media was 
added to each well. To this, 500 μl cell suspension was added, seeding 1 x 106 cells per 
well. 
 
2.11.2.2 Maintenance of differentiating neurons 
During differentiation, cells were fed on Mondays, Wednesdays and Fridays. Extra 
feedings were performed on Tuesdays and Thursdays if deemed necessary based on 
the colour of the culture media. Neurons were differentiated over 5 weeks. Cells were 
fed with Default media in week 1, Default + Forskolin media in weeks 2-3, and Default 
+ BDNF + GDNF media in weeks 4-5. For the first feed, 500 μl was gently added to 
each well, tilting the plate to avoid disrupting the cells. Subsequent feedings involved 
removing 750 μl media and adding 750 μl fresh media. Following seeding, 
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differentiating neurons were fed with Default media until the following Monday. 
Neurons were harvested the Monday following the fifth week of differentiation. 
 
2.11.2.3 Harvesting neurons for downstream DNA extraction 
Cell culture media were removed from 4 wells of the 12-well plate and set aside. Cell 
dissociation was initiated by adding 500 μl Accutase dissociation reagent for 30 
seconds. The dissociation reaction was neutralised by adding 500 μl conditioned media 
and the neurons were dissociated by flushing the wells with a pipette, as with the 
NPCs. Neurons were transferred to a 15 ml falcon and centrifuged at 2500 rpm for 5 
minutes. The supernatant was removed using an aspirator vacuum pump and the pellet 
was washed with 7 ml PBS. The cells were centrifuged again at 2500 rpm for 5 minutes 
and the supernatant removed. The neurons were resuspended in 200 μl PBS and stored 
at -20°C for DNA extraction at a later date. 
 
2.11.3 DNA extraction from neurons 
DNA was extracted using a DNeasy kit (Qiagen). 180 μl Buffer ATL and 20 μl 
proteinase K were added to the to the 200 μl PBS containing cell pellets followed by 
incubation of samples at 56°C for 10 minutes to lyse cells. Following vortexing for 
15 seconds, 200 μl Buffer AL was added and mixed by vortexing. This was followed 
by 200 μl 100% ethanol. Following vortexing, mixtures were transferred to a spin 
column in a 2 ml collection tube and centrifuged at 6000 x g for 1 minute after which 
flow-through and collection tubes were discarded. Spin columns were transferred to 
new 2 ml collection tubes and 500 μl Buffer AW1 was added. Samples were 
centrifuged at 6000 x g for 1 minute. Spin columns were transferred to new 2 ml 
collection tubes and 500 μl Buffer AW2 was added. Samples were centrifuged for 3 
minutes at 20,000 x g. Spin columns were placed in a clean 1.5 ml microcentrifuge 
tube and 200 μl Buffer AE was placed directly on the column. Following a 1 minute 
incubation at room temperature, samples were eluted by centrifuging for 1 minute at 
6000 x g. DNA eluates were stored at -20°C for later use. 
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2.12 Collection of L100P and wild-type mouse samples 
2.12.1 Mouse strains 
L100P heterozygote mice were obtained from Malgorzata Borkowska (Centre for 
Integrative Physiology, University of Edinburgh). The mice were the products of 
crosses between L100P homozygote mice RIKEN BRC (Tsukuba, Japan) and 
C57BL/6J. 
 
2.12.2 Dissection of embryonic and postnatal brains. 
Whole embryonic brains were harvested at 13.5, 15.5 and 18.5 days post conception 
(DPC). These timings were calculated from the point a vaginal plug was observed in 
a female mouse, indicative of mating, beginning at 0.5 DPC. Pregnant dams were 
sacrificed by cervical dislocation for embryonic sample collection. Pups were 
extracted from the uterus using sterile scissors and placed in a petri dish containing 
cooled PBS.  Whole brains were removed and placed in a tube containing pre-chilled 
RNAlater (Thermo Fisher Scientific). Whole brains were also collected from mice at 
postnatal days 1, 7 and 20. Hippocampi were dissected from adult mice under a 
dissection microscope, following permeation of samples with RNAlater. 
 
2.12.3 RNA extraction from mouse brain tissue 
Samples were transferred from RNAlater to homogeniser tubes containing ceramic 
beads. 1 ml Trizol® reagent (Thermo Fisher Scientific) was added to the tubes and 
samples were homogenised on a precellys 24 homogeniser (Bertin Technologies). 
The homogenate was transferred to a microcentrifuge tube and incubated at room 
temperature for 5 minutes, followed by the addition of 200 μl chloroform. Tubes 
were shaken vigorously for 20 seconds and centrifuged at 10,000 x g for 18 minutes 
at 4°C. The aqueous phase then underwent RNA extraction following the procedure 
described in section 2.5. The remaining phases, containing protein and DNA, were 
stored at -80°C for future use. 
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2.12.4 Genomic DNA extraction from mouse tissue 
Ear notches from adult mice were used to extract DNA for genotyping. For 
embryonic and samples up to post-natal day 20, tail tips were used. 300μl 50mM 
NaOH was added to the ear notches and tail tips at room temperature followed by 
incubation at 95°C for 15 minutes to break down the tissues. Samples were mixed by 
vortex and pulse spun in a centrifuge to collect any condensation. 50μl 1M Tris-HCl 
was added and samples vortexed for 15 seconds. Samples centrifuged at 13,000rpm 
for 6 minutes and the supernatant as collected for genotyping. Samples were stored 
at -20°C until required. 
 
2.12.5 Sex determination 
Adult mice were sexed by visual inspection. Sex was determined in the remaining 
mice by PCR amplification of exons 9 and 10 of Jarid1c on the X-chromosome and 
Jarid1d on the Y-chromosome (Clapcote and Roder, 2005). This results in two 
products of 302 and 331 bp in male samples, and a single product of 331 bp in 
females. 
 
2.12.6 L100P genotyping 
Genomic DNA was amplified by PCR using the following primers: forward 5’-AGA 
CCA GGC TAC ATG AGA AGC-3’, and reverse 5’-AAG CTG GAA GTG AAG 
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2.13 Genetic association analysis 
2.13.1 Sample information 
The Generation Scotland cohort was used for the genetic association analysis (Smith et 
al., 2013). Genotype data were available from 19,994 individuals for 561,125 SNPs. 
 
2.13.2 Selection of markers 
2.13.2.1 Quality control 
For each gene, markers from subset of control individuals (N=100, 50% male) including 
markers within approximately 1 Mb of the gene’s flanking regions were uploaded to 
Haploview. Markers were filtered out of the analysis if they had (i) a Hardy-Weinberg p-
value of ≥ 0.001, (ii) a genotype % of ≤ 94 %, (iii) at least one Mendelian error, or (iv) a 
minor allele frequency of ≥ 0.05.  
 
2.13.2.2 Defining the gene region 
Linkage Disequilibrium (LD) blocks were drawn based on the solid spine method, 
whereby the first and last marker of a block are in tight LD with intermediate markers (D’ 
≥ 0.8), but intermediate markers may not necessarily be in LD with one another. LD 
blocks were manually combined if adjacent blocks had a multiallelic D’ of ≥ 0.8 to 
generate blocks up to a maximum length of 500 kb. Singleton markers were manually 
assigned to individual blocks and adjacent blocks were joined if they met the D’ 
requirements. The gene region was defined as the range between the 5’-most marker of 
the block containing the gene’s TSS, and the 3’-most marker of the block containing the 
end of the transcript, based on UCSC Genome Browser’s hg19 coordinates (GRCh37). 
 
2.13.2.3 Identification of tagging SNPs 
All markers within the LD-block defined gene region for 4700 non-depressed individuals 
were submitted to Haploview’s Tagger to identify tagging SNPs using an R2 cut-off of ≥ 
0.8. 
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2.13.2.4 Random forest implementation 
The Random Jungle program was used to perform random forest analysis on SNP lists 
(Schwarz et al., 2010). Files were prepared in .ped and .map formats containing tagging 
SNPs for the genes to be tested for association and phenotype in PLINK (Purcell et al., 
2007), using the following command in a Linux terminal window: 
 
plink --recode --bfile [binary pedfile name] --extract [tag SNP filename.txt] --out 
[output filename] 
 
The output file was converted to a .raw format displaying minor allele counts (0, 1 and 2) 
for each marker in each individual using the following command: 
 
plink --recodeA --file [filename] --out [output file] 
 
The .raw file was read into R for further analysis. As the random forest algorithm cannot 
handle missing data, “NA” values related to each marker were converted to the median 
minor allele count in the sample set for that marker using randomForest’s na.roughfix() 
function. A copy of this file was created and the phenotype was permuted using the base 
function sample(). Random forest analysis was performed on the original .raw file and 
the permuted .raw file 100 and 1000 times, respectively, using the following command: 
 
rjungle –f [file] –i 4 –ntree 1000 –z n –u –D PHENOTYPE –U 63 –o [Outputfile.$i]  
  
This command performs random forest on the .raw file using 1000 trees for each of 
iteration (-ntree argument). Bootstrap aggregating (bagging) was performed without 
replacement (-u argument) and the raw permutation importance measure was selected as 
the method for estimating variable importance (-i argument). If the outcome variable was 
continuous, an additional argument “–y 3” was added to select the appropriate base 
classifier. 
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Empirical p-values were calculated based from the real and permuted VIMs for each SNP 
using the following calculation: 
 
PSNPX =  (Permuted VIMSNPX > Median Real VIMSNPX) / 1000 
 
SNPs with an empirical p-value ≤ 0.05 were selected for analysis of epistatic interactions. 
 
2.13.3  Identification of gene-gene interactions 
Allele counts of genes selected for the epistasis study were read into R. For pairwise 
tests, a table of all possible two-way combinations from the gene set was generated using 
the combn() function available in the utils package. Combinations were considered if 
they involved SNPs within at least two genes. Logistic and linear regression was 
performed depending on whether the phenotype was categorical or quantititave, 
respectively. For each SNP combination, a full model was created containing the 
additive terms of each gene, along with the an interaction term using the glm() function 
available in the stats package. The top 20 principal components as estimated by GCTA 
(Yang et al., 2011) were fitted to account for population structure. 
 
 
Two-SNP interaction: Phenotype ~ β1SNP1 + β2SNP2 + β3(SNP1 * SNP2) + PC1-20 
Three-SNP interaction: Phenotype ~ β1SNP1 + β2SNP2 + β3SNP3 + β4(SNP1 * SNP2) 
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A reduced model was also created, omitting the interaction term: 
 
Two-SNP interaction: Phenotype ~ β1SNP1 + β2SNP2 + PC1-20 
Three-SNP interaction: Phenotype ~ β1SNP1 + β2SNP2 + β3SNP3 + β4(SNP1 * SNP2) 
+ β5(SNP1 * SNP3) + β6(SNP2 * SNP3) + PC1-20 
 
The full and reduced models were compared using a likelihood ratio test (LRT) to     
assess whether the interaction term significantly affects the goodness-of-fit of the full 
model. A chi–square p–value threshold of ≤ 0.05 was implemented to define a significant 
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3 Analysis of gene expression in t(1;11) family lymphoblastoid 
cell lines 
3.1 Introduction 
Several lines of evidence support a role for DISC1 in transcriptional dysregulation. 
Malavasi et al. (2012) reported that DISC1 had a dose-dependent inhibitory effect on 
ATF4-mediated gene expression. DISC1 has also been linked to cAMP-signalling 
through its interaction with PDE4B (Millar et al., 2005), which may result in 
dysregulation of cAMP-responsive genes in translocation carriers where DISC1 
expression is altered. Haploinsufficiency of DISC1 has been reported in t(1;11) LCL 
samples (Millar et al., 2005). Taken together, these findings suggest that t(1;11)-mediated 
reductions in DISC1 protein expression may result in altered expression of other genes. 
Another mechanism whereby the translocation might impact upon gene expression is 
through its impact on DISC2 - the non-coding RNA antisense to DISC1. Natural antisense 
transcripts (NATs), such as DISC2, have been implicated in multiple processes, including 
transcriptional regulation and disease (Faghihi and Wahlestedt, 2009). Furthermore, 
DISC2 has been proposed to play a regulatory role in DISC1 expression (Millar et al., 
2004; Chubb et al., 2008). In the context of the t(1;11) translocation, like DISC1, DISC2 
expression may also be disrupted. On chromosome 11, the translocation directly disrupts 
the non-coding transcript Boymaw, a brain-expressed NAT. Zhou et al. (2010) proposed 
that Boymaw has a regulatory effect on CHORDC1, a gene with which it partially overlaps 
on the antisense strand. In addition to the direct disruption of the genes on these 
chromosomes, fusion proteins generated by the t(1;11) translocation have been proposed 
to result in aberrant interactions with binding partners of DISC1, potentially affecting its 
downstream effects on gene expression (Eykelenboom  et al., 2012). A further 
mechanism through which the translocation might impact upon gene expression is 
through the passive transmission of regulatory variants, i.e. eQTLs, on the derived 
chromosomes. 
 
This chapter describes an analysis of differential gene expression in LCL-derived RNA 
from 13 individuals from the t(1;11) family. The underlying hypothesis of this work was 
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that the t(1;11) translocation might have far-reaching effects on gene expression, not only 
through the direct disruption of the breakpoint genes and their regulatory functions 
described above, but also through downstream effects due to the disruption of putative 
regulatory roles of these genes, and factors in linkage disequilibrium with the 
translocation. 
 
3.2 Sample quality control measures 
3.2.1 RNA integrity 
High quality, intact total RNA is a necessity for obtaining reliable information from 
gene expression experiments. The quality of LCL-derived RNA samples from thirteen 
t(1;11) family members was assessed on the Agilent 2100 Bioanalyser by Audrey 
Duncan at the Wellcome Trust Clinical Research Facility (WTCRF), Edinburgh. The 
output - RNA integrity number (RIN) - was used as a metric for sample quality. A study 
by Thompson et al., (2007) observed a substantial increase in false positives in 
microarray analysis of rat liver RNA samples with a RIN value of ≤ 7. This value was 
therefore set as the minimum acceptable measure of sample quality. RIN values of the 
LCL samples tested were high, ranging from 9.7 to 10 (Figure 3.1). 
 
3.2.2 Assessment of genomic DNA contamination 
To ensure successful DNase treatment during RNA preparation, synthesised cDNA 
samples underwent PCR analysis with an assay that amplifies a region spanning exons 
7-8 of the WD repeat domain 1 gene (WDR1) on chromosome 4. A genomic DNA 
positive control sample and negative controls for both the reverse transcription reaction 
(non-enzyme and non-template controls), and a negative PCR control (non-template 
control) were also subject to amplification. All cDNA PCR products were the expected 
size of 238 bp corresponding to the spliced region, while the larger, intron-containing 
product of 590 bp was observed in the genomic DNA control samples. This indicated 








Figure 3.1: Agilent Bioanalyser’s electropherogram output for visualising RNA 
integrity. 
Electropherograms are displayed for thirteen RNA samples from t(1;11) family LCLs. The 
associated RIN value accompanies the sample ID. Time in seconds is shown on the x-axis while 
fluorescence units are presented on the y-axis. The left and right peaks in each sample prefixed 
with “KK” represent the 18S and 28S ribosomal subunits respectively. The peak in the sample 
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Figure 3.2: Assessment of genomic DNA contamination in t(1;11) RNA. 
Shown are the PCR amplicons of WDR1 exons 7-8 run for t(1;11) cDNA samples, two genomic 
DNA control samples, and negative non-template, non-enzyme and non-RNA controls. Lower 
bands (238 bp) consist correspond to cDNA samples while upper bands (590 bp) correspond to 
genomic DNA control samples. In each lane, cDNA samples are presented (prefixed “KK”), non-
template controls (NTC), non-RNA controls (-RNA), non-reverse transriptase controls (-RT), and 
genomic DNA controls (prefixed “GC”). 
 
3.3 Microarray-based gene expression analysis of t(1;11) LCLs 
3.3.1 Quality control measures 
The quality of the microarray data was assessed using both internal, array-based 
controls and custom measures available in the R package lumi. Probe hybridisation, 
staining, sample integrity, probe-binding specificity, sample variance and sample 
reproducibility were all assessed. 
 
3.3.1.1 Internal control probes 
The Illumina HumanHT-12 v4 expression array has five sets of internal controls. These 
allow the user to assess sample integrity and ensure hybridisation and biotin-labelling 
steps were successful. Figure 3.3 provide a summary of the findings from each set of 
control probes. 
 
Three sets of hybridisation controls are present on the array: Cy3-labelled hybridisation 
controls, low stringency controls, and high stringency controls. The Cy-3-labelled 
controls consist of three pairs of probes targeting oligonucleotides present at low, medium 
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and high concentrations on the array to determine successful hybridisation. If successful 
hybridisation has occurred, such probes would be expected to yield a signal gradient 
consistent with their targets’ concentration on the array (i.e. low, medium and high 
signal). Signal from these probes suggested hybridisation was successful as the expected 
gradient of low, intermediate and high signal was observed for the corresponding probes 
(Figure 3.3A).  
 
Probe hybridisation stringency is determined by two sets of control probes. There are 
eight low-stringency control probes present on each array: four containing probes with 
two mismatched bases (mm2), and four containing the corresponding perfect-match 
sequence (pm). Signal from mm2 probes should be significantly lower than that of the 
pm probes under appropriate levels of hybridisation stringency. The mean signal observed 
in the pm probes was 4880 units - significantly higher than that observed in the mm2 
probes, at 640 units (Welch’s t-test p = 3.68 x 10-28; Figure 3.3B). Signal generation was 
assessed by two probes hybridizing to biotin-labelled targets in the hybridisation buffer. 
A positive hybridisation signal was observed for these probes, indicating successful 
staining (Figure 3.3C).  
 
Two sets of internal controls are present on the array to determine sample integrity. Each 
array contains 770 negative control probes with permuted sequences non-specific to the 
human genome. Any signal detected from these probes would be deemed an artefact due 
to background, non-specific binding, or cross-hybridisation. Background signal intensity 
was calculated from the mean signal intensity of 82.6 units for these probes. Noise in the 
array was determined by the standard deviation of the signal of the negative control 
probes (Figure 3.3D). Seven control probes targeting housekeeping genes provide a 
measure of the integrity of each sample on the array. It would be expected that the signal 
for these probes be significantly higher than the average signal obtained across all genes 
on the array if a sample were intact. The average signal intensity obtained from the 
housekeeping probes across all samples was 7099 units while the average signal intensity 
across all genes was 212. This indicated the samples were of high quality (Welch’s t-test 
p = 1.62 x 10-16; Figure 3.3E). 
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Figure 3.3: Illumina HT-12 control probe summary provided by GenomeStudio software. 
Shown is a screenshot of control probe plots as displayed in GenomeStudio for signal from (A) hybridisiation controls, (B) low stringency controls 
consisting of mismatched (left) and perfectly matched (right) probes, (C) biotin staining controls, (D) housekeeping gene control probes, and (E) 
negative controls. Control probe types are displayed on the x-axes and are represented by bars.
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3.3.1.2 Technical replicates 
In order to assess the degree of reproducibility and inter-chip variability of the HumanHT-
12 array, a technical replicate was used. One sample selected at random, a t(1;11) carrier 
sample (KK108), was used as a technical replicate. This sample was run in triplicate on 
one chip, one replicate being run on array position K. A between-chip replicate was also 
run in position K on the second chip. 
 
Reproducibility was assessed by pairwise comparisons of the replicate samples both 
within and between chips. High correlation was observed between within-chip replicate 
samples, and between-chip replicates (Pearson’s R2 ≥ 0.995; Figure 3.4). The coefficient 
of variation (CV) was calculated for the within-chip triplicates to determine the variation 
of 47,323 probes across each array. The median CV was 3.5% and more than 99.9% of 
probes had a CV of < 20% between the three replicates. This was repeated on the two 
inter-chip samples. A marginal increase in variation was observed between chips. The 
median CV was 4.7 % and 98.4 % of probes had a CV of <20 % between replicates. These 
results suggested both within- and between-chip variability was negligible. 
 
3.3.1.3 Confirmation of sample gender 
To identify samples whose gender might have been incorrectly annotated, 
multidimensional scaling was performed on Y-chromosome probes, with the expectation 
that samples would cluster by gender. Samples were annotated “M” and “F” 
corresponding to males and females, respectively, based on their annotation. Two visible 
clusters were present corresponding to gender, suggesting all samples were annotated 
correctly for gender (Figure 3.5A). To support this, hierarchical clustering analysis of 
expression data from Y-chromosome probes with CV ≥ 0.2 was performed. Two clusters 
were present corresponding to males and females (Figure 3.5B). 
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Figure 3.4: Pairwise analysis of technical replicate samples. 
Shown are all pairwise comparisons between four technical replicate samples (KK108). Density 
plots of signal for each technical replicate are shown in the diagonal. Below the diagonal are 
Pearson’s correlation coefficients (R2) for each pairwise comparison. Above the diagonal are 
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Figure 3.5: MDS and hierarchical clustering of Y-chromosome expression. 
Shown in Figure 3.6A is a multidimensional scaling plot of expression data for Y-chromosome probes in thirteen LCL-derived RNA samples. The 
relationship between samples was assessed in two dimensions (x- and y-axes). Shown in Figure 3.5B is a dendrogram based on expression data from 
variable Y-chromosome probes (CV >0.2; Figure 3.5B). Male (“M”) samples and female (“F”) samples are color-coded red and blue, respectively. 
Dendrogram height is representative of variability between samples. Sample IDs are prefixed with “KK”. The four technical replicates (KK108) are 
suffixed with numbers 1-4. 
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3.3.1 Data preprocessing 
Due to the high-dimensionality and noise associated with array-based data, a critical 
step prior to analysis is data preprocessing. Data were first transformed to reduce 
within-array variance and normalised to remove background noise. Probes were then 
filtered based on their detection p–value, thus removing the burden of unnecessary 
multiple tests, and to ensure the dataset consisted of signal from informative probes 
only. 
 
3.3.1.1 Data transformation 
As variance generally increases with signal intensity, transformation is a common step 
prior to the analysis of microarray data. In order to stabilise the variance to meet the 
assumptions of downstream statistical tests, Log transformation is commonly used. As 
this can cause problems such as inflation of variance in low-signal probes, Lin et al. 
(2008) have designed a method of variance stabilisation based on variance stabilising 
normalisation (Rocke and Durbin, 2001). Variance stabilising transformation (VST) uses 
within-array technical replicates to model the relationship of the mean and variance in 
each sample. Samples were transformed by VST (Figure 3.6). 
 
3.3.1.2 Data normalisation 
In order to remove systematic sources of variation such as hybridisation or levels of RNA, 
robust spline normalisation (RSN) was performed on the data. RSN combines features of 
quantile normalisation and loess normalisation (Du et al., 2008). Hierarchical cluster 
analysis was performed on the data pre- and post-normalisation (Figure 3.7). A reduction 
in variability was observed across the data as demonstrated by a reduction in the height 
of the dendrogram (3.7B). 
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Figure 3.6: Distribution of gene expression signal pre- and post-variance stabilising transformation. 
Box and whisker plots are shown corresponding to each sample (x-axis) displaying the distribution of background-subtracted signal (y-axis) before 
variance stabilising transformation (A), and after transformation (B).Thick horizontal lines in boxes represent the median signal per sample, upper and 
lower bounds of the boxes represent the third and first quartiles, respectively, and whiskers extend to the minimum and maximum signal detected in each 
sample. 
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Figure 3.7: Dendrogram of gene expression data for 13 lymphoblastoid samples before and after normalisation. 
Cluster dendrograms are presented pre- transformation and normalisation (A) and post- transformation and normalisation (B).  The height of the 
dendrogram (y-axis) represents sample variability. Red values at each node correspond to the approximately unbiased (au) p-value while green values 
correspond to the bootstrap probability (bp) percentage p–values. au values > 95 clusters that are strongly supported by the data. Grey digits indicate 
edge numbers. 
 
Chapter 3  94 
 
 
   
3.3.1.3 Probe filtering 
Data filtering was performed to ensure all probes tested for differential expression 
mapped to genes detected above background on the array. This has the additional benefit 
of reducing the burden of multiple testing. Probes with a detection p–value of ≥ 0.05 were 
removed from the dataset prior to differential expression analysis. Before probe filtering, 
a total of 47,323 probes were detected on the array. Post-probe filtering, data from 29,497 
probes remained for analysis of differential gene expression. 
 
3.3.2 Array-based identification of differentially expressed transcripts 
To identify latent, unmodeled sources of variation in the data, surrogate variable 
analysis (SVA) was performed, identifying one significant surrogate variable. 
Differential gene expression was assessed between t(1;11) carriers and non-carriers by 
linear regression fitting gender and the surrogate variable identified by SVA. No 
transcripts were found to be significantly differentially-expressed after correction for 
multiple testing (Benjamini-Hochberg FDR q ≥ 0.05 for all sites). The genomic inflation 
factor (λ) was calculated from the data showing deflation of p-values for differential 
expression between t(1;11) carriers and non-carriers (λ = 0.93; Figure 3.8). This might 
suggest the study was underpowered to detect genome-wide significant results. 
Therefore, probes nominally significant for differential expression in t(1;11) carriers 
were considered for further analysis (p ≤ 0.05), and a fold-change cut-off threshold of 
±1.2 was applied to these probes to define differential expression (n = 303; Figure 3.9; 
Table 3.1).  
 
Among the 303 genes that met these criteria, the largest negative fold-change in 
expression seen in t(1;11) carriers was observed at ependymin related 1, on chromosome 
7  (EPDR1: p = 6.32 x 10-5, FC = -2.62). The greatest positive fold-change in expression 
seen in carriers was also observed on a chromosome 7 gene, GTPase, IMAP family 
member 6 (GIMAP6: p = 5.02 x 10-3, FC = 1.70). The lowest p-value for differential 
expression was associated with interleukin-17 receptor B, on chromosome 3 (IL17RB; 
p = 3.52 x 10-6, FC = -2.58). 
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Figure 3.8: Quantile-quantile plot of p-values for differential gene expression 
between t(1;11) carriers and non-carriers. 
Shown are observed unadjusted –log10 p-values (y-axis; circular points) plotted over the expected 
distribution of –log10 p-values under the null (x-axis; solid diagonal line). The genomic inflation 
factor λ is presented in the upper-left corner of the plot. 
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Figure 3.9: Volcano plot of gene expression data comparing t(1;11) carriers to non-
carriers. 
Each point represents a transcript measured by the Illumina HT12 array in this experiment. The 
x-axis displays the log2 fold-change of a given transcript while the y-axis presents the –log10 p – 
value. Blue points represent probes that have met the both the p-value cut-off of 0.05 and absolute 
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ILMN_1767523 3 IL17RB -2.58 -9.89 3.52 x 10-6 
ILMN_2098446 18 PMAIP1 -1.46 -7.10 5.27 x 10-5 
ILMN_1675797 7 EPDR1 -2.63 -6.94 6.32 x 10-5 
ILMN_2046470 14 DAAM1* -1.43 -6.21 0.0001 
ILMN_1659270 5 OTP -1.72 -5.73 0.0003 
ILMN_1709484 15 BLM 1.32 5.26 0.0005 
ILMN_1708936 9 EXOSC3 1.23 5.22 0.0005 
ILMN_1724181 4 IL15 -1.25 -5.13 0.0006 
ILMN_1789106 1 IPP -1.21 -5.10 0.0006 
ILMN_3251423 3 CHDH -1.50 -5.05 0.0007 
Table 3.1: Differentially expressed genes in t(1;11) carrier LCL RNA. 
Summary of genes meeting an absolute expression fold-change ≥ 1.2 in t(1;11) carriers with an 
associated p-value ≤ 0.05 for differential expression. In order of column appearance are the HT12 
array probe’s associated Illumina ID, the probe’s target chromosome, gene name, fold-change 
in t(1;11) carriers, differential expression t-statistic, and unadjusted p-value for differential 
expression between t(1;11) carriers and non-carriers. Genes flagged with a red asterisk (*) are 
those with multiple non-overlapping probes meeting the criteria for differential expression in 
t(1;11) carriers. Shown are the top 10 differentially expressed genes ranked by p-value. The total 
list of genes meeting the p-value and fold-change cut-off is presented in Appendix I (Table A1). 
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During the probe filtering step, a probe was retained for analysis if it was expressed 
above background in at least one sample (detection p ≤ 0.05). As this may have led to 
the inclusion or exclusion of probes expressed in a group-specific manner, a Fisher’s 
exact test was performed to determine the relationship between probe detection and 
translocation carrier status. Of the 47,323 probes present on the array, 17,826 were not 
expressed in any samples, while 13,237 were expressed above background in all 
samples. The expression levels of the remaining 16,260 probes were assessed for 
association with t(1;11) carrier status: a total of 170 probes showed significant 
association (Fisher’s exact test p  ≤ 0.05). Of these, one probe was expressed above 
background level only in those samples without the t(1;11) chromosome (Fisher’s exact 
test p = 0.0008). This probe corresponded to a region the chromosome 15 gene ATPase, 
class V, type 10A (ATP10A). Of these 170 probes, only two met the both the fold-change 
and p–value criteria for differential gene expression: the chromosome 3 gene 
peroxisome proliferator-activated receptor, gamma (PPARG, p = 0.007, FC = -1.28), 
and the chromosome 1 gene, coagulation factor V (F5, p = 0.01, FC = -1.25).  
 
Among the genes detected by multiple probes on the HT-12 expression array, 16 were 
significantly differentially expressed in t(1;11) carriers. These comprised 15 pairs of 
probes corresponding to 15 genes, and one set of three probes which mapped to the 
chromosome 1 gene ATPase, Na+/K+ transporting, beta 1 polypeptide (ATP1B1, p ≤ 
0.03, average FC = -1.56). For all of these gene sets, directions of expression fold-
change were consistent among their associated probes. 
 
With regards to the translocation-affected chromosomes, 1 and 11, 30 and 17 genes were 
differentially expressed, respectively. DISC1 was not assessed for differential 
expression as none of the four probes present on the array mapping to the gene were 
detected above background in these samples, and were therefore removed at the probe-
filtering stage. A summary of the DISC1-targeting probes on the HumanHT-12 array, 
relative to the t(1;11) breakpoint is presented in Figure 3.10. Among the differentially 
expressed genes on chromosome 11 was SORL1, a member of the brain-expressed 
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Sortilin gene family. SORL1 was downregulated in t(1;11) carriers (p = 0.007, FC = -
1.29).  
 
3.3.3 Gene ontology analysis of differentially expressed transcripts 
To determine which, if any, molecular functions, biological processes or cellular 
components were over-represented amongst the above differentially expressed genes, 
gene ontology analysis was performed on the data. A list of genes ranked by differential 
expression p-value was submitted to GOrilla for this analysis (n = 16,078 genes). In 
total, 26 terms were significantly over-represented amongst differentially expressed 
genes (q ≤ 0.05; Table 3.2). The most significantly enriched term overall was “nuclear 
part” (q = 0.0055), in the GO component class. The most significantly enriched GO 
function was “purine nucleoside binding” (q = 0.0127), while “regulation of protein 
metabolic process” was the most over-represented GO process (q = 0.0276) 
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Figure 3.10: Locations of Illumina HT12-v4 probes mapping to DISC1. 
Shown is a UCSC genome browser screenshot of DISC1 isoforms, DISC2 (blue) and the binding sites Illumina HT12-v4 probes mapping to the region 
(brown). The vertical red line represents the t(1;11) chromosome 1 breakpoint.  Transcripts are represented by horizontal blue lines with each exon 
indicated by transections. 
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GO term Description Class Enrichment 
Enrichment 
p-value 
FDR   
q-value 
GO:0044428 Nuclear part Component 221/642 3.28 X 10-6 0.0055 
GO:0001883 Purine nucleoside binding Function 197/1294 1.24 X 10-5 0.0127 
GO:0032550 Purine ribonucleoside binding Function 197/1294 1.08 X 10-5 0.0148 
GO:0032553 Ribonucleotide binding Function 199/1294 1.84 X 10-5 0.0151 
GO:0017076 Purine nucleotide binding Function 198/1294 3.19 X 10-5 0.0163 
GO:0035639 
Purine ribonucleoside triphosphate 
binding 
Function 194/1294 2.86 X 10-5 0.0167 
GO:0032549 Ribonucleoside binding Function 198/1294 8.44 X 10-6 0.0173 
GO:0032555 Purine ribonucleotide binding Function 197/1294 2.57 X 10-5 0.0175 
GO:0005654 Nucleoplasm Component 163/640 6.91 X 10-5 0.0192 




Component 197/878 3.71 X 10-5 0.0206 
GO:0044464 Cell part Component 598/640 6.60 X 10-5 0.022 
GO:0044424 Intracellular part Component 990/1178 5.33 X 10-5 0.0222 
GO:0097367 Carbohydrate derivative binding Function 228/1346 5.11 X 10-5 0.0232 
GO:0051246 
Regulation of protein metabolic 
process 
Process 46/149 4.06 X 10-6 0.0276 
GO:0043228 Non-membrane-bounded organelle Component 197/878 3.71 X 10-5 0.0309 
GO:0030554 Adenyl nucleotide binding Function 165/1294 8.61 X 10-5 0.032 
GO:0032559 Adenyl ribonucleotide binding Function 164/1294 7.92 X 10-5 0.0324 
GO:0016462 Pyrophosphatase activity Function 105/1382 0.0001 0.0338 
GO:0005524 ATP binding Function 161/1294 0.0001 0.0348 
GO:0016818 
Hydrolase activity, acting on acid 
anhydrides, in phosphorus-
containing anhydrides 
Function 105/1382 0.0001 0.0356 
GO:0016817 
Hydrolase activity, acting on acid 
anhydrides 
Function 105/1382 0.0001 0.0362 
GO:1901265 Nucleoside phosphate binding Function 277/1549 0.0002 0.0368 
GO:0000166 Nucleotide binding Function 277/1549 0.0001 0.0369 
GO:0051247 
Positive regulation of protein 
metabolic process 
Process 43/214 3.02 X 10-6 0.041 
GO:1901363 Heterocyclic compound binding Function 369/896 0.0002 0.0456 
Table 3.2: Summary of GO terms enriched for differentially methylated genes in 
t(1;11) carriers. 
Shown in order of column appearance are the GO identifiers, the GO terms, the enrichment p-





Chapter 3  102 
  
3.4 Analysis of differential gene expression in t(1;11) LCLs by qRT-
PCR 
3.4.1 Selection of genes for qRT-PCR validation 
Prior to the commencement of this PhD, a study was carried out by Dr. Kirsty Millar 
and Prof. David Porteous in collaboration with Dr. Miguel Camargo (Merck, Sharp and 
Dohme), to investigate differential gene expression in an independent growth of cells 
from the same individuals as above. Gene expression was profiled using a 
Rosetta/Merck Human RSTA Custom Affymetrix 2.0 microarray (Affymetrix). Results 
from this experiment were validated by qRT-PCR by an MSc student, Xu Tang (XT).  
 
Expression levels of 14 genes were examined by XT by qRT-PCR. These genes were 
selected on the basis of evidence for dysregulation in the L100P Disc1 mouse model 
(Clapcote et al., 2007; Brown et al., unpublished data), and for localisation to CNVs 
implicated in schizophrenia (Walsh et al., 2008; Xu et al., 2008).  Differential 
expression was confirmed in eight of the 14 genes by XT (Table 3.3). Amongst the eight 
genes validated by XT was HIPK2, which was also found to be differentially expressed 
in t(1;11) carriers in the microarray experiment described in section 3.3 (p = 0.0068; FC 
= 1.25; Table 3.1). There was no evidence for significant differential expression of the 
remaining seven genes in the microarray analysis described in section 3.3. However, a 
member of the Sortilin gene family, SORL1, was found to be downregulated in t(1;11) 
carriers. Due to prior evidence of dysregulation of Sortilin gene family members in the 
L100P Disc1 mouse (Brown et al., unpublished data), SORL1 was selected as an 
additional gene for qRT-PCR validation, along with the eight genes previously 
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Table 3.3: Genes previously assessed for differential expression in t(1;11) 
lymphoblastoid samples. 
Genes are presented with corresponding p – values and fold changes for differential expression 
for the qRT-PCR validation of the original microarray results, and the qRT-PCR validation 
performed by Xu Tang. Results are colour-coded for whether a gene was significantly 
differentially expressed (p ≤ 0.05) in the microarray analysis only (yellow) or both microarray 









 Microarray Results 
qRT-PCR Validation (Xu 
Tang) 
Gene (Symbol) P-value Fold-Change P-value Fold-Change 
Cortactin (CTTN) 0.0004 1.56 0.06 2.82 
Abnormal spindle homologue, microencephaly 
associated (ASPM) 
0.001 -1.03 0.46 -2 
Phosphoinositide-3-kinase, catalytic, Delta 
polypeptide (PIK3CD) 
0.002 1.41 0.1 1.48 
Polo-like kinase 1 (PLK1) 0.003 -1.13 0.37 -1.84 
Cell division cycle 25 homologue B (CDC25B) 0.003 -1.03 0.46 -1.65 
Protein tyrosine kinase 2, Beta (PTK2B) 0.02 1.18 0.27 1.28 
Fragile histidine triad gene (FHIT) 0.01 -2.11 0.05 1.49 
Synaptic vesicle glycoprotein 2B (SV2B) 0.01 7.7 0.02 8.44 
Nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 2 (NFKB2) 
0.0005 1.87 0.02 1.72 
Nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, Alpha (NFKBIA) 
0.02 1.56 0.03 1.45 
Discs large homologue-associated protein 
(DLGAP1) 
0.003 -3.38 0.02 -5.58 
Homeodomain-interacting protein kinase 2 
(HIPK2) 
0.005 1.82 0.0009 1.55 
MyoD family inhibitor domain containing 
(MDFIC) 
0.009 1.79 0.04 1.51 
Neurexin-3, Alpha (NRXN3) 0.02 5.07 0.03 2.67 
 
Chapter 3  104 
  
3.4.2 Reference gene selection for qRT-PCR 
A panel of eight reference assays was used to select the optimum number of reference 
genes to which expression of the genes of interest would be normalised. Raw expression 
data from the thirteen LCL-derived cDNA samples was input into the geNorm program 
for analysis (Vandesompele et al., 2002). In order of increasing stability, based on the 
geNorm-M value, were TBP, ATP5B, CYC1, NCBP2, HNRNPD, RPLP0, UBC, and 
GAPDH (Figure 3.11). The optimum number of reference genes was determined to be 
two, based on the geNorm-V value of ≤ 0.15 for V 2/3. This indicated that the use of 
three or more reference genes for data normalisation would not be significantly better 
than using two genes (Figure 3.11). Based on these results, the two most stably-
expressed reference genes from this panel (GAPDH and UBC) were selected as 
reference genes. 
 
3.4.3 Analysis of differential gene expression by qRT-PCR 
Expression levels were examined in nine genes in t(1;11) LCL cDNA samples using 
Taqman® gene expression assays. Raw data were normalised to UBC and GAPDH as 
determined by geNorm analysis. Translocation carriers were compared to non-carriers 
using linear regression, covarying for gender. Significant differential expression was 
observed for HIPK2 (p = 0.002, FC = 1.61), and SORL1 (p = 0.045, FC = -1.50). The 
directions of effect observed at these genes were consistent with those observed in the 
microarray analysis (Figure 3.12; Table 3.4).  
 
In addition, significant differential expression was observed for DLGAP1 (p = 0.022, 
FC = 4.30; Figure 3.13), and SV2B (p = 6.02 x 10-5, FC = -4.36; Figure 3.13). SV2B was 
not found to be differentially expressed in the microarray analysis described in section 
3.3 (p = 0.48), while DLGAP1 expression was not detected above background on the 
array. 
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Figure 3.11: Identification of the most stable reference gene across samples using geNorm. 
Shown are geNorm M (line) and geNorm V (bar) plots. The geNorm M plot presents genes in order of increasing expression stability from left to right 
while the geNorm V plot presents the average pairwise variation between gene sets. The red horizontal line represents the geNorm V threshold of 0.15 
below which gene sets are stably expressed. 
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Figure 3.12: HIPK2 and SORL1 expression in t(1;11) family LCL samples as 
measured by microarray and qRT-PCR. 
Shown are normalised expression values (y-axes) plotted against t(1;11) carrier status (x-axes; 
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Table 3.4: Genes assessed for differential expression by both microarray and 
qRT-PCR analyses in the current study. 
Genes are presented with corresponding p–values and fold changes for differential expression 
for the microarray results, and the qRT-PCR validation. Yellow cells contain data for genes that 
were originally found to be differentially expressed by microarray and qRT-PCR analyses in an 
independent batch of LCLs, but not the current study. Blue cells contain data for genes that were 
originally found to be differentially expressed in the independent batch of LCLs by microarray 
analysis and qRT-PCR, with differential expression observed by at least one method in the current 
study. Orange cells contain data for SORL1 – a gene selected for validation by qRT-PCR in the 
current study based on its functional relevance in psychiatric illness. “NA” indicates genes that 
were not detected by either the microarray or qRT-PCR assay used in these samples. Italicised 
p-values correspond to those obtained using a Mann-Whitney U test whilst non-italicised p-values 
correspond to those obtained using a two-tailed Welch’s t-test, depending on the distribution of 
the data for that gene. 
 
 
Figure 3.13: DLGAP1 and SV2B expression in t(1;11) family LCL samples as 
measured by qRT-PCR. 
Shown are normalised expression values (y-axes) plotted against t(1;11) carrier status (x-axes; 
“N” = non-carrier, “T” = t(1;11) carrier) for DLGAP1 and SV2B. 
 Microarray Results qRT-PCR Validation 
Gene (Symbol) P-value Fold-Change P-value Fold-Change 
Fragile histidine triad gene (FHIT) 0.254 1.23 0.196 -1.43 
Nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 2 (NFKB2) 
0.398 -1.14 0.085 -1.46 
Nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, Alpha (NFKBIA) 
0.818 -1.04 0.214 -1.57 
MyoD family inhibitor domain containing 
(MDFIC) 
0.894 -1.02 0.506 1.21 
Neurexin-3, Alpha (NRXN3) 0.456 1.05 1 1.35 
Synaptic vesicle glycoprotein 2B (SV2B) 0.482 1.12 0.022 4.30 
Discs large homologue-associated protein 
(DLGAP1) 
NA NA 6.02 x 10-5 -4.36 
Homeodomain-interacting protein kinase 2 
(HIPK2) 
0.007 1.25 0.002 1.61 
Sortilin-related receptor, L(DLR class) A 
(SORL1) 
0.007 -1.29 0.045 -1.50 
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3.5 Discussion 
Gene expression was assessed in LCL-derived RNA, comparing levels in t(1;11) 
carriers to those in non-carriers. The work described in this chapter was based on the 
hypothesis that the t(1;11) translocation might affect gene expression not only at 
DISC1, as previously observed (Millar et al., 2005), but also elsewhere in the genome. 
This may be directly, through disruption of the genes at the chromosome 1 and 11 
breakpoints; or indirectly, through transmission of variants on the derived 
chromosomes that affect gene expression. 
 
It is important to consider the limitations of this analysis prior to interpreting the 
findings. A major drawback to the current study is the use of LCL-derived RNA. Cell-
line derived samples may be prone to technical confounders, as well as biological 
aberrations randomly accumulated during the culturing process.  
 
Thirteen samples were profiled for gene expression. Prior to analysis, sample quality 
was assessed at the RNA level, and the cDNA level following reverse-transcription of 
RNA. RNA was found to be intact while cDNA samples were found to be free of 
genomic DNA contamination. Upon analysis of differential gene expression between 
t(1;11) carriers and non-carriers, no differences were observed at the genome-wide 
significant level. Deflation of p-values was observed which might suggest that, at 13 
samples, the study was underpowered to detect genome-wide significant differences 
in gene expression. To determine this, a post-hoc power calculation was performed 
using the R package, pwr (Champely, 2017). This revealed that at the current sample 
size, the study had 80 % power to detect an effect size of 3.26 at an alpha of 0.000001 
(Bonferroni  p = 0.05). To attain 80% power at the fold-change and significance 
thresholds used in this study, a further seven t(1;11) samples would be required. The 
results should therefore be interpreted with caution. As it is unlikely that LCLs will be 
generated from additional t(1;11) family members, any functional follow-up of these 
findings should be preceded by targeted validation, such as qRT-PCR, in an 
independent batch of samples. 
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Three hundred and three genes showed nominally significant differential expression 
in t(1;11) carriers (p ≤ 0.05) at an arbitrary absolute fold-change cut-off of 1.2. Using 
this less conservative threshold to define differential expression, the most significantly 
differentially expressed gene was IL17RB (p = 3.52 x 10-6, FC = -2.58). It is of interest 
that a study by Wen et al. (2014) observed upregulation of this gene in iPSC-derived 
neurons from patients with a 4 bp frameshift mutation in DISC1 (p = 0.0001, FC = 
4.14). Downregulation of this gene has, however, been reported by Kim et al. (2014) 
in cases of suicide among schizophrenia patients.  
 
Among the 303 differentially expressed transcripts, 23 were also reported as 
dysregulated in the study by Wen et al. (2014). This study compared samples in 
triplicate, from two individuals with a DISC1 frameshift and one without. Considering 
the small sample size, the number of significantly differentially expressed genes in 
their study (n = 2012) might suggest the authors treated each triplicate as an individual 
data point. Such an approach might result in inflation of significant results for 
differential expression due to the high degree of correlation expected between data 
points corresponding to a given individual. This caveat aside, a particularly noteworthy 
example of an overlapping gene between this study and the t(1;11) study is FABP5. 
This gene was upregulated both in t(1;11) carriers (p = 0.0036, FC = 1.35) and in 
DISC1 mutant neurons reported by Wen et al. (2014; p = 1.69 x 10-5, FC = 3.52). 
FABP5 is a member of a gene family encoding fatty acid binding transport proteins 
(FABPs). Shimamoto et al. (2014) reported upregulation of FABP5 in schizophrenia 
post-mortem brain. Furthermore, there is evidence for a role of FABP5 in regulating 
hippocampal cognitive function (Yu et al., 2014), while depletion of FABPs has been 
observed in the synaptosomes of aged mouse brains (Pu et al., 1999). Other members 
of this family were also upregulated in t(1;11) carriers: two probes corresponding to 
FABP5L2, and one probe corresponding to FABP5L9. The findings of differential 
FABP expression here support existing evidence for a role for these genes in 
psychiatric illness, and may indicate a potential mechanism by which illness occurs in 
t(1;11) individuals through abnormal fatty acid transport. Such an effect may have 
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detrimental results in the brain by disrupting normal fatty acid levels and signalling 
processes (Bazinet and Layé, 2014). 
 
The greatest positive fold-change in expression amongst the 303 differentially 
expressed genes was observed in GIMAP6. This gene is a member of the GIMAP 
family, members of which function in the regulation of cell survival (Kruken et al., 
2004). A study by Gregg et al. (2008) reported upregulation of GIMAP6 in children 
with early-onset autism compared to the general population. Given the reported 
overlap in the genetic architecture of autism and other psychiatric disorders (Smoller 
et al., 2013), these findings may support GIMAP6 as a risk gene for pathogenesis in 
the t(1;11) family. The greatest negative fold-change in expression reported in t(1;11) 
carriers was observed in EPDR1. In zebrafish, the proposed homologue of this gene 
regulates aggressive behaviour, and functions as a neuronal cell adhesion molecule 
(CAM). Neuronal CAMs have previously been implicated in schizophrenia and 
bipolar disorder (Hargreaves et al., 2014). Should downregulation of EPDR1 occur in 
the brains of t(1;11) individuals, it is possible the CAM pathway might be affected, 
thus conferring increased risk of illness in these individuals. Further work is required, 
however, to determine the function of EPDR1 in humans. Assessment of whether these 
fold-changes are observed at the protein levels for these genes would further clarify 
whether cell survival and/or CAM pathways are disrupted in t(1;11) individuals. To 
this end, the recently-generated iPSC-derived neurons may prove a useful resource. 
 
Millar et al. (2005), previously reported lower levels of DISC1 expression in t(1;11) 
LCLs. Four probes are present on the HT-12 array to measure DISC1 expression. In 
the above study, these probes had detection p–values > 0.05 in all samples and were 
therefore filtered prior to analysis of differential expression. Millar et al. (2005) 
quantified DISC1 expression LCL samples by qRT-PCR. It is likely that the qRT-PCR 
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Although DISC1 was not detected above background in any sample, a correlation was 
observed between translocation carrier status and detection above background for 170 
genes. Of these, ATP10A was exclusively detected in non-carriers of the translocation 
(Fisher’s exact test p = 0.0008). ATP10A is maternally imprinted in the brain, and is 
located at chromosome 15q11-q13, an autism susceptibility region (Bolton et al., 
2004). Its putative function involves maintenance of cell membrane integrity which 
may suggest a regulatory role for the gene in neurotransmission, when expressed in 
the brain (Herzing et al., 2001).  
 
Upregulation of MAPK1 was observed in translocation carriers (p = 0.0025, FC = 
1.21). MAPK1 encodes ERK2, a key component of MAPK signalling pathway. DISC1 
has previously been implicated in ERK signaling where it is thought to play a role in 
the pathogenesis of MDD, and regulation of gene expression in astrocytes (Hashimoto 
et al., 2006; Wang et al., 2016). In the MAPK signalling cascade, ERK activation 
results in CREB phosphorylation and binding to cAMP response elements to regulate 
transcription. It is therefore possible that the genome wide differences in expression 
may occur, at least in part, through the downstream effects of altered ERK2 levels in 
these individuals. 
 
Nine genes were selected for validation by qRT-PCR based on the findings from this 
microarray experiment, and findings from a previous study of expression in t(1;11) 
LCLs. Of these nine genes, four were differentially expressed in t(1;11) carriers: 
HIPK2, SORL1, SV2B and DLGAP1. Of these genes, HIPK2 and SORL1 were the only 
ones to show differential expression both in the microarray and qRT-PCR analyses 
presented above.  
 
Upregulation of HIPK2 had previously been reported in t(1;11) carriers by Xu Tang 
and Miguel Camargo. Overexpression of HIPK2 has been associated with apoptotic 
cell death (Bracaglia et al., 2009). Apoptosis has been reported in cases of bipolar 
disorder and schizophrenia (Benes, 2006). If overexpressed in the brains of t(1;11) 
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individuals, it is possible that HIPK2 may mediate apoptosis, contributing to an 
increased risk of illness. 
 
Downregulation of SORL1 was observed in t(1;11) carriers on the expression array, a 
finding which was validated by qRT-PCR analysis. SORL1 is a member of the Sortilin 
gene family which has been shown to play a role in processing of amyloid precursor 
protein (APP). APP processing can occur via the amyloidogenic pathway by the action 
of BACE1 – or β-secretase - and subsequent γ–secretase-mediated processing, or the 
non-amyloidogenic pathway via α–secretase and subsequent γ–secretase-mediated 
processing. ADAM17, an α–secretase-encoding gene, was also downregulated in 
t(1;11) carriers. The amyloidogenic pathway results in the formation of neurotoxic 
Amyloid-β plaques, a key feature of Alzheimer’s disease pathology. Conversely, the 
non-amyloidogenic pathway has been associated with neurotrophic effects through the 
secretion of the APP ectodomain (sAPP-α; Hartl et al., 2013). Others have 
demonstrated a negative correlation between expression of SORL1, and both 
amyloidogenic and non-amyloidogenic processing of APP (Gustafsen et al., 2013). 
DISC1 has been shown to interact with APP in neurodevelopment (Young-Pearse et 
al., 2011), and there is evidence for a role of DISC1 in APP processing (Shahani et al., 
2015). Taken together, these findings suggest a possible link between the t(1;11) 
translocation and the APP processing pathway through transcriptional dysregulation 
of multiple constituent genes in the pathway. The Illumina HT-12 expression array 
contains two probes to measure expression of the BACE1 gene. Neither of these probes 
were expressed above background in any of the LCL samples (ILMN_2320349 
detection p–value = 0.17, ILMN_1797804 detection p–value = 0.16). This would 
suggest that BACE1 activity, and therefore, Amyloid-β is not present in these samples. 
A cellular model from the t(1;11) family expressing all members of the APP 
processing pathway would be required to determine whether the translocation is linked 
to APP processing through altered expression and/or interaction between the above 
genes. Neurons derived from t(1;11) family iPSCs have recently become available and 
these may be a useful resource to investigate this further. To determine whether DISC1 
and the APP processing pathway genes might interact in cognitive or depressive 
phenotypes, an in-silico approach was taken with an aim to identify epistatic 
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interactions between these genes in an unrelated sample of Scottish ancestry. This 
work is described in Chapter 7.  
 
Of the remaining seven genes tested for differential expression by qRT-PCR, 
dysregulation of DLGAP1 and SV2B was observed in t(1;11) carriers. SV2B was 
downregulated in t(1;11) carriers, a finding which was not observed in the microarray 
analysis (p=0.48). The HT-12 array contains three probes to measure SV2B expression. 
These probes map to last exon of all SV2B transcript variants reported on UCSC 
genome browser (http://genome.ucsc.edu), with the exception of a UCSC transcript 
(uc002bqt.3). The Taqman® assay used to measure SV2B expression by qRT-PCR 
(Hs00916046_m1) maps to an exon boundary common to all reported isoforms, 
including uc002bqt.3. It is therefore possible that differential expression of SV2B in 
t(1;11) LCLs is specific to this isoform, which would not be detected by the HT-12 
array. SV2B encodes a synaptic vesicle protein and functions in regulating presynaptic 
calcium levels (Wan et al., 2010). If misexpressed in the brains of t(1;11) carriers, 
SV2B might contribute to defective neurotransmission. 
 
DLGAP1 expression was not detected in t(1;11) family LCLs by the HT-12 array. It 
was, however, found to be upregulated in t(1;11) carriers by qRT-PCR. The HT-12 
array contains two probes to measure expression of all reported DLGAP1 isoforms. 
Similarly, the Taqman® assay used to measure DLGAP1 expression 
(Hs00191052_m1) was also designed to measure expression of all known isoforms. It 
is possible that DLGAP1 expression levels in LCLs are too low for detection by the 
HT-12 array, and is only measurable in these samples by more sensitive methods, such 
as qRT-PCR. DLGAP1 is located on chromosome 18p, a region in which Pickard et 
al. (2005) reported an inversion associated with schizophrenia and bipolar disorder in 
a Danish family. Although not directly disrupted by the inversion, they proposed 
DLGAP1 expression might be altered by the inversion through the disruption of nearby 
regulatory elements. DLGAP1 interacts with PSD-95 at the post-synaptic density (Kim 
et al., 1997). PSD-95 functions in synaptic regulation of neurotransmitter receptors 
and adhesion of pre- and post-synaptic terminals (Ziff, 1997). DLGAP1, among other 
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interactors, may function to anchor ion-channel/PSD-95 complexes to the postsynaptic 
density (Kim et al., 1997). This might suggest dysregulation of DLGAP1 in the brain, 
like SV2B, might affect neurotransmission, rendering both genes attractive functional 
candidates for pathogenesis in the family. 
 
Gene ontology analysis was performed on the data to identify over-represented terms 
amongst the most differentially expressed genes which might indicate processes 
disrupted by the t(1;11) translocation relevant to pathogenesis. There was no 
enrichment of differentially expressed genes for brain-specific terms. This is perhaps 
not unexpected, given the use of LCLs. The most significant over-represented term 
was nuclear part (q = 0.005). 
 
A major limitation to this study is the use of LCL-derived RNA. In the context of a 
translocation linked to major mental illness, the optimum tissue would be t(1;11) 
family-derived neuronal material. The small sample size also posed a challenge, 
probably rendering the study underpowered to detect any genome-wide significant 
differences in expression. In addition, cell passage numbers were unavailable for these 
samples. Grafodatskaya et al. (2010) reported randomly distributed differential 
methylation patterns in high passage LCLs, which could impact upon gene expression. 
Moreover, spontaneous aneuploidy is a known feature of long term cell culture, 
including LCLs (Miyai et al., 2008; Shirley et al., 2012). It is therefore recommended 
that subsequent work involving these cell lines should involve karyotyping as a quality 
control measure. Recently, iPSC-derived neuronal samples have become available 
from a subset of t(1;11) family members. Analysis of gene expression in these samples 
is ongoing. Identification of differentially expressed genes common to both iPSC-
derivatives and LCLs may inform upon tissue-agnostic effects of the t(1;11) 
translocation on gene expression. However, findings from the iPSC-derivatives are 
likely to provide a more physiologically relevant representation of differential gene 
expression in the brains of t(1;11) carriers.  
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4 Analysis of DNA methylation in t(1;11) family whole blood-
derived samples 
4.1 Overview 
DNA methylation is a fundamental epigenetic modification which plays a key 
regulatory role in the development and establishment of cellular identity. Its capacity 
to be modulated by non-genetic factors has rendered it an attractive candidate to assess 
the impact of environmental effects on complex traits. In addition to environmental 
factors, genetic factors can also regulate levels of DNA methylation (Lemire et al., 
2015). DNA methylation is thought to play a regulatory role in gene expression 
through remodelling of chromatin structure (Lewis and Bird, 1991; Hashimshony et 
al., 2003). Aberrant DNA methylation has been observed in numerous disorders, 
including psychiatric illness (Gopalakrishnan et al., 2008; Grayson and Guidotti, 
2013). The work presented in this chapter was performed with the aim of determining 
whether the t(1;11) translocation was associated with differential DNA methylation in 
the family, and whether these differences might be correlated with diagnosis in 
individuals carrying the translocation.  
 
Methylation of whole blood-derived DNA was profiled in 17 t(1;11) carriers and 24 
non-carrying relatives using the Infinium HumanMethylation450 BeadChip 
(Illumina®, San Diego, California; 450k array). The 450k array interrogates DNA 
methylation at 485,577 sites across the genome (Bibikova et al., 2011). Two 
comparisons of DNA methylation were performed: an analysis between t(1;11) 
carriers and non-carriers; and an between t(1;11) carriers with a psychotic disorder and 
those with a non-psychotic disorder. The aim of the first comparison was to investigate 
whether any methylation disruption occurred as a in the context of the t(1;11) 
translocation, either locally within the t(1;11) breakpoint regions (e.g. as a direct result 
of an effect of the translocation on chromatin structure), or by means of a trans- effect 
at regions across the genome (e.g. due to methylation quantitative trait loci). The aim 
of the second comparison was to identify whether differences in methylation levels 
within affected t(1;11) carriers may be correlated with a psychiatric phenotype (i.e. 
psychosis) in these individuals.  
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4.2 Comparison of DNA methylation between t(1;11) carriers and 
non-carriers 
4.2.1 Data preprocessing 
Raw methylation data for the entire 450k array (n = 485,577 probes) were read into 
R. The initial filtering step involved the removal of probes with predicted cross-
hybridising potential (Chen et al., 2013; n = 30,969). A second filtering step was 
performed to remove probes with a variant at the target CpG, and, in the case of type 
I probes, the site of single base extension (the base before C), based on whole genome 
sequence data from the family (n = 10,548). 
 
Based on the filtering criteria described in Chapter 2.10.2, the pfilter() function 
removed 799 probes and 0 samples, based on the proportion of probes with a 
detection p – value of  > 0.05, and the proportion of these probes in a given sample, 
respectively. This resulted in a final sample set of 41 individuals for whom 443,196 
sites were profiled for methylation. 
 
Chapter 4  118 
 
4.2.2 Estimation of cellular proportions in whole blood 
This study used whole blood-derived DNA: a heterogeneous tissue in terms of 
cellular composition. Estimated cell counts were compared between groups to 
determine whether cellular proportions differed as this may confound subsequent 
analyses. Estimated cell counts were calculated using the estimateCellCounts() 
function in minfi. A t-test was performed to compare these estimated cell 
proportions between t(1;11) carriers and non-carriers. No significant between-
group differences were observed in cell count estimates for B-lymphocytes, 
granulocytes, monocytes, natural killer cells, CD4+ T-lymphocytes and CD8+ T-
lymphocytes (Student’s two-tailed independent samples t-test p ≥ 0.41; Table 4.1). 
Based on this information, cellular estimates were not included as covariates in this 










B-Cells Monocytes Granulocytes 
Mean 
proportion  in 
t(1;11) 
carriers 





0.048 0.161 0.065 0.051 0.069 0.615 
p-value 0.704 0.578 0.502 0.408 0.846 0.866 
Table 4.1: Estimated cellular proportions of blood in t(1;11) carriers and non-
carriers. 
Table summarises the minfi package’s estimateCellCounts() function’s estimated proportions 
of CD8+ and CD4+ T-cells, natural killer cells, B-cells, monocytes and granulocytes. Mean 
proportions for each group are presented for each cell type along with an unpaired t-test p-
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4.2.3 Selection of normalisation method 
The raw data were normalised by 14 methods: SWAN, Noob, beta mixture quantile 
normalisation (BMIQ), dasen, nasen, nanet, naten, nanes, danes, danet, danen, 
daten1, daten2 and peak-based correction (PBC) (Table 4.2). Using the three metrics 
described in Chapter 2.10.3, each method’s ability to reduce technical error was 
assessed and ranked with dasen achieving the highest overall rank. The data were 
then normalised by dasen. This method equalises type I and type II backgrounds, 
followed by quantile normalisation of methylated and unmethylated intensities 















dasen 1 11.5 2 4.833 1 
nasen 2 11.5 3 5.5 2.5 
danes 3 3.5 10 5.5 2.5 
daten1 4 8 5 5.666 4 
danen 11 7 1 6.333 5.5 
daten2 6 9 4 6.333 5.5 
nanes 7 3.5 11 7.1666 7 
raw 12 5.5 6 7.8333 8 
SWAN 10 2 12 8 9 
danet 5 14 7 8.666 10 
naten 9 10 8 9 11 
BMIQ 14 1 14 9.666 12 
nanet 8 13 9 10 13 
Noob 13 5.5 13 10.5 14 
PBC 15 15 15 15 15 
Table 4.2: Assessment of the performance of 14 methods used to normalise 
the raw methylation data. 
Table summarises the rankings of three metrics used to assess the performance of 14 
normalisation strategies. From left to right, columns show the normalisation strategy, DMR-
standard error (DMRSE) rank, genotype-combined standard error (GCOSE) rank, 1 - Seabird 
AUC rank, mean rank of the three metrics, and the rank of mean ranks. 
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4.2.4 Identification of differentially methylated positions 
Linear regression was performed to identify differentially methylated positions 
(DMPs) between t(1;11) carriers and non-carriers. Surrogate variable analysis (SVA) 
was performed on the data to identify latent sources of variation. Seven surrogate 
variables (SVs) were identified and fitted as covariates, along with age and gender. 
The genomic inflation factor λ was calculated from the p-values for differential 
methylation to assess the goodness-of-fit of the model. This was within the 
acceptable range of 1-1.1 as defined by GenABLE (λ = 1.05; Wang and Leal, 2012; 
Figure 4.1) 
 
Thirteen significant DMPs were identified in the comparison of  t(1;11) carriers and 
non-carriers (FDR q ≤ 0.05; Figure 4.2; Table 4.3). Four of these sites were in the 
DISC1 gene itself: three mapping to the gene body and one to the 3’ UTR. With the 
exception of one site on chromosome 10 (cg24508974), all were on either 
chromosome 1 or 11. Hypomethylation was observed in all but two of the DMPs in 
t(1;11) carriers. The two loci displaying hypermethylation were at an intergenic site 
on chromosome 10, and one site within the gene body of EGLN1, on chromosome 1. 
With regards to the translocation breakpoints, the most distal sites showing 
significant differential methylation on chromosomes 1 and 11 were approximately 
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Figure 4.1: Quantile-quantile plot showing observed vs. expected p-values for 
differential methylation between t(1;11) carriers and non-carriers. 
Shown are observed unadjusted –log10 p-values (y-axis; circular points) plotted against the 
expected distribution of –log10 p-values under the null hypothesis (x-axis; solid diagonal line). 
The genomic inflation factor λ is presented in the upper-left corner of the plot. 
 




Figure 4.2: Manhattan plot for DNA methylation analysis of t(1;11) carriers and non-carriers. 
Figure shows –log10 p – values for differential methylation between t(1;11) carriers and non-carriers (y–axis) plotted against chromosomal position (x–
axis). The horizontal red line represents the –log10 p – value threshold for genome wide significance (FDR q = 0.05) 
 















Table 4.3: Significantly differentially methylated positions between t(1;11) carriers and non-carriers. 
Table summarises significantly differentially methylated sites between t(1;11) carriers and non-carriers (FDR q ≤ 0.05). In order of column appearance 
are probe identifiers, Hg19 genomic coordinates, UCSC reference gene names (“NA” denotes intergenic regions), between-group difference in mean 
beta value, fold-change between groups, moderated t-statistic, p-value for differential methylation and FDR-adjusted p-value. 
Probe ID Hg19 Coordinates Gene Beta Difference Fold-Change t p-value q - value 
cg09186051 Chr1:231981906 DISC1;TSNAX-DISC1 -0.07 -1.31 -11.81 1.17 x 10-13 5.20 x 10-8 
cg26728851 Chr11:76430375 GUCY2E -0.03 -1.63 -9.72 2.09 x 10-11 4.64 x 10-6 
cg15157974 Chr1:232144702 DISC1;TSNAX-DISC1 -0.04 -1.27 -9.04 1.30 x 10-10 1.92 x 10-5 
cg05656812 Chr1:232021560 DISC1;TSNAX-DISC1 -0.06 -1.33 -8.44 6.73 x 10-10 7.46 x 10-5 
cg06928246 Chr1:227974645 NA -0.07 -1.56 -7.99 2.41 x 10-09 0.0002 
cg16177633 Chr1:232172585 DISC1;TSNAX-DISC1 -0.03 -1.20 -7.23 2.13 x 10-08 0.0016 
cg18815120 Chr1:231512676 EGLN1 -0.12 -2.10 -6.99 4.29 x 10-08 0.003 
cg25899154 Chr11:72897143 NA -0.07 -1.28 -6.75 8.73 x 10-08 0.005 
cg02771260 Chr11:59836817 MS4A3 -0.13 -1.79 -6.66 1.13 x 10-07 0.006 
cg24508974 Chr10:103330391 NA 0.01 1.17 6.61 1.32 x 10-07 0.006 
cg21875980 Chr1:231553510 EGLN1 0.06 1.40 6.54 1.64 x 10-07 0.007 
cg26355502 Chr1:221916303 DUSP10 -0.01 -1.30 -6.24 4.05 x 10-07 0.01 
cg00965168 Chr1:227974541 NA -0.05 -1.42 -6.10 6.03 x 10-07 0.02 
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4.2.5 Gene ontology analysis of differentially methylated genes in 
t(1;11) carriers 
To identify whether any biological processes, molecular functions or cellular 
components were significantly over-represented amongst the most significant DMPs, 
a p–value ranked list of DMP-containing genes was submitted to GOrilla for 
ontology analysis (http://cbl-gorilla.cs.technion.ac.il/; Eden et al., 2009; n = 20,752 
genes submitted). In cases of multiple probes per gene, the probe with the lowest 
DMP p-value was selected.  
 
Overall, 62 GO categories were significantly over-represented in these data (q ≤ 0.05; 
Table 4.4). Categories are split into processes, components and functions by GOrilla. 
All significant terms were within the “process” and “component” categories. The 
most significantly over-represented term in this analysis was “neuron projection” 
(GO:0043005; q = 3.72 x 10-6). Additional categories relating to neuronal function 
were also significantly over-represented. These included “regulation of nervous 
system development”, “regulation of synapse organisation”, and “axon”.  
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GO Term Description Class Enrichment p-value q-value 
GO:0043005 neuron projection Component 1.73 2.29 X 10-9 3.72 X 10-6 
GO:0042995 cell projection Component 1.44 3.63 X 10-7 0.0003 




Process 1.5 6.49 X 10-8 0.0009 
GO:0097458 neuron part Component 1.96 1.93 X 10-6 0.001 
GO:0009987 cellular process Process 1.33 5.98 X 10-7 0.002 
GO:0048562 embryonic organ morphogenesis Process 4.36 4.93 X 10-7 0.0022 
GO:0048856 anatomical structure development Process 1.07 4.14 X 10-7 0.0028 
GO:0048731 system development Process 1.72 1.04 X 10-6 0.0028 
GO:0030424 axon Component 1.12 3.05 X 10-5 0.0083 
GO:0044444 cytoplasmic part Component 4.26 2.75 X 10-5 0.0089 
GO:0032502 developmental process Process 1.3 6.12 X 10-6 0.0093 
Table 4.4: Summary of GO terms enriched amongst differentially methylated 
genes in t(1;11) carriers. 
For each GO term, table summarises the GO identifier, the GO description, the GO class, 
enrichment, the enrichment p-values, and enrichment FDR q-values for genes showing the 
most differential methylation in t(1,11) carriers compared to non-carriers. Enrichment is 
defined as (b/n) / (B/N), where b = the number of genes at the top of the p-value ranked list 
that is associated with a given GO term, n = the number of genes at the top of the p-value-
ranked gene list, B = the total number of genes associated with a given GO term, and N = the 
total number of genes. Shown are the top 10 enrichments ranked by p-value. The total list of 
significant enrichments is presented in Appendix I (Table A2). 
 
 
4.2.6 Identification of differentially methylated regions 
To identify genomic regions containing multiple nominally significant differentially 
sites between t(1;11) carriers and non-carriers (p ≤ 0.05), differentially methylated 
region (DMR) analysis was performed. An advantage of the DMR analysis is the 
increased statistical power to detect small methylation differences in the context of 
multiple signals within a given region (Robinson et al., 2014). The ChAMP 
package’s DMR-calling algorithm, probe lasso, was used (Morris et al., 2014; 
Butcher and Beck, 2015). This algorithm is agnostic to the direction of effect of 
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Using the ChAMP package’s ChAMP.lasso() function,  123 DMRs were identified 
(Table 4.5). The most significant DMR in t(1;11) carriers spanned a 1.6 kb region in 
the gene body of the chromosome 6 gene TNXB (p = 2.46 x 10-13). This DMR also 
comprises the most probes (n = 51). The largest region spanned 4.8 kb over nine 
probes and was located in an intergenic region on chromosome 1, approximately 84 
Mb centromeric to the chromosome 1 breakpoint (p = 0.0001). The closest DMRs to 
the chromosome 1 breakpoint was approximately 4 Mb centromeric, in the gene body 
of RHOU (p = 0.0007). The closest DMR to the chromosome 11 breakpoint was 
located approximately 3 Mb telomeric, within 1500 bp of the TSS of C11orf75 (p = 
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Gene(s) Feature(s) Region Probes DMR p-value 
TNXB Body Chr6:32063516-32065113 51 2.46 x 10-13 
NA IGR Chr3:196704439-196707088 5 7.89 x 10-10 
C11orf75 TSS1500 Chr11:93277097-93277255 3 1.67 x 10-9 
NA;PRRT1 IGR, 3'UTR Chr6:32115866-32116728 14 2.60 x 10-9 
RNF5P1;AGPAT1 TSS1500, TSS200 Chr6:32145233-32145902 20 6.26 x 10-9 
GABRG1 TSS1500, TSS200, 5'UTR Chr4:46125801-46126455 7 7.27 x 10-9 
KRTAP5-9 TSS1500, TSS200, 5'UTR Chr11:71259142-71259846 5 3.17 x 10-8 
CYP2E1 Body Chr10:135343047-135343426 3 5.93 x 10-8 
XRRA1 TSS200 Chr11:74660246-74660274 4 6.07 x 10-8 
RHOD 3'UTR Chr11:66839183-66839543 3 8.99 x 10-8 
Table 4.5: Summary of t(1;11)-associated DMRs identified by the probe lasso 
algorithm.                                       
Summary of the genes (if applicable), genomic features, hg19 genomic coordinates, number 
of probes and p-value associated with each DMR. “NA” in the “Gene” column represents 
intergenic regions (i.e. regions not annotated to a RefSeq gene). Genomic features are coded 
“IGR” for intergenic regions, “TSS200” and “TSS1500” for probes occurring within 200 and 
1500 of a gene’s transcription start site, respectively; “5’UTR” and “3’UTR” for probes 
occurring within a gene’s 5’ and 3’ untranslated region, respectively, “1stExon” for probes 
occurring within the first exon of a gene, and “Body” for probes occurring within the gene 
body. Shown are the top 10 DMRs ranked by p-value. The total list of significant DMRs is 
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4.2.7 Identification of methylation quantitative trait loci 
An analysis of methylation quantitative trait loci (meQTLs) was performed to 
determine whether the observed differences in methylation in t(1;11) carriers was 
associated with genotype at sites in linkage disequilibrium with the translocation. 
The thirteen loci displaying genome-wide significant methylation between 
translocation carriers and non-carriers were cross-referenced to a previously 
published list of cis- and trans- meQTLs identified in lymphocyte DNA by Lemire 
et al. (2015). Of the 13 DMPs, seven were present in this list, all of which were cis-
acting (less than 1 Mb between SNP and CpG; Lemire et al., 2015). Genotypes were 
obtained from whole-genome sequence data from the family at these previously-
reported sites and their role in regulating DNA methylation was assessed. Six of the 
seven previously-reported meQTLs were significantly associated with translocation 
carrier status (p ≤ 0.05; Table 4.6). Minor allele count at these meQTLs were 
significantly associated with DNA methylation at five of the seven sites assessed (p 
≤ 0.05; Figure 4.3; Table 4.6).  
 










Probe Gene meQTL Gene Translocation~meQTL+Sex 
meQTL p-value 
(Age+Sex) 
rs2486729* cg18815120 23 kb EGLN1 EGLN1 2.71 x 10-8 2.02 x 10-16 
rs17154511* cg02771260 11 kb MS4A3 MS4A3 9.84 x 10-6 8.14 x 10-11 
rs10899287* cg26728851 84 kb GUCY2E Intergenic 7.26 x 10-10 0.0002 














rs9419922 cg24508974 50 kb Intergenic Intergenic 0.4518 0.548 
Table 4.6: Summary of meQTLs reported to regulate DNA methylation at differentially methylated loci identified between t(1;11) 
carriers and non-carriers. 
From left to right, columns show the probe identifier, the corresponding probe’s associated gene, the meQTL reported by Lemire et al. (2015), the gene 
containing the meQTL, the p-value for the relationship between the translocation and meQTL genotype, adjusting for sex; and the p-value for the 
relationship between DNA methylation and meQTL genotype, adjusting for age and sex. meQTLs accompanied by an asterisk (*) denote those that are 
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Figure 4.3: Significantly differentially methylated loci between t(1;11) carriers 
and non-carriers associated with genotype at previously-reported meQTLs (p ≤ 
0.05; Lemire et al., 2015).                     
Panels A-E display methylation β-values at five CpG sites (y-axes) plotted against minor allele 
counts of meQTLs (p ≤ 0.05, x-axes). Titles of each panel identify the CpG probe and the SNP 
involved in each meQTL in the format “probe ID:SNP ID”. Red points represent individuals 
homozygous for the major allele, blue points represent heterozygotes and green points 
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4.3 Analysis of DNA methylation in t(1;11) carriers with a 
psychotic disorder 
4.3.1 Sample information 
In order to determine whether DNA methylation could be associated with phenotypic 
outcome (i.e. diagnosis) in t(1;11) carriers, a second analysis was performed. DNA 
methylation was compared between eight individuals with a psychotic disorder (i.e. 
schizophrenia, bipolar disorder or schizoaffective disorder, all presenting 
hallucinations or delusions) and five individuals with a non-psychotic disorder (i.e. 
single episode MDD, cyclothymia, conduct disorder, generalised anxiety disorder). 
The aim of this study was to determine whether DNA methylation was associated 
with psychosis in affected t(1;11) carriers. Thirteen t(1;11) carriers were analysed: 
eight individuals with a non-psychotic disorder and five with a psychotic disorder. 
The remaining three t(1;11) carriers in this study had a diagnosis of recurrent MDD. 
These samples were omitted from the analysis in order to also permit a comparison 
between “severe” (i.e. psychotic) diagnoses and “minor” diagnoses, based on the 
assumption that the burden of illness in recurrent MDD is greater than that in single 
episode MDD but lesser than that in psychosis. 
 
4.3.2 Estimation of cellular proportions in whole blood  
The estimateCellCounts() function was performed to estimate proportions of B-
lymphocytes, granulocytes, monocytes, natural killer cells, CD4+ T-lymphocytes and 
CD8+ T-lymphocytes in this subset of individuals. The mean estimated proportion of 
each cell type was compared between individuals with a psychotic disorder and those 
with a non-psychotic disorder using a two-tailed Student’s unpaired t–test. No 
significant between-group differences were observed (p ≥ 0.16; Table 4.7). 
Therefore, cellular estimates were not included as covariates in the differential 
methylation analysis. 
 
4.3.3 Data normalisation 
The sample subset was normalised using 14 methods described previously (Table 
2.3), and each method was scored based on its ability to reduce technical variation, 
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as described in Chapter 2.10.3. As with the analysis of the total sample set, dasen 





Table 4.7: Estimated cellular proportions of whole blood within t(1;11) carriers 
with psychotic and non-psychotic disorders. 
From left to right, columns show the minfi package’s estimateCellCounts() function’s 
estimated proportions of CD8+ and CD4+ T-cells, natural killer cells, B-cells, monocytes and 
granulocytes. Mean proportions per experimental group are presented for each cell type along 











B-Cells Monocytes Granulocytes 
Mean 











0.040 0.155 0.063 0.048 0.073 0.629 
p- value 0.189 0.797 0.982 0.174 0.470 0.285 
 
















dasen 3 7.5 5 5.17 1 
daten1 5 9 4 6 2.5 
daten2 4 11 3 6 2.5 
naten 9 10 2 7 4 
nanes 8 7.5 6 7.166 5 
danes 1 14.5 8 7.833 6 
nanet 10 13 1 8 7 
Raw 12 1.5 11 8.17 8 
danet 6 12 7 8.33 9 
nasen 2 14.5 9 8.50 10 
SWAN 7 6 14 9 11.5 
danen 11 3 13 9 11.5 
BMIQ 15 4 10 9.66 13 
Noob 13 1.5 15 9.83 14 
PBC 14 5 12 10.33 15 
Table 4.8: Performance of 14 normalisation methods tested in 13 samples. 
Table summarises the rankings of three metrics used to assess the performance of 14 
normalisation strategies. In order of appearance, columns show the normalisation strategy, 
DMR-standard error (DMRSE) rank, genotype-combined standard error (GCOSE) rank, 1 - 
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4.3.4 Identification of differentially methylated positions 
Linear regression was performed to identify differentially methylated positions 
(DMPs) between t(1;11) carriers with psychosis and those without psychosis. SVA 
was performed on the data to identify latent sources of variation. Three SVs were 
identified and fitted as covariates, along with age and gender. The goodness-of-fit of 
the model was assessed by calculating the genomic inflation factor λ. This was within 
the acceptable range of 1-1.1 as defined by GenABLE (Wang and Leal, 2012; λ = 
1.08; Figure 4.4) 
 
Three sites were identified as being significantly differentially methylated in t(1;11) 
carriers with a psychotic disorder compared to carriers with a non-psychotic disorder 
(q ≤ 0.05; Table 4.9; Figure 4.5). The most significantly differentially methylated site 
from this comparison was hypomethylated in individuals with a psychotic disorder, 
and was located within 1500 bp of the transcription start site of the chromosome 8 
gene STC1 (q = 0.02).  A further two loci were also hypomethylated in t(1;11) carriers 
with psychosis, located within 10 kb of one another in major histocompatibility 
complex (MHC) region on chromosome 6: DPCR1 (q = 0.03) and SFTA2 (q = 0.03). 
Although not significant after correction for multiple testing, three sites within the 
Protocadherin-γ gene cluster (PCDHGA) on chromosome 5 were present within the 
top 20 DMPs when ranked by p – value. All three sites showed hypermethylation in 
individuals with psychosis (q ≤ 0.056). 
 
The bimodal distribution of the methylation signal at these three sites indicated a 
possible SNP effect. To investigate whether genetic variation was driving the 
differential methylation signal at these sites, their genomic coordinates were cross-
referenced to a table of potential signal-affecting genetic variants provided by Chen 
et al. (2013). Common variants (European minor allele frequency ≥ 0.05) were 
reported to be present at all three of these sites. Targeted Sanger-based sequencing 
was performed at these loci by Susan Anderson, confirming the presence of genetic 
variation as predicted based on methylation levels (i.e. lower levels in an individual 
carrying a CpG-abolishing variant). Although not all samples were successfully 
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sequenced, confirmation that the expected genetic variation was present in a subset 
of individuals was sufficient evidence that these findings were driven by the presence 




Figure 4.4: Quantile-quantile plot showing observed vs. expected p-values for 
differential methylation between t(1;11) carriers with a psychotic disorder and 
carriers with a non-psychotic disorder. 
Shown are observed unadjusted –log10 p-values (y-axis; circular points) plotted against the 
expected distribution of –log10 p-values under the null hypothesis (x-axis; solid diagonal line). 
The genomic inflation factor λ is presented in the upper-left corner of the plot. 
 








Table 4.9: Significantly differentially methylated positions between t(1;11) carriers with a psychotic disorder and t(1;11) carriers 
with a non-psychotic disorder. 
Table summarises significantly differentially methylated sites between t(1;11) carriers with a psychotic disorder and carriers with a non-psychotic 
disorder (FDR q ≤ 0.05). Shown are: probe identifiers, Hg19 genomic coordinates, UCSC reference gene symbols, between-group differences in mean 
beta values, fold-change between groups, moderated t-statistic, p-value for differential methylation, and FDR-adjusted p-value. 
Probe ID Hg19 Coordinates Gene Symbol Beta Difference Fold-Change t p-value q - value 
cg16688533 Chr8:23713016 STC1 -0.19 -2.44 -12.98 3.69E-08 0.02 
cg04559908 Chr6:30920123 DPCR1 0.30 4.28 11.41 1.44E-07 0.03 
cg13561028 Chr6:30899649 SFTA2 0.18 2.50 11.03 2.06E-07 0.03 
 

















Figure 4.5: Manhattan plot for comparison of DNA methylation between t(1;11) carriers with a psychotic disorder and t(1;11)  
carriers with a non-psychotic disorder. 
Shown are –log10 p – values for differential methylation between t(1;11) carriers with psychotic disorders and those with non-psychotic disorders (y – 
axis), plotted against chromosomal position (x – axis). The horizontal red line represents the –log10 p – value threshold for genome wide significance 
(FDR q = 0.05). 
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4.3.5 Gene ontology analysis of differentially methylated genes in 
psychosis 
As with the analysis between carriers of the translocation non-carriers, a p-value-
ranked list of genes containing DMPs was submitted to GORilla for ontology 
analysis (n = 20,752 genes). 
 
A list of ten most significantly enriched GO terms is presented in Table 4.10. A 
complete list is available in Appendix I (Table A4). Of the 87 categories significantly 
over-represented amongst differentially methylated genes in t(1;11) carriers with 
psychosis (q ≤ 0.05), several related to neuronal function. These included 
“Regulation of nervous system development”, “Regulation of neurogenesis” and 
“postsynaptic density”. The most significantly overrepresented term was “Integral 
component of lumenal side of endoplasmic reticulum membrane”, in the “GO 
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GO Term Description Class Enrichment p-value q-value 
GO:0071556 
integral component of lumenal 
side of endoplasmic reticulum 
membrane 
Component 82.96 3.55 x 10-8 5.89 x 10-5 
GO:0042611 MHC protein complex Component 140.38 1.45 x 10-7 0.0001 
GO:0030658 transport vesicle membrane Component 30.85 5.56 x 10-7 0.0003 
GO:0048518 
positive regulation of 
biological process 
Process 1.19 8.43 x 10-8 0.0012 
GO:0012507 
ER to Golgi transport vesicle 
membrane 
Component 68.76 3.41 x 10-6 0.0014 
GO:0048522 
positive regulation of cellular 
process 
Process 1.2 5.73 x 10-7 0.0020 
GO:0042605 peptide antigen binding Function 4.97 2.29 x 10-6 0.0024 
GO:0042995 cell projection Component 1.38 7.47 x 10-6 0.0025 
GO:0051960 
regulation of nervous system 
development 




Process 1.28 4.57 x 10-7 0.0032 
Table 4.10: Summary of GO terms enriched for differentially methylated genes 
in t(1;11) carriers with a psychotic disorder. 
For each GO term, table summarises the GO identifier, the GO description, the GO class, 
enrichment, the enrichment p-values, and enrichment FDR q-values for genes showing the 
most differential methylation in t(1,11) carriers with psychotic disorders compared to carriers 
with a non-psychotic disorder. Enrichment is defined as (b/n) / (B/N), where b = the number 
of genes at the top of the p-value ranked list that is associated with a given GO term, n = the 
number of genes at the top of the p-value-ranked gene list, B = the total number of genes 
associated with a given GO term, and N = the total number of genes. Shown are the top 10 
enrichments ranked by p-value. The total list of significant enrichments is presented in 
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4.3.1 Identification of differentially methylated regions in t(1;11) 
carriers with a psychotic disorder 
To identify genomic regions containing multiple nominally significant differentially 
sites between t(1;11) carriers with a psychotic illness and those with a non-psychotic 
illness (p ≤ 0.05), DMR analysis was performed. 
 
A total of 238 DMRs were identified using the ChAMP package (Table 4.11). The 
most significant DMR in t(1;11) carriers with psychosis occurred within the gene 
body of RPTOR, spanning eight probes (p = 1.55 x 10-21). The largest region was 
detected in an intergenic region on chromosome 13, consisting of 13 probes over 5.6 
kb (p = 0.0004). The DMR with the most probes spanned 2.6 kb within TNXB, on 
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RPTOR Body Chr17:78865119-78867431 8 1.55 x 10-21 
NA, MIR886 IGR, TSS200, Body Chr5:135415531-135416414 13 1.18 x 10-19 
PTPRN2 Body Chr7:158045532-158046806 6 2.13 x 10-15 
TNXB Body Chr6:32064430-32064738 13 1.49 x 10-13 
NA IGR Chr6:29721548-29725160 4 1.6 x 10-13 
NA IGR Chr13:113295067-113297572 4 4.17 x 10-13 
SLC38A4 TSS200, 5'UTR, 1stExon Chr12:47219385-47219867 6 4.95 x 10-12 
HCG27 TSS1500 Chr6:31164851-31165031 8 3.24 x 10-11 
NA IGR Chr6:29520536-29521310 15 4.37 x 10-11 
NA IGR Chr6:25882428-25882752 3 7.78 x 10-11 
Table 4.11: Psychosis-associated DMRs identified by the probe lasso algorithm.  
Table summarises the genes (if applicable), genomic features, hg19 genomic coordinates, 
number of probes and p-value associated with each DMR. “NA” in the “Gene” column 
represents intergenic regions (i.e. regions not annotated to a RefSeq gene). Genomic features 
are coded “IGR” for intergenic regions, “TSS200” and “TSS1500” for probes occurring 
within 200 and 1500 bp of a gene’s transcription start site, respectively; “5’UTR” and 
“3’UTR” for probes occurring within a gene’s 5’ and 3’ untranslated region, respectively, 
“1stExon” for probes occurring within the first exon of a gene, and “Body” for probes 
occurring within the gene body. Shown are the top 10 DMRs ranked by p-value. The total list 
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4.4 Assessment of DNA methylation at sites correlated between 
blood and brain 
A study by Walton et al. (2015) presented a list of 100 probes from the 450k 
methylation array where methylation levels were highly correlated between blood and 
brain (Spearman’s rho ≥ 0.94). To determine whether any of these sites were 
differentially methylated between groups in blood from the t(1;11) family, methylation 
was examined in a subset of these probes that had passed quality control in the above 
analyses (n = 70). Within this set of a probes, a multiple testing correction was applied 
using a false discovery rate of 5% (Benjamini and Hochberg, 1995).  
 
Of the 70 probes reported as correlated between blood and brain (Walton et al., 2015), 
two sites were significantly differentially methylated between t(1;11) carriers and non-
carriers (q ≤ 0.05; Table 4.12). These probes were located within 350 bp of one another 
in the body of CYP2E1, on chromosome 10.  
 
The same 70 probes were assessed for differential methylation between t(1;11) carriers 
with a psychotic disorder and those with a non-psychotic disorder. Two sites were 
significantly differentially methylated between groups (q ≤ 0.05; Table 4.12). The 
most significantly differentially methylated site was located in the MHC region on 
chromosome 6, within the body of HLA-DQB2. The second site was within 1500 bp 
of the TSS of MRI1, on chromosome 19. Methylation at each of these loci was reported 
by Lemire et al. (2015) to be associated with a meQTL. To determine whether the 
difference in methylation was associated with this meQTL, whole-genome sequence 
data from the family were queried for this variant. None of the individuals sequenced 
showed variation at this site. 
 









Table 4.12: Significantly differentially methylated positions in probes reported to be correlated between blood and brain by Walton 
et al. (2015). 
Table summarises sites showing significant differential methylation in a set of 70 probes reported by Walton et al. (2015) to be correlated between blood 
and brain. From left to right, columns show the probe identifiers, Hg19 genomic coordinates, UCSC reference gene IDs, between-group difference in 
mean beta value, fold-change between groups, average methylation M-value, moderated t-statistic, p-value for differential methylation, FDR-adjusted p-
value, log odds for differential methylation and the study in which significant differential methylation was observed. 
Probe ID Hg19 Coordinates Gene Beta Difference Fold-Change t p-value q - value Study 




cg10862468 Chr10:  135342218 CYP2E1 0.12 1.57 3.67 0.0008 0.03 




cg16474696 Chr19: 13875014 MRI1 0.01 1.60 4.39 0.001 0.035 
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4.5 Estimation of DNA methylation age 
Based on Illumina methylation array profiles from over 7,800 samples across 82 
datasets, Horvath (2013) developed a DNA methylation age predictor applicable to 
the methylation profiles of multiple tissues, including whole blood. DNA 
methylation age has been proposed to reflect a cumulative effect of epigenetic 
maintenance, and is highly correlated with chronological age.  
 
To assess whether carrying the translocation was associated with differences in DNA 
methylation age, age acceleration (i.e. the difference between DNA methylation age 
and chronological age) was compared between t(1;11) carriers and non-carriers. 
DNA methylation age and chronological age were highly correlated overall (p < 2.2 
x 10-16, R2 = 0.94; Figure 4.6), as well as within groups (translocation carriers p = 
1.23 x 10-10, R2 = 0.94; non-carriers p = 1.16 x 10-14, r2 = 0.94). No significant 
differences in age acceleration (i.e the difference between chronological age and 
DNA methylation age) were observed between t(1;11) carriers and non-carriers 
(Student’s two-tailed independent samples t-test p = 0.4; Figure 4.7). 
 
To determine whether psychosis may be related to an effect on DNA methylation age 
in t(1;11) carriers, DNA methylation age was compared between t(1;11) carriers with 
a psychotic disorder and those with a non-psychotic disorder. No significant 













Figure 4.6: Relationship between DNA methylation age and chronological age 
in 41 blood-derived samples. 
Chronological age (x-axis) is plotted against DNA methylation age (y-axis) derived from 
Horvath’s DNA methylation age calculator (Horvath, 2013). The linear relationship between 












Figure 4.7: Age acceleration between t(1;11) carriers and non-carriers. 
Mean age acceleration as calculated as the difference between methylation age and 
chronological age (y-axis) is plotted against translocation carrier status. “N” denotes t(1;11) 
non-carriers (blue bar), “T” denotes t(1;11) carriers (red bar). Error bars show the standard 
deviation from mean age acceleration in each group. 
 
 
Figure 4.8: Age acceleration between t(1;11) carriers with a non-psychotic 
disorder and carriers with a psychotic disorder. 
Mean age acceleration as calculated as the difference between methylation age and 
chronological age (y-axis) is plotted against diagnosis class. The blue bar shows the mean 
age acceleration age in t(1;11) carriers with a non-psychotic disorder while the red bar shows 
the mean age acceleration in t(1;11) carriers with a psychotic disorder. Error bars show the 
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4.6 DNA methylation at polymorphic sites 
Prior to the analysis of the methylation data, probes affected by polymorphisms at their 
target sites were removed as a quality control measure. Differences in signal can be 
observed at such sites in the form of a tri-modal distribution of the three possible 
genotypes of the underlying variant (i.e. major allele homozygous, heterozygous, and 
minor allele homozygous). Such polymorphisms may result in disrupted DNA 
methylation and disruption of downstream regulatory functions through the abolition 
of CpG sites. To determine whether such polymorphisms were present in the t(1;11) 
family, methylation data were reanalysed, including these probes.  
 
4.7 Selection of normalisation strategy for polymorphic probe set 
The data were normalised by the 14 methods described in Table 2.3 and each method 
was scored based on its ability to minimise technical variation as described in Chapter 































dasen 1 11.5 2 4.83 1 
danes 3 3.5 9 5.16 2 
nasen 2 11.5 3 5.5 3 
daten1 4 8 5 5.66 4 
daten2 5 9 4 6 5 
danen 11 7 1 6.33 6 
nanes 7 3.5 11 7.16 7 
raw 12 5.5 6 7.83 8 
SWAN 10 2 12 8 9 
naten 8 10 8 8.66 10 
danet 6 14 7 9 11 
BMIQ 14 1 14 9.66 12 
noob 13 5.5 13 10.5 13 
nanet 9 13 10 10.66 14 
PBC 15 15 15 15 15 
Table 4.13: Performance of 14 normalisation methods tested in the dataset 
containing polymorphism-targeting probes 
Table summarises the rankings of three metrics used to assess the performance of 14 
normalisation strategies. From left to right, columns show the normalisation strategy, DMR-
standard error (DMRSE) rank, genotype-combined standard error (GCOSE) rank, 1 - Seabird 
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4.8 Identification of differentially methylated positions in the 
polymorphic probe set 
To identify latent sources of variation present in the data, surrogate variable analysis 
was performed. Nine significant surrogate variables were identified. Carriers of the 
translocation were compared to non-carriers by linear regression, fitting age, gender 
and the nine surrogate variables as covariates. In total, 20 sites were significantly 
differentially methylated between t(1;11) carriers and non-carriers (q ≤ 0.05; Figure 
4.9; Table 4.14). Among these sites were the 13 significantly differentially methylated 
loci identified in the SNP-filtered comparison of t(1;11) carriers and non-carriers. The 
two most significantly differentially methylated probes identified were on 
chromosome 11, within CHRDL2 (q = 3.16 x 10-28; Figure 4.10) and SHANK2 (q = 
1.12 x 10-9; Figure 4.10). Cross-referencing of the genomic coordinates of these targets 
to 1000 genomes phase 3 data (1000 Genomes Project Consortium, 2015) confirmed 
the presence of variation at both sites. The SHANK2 probe targets a common 
polymorphism (rs1000968; European MAF = 0.87) while the CHRDL2 probe targets 
a rare polymorphism (rs75439151; European MAF = 0.005). Whole-genome sequence 
data from the family confirmed the presence of these variants.  The rare CHRDL2 
variant was present exclusively among t(1;11) carriers while the SHANK2 variant was 
observed in all t(1;11) carriers and two non-carriers. Methylation profiles were 
consistent with genotype: CpG homozygotes showed methylation levels 
approximately twice those seen in heterozygotes of these CpG-abolishing variants 
(Figure 4.10).  
 
 





Figure 4.9: Manhattan plot of differentially methylated positions between t(1;11) carriers and non-carriers in the polymorphic probe 
set.  
Shown are –log10 p–values for differential methylation between t(1;11) carriers with psychotic disorders and those with non-psychotic disorders (y–axis), 
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Probe ID Hg19 Coordinates Gene Beta Difference Fold-Change t p-value q - value 
cg16056964 Chr11:74430117 CHRDL2 -0.39 -7.49 -55.94 6.96X 10
-34 3.16X 10-28 
cg09157251 Chr11:70733251 SHANK2 0.44 7.86 13.68 4.94X 10-15 1.12X 10-09 
cg09186051 Chr1:231981906 DISC1,TSNAX-DISC1 -0.07 -1.30 -10.82 2.61X 10-12 3.94X 10-07 
cg10109470 Chr11:76430445 GUCY2E -0.08 -1.77 -9.73 3.79X 10-11 4.29X 10-06 
cg26728851 Chr11:76430375 GUCY2E -0.03 -1.64 -9.12 1.79X 10-10 1.62X 10-05 
cg15157974 Chr1:232144702 DISC1,TSNAX-DISC1 -0.04 -1.26 -7.97 3.77X 10-09 0.0003 
cg05656812 Chr1:232021560 DISC1,TSNAX-DISC1 -0.06 -1.31 -7.94 4.17X 10-09 0.0003 
cg06928246 Chr1:227974645 NA -0.07 -1.58 -7.74 7.09X 10-09 0.0004 
cg09674468 Chr1:234300299 SLC35F3 -0.08 -1.44 -7.47 1.51X 10-08 0.0008 
cg18815120 Chr1:231512676 EGLN1 -0.12 -1.99 -7.05 4.92X 10-08 0.002 
cg16177633 Chr1:232172585 DISC1,TSNAX-DISC1 -0.03 -1.19 -6.71 1.32X 10-07 0.005 
cg24508974 Chr10:103330391 NA -0.01 -1.19 6.50 2.38X 10-07 0.009 
cg02771260 Chr11:59836817 MS4A3 -0.13 -1.81 -6.33 3.87X 10-07 0.013 
cg25899154 Chr11:72897143 NA -0.07 -1.30 -6.20 5.66X 10-07 0.018 
cg26355502 Chr1:221916303 DUSP10 -0.01 -1.30 -5.94 1.20X 10-06 0.033 
cg25191850 Chr1:233749633 KCNK1 0.03 -1.31 5.93 1.26X 10-06 0.033 
cg03807330 Chr11:76327232 NA 0.05 -1.33 5.92 1.28X 10-06 0.033 
cg00892096 Chr1:220987469 MOSC1 0.04 -1.36 5.91 1.32X 10-06 0.033 
cg00965168 Chr1:227974541 NA -0.05 -1.44 -5.80 1.83X 10-06 0.044 
cg21875980 Chr1:231553510 EGLN1 0.06 -1.41 5.78 1.93X 10-06 0.044 
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Table 4.14: Table of differentially methylated positions between t(1;11) carriers 
and non-carriers in the polymorphic dataset. 
Table summarises significantly differentially methylated sites between t(1,11) carriers and 
non-carriers in a dataset including polymorphic probes. From left to right, columns show 
probe identifiers, Hg19 genomic coordinates, UCSC reference gene IDs (“NA” denotes 
intergenic), between-group difference in mean beta value, fold-change between groups, 




Figure 4.10: Top two significantly differentially methylated polymorphic CpGs 
in t(1;11) carriers. 
Methylation β-values (y-axis) are plotted against t(1,11) carrier status at significantly 
differentially methylated polymorphic CpG sites in SHANK2 (cg09157251) and CHRDL2 
(cg16056964). “N” denotes t(1,11) non-carriers (blue points) and “T” denotes t(1,11) 





















This chapter describes an analysis of methylation in whole blood-derived DNA from 
individuals from the t(1;11) family. Two comparisons were performed: first, DNA 
methylation was compared between t(1;11) carriers and non-carriers, and second, 
methylation in t(1;11) carriers with a psychotic disorder was compared to those with a 
non-psychotic disorder.  The aim of the former study was to determine whether 
differential DNA methylation was associated with the translocation in carriers, while the 
aim of the latter study was to determine whether DNA methylation differences could be 
observed between psychotic and non-psychotic illness in t(1;11) carriers.  
 
Comparison of DNA methylation between translocation carriers and non-carriers resulted 
in the identification of 13 DMPs: nine on chromosome 1, three on chromosome 11, and 
one on chromosome 10. With the exception of the chromosome 10 DMP, all probes 
mapped to the regions surrounding the translocation breakpoints. However, not all CpGs 
immediately adjacent to the translocation breakpoints showed differential methylation. 
These findings could be due to the co-inheritance of meQTLs with the translocation. 
Alternatively, this could be an issue of power, as the sample size was relatively small. To 
investigate this, a post-hoc power analysis revealed the study was 80 % powered to detect 
an effect size of a fold-change of at least 1.95 at an alpha of 1.13 x 10-7 (Bonferroni p = 
0.05). This may indicate that smaller effects in the region of the translocation may not be 
detected, at the current sample size. 
 
Four DMPs mapped within the DISC1 gene, which is directly disrupted by the 
translocation on chromosome 1. DISC1 has been implicated in neurodevelopment, 
cognitive function and disease risk in psychiatric illness (Brandon and Sawa, 2011; 
Carless et al., 2011; Thomson et al., 2013; Rampino et al., 2014). Two DMPs mapped to 
the EGLN1 gene, which encodes prolyl hydroxylase domain-containing protein 2 
(PHD2), and is located within 500 kb of the chromosome 1 breakpoint. PHD2 regulates 
the transcription factor HIF-1α, the master transcriptional regulator of the cellular 
response to hypoxia (Berra et al., 2003). Hypoxia is a previously reported obstetric and 
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developmental risk factor for schizophrenia (Dalman et al., 2001; Byrne et al., 2007; 
Schmidt-Kastner et al., 2006). Differential methylation at this gene might indicate a 
mechanism whereby increased risk of illness is conferred by the translocation, through a 
disruption to the cellular response to hypoxia.  
 
Comparison of t(1;11) carriers and non-carriers also identified a significantly 
differentially methylated site on chromosome 10 (cg24508974). This site is located in an 
intergenic region flanked by two RefSeq genes: BTRC centromeric, and POLL telomeric, 
as reported by RefSeq. ChIP-seq data from ENCODE data reports a transcription factor 
binding site at this locus in K562 cells (ZNF263; Gerstein et al., 2012). This suggests that 
this locus is involved in regulating the expression of the nearby genes. Zariwala et al. 
(2004) reported a phenotype reminiscent of primary ciliary dyskinesia (PCD) in mice 
following deletion of Poll. DISC1 regulates the maintenance of dopamine receptor-
expressing primary cilia in the brain (Marley and von Zastrow, 2010). However, there is 
currently no evidence to suggest that DISC1 and POLL act together in regulating primary 
cilia. Although this site has been previously reported to be regulated by a meQTL by 
Lemire et al. (2015), this was not replicated in the above study (Table 4.6). 
 
In order to identify biological processes that may be affected by differential methylation 
associated with the translocation, gene ontology analysis was performed. This analysis 
identified several neurologically-relevant processes, including “regulation of nervous 
system development”, “regulation of neurogenesis” and “positive regulation of nervous 
system development”. These findings are in keeping with the theory of the 
neurodevelopmental origin of schizophrenia (reviewed by Rapoport et al., 2012), pointing 
additionally to the possibility of neurodevelopmental abnormalities in t(1;11) carriers. 
Recent work has identified structural differences in the brains of t(1;11) carriers compared 
to non-carriers. Doyle et al. (2015) reported reductions in cortical thickness 
measurements in t(1;11) carriers consistent with those observed in schizophrenia patients. 
Furthermore, deficits in white matter integrity have been reported in t(1;11) carriers by 
Whalley et al. (2015), while Thomson et al. (2016) reported t(1;11)-associated reductions 
in gyrification. It should be noted, however, that the enriched neurologically-relevant 
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terms were not the most significant findings in the two analyses when considering 
enrichment p-value in the psychotic vs. non-psychotic comparison. Here, the most 
enriched term was “integral component of lumenal side of endoplasmic reticulum 
membrane”. Such enrichments may support a hypothesis of more general (i.e. non-brain-
specific) effects of the translocation on basic cell functioning. 
Other studies of DNA methylation in the context of chromosomal translocations and 
disease have generally been cancer-based. These studies have also reported significant 
differences in DNA methylation associated with translocations. Busche et al. (2013) 
examined DNA methylation in leukaemia patients with a t(12;21) translocation. They 
reported differential methylation associated with this translocation but, in contrast to the 
observations here, this was not in the regions surrounding the breakpoints. Walker et al. 
(2011) reported on methylation in 12 cancer-associated chromosomal abnormalities. 
They found the greatest differences in methylation to occur in the context of a t(4;14) 
translocation. Here, significant DMPs occurred throughout the genome with no apparent 
enrichment on the translocated chromosomes. However, the same study also reported on 
differential methylation associated with a t(11;14) translocation where the top six ranked 
DMPs were hypomethylated and located within CCND1: the chromosome 11 gene 
disrupted by this translocation.  
 
Another possible mechanism for differential methylation at the t(1;11) breakpoint regions 
may relate to the passive transmission on the translocated chromosomes of meQTLs 
associated with methylation at sites around these breakpoints. Support has been provided 
for this mechanism in the results presented here. Of the 13 significant DMPs identified 
between t(1;11) carriers and non-carriers (q ≤ 0.05), seven were previously reported to be 
influenced by a meQTL in a study of lymphocyte DNA methylation (Lemire et al., 2015). 
These findings were replicated for five of these seven probes. The failure to replicate the 
remaining loci may be attributable to limited statistical power due to the small number of 
homozygote carriers of the minor allele of the meQTL. 
 
To determine whether DNA methylation differences were associated with a phenotypic 
outcome (i.e. diagnosis) in t(1;11) carriers, five individuals with a psychotic disorder were 
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compared to eight individuals with a non-psychotic disorder. Three DMPs were identified 
in this analysis: one on chromosome 8 and two on chromosome 6. These results were 
found to be due to genetic variation at the target locus for all three sites. Filtering of probes 
affected by polymorphisms at their target site was performed on the data prior to analysis, 
based on whole-genome sequence data from the family. However, it is clear from these 
results that a proportion of such probes still remained. Factors such as sequencing errors 
and variable read depth may limit the accuracy of variant detection and, therefore, pose 
limitations for this strategy. An alternative approach would be to filter based on 
population-based information, such as 1000 genomes data, as has been performed in other 
epigenome-wide association studies (1000 Genomes Consortium, 2015; Chen et al., 
2013). However, in the context of a family study, this strategy may result in the 
superfluous removal of probes targeting non-polymorphic sites or, alternatively, the 
failure to identify rare, family-specific variants. There may be some situations where 
retaining such probes may be desirable. For example, a difference in methylation due to 
a SNP that creates or destroys a CpG at a target site is informative if it represents the 
mechanism by which the SNP confers a change in disease risk. One site proximal to the 
chromosome 11 breakpoint was found to possess a rare CpG-abolishing variant, present 
exclusively in t(1;11) carriers (cg16056964; Figure 4.10). It is likely that the regions 
flanking the t(1;11) breakpoints will contain many similar sites simply due to being in 
linkage disequilibrium with the translocation. However, further experiments would be 
required to determine which, if any, of these variants have risk-conferring effects.  
 
GO analysis of the DMPs identified from the within-carrier comparison of psychotic and 
non-psychotic disorders revealed significant enrichment for neurodevelopmental terms, 
including “negative regulation of nervous system development” and “negative regulation 
of neurogenesis” (Table 4.12). These findings may indicate that diagnostic differences in 
carriers of the translocation might, at least in part, be developmental in origin. 
Alternatively, it is possible that adult neurogenesis is disrupted by the translocation: a 
process in which DISC1 has been implicated (Lee et al., 2015). 
DMP analysis assesses altered methylation on a site-by-site basis, thus ignoring 
potentially informative signal present at neighbouring sites. It can be hypothesised that 
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sub-genome-wide significant differences in methylation across a number of nearby sites 
might confer a biologically meaningful effect, but would remain undetected by DMP 
analysis. To address this, DMR analyses were carried out for both the translocation carrier 
vs. non-carrier and psychotic vs. non-psychotic disorder comparisons. These analyses 
identified one gene, TNXB, as being particularly noteworthy. This gene contained the 
most significant DMR, which comprised 51 probes spanning approximately 1.6 kb, 
identified in the comparison of t(1;11) carriers and non-carriers. This comparison also 
identified a second region within TNXB, 325 bp in length, which comprised eight probes. 
In the comparison of t(1;11) carriers with psychotic and non-psychotic disorders, four 
further TNXB DMRs were identified, one of which fell within the 51-probe DMR 
described above. TNXB encodes Tenascin X, an extracellular glycoprotein, which is 
predominantly expressed in connective tissues. It has been associated with schizophrenia 
in a study of 122 British trios (Wei and Hemmings, 2003) and is located within the 
extended MHC region, which was identified as the most significant locus in a recent 
GWAS of schizophrenia (Ripke et al., 2014).  There is both long-term and recent evidence 
for altered immune function in psychiatric illness (Smith, 1992; Corvin and Morris, 2014; 
Sekar et al., 2016).  
 
Along with the MHC, three additional DMRs were identified within genes from the same 
Psychiatric Genomics Consortium’s most recent GWAS of schizophrenia (Ripke et al., 
2014). Two regions within the genes IGSF9B and CNTN4 showed differential 
methylation in the comparison between t(1;11) carriers and non-carriers. The third, 
identified in the comparison of individuals with psychotic versus non-psychotic disorders, 
was within the cell cycle-regulating gene MAD1L1. This gene has also been found to be 
significantly differentially methylated in a large-scale DNA methylation study of 
schizophrenia (Montano et al., 2016). Montano et al. (2016) also reported significant 
differential methylation of a locus within RPTOR: a gene in which three DMRs were 
identified in the present analyses: one in the comparison of t(1;11) carriers and non-
carriers, and two in the comparison of  t(1;11) carriers with a psychotic disorder compared 
to those with non-psychotic disorders. One of the RPTOR DMRs identified in the 
comparison of individuals with a psychotic disorder vs. non-psychotic disorder consisted 
of four probes, two of which (cg22091236 and cg27457201; both hypermethylated in 
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individuals with a psychotic disorder) have been reported to be hypermethylated in 
schizophrenia by Montano et al. (2016). RPTOR is a key component of mTOR signalling, 
which has been implicated in synaptic plasticity (Reviewed by Graber et al., 2013). 
Another DMR identified in the comparison of t(1;11) carriers with psychotic and non-
psychotic illness which might be relevant to disease is located within 1500 bp of the TSS 
of HTR2A, a serotonin receptor gene. This DMR was hypermethylated in t(1;11) carriers 
with psychosis (p = 0.0003). This region is within 1 kb of rs6311, which has been shown 
by Abdolmaleky et al. (2011) to be associated with hypermethylation of the promoter 
region of HTR2A in post-mortem brains of schizophrenia and bipolar disorder patients. 
The same study also reported that reduced expression of HTR2A, and age-of-onset of 
disease was associated with hypermethylation of the gene’s promoter region. The 
serotonin pathway is a target of mood stabilising and antipsychotic drugs (Schloss et al., 
1998; Meltzer et al., 2012). It is possible that this difference is due to an effect of 
medication in these individuals. However, the relationship between methylation and 
medication status could not be assessed as information regarding medication status of 
these individuals was unavailable. This was also the case for other potential confounders, 
such as smoking status and alcohol intake: both of which have been shown to influence 
DNA methylation (Philibert et al., 2012; Ambatipudi et al., 2016). Should they be 
independent of t(1;11) carrier status or diagnosis, it is hoped that surrogate variable 
analysis would account for these factors. In order to attain information regarding these 
factors, follow-up of these family members is warranted. 
 
A further DMR identified in the comparison of t(1;11) carriers and non-carriers worth 
noting was within a gene coding for the DISC1 interactor TRAK1. TRAK1 and DISC1 
have been shown to interact in mitochondrial trafficking complexes in neurons (Ogawa 
et al., 2014). Mitochondrial trafficking is a critical process in neurons in order to meet 
high-energy requirements at specific regions, such as sites of neurotransmission 
(reviewed by Vos et al., 2010).  
 
It is important to note that none of the DMRs identified contained any of the 13 significant 
DMPs identified when comparing t(1;11) carriers and non-carriers. Of these thirteen 
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DMPs, seven could not have been found to contribute to DMRs due to the fact that they 
are located more than 2000 bp away from the nearest nominally significant DMP – 
outside the bounds of the DMR-calling lasso radius. This highlights a limitation of DMR 
analysis: the identification of DMRs requires several parameters, such as the minimum 
number of probes required to form a DMR and the distance permissible between these 
probes, to be set. As there is a dearth of experimental evidence linking the selection of 
DMR parameters to the identification of biologically meaningful DMRs, the setting of 
these parameters is arbitrary. Bearing this in mind, it may be of interest that three adjacent 
probes immediately telomeric to the chromosome 1 breakpoint were nominally 
significantly hypomethylated in t(1;11) carriers, all mapping to DISC1 and DISC2, 
spanning a 1088 bp region (cg12751277, cg05812666 and cg10483534; unadjusted p ≤ 
0.05). However, these did not meet the criteria for DMR calling as they were spaced 
slightly too far apart. 
 
It is not possible to distinguish between DNA methylation and hydroxymethylation by 
the methods used in this study, posing a limitation to the work presented in this chapter. 
Hydroxymethylation may act as an intermediate between methylation and demethylation 
of DNA. It is possible that the results presented in this chapter are due to mixed effects 
of DNA methylation and hydroxymethylation. However, the reported levels of global 
DNA hydroxymethylation are low in blood (Nestor et al., 2012; Stewart et al., 2015). 
Should both processes be occurring in these samples, further work would be required such 
as oxidative bisulphite treatment in order to determine their individual effects (Booth et 
al., 2013) 
 
It was not possible to determine whether the observed differential methylation was 
associated with a change in gene expression, due to lack of sample availability. This 
presents a challenge in identifying downstream effects of differential DNA methylation 
in these individuals. The recent availability of DNA, RNA and protein from t(1;11) family 
iPSC-derived neurons should go some way to address this. Methylation analysis has been 
performed in these samples, and is the subject of Chapter 5. This work was performed to 
address the hypothesis that the differences in methylation observed at the t(1;11) 
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breakpoints might be observed in other cell types – specifically neurons. Analysis of gene 
expression data from these samples is ongoing which will also allow for the assessment 
of the relationship between DNA methylation and gene expression in t(1;11) individuals.  
 
It has yet to be determined whether the above blood-based methylation differences are 
also present in the brains of these individuals. Walton et al. (2015) reported that only 
4.1% of 450k methylation array probes were strongly correlated between blood and 
neocortex biopsied at the point of surgical intervention for pharmaco-resistant epilepsy 
from the same individual. In contrast, others have reported meQTLs to be consistently 
detected across tissue types (Smith et al., 2014). By virtue of the nature of recombination 
events, it is likely that the translocation is flanked by regions of DNA that are shared more 
frequently between translocation carriers than between non-carriers. As such, it is 
possible that certain translocation-associated effects on methylation might be conveyed 
indirectly by co-inherited genetic sequence. Should the differences in methylation 
observed on chromosomes 1 and 11 in the t(1;11) carrier vs. non-carrier comparison 
reflect the effects of variants in linkage disequilibrium with the translocation, these 
methylation differences might consistently be observed across tissue types.  
 
The results presented in this chapter provide evidence for disrupted DNA methylation in 
the context of a translocation linked to psychiatric illness. However, further experiments 
will be required to determine whether the differences observed here are also present in 
the brains of the individuals profiled, and whether such differences might lead to altered 
gene expression and increased risk of illness.
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5 DNA methylation analysis of t(1;11) family iPSC-derived 
neurons 
5.1 Background and motivation 
Until recently, a major limitation in psychiatric research has been the lack of reliable 
cellular models for illness. One option is post-mortem tissue. However, several 
confounding factors can affect studies of post-mortem brain tissue including post-mortem 
interval, cause of death and age of death (McCullumsmith et al., 2014). Furthermore, it 
is not possible to perform functional assays on post-mortem tissue. Animal models go 
some way to address these issues, but they cannot fully recapitulate the genetic 
architecture or the phenotypic complexity underlying these human-specific disorders. The 
last decade has seen the development of induced pluripotent stem cell (iPSC) technology 
(Takahashi et al., 2007). These cells have the potential to differentiate into any cell type, 
which has permitted the development of specialised in-vitro human disease models using 
relevant cellular systems (reviewed by Ebert et al., 2013).  
 
Chapter 4 describes the assessment of genome-wide DNA methylation in whole-blood 
derived DNA from the t(1;11) family using the Illumina Infinium HumanMethylation450 
BeadChip (450k array; Illumina, San Diego, CA; Bibikova et al., 2011). The 450k array 
was ceased as of December 2015 and has since been superseded by the Illumina Infinium 
HumanMethylationEPIC BeadChip (EPIC array). The EPIC array uses the same 
chemistry as its predecessor to detect methylation using a combination of Type I probes, 
which detect methylated and unmethylated loci using individual assays; and Type II 
probes, which detect both methylated and unmethylated loci with a single assay. Both 
probe types rely on single base extension of a fluorescently labelled nucleotide to generate 
signal. Containing 866,836 probes, the EPIC platform interrogates methylation at 
approximately twice as many loci as the 450k array. The EPIC array includes 
approximately 90% of the 450k array’s probes, thus allowing for high inter-platform 
reproducibility.  
The data described in this chapter were obtained using the EPIC array, using a cellular 
model more physiologically relevant to psychiatric illness than whole blood: iPSC-
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derived cortical neurons from the t(1;11) family. These neurons were differentiated from 
neuronal precursor cells (NPCs) as described in section 2.11. Briefly, NPCs from three 
t(1;11) carriers and three non-carriers were grown to confluency across two six-well 
plates. This was followed by a 5 week differentiation protocol after which DNA, RNA 
and protein were harvested. This was performed three times for each of the six 
individuals, resulting in three technical replicates per individual (n = 18 samples). This 
portion of the work was performed over approximately ten months by Susan Anderson, 
Helen Torrance, Dr. Kirsty Millar and myself. Expression of the neuronal marker βIII-
tubulin was confirmed in these samples by immunocytochemistry experiments performed 
by Dr. Kirsty Millar. There were two aims to this work. Firstly, to investigate whether the 
translocation was associated with differential DNA methylation in these neurons, and 
secondly, to permit the comparison of methylation profiles observed in blood and iPSC-
derived neurons. The work described below was based on the hypothesis that DISC1 
would display differential methylation in t(1;11) neurons as previously observed in whole 
blood (Chapter 4). 
 
5.2 Identification of sub-optimal probes on the Infinium 
HumanMethylationEPIC BeadChip 
At the time of writing this thesis, few resources were available for the analysis of data 
generated on the EPIC array. Quality control and analysis strategies performed on the 
450k array are largely transferable to this platform, due to the similarity of the two arrays. 
However, while Chen et al. (2013) had previously described probes with the potential for 
non-specific binding and probes targeting polymorphic sites on the 450k array, such 
issues had yet to be addressed on the EPIC array.  
 
Prior to the analysis of DNA methylation in iPSC-derived neurons, a list of EPIC array 
probes with non-specific binding potential was generated by following the protocol 
described by Chen et al. (2013), described in section 2.10.2. Additionally, to identify 
probes targeting polymorphic loci, the coordinates of signal-generating sites (i.e. target 
cytosines, guanines and sites of single base extension) were cross-referenced to the 
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current release of the 1000 Genomes Project by Stewart Morris (Phase 3; 1000 Genomes 
Project Consortium, 2015). This resulted in a list of probes with potentially polymorphic 
targets. 
 
5.2.1 Infinium MethylationEPIC BeadChip probes with cross-
hybridisation potential 
Chen et al. (2013) defined cross-hybridising probes as those with ≥ 47 nucleotide off-
target matches that included the end base. This was based on an observed enrichment of 
such autosome-targeting probes which cross-hybridised to sites on the sex 
chromosomes, resulting in spurious sex-associated signals (Chen et al., 2013). To 
identify potentially cross-hybridising probes on the EPIC array, all probe sequences 
were aligned in-silico to eight bisulphite converted genomes (hg19 sequence), each 
representing forward methylated, reverse methylated, forward unmethylated, reverse 
unmethylated genomes, and their complements. In total, 44,210 potentially cross-
hybridising probes, meeting the criteria of ≥ 47 nucleotide off-target matches including 
the end base were identified. These comprised 11,772 Type I probes and 32,438 Type 
II probes. 
 
Consistent with findings on the 450k array (Chen et al., 2013), a larger proportion of 
non-CpG-targeting (CpH) probes (Probe ID prefix = “ch”) were identified as potentially 
cross-hybridising compared with CpG-targeting probes (Probe ID prefix = “cg”). Of 
863,904 CpG-targeting probes present on the array, 42,558 (5% of the total CpG-
targeting probes) were identified as potentially cross-hybridising. In contrast, of 2,932 
CpH-targeting probes, 1,652 were found to be potentially cross-hybridising (56% of the 
total non-CpG-targeting probes). 
 
5.2.2 Infinium MethylationEPIC BeadChip probes with polymorphic 
targets 
Coordinates for the 866,836 probes on the EPIC array were obtained from the array’s 
manifest downloaded on the 8th February 2016. Excluding control probes, the array 
contains 142,262 Type I probes (426,786 potential signal-affecting positions), and 
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724,574 Type II probes (1,449,148 potential signal-affecting positions), giving a total 
of 1,875,934 sites. This list of coordinates was cross-referenced to 1000 genomes data 
(phase 3; 1000 Genomes Project Consortium, 2015). 
 
In total, 340,327 sites were identified with either single nucleotide polymorphisms 
(SNPs), or insertions or deletions (indels). These sites were targeted by 297,744 unique 
probes: 34% of the total probe content of the array. Of these, 23,399 probes (2.7% of 
the total probe content) targeted polymorphic sites with a minor allele frequency (MAF) 
of ≥ 5% in at least one population studied. A table of probes affected by polymorphisms, 
with minor allele frequencies corresponding to African, admixed American, European, 
South Asian, and East Asian populations (AFR, AMR, EUR, SAS, EAS; respectively) 
was compiled as a resource for others to perform population-specific probe filtering.  
 
These lists of potentially cross-hybridising and polymorphism-targeting probes were 
submitted as supplementary information to a publication on these findings, intended to 
be used as a resource for others when analysing data derived from the EPIC array 
(McCartney et al., 2016; Appendix 1). 
 
5.3 Sample information 
DNA from iPSC-derived cortical neurons of three t(1;11) carriers and three non-carriers 
was assessed for differential methylation on the EPIC array. This study consisted of four 
females and two males. The relationship between gender and t(1;11) status was assessed 
by a Fisher’s exact test. A significant relationship was observed between sample carrier 
status and gender (Fisher’s exact test p = 0.001). This was as expected due to sample 
availability: the non-carrier group consisted exclusively of females, with two males 
present among the three t(1;11) carriers. Eighteen samples (i.e. three independent 
neuronal differentiations from each individual) were distributed across three slides, with 
each slide containing one technical replicate per individual. 
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5.3.1 Assessment of Intra-Individual Correlation 
In order to identify outliers among technical replicates which might confound the data, 
correlation of raw methylation data (i.e. pre-normalisation) was assessed for all pairwise 
combinations of each triplicate within each individual. Pearson’s correlation 
coefficients > 0.98 were observed between technical replicates, indicative of high intra-
individual reproducibility (Table 5.1A-F). Cluster analysis was performed across all 
samples on variable probes with a coefficient of variation (CV) > 0.2 (n = 327,588). 
Significant clusters were observed corresponding to technical replicates, gender and an 
unknown factor separating one sample (individual A) from the remaining individuals 
(Figure 5.1). 
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A     B     C    
Sample A1 A2 A3  Sample B1 B2 B3  Sample C1 C2 C3 
A1 1 0.992 0.982  B1 1 0.995 0.995  C1 1 0.988 0.981 
A2 0.992 1 0.986  B2 0.995 1 0.995  C2 0.988 1 0.987 
A3 0.982 0.986 1  B3 0.995 0.995 1  C3 0.981 0.987 1 
              
              
D     E     F    
Sample D1 D2 D3  Sample E1 E2 E3  Sample F1 F2 F3 
D1 1 0.994 0.992  E1 1 0.991 0.991  F1 1 0.994 0.994 
D2 0.994 1 0.995  E2 0.991 1 0.995  F2 0.994 1 0.992 
D3 0.992 0.995 1  E3 0.991 0.995 1  F3 0.994 0.992 1 
Table 5.1: Correlation coefficients between technical replicates for six t(1;11) family members profiled for DNA methylation in 
iPSC-derived neurons. 
Each table presents Pearson’s coefficients of determination (R2) between pairs of DNA methylation profiles from an individual profiled for DNA 
methylation in triplicate. Tables correspond to individuals coded A-F, respectively. Sample IDs are suffixed with numbers 1-3 corresponding to 
neuronal differentiations performed in triplicate for each individual. 
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Figure 5.1: Hierarchical cluster analysis of raw (pre-normalised) methylation data 
from 18 iPSC-derived neuronal samples. 
Shown is a dendrogram assessing the relationship between 18 iPSC-derived neuronal samples 
from six individuals (A-F) based on the raw methylation data. The height of the dendrogram (y-
axis) represents sample variability. Red values at each node correspond to the approximately 
unbiased (au) p-value and green values correspond to the bootstrap probability (bp) percentage 
p–values. au values > 95 indicate clusters supported by the data. Grey numbers at each node 
indicate the edge number. Green boxes highlight the technical replicate clusters (3 per 
individual), blue boxes highlight clustering by gender and red boxes highlight an unknown cluster 
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5.4 Preprocessing of the data generated by analysis of iPSC-
derived neuronal samples 
Prior to analysis of differential methylation, quality control procedures including probe 
filtering and normalisation were performed on the data. Probe filtering was performed to 
ensure only correctly functioning probes were assessed for differential methylation, thus 
reducing both the likelihood of type I error and the multiple testing burden. Normalisation 
was performed to remove systematic sources of variation such as array position and signal 
bias relating to probe type (Teschendorff et al., 2013). Raw (i.e. non-normalised) 
methylation data was read into R with a starting probe count of 866,836. Probes with 
predicted cross-hybridisation potential identified in section 5.2 were removed (n = 
44,210). Whole-genome sequence data from the family were cross-referenced to probe 
coordinates to identify sites containing genetic variation at target CpGs, and sites of single 
base extension, which were also removed (n = 10,107). 
 
Using the filtering criteria described in section 2.10.3, 13,667 probes were removed due 
to having a beadcount of < 3 in 5% of samples, and 2026 probes based on a detection p–
value  > 0.05 in > 1% of samples. None of the samples met these exclusion criteria. 
Following this filtering step, 810,344 probes measuring methylation 18 samples 
remained. 
 
5.5 Selection of normalisation strategy 
In order to determine the optimum normalisation method for this dataset, fourteen 
normalisation methods were compared based on their performance at reducing technical 
variation using three metrics: DMRSE, GCOSE and Seabird (Pidsley et al., 2013; 
Schalkwyk et al., 2013). The top-ranking method was danet (Table 5.2). This method 
equalises background from type I and type II probes, performs quantile normalisation of 
methylated and unmethylated intensities together, and then calculates normalised 
methylation β-values. As there was a significant relationship between t(1;11) carrier 
status and gender, probes targeting the sex chromosomes were removed prior to analysis 
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(n = 17,920). The 59 “rs”-prefixed control probes were also removed at this stage leaving 
781,000 probes in the final dataset.  
 
To determine whether these steps removed the clustering effects identified in Chapter 
6.3.1, hierarchical cluster analysis was performed again on the normalised methylation 
data on probes with a CV ≥ 0.2 (n = 143,852). Six clusters were observed corresponding 
to each individual (Figure 5.2). Data normalisation, along with the removal of sex 
chromosome and control probes resulted in the elimination of the significant gender-
associated cluster, and the cluster separating one individual (individual A) from the rest 


































danet 3 6 2 3.66 1 
nanet 4 7 1 4 2.5 
daten1 5 1 6 4 2.5 
nanes 2 8.5 3 4.5 4.5 
danes 1 8.5 4 4.5 4.5 
naten 7 3 5 5 6.5 
daten2 6 2 7 5 6.5 
dasen 8 4.5 9 7.16 8.5 
nasen 9 4.5 8 7.16 8.5 
SWAN 10 10 12 10.66 10 
BMIQ 11 14 11 12 11 
Noob 14 12.5 10 12.16 12 
PBC 12 11 15 12.66 13 
Raw 13 12.5 13 12.83 14 
danen 15 15 14 14.66 15 
Table 5.2: Performance of fourteen normalisation strategies in neuronal DNA 
methylation samples.  
Table summarises the rankings of three metrics used to assess the performance of 14 
normalisation strategies applied to methylation data, along with non-normalised data (Raw) from 
18 iPSC-derived neuronal samples (i.e. three replicates from six individuals). In order of 
appearance, columns show the normalisation strategy, DMR-standard error (DMRSE) rank, 
genotype-combined standard error (GCOSE) rank, 1 - Seabird AUC rank, mean rank of the three 














Figure 5.2: Hierarchical cluster analysis of danet-normalised methylation data 
from 18 iPSC-derived neuronal samples. 
A dendrogram is presented assessing the relationship between 18 iPSC-derived neuronal samples 
based on the danet-normalised DNA methylation data after removing sex-chromosome probes 
and control probes. The height of the dendrogram (y-axis) represents sample variability. Red 
values at each node correspond to the approximately unbiased (au) p-value and green values 
correspond to the bootstrap probability (bp) percentage p–values. au values > 95 indicate 
clusters supported by the data. Grey numbers at each node indicate the edge number. Red boxes 
highlight clustering by triplicates from each individual (A-F). 
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5.6 Identification of differentially methylated positions in iPSC-
derived neurons 
In order to identify sites showing differential methylation associated with the t(1;11) 
translocation, linear regression was performed. For each set of technical replicates, the 
mean methylation β-value was assessed, comparing six data points. Carriers of the 
translocation (n = 3) were compared to non-carrying individuals (n = 3), covarying for 
gender and mean passage number of NPCs per individual at the point of neuronal 
differentiation. Surrogate variable analysis (SVA) was performed to identify potential 
latent sources of variation present in the data. No significant surrogate variables were 
identified. No DMPs were identified following correction for multiple testing (FDR q 
> 0.05 for all probes; Figure 5.3). A quantile-quantile plot and calculation of the 
genomic inflation factor (λ) indicated deflation of p-values (λ = 0.84; Figure 5.4).  
 
The most significant differential methylation signal was observed within a 443 bp 
intergenic region of chromosome 5. This region contained three probes which were 
hypomethylated in t(1;11) carriers. The top 10 sites ranked by p-value for differential 
methylation are presented in Table 5.3. Large differences in average methylation were 
observed between groups at all of these sites. Beeswarm plots were drawn to visualise 
the distribution of methylation at these sites (Figure 5.5A-J). At nine of these sites, 
clustering was observed around a β-value of 0.2 for all individuals the exception of a 
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Figure 5.3: Manhattan plot of sites assessed for DNA methylation in iPSC-derived neurons from t(1;11) carriers and non-carriers. 
Manhattan plot of the –log10 p–value for differential methylation between t(1;11) carriers and non-carriers (y–axis) against chromosome and position 
(x–axis). The horizontal red line represents the –log10 p–value threshold for genome wide significance corresponding to a false discovery rate of 5%. 
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Figure 5.4: Quantile-quantile plot showing observed vs expected p-values for 
differential methylation between t(1;11) carriers and non-carriers. 
Observed unadjusted –log10 p-values (y-axis; circular points) are plotted against the expected 
distribution of –log10 p-values under the null hypothesis (x-axis; solid diagonal line). The genomic 
inflation factor λ is presented in the upper-left corner of the plot. 
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Table 5.3: Top ten nominally significant differentially methylated positions identified (ranked by p-value) in the comparison of 
DNA methylation profiles from iPSC-derived neurons in t(1;11) carriers and non-carriers. 
Shown are nominally significantly differentially methylated sites between t(1;11) carriers and non-carriers in iPSC-derived neuronal DNA (p ≤ 0.05). In 
order of column appearance are probe identifiers, Hg19 genomic coordinates, UCSC reference gene names (“NA” denotes intergenic regions), between-
group difference in mean beta-value, fold-change in methylation between groups, moderated t-statistic, p-value for differential methylation and FDR-
adjusted p-value. 
 
Probe ID Hg19 Coordinates Gene Beta Difference Fold-Change t DMP p-value DMP q - value 
cg07137955 Chr5:42992774 NA 0.313916337 7.19 36.06 7.31 x 10-6 1 
cg21889472 Chr5:42992555 NA 0.259492632 6.78 33.74 9.35 x 10-6 1 
cg03894174 Chr5:42992998 NA 0.247769856 5.25 31.79 1.16 x 10-5 1 
cg12356111 Chr2:203879443 NBEAL1 0.185736306 5.15 27.30 2.05 x 10-5 1 
cg26171523 Chr19:13858605 CCDC130 0.178365793 6.17 27.06 2.11 x 10-5 1 
cg24153071 Chr19:13858573 CCDC130 0.19816271 4.62 26.5 2.29 x 10-5 1 
cg20146541 Chr1:248020697 TRIM58 0.583503247 12.92 26.35 2.33 x 10-5 1 
cg09209679 Chr22:49051077 FAM19A5;FAM19A5 0.227795233 2.35 24.21 3.19 x 10-5 1 
cg11631775 Chr11:36616251 C11orf74;RAG2 0.169545168 3.76 24.12 3.23 x 10-5 1 
cg26494441 Chr22:32601101 RFPL2 0.171565868 3.77 23.77 3.41 x 10-5 1 
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Figure 5.5: Beeswarm plots of top 10 differentially methylated sites in iPSC-derived t(1;11) samples. 
Shown are methylation β-values for each sample (y-axis) plotted against t(1;11) status (x-axis) for the top 10 differentially methylated sites between 
t(1;11) carriers and non-carriers. Non-carriers of the translocation are denoted “N” while carriers are denoted “T”. Mean methylation β-values from 
triplicates corresponding to each individual are represented by a point on each plot. Points are colour-coded blue for translocation non-carriers and red 
for t(1;11) carriers. 
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5.7 Gene ontology analysis of differentially methylated positions in 
iPSC-derived neurons 
To identify any biological processes, molecular functions or cellular components that 
were significantly over-represented amongst the genes showing the most significant 
differences in methylation in t(1;11) carriers, gene ontology analysis was performed. A 
ranked list of p–values for differential methylation between t(1;11) carriers and non-
carriers was submitted to GOrilla for analysis. A total of 194 terms were significantly 
over-represented amongst the most differentially methylated genes (q ≤ 0.05; Table 5.4). 
The most significantly over-represented term was “plasma membrane part” 
(GO:0044459; q = 3.57 x 10-12), present in the GO components class. The most 
significantly over-represented GO process was “organ morphogenesis” (GO:0009887; q 
= 4.72 x 10-11) while the most significantly over-represented GO function was “sequence-
specific DNA binding” (GO:0043565; q = 9.02 x 10-5). Multiple terms relating to 
neuronal function and neurodevelopment were enriched amongst the differentially 
methylated genes in t(1;11) carriers, including “glutamate receptor activity” 
(GO:0008066; q = 0.0001), “modulation of synaptic transmission” (GO:0050804; q = 
9.36 x 10-7), “neuron part” (7.11 x 10-6) and “central nervous system development” 
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GO Term Description Class Enrichment P-value FDR q-value 
GO:0044459 Plasma membrane part Component 433/2385 2.09 x 10-15 3.57 x 10-12 
GO:0009887 Organ morphogenesis Process 114/424 3.32 x 10-15 4.72 x 10-11 
GO:0048856 Anatomical structure development Process 516/2969 3.81 x 10-14 2.70 x 10-10 
GO:0032502 Developmental process Process 654/3896 3.86 x 10-13 1.82 x 10-9 
GO:0005886 Plasma membrane Component 596/3766 2.49 x 10-11 2.12 x 10-8 
GO:0048731 System development Process 141/629 7.86 x 10-12 2.79 x 10-8 
GO:0009653 Anatomical structure morphogenesis Process 245/1229 1.61 x 10-11 4.58 x 10-8 




Process 567/3416 2.31 x 10-10 4.69 x 10-7 
GO:0048562 Embryonic organ morphogenesis Process 41/115 3.37 x 10-10 5.99 x 10-7 
Table 5.4: Summary of GO terms found to be enriched amongst the most 
differentially methylated genes in iPSC-derived neurons of t(1;11) carriers. 
For each GO term, table summarises the GO identifier, the GO description, the GO class, 
enrichment, the enrichment p-values, and enrichment FDR q-values for genes showing the most 
differential methylation in t(1,11) carriers compared to non-carriers. Enrichment is defined as 
(b/n) / (B/N), where b = the number of genes at the top of the p-value ranked list that is associated 
with a given GO term, n = the number of genes at the top of the p-value-ranked gene list, B = the 
total number of genes associated with a given GO term, and N = the total number of genes. Shown 
are the top 10 enrichments ranked by p-value. The total list of significant enrichments is presented 
in Appendix I (Table A6). 
 
5.8 Identification of differentially methylated regions in iPSC-
derived neurons 
In order to identify discrete genomic regions containing multiple nominally significantly 
differentially methylated probes (p ≤ 0.05) in t(1;11) carriers, differentially methylated 
region (DMR) analysis was performed. DMRs were assessed using the ChAMP package’s 
probe lasso algorithm (Butcher and Beck, 2015). A total of 424 nominally significant 
DMRs (p ≤ 0.05) were identified between t(1;11) carriers and non-carriers. The most 
significant DMR in t(1;11) carriers overlapped two genes, mapping to IER3, and FLOT1, 
which is located antisense to IER3 (p = 7.72 x 10-29). This region is within the major 
histocompatibility complex (MHC). The nearest DMR to the chromosome 1 translocation 
breakpoint is located approximately 12 Mb telomeric in an intergenic region (chr1: 
244395115-244395352; p = 0.0002). On chromosome 11, the nearest DMR to the 
 
Chapter 5  181 
    
breakpoint is approximately 21 Mb centromeric, also within an intergenic region 
(Chr11:69286177-69286467; p = 0.0002).  
 
The largest DMR identified fell within the chromosome 10 gene MGMT, spanning 8.9 kb 
and extending from the gene body to an intergenic region downstream of the gene. A 
further nine DMRs were identified within MGMT. Along with MGMT, 13 additional 
genes were identified containing multiple DMRs. Of these, SORCS1, a member of the 
Sortilin gene family, contained two DMRs (p = 1.57 x 10-5 and p = 0.0004). Four DMRs 
were identified within DLGAP2 (p = 4.26 x 10-5 – 0.0118). A single DMR was present in 
SV2B: a gene found to be differentially expressed in t(1;11) carrier lymphoblastoids in 
Chapter 3 (DMR p = 0.0036).  Seven DMRs were within genes found to contain DMRs 
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FLOT1, IER3 TSS1500, 3'UTR, Body Chr6:30710912-30711968 26 7.72 x 10-29 
GNASAS, GNAS 3'UTR, TSS1500 Chr20:57425870-57427652 51 1.96 x 10-20 
CCDC130 TSS1500, TSS200 Chr19:13858480-13858585 5 1.46 x 10-15 
SNORD116-15 - SNORD116-19 TSS1500, TSS200, Body Chr15:25325510-25330514 16 1.46 x 10-15 
C22orf32, SMDT1 TSS200, 1stExon Chr22:42475680-42475844 6 4.10 x 10-15 
MIR4458HG, LOC729506 Body Chr5:8457127-8457933 7 1.89 x 10-14 




Chr13:36871465-36872189 10 6.16 x 10-13 
GDNF Body, 5'UTR Chr5:37834742-37835348 9 1.18 x 10-12 
RFPL2 TSS1500 Chr22:32601040-32601418 4 2.08 x 10-12 
Table 5.5: DMRs identified between t(1;11) carriers and non-carriers in iPSC-
derived neurons. 
From left to right, columns summarise the DMR-containing genes, the DMR’s underlying 
genomic features, the Hg19 genomic coordinates of each DMR, the number of probes within each 
DMR, and the p-value for differential methylation in t(1;11) carriers. Genes highlighted with a 
red asterisk (*) indicate those that also contained t(1;11)-associated DMRs identified in blood. 
Shown are the top 10 DMRs ranked by p-value. The total list of significant DMRs is presented in 
Appendix I (Table A7). 
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5.9 Comparison with results obtained from the profiling of DNA 
methylation in blood samples from t(1;11) carriers and non-
carriers 
In order to compare the neuronal results to the t(1;11)-associated findings in blood 
(Chapter 4), a direct assessment of DNA methylation in neurons was carried out at the 13 
differentially methylated probes identified in blood (q ≤ 0.05; Table 4.3). Of these 13 
probes, one showed nominally significant differential methylation between t(1;11) 
carriers and non-carriers in neurons (cg26728851; p = 0.017; Table 5.6). This probe 
mapped to the 3’UTR of GUCY2E, on chromosome 11 and was hypomethylated in t(1;11) 
carriers in both blood and iPSC-derived neurons. 
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Table 5.6: DNA methylation in iPSC-derived neurons at 13 probes found to show significant differential methylation in a 
comparison of blood DNA from t(1;11) carriers and non-carriers.                    
Summary of DNA methylation in iPSC-derivatives at the thirteen probes significantly differentially methylated in blood. Columns show the probe 
identifiers, Hg19 genomic coordinates, UCSC reference gene names (“NA” denotes intergenic regions). From the methylation analysis in blood, shown 
are mean methylation β-values in t(1;11) carriers, mean methylation β-values in t(1;11) non-carriers, and between-group difference in mean methylation 
β-values are presented. From the methylation analysis in iPSC-derived neurons, shown are mean methylation β-values in t(1;11) carriers, mean 
Probe ID Hg19 Coordinates Gene 





























cg26728851 Chr11:76430375 GUCY2E 0.93 0.90 -0.07 0.94 0.87 -0.07 -1.07 -4.05 0.02 1.00 
cg26355502 Chr1:221916303 DUSP10 0.07 0.06 -0.01 0.08 0.06 -0.02 -1.27 -2.22 0.10 1.00 
cg02771260 Chr11:59836817 MS4A3 0.58 0.45 -0.13 0.50 0.32 -0.18 -1.58 -1.60 0.19 1.00 
cg24508974 Chr10:103330391 NA 0.12 0.14 0.02 0.25 0.22 -0.03 -1.14 -1.50 0.21 1.00 












0.81 0.78 -0.03 0.50 0.43 -0.07 -1.16 -0.28 0.79 1.00 
cg18815120 Chr1:231512676 EGLN1 0.34 0.22 -0.12 0.81 0.81 0.00 1.01 -0.16 0.88 1.00 
cg06928246 Chr1:227974645 NA 0.66 0.59 -0.07 0.76 0.67 -0.09 -1.13 0.15 0.89 1.00 
cg21875980 Chr1:231553510 EGLN1 0.42 0.48 0.06 0.43 0.39 -0.04 -1.10 -0.13 0.91 1.00 




0.74 0.67 -0.07 0.58 0.61 0.03 1.06 -0.05 0.96 1.00 
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methylation β-values in t(1;11) non-carriers, between-group difference in mean methylation β-values, fold-change between groups, moderated t-statistic, 
p-value for differential methylation and FDR-adjusted p-value (q-value). 
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5.10 DNA Methylation in six blood samples corresponding to iPSC-
derived neurons 
To determine whether the results in neurons might be more comparable to those in blood 
given the same set of individuals, the blood-based dataset described in Chapter 5 was 
subsetted to contain the same six individuals for whom neuronal DNA methylation was 
measured. As gender and t(1;11) status were significantly correlated in these individuals 
(section 5.3, Fisher’s exact test p = 0.001), sex chromosome probes were removed. 
Surrogate variable analysis was performed on this dataset with no significant surrogate 
variables identified. Linear regression was performed to assess differential methylation 
in t(1;11) carriers, covarying for age and gender.  
 
Six sites were significantly differentially methylated in the comparison of blood DNA 
from three t(1;11) carriers and three non-carriers (q ≤ 0.05; Figure 5.6; Table 5.7). None 
of these six sites were among the 13 found to show differential methylation in the 
complete blood DNA sample set (n = 41 individuals). However, in the six blood samples, 
nine of these 13 sites showed nominally significant differential methylation between 
t(1;11) carriers and non-carriers, all of which showed the same direction of effect as in 
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Figure 5.6:  Manhattan plot of sites assessed for DNA methylation in six blood samples corresponding to iPS-derived neuronal 
samples.                             
Shown are –log10 p – values between t(1;11) carriers and non-carriers (y – axis) plotted against chromosomal position (x–axis). The horizontal red line 




Chapter 5        188 







Table 5.7: Table of significantly differentially methylated positions between t(1;11) carriers and non-carriers in the six blood 
samples corresponding to iPSC-derived neuronal samples. 
Differentially methylated sites between t(1;11) carriers and non-carriers in six blood samples corresponding to iPSC-derived neuronal samples (q ≤ 
0.05). From left to right, columns show the probe identifiers, Hg19 genomic coordinates, UCSC reference gene names (“NA” denotes intergenic regions), 
between-group difference in mean methylation β-values, fold-change between groups, moderated t-statistic, p-value for differential methylation, and 







Probe ID Hg19 Coordinates Gene Beta Difference Fold-Change t DMP p-value DMP q-value 
cg27319123 Chr11:30038286 KCNA4 0.17 2.39 22.32 2.51 x 10
-8 0.011 
cg06850186 Chr7:104580787 NA -0.39 -1.72 -19.46 7.16 x 10-8 0.015 
cg24668570 Chr10:134973778 KNDC1 0.18 2.12 18.19 1.20 x 10-7 0.017 
cg23203918 Chr8:128235836 NA -0.12 -1.17 -16.70 2.29 x 10-7 0.025 
cg15668967 Chr5:1180364 NA -0.12 -1.18 -15.41 4.22 x 10-7 0.036 
cg24801230 Chr17:43978533 MAPT -0.38 -1.96 -15.07 4.99 x 10-7 0.036 
 
Chapter 5        189 













    
Table 5.8: Summary of DNA methylation in the blood sample subset (n =6) at probes significantly differentially methylated in the 
blood sample superset (n =41). 
Columns show probe identifiers, Hg19 genomic coordinates, UCSC reference gene names (“NA” denotes intergenic regions), between-group difference 
in mean methylation β-values, fold-change between groups, moderated t-statistic, p-value for differential methylation and FDR-adjusted p-value (q-value) 
for six blood samples at 13 sites previously found to be significantly differentially methylated in the total blood sample (n = 41; q ≤ 0.05). 
Probe ID Hg19 Coordinates Gene Beta Difference Fold-Change t DMP p-value DMP q - value 
cg02771260 Chr11:59836817 MS4A3 -0.16 -1.42 -6.49 0.0002 0.60 
cg21875980 Chr1:231553510 EGLN1 0.19 1.58 5.18 0.0009 0.97 
cg26728851 Chr11:76430375 GUCY2E -0.04 -1.05 -4.45 0.002 0.97 
cg06928246 Chr1:227974645 NA -0.06 -1.11 -3.08 0.016 0.97 
cg15157974 Chr1:232144702 DISC1;TSNAX-DISC1 -0.05 -1.06 -2.93 0.02 0.97 
cg05656812 Chr1:232021560 DISC1;TSNAX-DISC1 -0.07 -1.10 -2.85 0.02 0.97 
cg18815120 Chr1:231512676 EGLN1 -0.05 -1.17 -2.83 0.02 0.97 
cg26355502 Chr1:221916303 DUSP10 -0.02 -1.40 -2.80 0.02 0.97 
cg00965168 Chr1:227974541 NA -0.07 -1.10 -2.70 0.03 0.97 
cg09186051 Chr1:231981906 DISC1;TSNAX-DISC1 -0.09 -1.13 -1.84 0.10 0.97 
cg24508974 Chr10:103330391 NA 0.04 1.36 1.24 0.25 0.97 
cg16177633 Chr1:232172585 DISC1;TSNAX-DISC1 -0.03 -1.04 -1.08 0.31 0.97 
cg25899154 Chr11:72897143 NA -0.008 -1.02 -0.25 0.81 0.99 
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5.11 Correlation between blood and iPSC-derived neurons 
As blood-based studies of DNA methylation in psychiatric disorders are unlikely to be 
entirely representative of DNA methylation in the brain, it is important to consider the 
correlation of methylation levels between tissues from the same individuals. Using 
cortical tissue biopsied from drug-resistant epilepsy patients, Walton et al., (2015) 
reported significant correlation between DNA methylation in blood and brain at 4.1 % of 
the probes of the 450k array. They reported a ranked list of the top 100 probes correlated 
between blood and brain (Spearman’s Rho ≥ 0.94). In order to determine whether the 
same correlation could be observed between whole blood and iPSC-derived neurons from 
the t(1;11) family, a pairwise analysis of methylation at the 397,244 probes common to 
both blood and neuronal analyses was performed. First, the 100 probes reported by 
Walton et al., (2015) as correlated between blood and brain were assessed in t(1;11) 
individuals. Among the 100 blood-brain correlated probes reported, 65 probes were 
present in both the blood and neuronal datasets, due to the removal of 35 probes during 
quality control procedures in these analyses. For the six individuals with both blood and 
iPSC-derived neuronal methylation data, Spearman’s correlation coefficients were 
calculated for methylation at these probes. These between-tissue correlation coefficients 
were compared with those by Walton et al. (2015) using a paired t-test. The mean 
difference between the correlation coefficients in the t(1;11) samples and the correlation 
coefficients presented by Walton et al., (2015) was significantly different from zero 
(paired sample t-test p  < 2.2 x 10-16; Figure 5.7). 
 
In order to assess whether the 13 DMPs identified in the t(1;11) blood-based analysis 
were correlated with iPSC-derived neurons, correlation coefficients were assessed at 
these sites. Of the 13 DMPs, the highest correlation was observed at cg26728851, 
mapping to GUCY2E on chromosome 11 (Spearman’s Rho = 0.91). This site showed 
nominally significant differential methylation (p < 0.05) in iPSC-derived neurons as well 
as the corresponding subset of blood samples. 
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Figure 5.7: Comparison of correlation coefficients for 65 probes reported by Walton et al. (2015) as correlated between blood and 
brain. 
Shown are Spearman’s correlation coefficients (Rho; y-axis) for 65 probes reported to be correlated between blood and brain by Walton et al. (2015; x-
axis). The red line represents the correlation coefficient between blood and iPSC-derivatives in six t(1;11) family samples. The blue line represents the 
correlation coefficients of same probes in blood and brain, as reported by Walton et al. (2015). 
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Table 5.9: Blood/iPSC-derived neuron correlation coefficients between 
significantly differentially methylated sites in blood. 
Table summarises DNA methylation data for 13 probes significantly differentially methylated 
between t(1;11) carriers and non-carriers in whole blood (n = 41 samples). From left to right, 
columns show the probe ID, the associated gene (“NA” denotes intergenic), the p-value for 
differential methylation in six blood samples corresponding to iPSC-derived neurons, the FDR 
adjusted p-value for differential methylation in the same samples, the p-value for differential 
methylation in six iPSC-derived neurons, the adjusted p-value for differential methylation in the 
same samples, and the correlation coefficient for the probe between six blood samples and the 























cg26728851 GUCY2E 0.002 0.97 0.02 1 0.91 
cg26355502 DUSP10 0.02 0.97 0.1 1 0.75 
cg09186051 DISC1;TSNAX-DISC1 0.1 0.97 0.96 1 0.41 
cg02771260 MS4A3 0.0002 0.6 0.19 1 0.40 
cg00965168  NA 0.03 0.97 0.94 1 0.34 
cg05656812 DISC1;TSNAX-DISC1 0.02 0.97 0.77 1 0.26 
cg18815120 EGLN1 0.02 0.97 0.88 1 0.19 
cg06928246  NA 0.016 0.97 0.89 1 0.16 
cg16177633 DISC1;TSNAX-DISC1 0.31 0.97 0.79 1 0.14 
cg24508974  NA 0.25 0.97 0.21 1 0.02 
cg15157974 DISC1;TSNAX-DISC1 0.02 0.97 0.48 1 0.003 
cg21875980 EGLN1 0.0009 0.97 0.91 1 0.003 
cg25899154  NA 0.81 0.99 0.26 1 0.003 
 
Chapter 5  193 
    
5.12 Analysis of methylation quantitative trait loci in iPSC-derived 
neurons 
DNA methylation can be influenced by both environmental and genetic variation at linked 
and independent loci (Lemire et al., 2015). A significant relationship was identified 
between DNA methylation and previously reported (Lemire et al., 2015) methylation 
quantitative trait loci (meQTLs) at five of the 13 DMPs identified in t(1;11) blood samples 
(section 4.2.7; Table 4.6; Figure 4.3). To determine whether the same SNPs might act as 
meQTLs in iPSC-derived neurons, linear regression was performed to assess the 
relationship between minor allele count and DNA methylation at these five sites. No 
significant relationship was observed between genotype and DNA methylation for any of 
these SNPs (p ≥ 0.57). To determine whether this could be due to the difference in the set 
of individuals tested for meQTLs, six blood samples corresponding to iPS neurons were 
also examined at these variants of interest. Here, a significant relationship was observed 
between genotype at rs4366301 and DNA methylation at cg16177633 (p = 0.01), with 
both the meQTL and CpG mapping to DISC1. For the remaining sites, no significant 





(n = 6) 
Blood p-value 
(n = 6) 
Blood p-value 
(n = 41) 
rs2486729/cg18815120 0.95 0.75 1.26 x 10
-16 
rs545937/cg21875980 0.99 0.41 4.26 x 10
-5 
rs4366301/cg16177633 0.78 0.01 0.001 
rs10899287/cg26728851 0.78 0.86 2.05 x 10
-5 
rs17154511/cg02771260 0.57 0.90 4.68 x 10
-12 
Table 5.10: Analysis of previously-reported meQTLs in blood and iPSC-derived 
neurons. 
Relationships were assessed between meQTL genotype and CpG methylation levels at previously 
reported meQTLs present in t(1;11) family blood-derived samples (n = 41). Shown in order of 
column appearance are the meQTL SNP ID and associated CpG probe, p-values for association 
between meQTL genotype and DNA methylation at the reported site in iPSC-derived neurons (n 
= 6), the subset of blood samples corresponding to neurons (n = 6), and the total blood sample 
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5.13 Estimation of DNA methylation age of iPSC-derived Neurons 
In order to assess whether the translocation had an effect on DNA methylation age in 
iPSC-derived neurons, DNA methylation age was calculated using Horvath’s DNA 
methylation age calculator (Horvath, 2013; section 4.5). An additional aim of this analysis 
was to determine whether DNA methylation age corresponded with patient age at the time 
of fibroblast biopsy, or whether it showed correlation with NPC passage number at the 
point of neuronal differentiation. Linear regression was performed to assess the 
correlation between DNA methylation age and age at the time of fibroblast biopsy. No 
significant correlation was observed between DNA methylation age and age of fibroblast 
biopsy (r2 = 0.003, p = 0.82). Additionally, correlation between DNA methylation age 
and cell passage number at the time of initiation of neuronal differentiation was assessed 
using linear regression. No significant correlation was observed between DNA 
methylation age and cell passage number (r2 = 0.13, p = 0.14).  
 
The average DNA methylation age of t(1;11) carriers was  9.9 years (SD = 6.11 years), 
while the average DNA methylation age of non-carriers was 7.01 (SD = 2.85 years). Age 
acceleration (i.e. DNA methylation age minus chronological age) was negative in all 
samples, with no significant between-group differences observed (student’s t-test p = 
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Figure 5.8: Age acceleration in iPSC-derived neurons. 
Age acceleration (y-axis) is plotted against sample group (x-axis) for 18 iPSC-derived neuronal 
samples (n = 9 per group: 3 technical replicates from 3 individuals). “N” indicates t(1;11)  non-
carriers (blue bar) while “T” indicates t(1;11) carriers (red bar). Age acceleration is calculated 
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Sample DNA methylation age NPC passage 
A1 7.17 18 
A2 7.44 18 
A3 14.08 25 
B1 4.89 27 
B2 4.99 27 
B3 4.67 27 
C1 22.35 27 
C2 15.86 34 
C3 14.27 36 
D1 6.09 16 
D2 6.66 20 
D3 7.11 22 
E1 6.16 26 
E2 5.65 29 
E3 7.52 30 
F1 5.58 25 
F2 6.45 28 
F3 5.32 26 
Table 5.11: Summary of DNA methylation age estimates in iPSC-derived neurons. 
Columns show sample IDs corresponding to three differentiations each from individuals A-F, the 
DNA methylation age estimate, and the passage number of NPCs at initiation of neuronal 
differentiation.
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5.14 Discussion 
The aim of this study was to determine whether the t(1;11) translocation was 
associated with differential methylation in a cellular model relevant to psychiatric 
illness: iPSC-derived neurons. An additional aim of this work was to compare DNA 
methylation differences between t(1;11) carriers and non-carriers identified in blood 
with those identified in iPSC-derived neurons. Three lines of iPSC-derived neuronal 
precursor cells from each of six t(1;11) family members were differentiated into 
cortical neurons for DNA methylation analysis using the Infinium MethylationEPIC 
BeadChip (EPIC array). Of these six individuals, three were t(1;11) carriers and three 
were non-carriers.  
 
Prior to analysing the data, sub-optimal probes present on the EPIC array were 
identified by in-silico methods, following a previously-published protocol (Chen et 
al., 2013). A list of probes targeting known polymorphic sites was generated along 
with a list of potentially cross-hybridising probes. These lists were published as a 
resource for others analysing data derived from the EPIC array, who may wish to 
consider such probes for removal as a quality control measure (Appendix 1; 
McCartney et al., 2016). 
 
To determine whether the translocation was associated with differential methylation 
in iPSC-derived neurons, DNA methylation was compared between t(1;11) carriers to 
non-carriers. Methylation differences in nine of the top ten ranked loci were mostly 
driven by a single individual - a t(1;11) carrier - which consistently displayed 
hypermethylation relative to the remaining five individuals profiled. Among the top 
ten differentially methylated loci between t(1;11) carriers and non-carriers, one locus 
did not show this effect, with consistent levels of hypermethylation observed among 
translocation carriers (cg20146541; Figure 5.3). This site was located in TRIM58, 
approximately 16 Mb telomeric of the chromosome 1 breakpoint, and was among three 
probes constituting a significant DMR identified in t(1;11) carriers (Chr1:248020638-
248020745, p = 4.74 x 10-10). This outlier sample was retained, having not been 
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flagged as a failure during the quality control check. It should therefore be noted that 
the results discussed here are in the context of this outlier sample. Due to the low 
number of samples in this study, it is possible that the methylation profile of this 
sample is not anomalous, but similar to the profiles of samples from other family 
members who have yet to be assessed for DNA methylation. This will likely be 
clarified should additional iPSC-derived neuronal samples undergo methylation 
profiling in the future. 
 
No differences in DNA methylation were observed between t(1;11) carriers and non-
carriers following correction for multiple testing (q ≤ 0.05). Deflation of p-values for 
differential methylation was observed, suggesting the study is underpowered to detect 
genome-wide significant differences in methylation. The most significant differential 
methylation signal observed was on chromosome 5, in a 224 bp region containing the 
top three sites ranked by p-value. Although not annotated to a gene by the Illumina 
manifest, UCSC genome browser reports the presence of a validated RefSeq gene at 
this site: an uncharacterised long noncoding RNA (lncRNA; FLJ32255). Furthermore, 
the region containing these probes is a DNAse hypersensitivity site and contains 
multiple chromatin immunoprecipitation (ChIP)-identified transcription factor binding 
sites as reported by ENCODE: features that suggest a regulatory role. Further 
investigation of the expression and/or function of this gene would be useful to 
determine whether its disrupted methylation might confer downstream effects in 
t(1;11) carriers.  
 
Gene ontology analysis was performed on the DMP data to identify functions, 
processes or components that are significantly enriched amongst the most 
differentially methylated genes. Multiple terms relating to synaptic activity, 
development and cell signalling were among those over-represented amongst the 
genes harbouring the most significant DMPs. This data might indicate that disrupted 
neurotransmission and neurodevelopment are associated with the translocation in 
neurons. This would be in keeping with the known functions of DISC1, which is 
interrupted by the translocation (Brandon and Sawa, 2011; section 1.4.3-4). The most 
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significantly over-represented function was “sequence-specific DNA binding” 
(GO0043565; q = 9.05 x 10-5). This may be indicative of downstream effects of the 
t(1;11) translocation on gene expression through disruptions to transcription factor 
binding. Soda et al. (2013) reported an interaction between the DISC1-ATF4 complex 
and the PDE4D locus, regulating its expression. Further experiments such as ChIP 
analysis of these samples might be useful to establish whether there are disruptions to 
such protein-DNA interactions in t(1;11) carriers, and whether such disruptions are 
linked to aberrant gene expression.  
 
A total of 424 DMRs were identified in t(1;11) carriers. Multiple DMRs were 
identified in 14 genes. Four DMRs were identified within DLGAP2, a gene in which a 
psychosis-associated DMR was also identified in t(1;11) blood samples in Chapter 5. 
DLGAP2 plays a role in synapse organisation and has been implicated in schizophrenia 
(Li et al., 2014). Ten DMRs were identified in the DNA-repair gene MGMT. A DMR 
was also identified within 1500 bp of the TSS of BRCA1, another DNA repair gene 
(Moynahan et al., 1999). Aberrant expression of DNA repair genes has been reported 
in psychotic disorders (Benes et al., 2009). It is possible that disrupted methylation in 
such genes may affect their capacity for DNA repair in t(1;11) carriers, conferring an 
increased risk of illness in these individuals. Amongst the genes containing multiple 
DMRs was SORCS1, in which two hypermethylated regions were observed. SORCS1 
is a member of the brain-expressed Sortilin gene family described in Chapter 4. 
Expression of another member of this gene family, SORL1, was found to be decreased 
in t(1;11) carrier lymphoblastoid samples, described in Chapter 3. Moreover, others 
have reported dysregulation of Sortilin family members in DISC1 mutant iPSC-
derived neurons (Wen et al., 2014; Srikanth et al., 2015). Taken together, these 
findings may suggest interplay between DISC1 and the Sortilin genes. Based on this, 
a regulatory relationship between DISC1 and Sortilin family members was further 
investigated. This work is reported in Chapters 6 and 7 of this thesis. 
 
A limitation to the DMR analysis which must be considered is that larger genes will 
contain more probes to interrogate methylation, and therefore a greater likelihood of 
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obtaining a significant p-value for differential methylation due to chance. With this in 
mind, of the fourteen genes containing multiple DMRs, the median probe count per 
gene was 72. The median gene count across all genes on the EPIC array is 20 (Phipson 
et al., 2016). Therefore, confirmation of findings from DMR analyses by targeted 
methods such as pyrosequencing of bisulphite-converted DNA is warranted, should 
meaningful conclusions be made from this analysis. 
 
Seven DMR-containing genes identified in this study were also found to contain 
DMRs in the blood-based study. Disrupted methylation in one of these genes, OR2L13, 
has been implicated in autism by two independent studies using different tissue sources 
(Wong et al., 2014 [peripheral blood]; Berko et al., 2014 [buccal endothelium]). 
OR2L13 is located at the telomeric end of chromosome 1q. Autism has not been 
reported in the t(1;11) family. However, overlap has been reported in the genetic 
architecture of several neuropsychiatric disorders, including autism, MDD, bipolar 
disorder and schizophrenia (Smoller et al., 2013). Individuals carrying the t(1;11) 
translocation have an increased risk of recurrent MDD, bipolar disorder and 
schizophrenia (Thomson et al., 2016). Therefore, expression and functional follow-up 
studies of OR2L13 in the t(1;11) family may inform of possible roles for the gene in 
conferring increased risk of illness in t(1;11) carriers. Another DMR-containing gene 
worth noting is COMT, which, although not associated with schizophrenia through 
GWAS, has been the subject of numerous candidate gene association studies of 
schizophrenia described in section 1.3. This DMR spanned the TSS region of the gene, 
which may be indicative of altered COMT expression in t(1;11) carriers, as previously 
observed in cases of schizophrenia (Bray et al., 2003).  
 
The work presented in Chapter 4 reported significant differential methylation in t(1;11) 
carriers at 13 sites in an analysis of 41 blood-derived DNA samples. Twelve of these 
sites were within the t(1;11) breakpoint regions. Differential methylation was not 
observed at the t(1;11) breakpoint regions in the iPSC-derived neuronal samples. To 
determine whether the discrepancy between these findings might have been 
attributable to the difference in the individuals assessed for methylation, blood-derived 
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methylation data was examined in the six individuals corresponding to the iPSC-
derived samples examined above. No genome-wide significant differences in 
methylation were observed at these 13 loci in the analysis of the subset of blood 
samples corresponding to the iPSC-derived neurons.  
 
There are several possible reasons for the differing results found in blood compared to 
iPSC-derived neurons. It is possible that the differences are due to tissue-specific 
differences DNA methylation, with blood and brain having distinct DNA methylation 
signatures in these individuals. However, it is not possible to determine this from 
iPSC-derived neurons as they cannot faithfully recapitulate the human brain. The 
artificial nature in which these samples were grown is unlikely to reflect the three-
dimensional system (i.e. the human brain) in which cortical neurons develop. 
Furthermore, the samples described in this analysis have undergone extensive 
reprogramming from the point of fibroblast biopsy, along with exposure to various cell 
culture conditions. Nazor et al. (2012) reported aberrant methylation levels at 
imprinted loci in iPSCs that were not repaired upon differentiation. It is possible that 
differential methylation is indeed present around the t(1;11) breakpoint regions in the 
brains of translocation carriers and this is not recapitulated by an iPSC-derived model 
due to disrupted DNA methylation during reprogramming. The small sample size may 
also have presented an issue with power to detect significant differential methylation. 
Horvath (2013) reported DNA methylation age in brain samples was significantly 
correlated with chronological age, as well as in whole blood. DNA methylation age 
and chronological age were significantly correlated in whole blood from these 
individuals (section 4.5, Figure 4.6) but not in the iPSC-derived neuronal samples. It 
is therefore likely that the methylomes of these samples are not reflective of those in 
the brains of t(1;11) family members. This is not unexpected, as others have reported 
significant correlation between transcriptomes of iPSC-derived neurons and foetal 
brains, but not adult brains (Handel et al., 2016). Analysis of DNA methylation in 
post-mortem or biopsied brain tissue from t(1;11) family members would be required 
to generate conclusive results as to whether differential methylation occurs at the 
t(1;11) breakpoint regions in the brain. Analysis of other primary tissues from these 
 
Chapter 5  202 
    
individuals might also be informative as to whether differential methylation at the 
t(1;11) breakpoint regions occurs across tissues in these individuals.  
 
Correlation between DNA methylation in iPSC-derived neurons and blood from the 
t(1;11) family was assessed for a set of probes that were previously reported by Walton 
et al. (2015) to be significantly correlated between blood and brain. No significant 
agreement was observed between these studies. The samples used by Walton et al. 
(2015) consisted of temporal lobe biopsies (neocortex) while the iPSC-derivatives 
from this study were representative of frontal cortical neurons. Hannon et al. (2015) 
have reported high levels of correlation of DNA methylation between different cortical 
regions. This would suggest correlation should have been observed between 
methylation in the iPSC-derived neurons and blood at the 65 probes reported by 
Walton et al. (2015), if these iPSC-derivatives were faithfully recapitulating the DNA 
methylation in the brain. It should be noted, however, that the patients assessed by 
Walton et al. (2015) suffered from cortical dysplasia, which may have biased their 
results. The relatively small sample from the t(1;11) family from whom blood and 
iPSC-derivatives were available may also present an issue in terms of power to detect 
significant correlations.  
 
The work described in Chapter 4 presented evidence in support of a role of meQTLs 
in driving the differential methylation signal at five of the 13 genome-wide significant 
DMPs associated with the translocation. To determine whether these variants were 
associated with methylation at the same sites in iPSC-derived neurons, the same SNP-
CpG associations were assessed. No significant associations were observed between 
SNP genotype and methylation. No significant correlations were observed between 
genotype and methylation observed at five of the six sites when examined in the subset 
of six blood samples. This may have been due to the small sample size, or alternatively, 
between-individual variation.  
 
A limitation of the blood-based DNA methylation analysis described in Chapter 5 was 
the absence of RNA to examine the effects of differential methylation on gene 
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expression. This shortcoming has been addressed in the iPSC-derived samples: RNA 
and protein were harvested concurrently with the DNA for transcriptomic and 
proteomic analyses, which are currently ongoing. This will provide the opportunity to 
cross-reference methylation data from these iPSC-derived neurons to data derived 
from gene and protein expression analyses in order to dissect the relationship between 
DNA methylation, gene expression and biological functions in these individuals. 
However, larger sample sizes will be required if meaningful conclusions are to be 
drawn from this work. 
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6 Analysis of Sortilin family expression in a Disc1 mutant 
mouse model 
6.1 Background and Motivation 
The complex aetiology and clinical features associated with psychiatric illnesses have 
made it challenging to model such disorders in non-human animals. Nonetheless, 
mouse models can display behavioural endophenotypes which may reflect human-
specific symptoms of psychiatric disorders. The use of animal models has also 
permitted insights into the underlying biology of several diseases, rendering them 
valuable resources for pharmacological and genetic studies both in-vivo and in-vitro 
(Salgado and Sandner, 2013). This chapter describes an analysis of gene expression in 
a mouse model of schizophrenia. This mouse contains a non-synonymous mutation in 
exon 2 of Disc1, whereby a leucine is substituted with a proline at amino acid position 
100 (100P; Clapcote et al., 2007). The aim of this chapter was to determine whether 
the Disc1 L100P mutation played a regulatory role in Sortilin family gene expression 
during neurodevelopment. Support for a regulatory relationship between DISC1 and 
Sortilin family members previously came from evidence of Sortilin dysregulation in 
DISC1 mutant iPS-derived neuronal models (Wen et al., 2014; Srikanth et al., 2015), 
as well as evidence of disrupted expression and methylation of SORL1 and SORCS1, 
respectively, in t(1;11) family samples described in Chapters 3 and 5 of this thesis. 
 
The Disc1 100P mouse was identified from a screen of N-ethyl-N-nitrosourea (ENU)-
mutagenised mice at the RIKEN Institute. The initial characterisation of this mouse by 
Clapcote et al. (2007) reported behavioural endophenotypes considered relevant to 
schizophrenia including hyperlocomotion, and deficits in pre-pulse and latent 
inhibition. Hyperlocomotion in mice is thought to reflect positive symptoms of 
schizophrenia observed in humans (Jones et al., 2011), while pre-pulse and latent 
inhibition are thought to reflect the cognitive deficits observed in schizophrenia 
(Leumann et al., 2002). These phenotypes were restored to wild-type levels in the 100P 
mice following antipsychotic treatment (Clapcote et al., 2007). The presence of these 
endophenotypes coupled with the effects of antipsychotic medication rendered these 
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mice an attractive model for schizophrenia. In addition to behavioural characteristics, 
neuroanatomical deficits were also observed in the form of reduced brain volumes in 
these mice, providing additional support for Disc1 in neurodevelopment. Furthermore, 
Lipina et al. (2012) reported dysregulated gene expression in the hippocampi and brain 
stems of these mice: a phenotype which was partially rescued following treatment with 
the mood stabiliser, valproic acid. This finding suggests that, through the 100P 
mutation, disruption of Disc1 affects the expression of genes which may be involved 
in brain function. 
 
Previously, a microarray-based analysis of gene expression was performed on brain-
derived RNA from these mice by Sarah Brown (SB), a former PhD student. Here, 
genome-wide expression was compared between brains of 100P mice and their wild-
type littermates at developmental stages from embryonic day 13 to adulthood using 
samples collected by Prof. John Roder’s group in Toronto, Canada (referred to 
subsequently as the “SB samples”). SB reported significant downregulation of Sort1 
in 100P homozygotes at E18 and adult stages by qRT-PCR analysis. Sort1 is a member 
of the Sortilin gene family, described in Chapter 1. A second member of the Sortilin 
gene family, SorCS2, was also found to be developmentally dysregulated in 100P 
homozygotes compared to wild-type mice from the SB samples by qRT-PCR. This 
work was performed by Franziska Sendfeld (FS), a former MSc. Student, who reported 
significant upregulation of SORCS2 at E13 and E18; and significant downregulation 
at P1. SORCS2 has previously been implicated in bipolar disorder by GWAS and 
follow-up studies (Baum et al., 2008a; Baum et al., 2008b; Ollila et al., 2009; 
Christoforou et al., 2011), although this has not been replicated at the genome-wide 
significant level in more recent, larger scale studies (Sklar et al., 2011; Muhleisen et 
al., 2014; Hou et al., 2016). The work described in Chapter 3 reported downregulation 
of SORL1, another Sortilin family member, in t(1;11) family-derived LCL samples. A 
study be Wen et al. (2014) examined gene expression in iPSC-derived neurons with a 
4 bp DISC1 frameshift mutation, in which synaptic deficits were observed. These cells 
showed dysregulation of SORCS1, SORCS2 and SORCS3. Moreover, Srikanth et al. 
(2015) reported upregulation of SORCS2 in iPSC-derived neurons containing a 
mutation predicted to induce nonsense-mediated decay in DISC1. Based on the above 
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findings it was hypothesised that a regulatory relationship might exist between DISC1 
and Sortilin family members.  
 
SB normalised the gene expression data from her samples to two reference genes, one 
of which was Gapdh. The assay used (Taqman® assay ID: Mm99999915_g1, Thermo 
Fisher Scientific) has since been shown to be unreliable due to its potential to detect 
genomic DNA in addition to Gapdh transcripts. Moreover, others have reported high 
inter-individual and inter-tissue variability in Gapdh, which may render it sub-optimal 
as a reference gene (Barber et al., 2005). Identifying an appropriate number of stably-
expressed internal control genes for data normalisation is an important step in qRT-
PCR-based analyses (Vandesompele et al., 2002). However, such steps were not 
performed in the original analyses of the 100P mice. Taken together, the analysis 
strategy undertaken by SB and FS may have compromised the validity of the findings 
of differential expression of Sort1 and SorCS2.  
 
The work described in this chapter describes the reanalysis of Sortilin family gene 
expression in the SB samples using an optimised normalisation protocol. A replication 
analysis was then performed in an independent batch of samples (DM samples). The 
optimised protocol involved the use of geNorm software (Vandesompele et al., 2002) 
to identify the reference genes that are most stably-expressed in the sample from a 
panel of six frequently used reference genes. This step is followed by normalisation of 
the gene-of-interest expression data to the geometric mean of the expression data from 
the recommended reference genes. Based on findings of differential expression of 
SORCS1-3 in the context of a DISC1 frameshift mutation (Wen et al., 2014), SorCS1 
and SorCS3 were included for gene expression analysis. Furthermore, as SORL1 was 
found to be differentially expressed in t(1;11) carriers (Chapter 3), this gene was also 
included for gene expression analysis in the 100P mice. 
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6.2 Results 
6.2.1 Reference gene selection in the SB samples 
As material from this batch of cDNA was limited, two samples containing sufficient 
volumes of cDNA were selected from each genotype (100P/100P and wild-type) for 
geNorm analysis at each developmental stage: embryonic days 13, 15 and 18; 
postnatal days 1,7 and 20; and adulthood (8 weeks). Six reference genes were tested 
in these samples: Ppid, Ubc, Sdha, Hmbs, Rplp0 and Hprt and geNorm analysis was 
performed on their expression data. Values for geNorm M and geNorm V were 
obtained for each developmental stage to determine the relative stability of each gene 
and the recommended number of genes to use for normalisation, respectively. M-
values correspond to the average pairwise variation for a given reference gene with 
all other reference genes considered, while V-values correspond to the stability of the 
normalisation factors for n reference genes compared to n+1 genes. Genes with a 
lower geNorm M-value are more stably expressed across all samples. A geNorm V-
value of < 0.15 indicates that the normalisation factor obtained from n+1 genes is not 
significantly different to the normalisation factor obtained from n genes.  
 
Using geNorm (Vandesompele et al., 2002), it was possible to determine the 
optimum reference genes for all stages with the exception of the adult stage, for 
which expression between samples was too variable. In this instance, the number of 
genes in the set corresponding to the lowest geNorm V-value (4/5) were used: Hmbs, 
Ppid, Ubc and Rplp0, as this was deemed by geNorm as the most stably-expressed 
combination of reference genes tested in the adult samples. The geNorm results for 
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Table 6.1: Summary of the results of geNorm analysis of a panel of six reference 
genes in the SB samples. 


















Optimum Number of Reference 
Genes (geNorm V < 0.15) 
Recommended Reference 
Genes 
E13 2 Hprt, Ubc 
E15 2 Hprt, Rplp0 
E18 2 Sdha, Ubc 
P1 2 Rplp0, Sdha 
P7 2 Ubc, Hprt 
P20 2 Hprt, Sdha 
Adult 4 (Lowest geNorm V =  0.18) Hmbs, Ppid, Ubc, Rplp0 
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6.2.2 Gene expression analysis in the SB samples 
Differences in the expression of the five Sortilin family members between 100P 
homozygotes and wild-type littermates (n = 6 per group) was assessed at seven 
developmental time points. Samples were derived from whole brains from all mice 
with the exception of the adult stage. In the case of adult mice, expression was 
assessed in hippocampal samples. Significant differential expression was observed 
in at least one developmental stage for all genes with the exception of Sort1 (Welch’s 
t-test p < 0.05; Figure 6.1A-E; Table 6.2A-E).  
 






 Sort1 E13 0.463 1.27 
 Sort1 E15 0.148 -2.43 
 Sort1 E18 0.111 -2.21 
 Sort1 P1 0.344 1.69 
 Sort1 P7 0.09 4.67 
 Sort1 P20 0.12 5.10 
 Sort1 Adult 0.38 2.41 
 






 SorCS1 E13 0.795 1.06 
 SorCS1 E15 0.0003 2.17 
 SorCS1 E18 0.340 1.38 
 SorCS1 P1 0.0003 8.50 
 SorCS1 P7 0.003 2.24 
 SorCS1 P20 0.476 4.12 
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 SorCS2 E13 0.073 -1.29 
 SorCS2 E15 0.021 1.86 
 SorCS2 E18 0.444 1.15 
 SorCS2 P1 0.088 2.36 
 SorCS2 P7 0.053 2.43 
 SorCS2 P20 0.029 5.02 
 SorCS2 Adult 0.144 9.29 
 






 SorCS3 E13 0.098 -1.31 
 SorCS3 E15 0.0002 1.62 
 SorCS3 E18 0.850 1.04 
 SorCS3 P1 0.010 7.17 
 SorCS3 P7 0.0004 1.87 
 SorCS3 P20 0.076 2.54 
 SorCS3 Adult 0.143 2.46 
 






 Sorl1 E13 0.007 2.01 
 Sorl1 E15 0.059 -2.89 
 Sorl1 E18 0.0004 -2.84 
 Sorl1 P1 0.002 12.05 
 Sorl1 P7 0.004 -3.17 
 Sorl1 P20 0.036 19.51 
 Sorl1 Adult 0.1143 8.09 
Table 6.2A-E: Summary of the analysis of gene expression of Sortilin family 
genes in the SB samples. 
Shown are the genes tested for differential expression, the developmental stage of mice, the p-
value for differential expression and the fold-change in 100P homozygotes. Red font indicates 
significant differential expression (p ≤ 0.05). Italicised p-values correspond to Mann-Whitney 
U test p-values whilst non-italicised p-values correspond to Welch’s t-test p-values, depending 
on the distribution of the data in each group (section 2.8.4). 
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Figure 6.1 A-E: Comparison of Sortilin family gene expression in 100P 
heterozygotes and wild-type littermates in the SB samples. 
Shown are bar plots for normalised gene expression values (y-axes; arbitrary units) of Sortilin 
family genes (A-E = Sort1, SorCS1, SorCS2, SorCS3, Sorl1; respectively) in wild-type mice 
(blue bars) and their 100P homozygous littermates (red bars) from stages E13 to postnatal 
week 8 (Adult) in the SB samples. Genotype and developmental stage are presented on the x-
axes. Error bars show the standard error of the mean. Significant differential expression is 
indicated by an asterisk (*) in the title of each plot. 
 
In an attempt to replicate these findings, this experiment was repeated in samples 
collected from an independent set of 100P samples, from mice bred in Edinburgh (DM 
samples). 
 
6.2.3 Analysis of differential gene expression in the DM samples 
6.2.3.1 Sample information and quality control 
100P heterozygote mice were obtained from Malgorzata Borkowska (Centre for 
Integrative Physiology, University of Edinburgh) for breeding. 100P homozygous 
mutants and their wild-type littermates were obtained from heterozygote crosses for 
gene expression analysis (N = 5-7 mice per group). As with the SB samples, gene 
expression was assessed at embryonic days 13, 15 and 18; postnatal days 1, 7 and 20; 
and adult mice. 
 
Samples were assessed for RNA degradation and genomic DNA contamination as 
described in Chapter 3. RNA integrity was assessed as a measure of sample quality 
taking a minimum RIN cut-off of 7 (Thomson et al., 2007). All samples were within 
the acceptable range of RIN scores (7 – 10), indicating intact RNA (Table 6.3). 
Genomic DNA contamination of cDNA was assessed using a primer pair spanning 
exons 24 to 25 of mouse Sorcs2, amplifying a 628 bp fragment from genomic DNA, 
and a 156 bp fragment from cDNA. Following reverse transcription of RNA, all cDNA 








Age Genotype Sex RIN 
175 Adult 100P M 8.2 
186 Adult 100P M 8.6 
188 Adult 100P M 9.1 
189 Adult 100P F 9.8 
198 Adult 100P M 9 
199 Adult 100P F 8.8 
177 Adult WT F 8.7 
179 Adult WT F 9.2 
183 Adult WT M 9.5 
191 Adult WT F 9.1 
193 Adult WT M 8.9 
E13 15 E13 100P M 9.8 
E13 2 E13 100P F 9.6 
E13 20 E13 100P M 10 
E13 25 E13 100P M 10 
E13 8 E13 100P M 9.7 
E13 11 E13 WT M 9.9 
E13 17 E13 WT F 9.9 
E13 21 E13 WT F 10 
E13 22 E13 WT F 10 
E13 23 E13 WT M 10 
E13 3 E13 WT M 9.7 
E13 9 E13 WT M 9.9 
E15 1 E15 100P F 9.9 
E15 13 E15 100P M 9.9 
E15 14 E15 100P F 9.9 
E15 15 E15 100P M 9.8 
E15 16 E15 100P M 9.9 
E15 2 E15 100P M 9.8 
E15 3 E15 100P M 9.8 
E15 20 E15 WT M 9.9 
E15 21 E15 WT F 9.9 
E15 22 E15 WT F 9.9 
 
Chapter 6  219 
 
E15 23 E15 WT M 9.9 
E15 9 E15 WT M 10 
E18 12 E18 100P F 9.7 
E18 16 E18 100P F 9.7 
E18 23 E18 100P F 9.6 
E18 3 E18 100P F 9.6 
E18 4 E18 100P F 9.6 
E18 6 E18 100P M 9.6 
E18 8 E18 100P M 9.6 
E18 18 E18 WT F 9.6 
E18 21 E18 WT M 9.6 
E18 22 E18 WT M 9.6 
E18 5 E18 WT F 9.7 
E18 7 E18 WT F 9.6 
P1 11 P1 100P M 9.5 
P1 13 P1 100P M 9.4 
P1 21 P1 100P F 7 
P1 31 P1 100P F 8.7 
P1 33 P1 100P M 8.6 
P1 38 P1 100P M 8.4 
P1 1 P1 WT F 9.6 
P1 10 P1 WT F 9.3 
P1 15 P1 WT M 7.4 
P1 19 P1 WT F 7.1 
P1 29 P1 WT M 8.7 
P1 8 P1 WT F 9.4 
P20 1 P20 100P M 8.1 
P20 17 P20 100P F 8.1 
P20 24 P20 100P M 7.2 
P20 25 P20 100P F 7.1 
P20 3 P20 100P M 7.7 
P20 8 P20 100P M 8.3 
P20 16 P20 WT M 8.3 
P20 21 P20 WT M 7.8 
P20 35 P20 WT F 7.2 
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P20 6 P20 WT F 8.3 
P20 7 P20 WT F 7.9 
P7 13 P7 100P M 8.7 
P7 17 P7 100P M 7.8 
P7 21 P7 100P M 7.5 
P7 27 P7 100P F 8.7 
P7 28 P7 100P F 8.9 
P7 7 P7 100P F 8.1 
P7 11 P7 WT F 8.2 
P7 15 P7 WT M 7.4 
P7 16 P7 WT M 8.2 
P7 2 P7 WT F 8.8 
P7 3 P7 WT M 7.7 
P7 5 P7 WT F 8.3 
Table 6.3: Summary of 100P RNA samples obtained from the DM samples. 
Shown are sample IDs for each mouse, developmental stage (prefix E = embryonic, prefix P 
= postnatal), 100P genotype (WT= wild-type, 100P = 100P homozygote), sex (M = male, F = 
female), and RIN value. 
 
6.2.3.2 Reference gene selection for the DM samples 
As described in section 6.3, geNorm analysis was performed to identify the most 
stably-expressed reference gene set for each developmental stage. All samples from 
the DM batch were included in this geNorm analysis.  It was possible to identify the 
most stably-expressed gene sets for all developmental stages with the exception of P7 
due to high variability in these samples. In this instance, five reference genes with the 
lowest corresponding geNorm V score were used (V = 0.16) as they were deemed by 
geNorm to be the most stably-expressed combination of genes amongst those tested in 
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Table 6.4: Summary of geNorm analysis using a panel of six reference genes in 
the DM samples. 
The developmental stage is shown with the corresponding geNorm V and geNorm M scores 
determining the optimum number of reference genes and the recommended reference genes 
respectively. 
 
6.2.3.3 qRT-PCR analysis of Sortilin family gene expression in the DM 
samples 
Differential expression was assessed between wild-type and 100P homozygotes 
following normalisation of gene expression data to geometric mean of the appropriate 
reference genes. Three genes showed significant differential expression in 100P 
homozygotes, each at a single developmental time point (Table 6.5A-E; Figure 6.2A-
E). At P20, 100P homozygotes showed a significant upregulation of SorCS2 (p = 0.04, 
two-tailed Welch’s t-test; FC = 1.47), and Sort1 (p = 0.03, Mann-Whitney U test; FC 
= 1.47); while a significant upregulation of Sorl1 was observed in 100P homozygotes 
at P7 (p = 0.017, two-tailed Welch’s t-test; FC = 1.33). The SorCS2 direction of effect 
in P20 100P homozygotes was consistent between the SB and DM samples, with both 






Optimum Number of Reference 
Genes (geNorm V < 0.15) 
Recommended Reference 
Genes 
E13 2 Ppid, Rplp0 
E15 2 Rplp0, Hmbs 
E18 2 Ppid, Hprt 
P1 2 Hprt, Sdha 
P7 
Undetermined (Lowest geNorm V = 
0.16) 
Rplp0, Hmbs, Ubc, Sdha, Ppid 
P20 2 Rplp0, Hmbs 
Adult 2 Ppid, Hprt 
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   DM Samples SB Samples 
A Gene Stage p-value 




Fold change in 
100P/100P vs 
wild type 
 Sort1 E13 0.930 1.01 0.463 1.27 
 Sort1 E15 0.604 1.03 0.148 -2.43 
 Sort1 E18 0.256 1.12 0.111 -2.21 
 Sort1 P1 0.410 1.04 0.344 1.69 
 Sort1 P7 0.254 1.18 0.09 4.67 
 Sort1 P20 0.038 1.33 0.12 5.10 
 Sort1 Adult 0.759 -1.07 0.381 2.41 
 
   DM Samples SB Samples 
B Gene Stage p-value 




Fold change in 
100P/100P vs 
wild type 
 SorCS1 E13 0.296 1.18 0.795 1.06 
 SorCS1 E15 0.1990 -1.13 0.0003 2.17 
 SorCS1 E18 0.090 1.17 0.340 1.38 
 SorCS1 P1 0.6730 1.02 0.0003 8.50 
 SorCS1 P7 0.739 1.08 0.003 2.24 
 SorCS1 P20 0.217 -1.13 0.476 4.12 
 SorCS1 Adult 0.992 -1.00 1 1.02 
 
   DM Samples SB Samples 
C Gene Stage p-value 




Fold change in 
100P/100P vs 
wild type 
 SorCS2 E13 0.462 -1.09 0.073 -1.29 
 SorCS2 E15 0.874 -1.02 0.021 1.86 
 SorCS2 E18 0.602 1.09 0.444 1.15 
 SorCS2 P1 0.721 1.03 0.088 2.36 
 SorCS2 P7 0.060 1.58 0.053 2.43 
 SorCS2 P20 0.040 1.47 0.029 5.02 
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   DM Samples SB Samples 
D Gene Stage p-value 




Fold change in 
100P/100P vs 
wild type 
 SorCS3 E13 0.557 -1.19 0.098 -1.31 
 SorCS3 E15 0.22 -1.06 0.0002 1.62 
 SorCS3 E18 0.602 1.15 0.850 1.04 
 SorCS3 P1 0.496 1.09 0.010 7.17 
 SorCS3 P7 0.2120 1.30 0.0004 1.87 
 SorCS3 P20 0.323 1.11 0.076 2.54 
 SorCS3 Adult 0.847 -1.03 0.143 2.46 
 
   DM Samples SB Samples 
E Gene Stage p-value 




Fold change in 
100P/100P vs wild 
type 
 Sorl1 E13 0.09 -1.06 0.007 2.01 
 Sorl1 E15 0.715 1.02 0.059 -2.89 
 Sorl1 E18 0.0820 1.49 0.0004 -2.84 
 Sorl1 P1 0.335 1.01 0.002 12.05 
 Sorl1 P7 0.017 1.33 0.004 -3.17 
 Sorl1 P20 0.392 1.18 0.036 19.51 
 Sorl1 Adult 0.283 -1.13 0.1143 8.09 
Table 6.5: Summary of gene expression analysis of Sortilin family genes in the 
DM samples compared with the SB samples. 
Shown are the genes tested for differential expression and the developmental stage. For both 
the DM samples and SB samples, the p-values for differential expression and the fold-changes 
in 100P homozygotes are shown. Red font indicates significantly differentially expressed genes 
(p ≤ 0.05). Italicised p-values correspond to Mann-Whitney U test p-values whilst non-
italicised p-values correspond to Welch’s t-test p-values, depending on the distribution of the 
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Figure 6.2A-E: Comparison of Sortilin family gene expression in 100P 
heterozygotes and wild-type littermates in the DM samples. 
Shown are bar plots for normalised gene expression values (y-axes; arbitrary units) of Sortilin 
family genes (A-E = Sort1, SorCS1, SorCS2, SorCS3, Sorl1; respectively) in wild-type mice 
(blue bars) and their 100P homozygous littermates (red bars) from stages E13 to postnatal 
week 8 (Adult) in the DM samples. Genotype and developmental stage are presented on the x-
axes. Error bars show the standard error of the mean. Significant differential expression is 
indicated by an asterisk (*) in the title of each plot. 
 
6.3 Discussion 
The aim of this chapter was to determine whether expression of members of the 
Sortilin gene family are dysregulated in a mutant mouse model that carries a 
homozygous nonsynonymous mutation in Disc1. This work aimed to address the 
hypothesis that Disc1 is involved in regulating Sortilin family gene expression. This 
hypothesis was based on findings by others in the Disc1 100P mouse, along with 
findings of differential expression and methylation of SORL1 and SORCS1, 
respectively, in carriers of t(1;11), which disrupts the DISC1 gene, reported in this 
thesis (Chapters 3 and 5). 
 
Previous work performed by SB and FS found Sort1 and SorCS2 expression to be 
altered during brain development in the 100P mouse. However, it was possible that 
these results may have been compromised by the use of a sub-optimal reference gene. 
These qRT-PCR experiments were repeated using an optimised protocol for reference 
gene selection. In addition to assessing the expression of Sort1 and SorCS2, the other 
Sortilin family members, SorCS1, SorCS3 and Sorl1, were also assessed for 
differential expression based on evidence for their dysregulation in the context of other 
DISC1 mutations (Chapter 3, Chapter 5, Wen et al., 2014, Srikanth et al., 2015). These 
experiments were carried out using the SB samples, from which the initial findings by 
SB and FS were reported.  In contrast to the data obtained by SB, Sort1 showed no 
differential expression following normalisation to geNorm-recommended reference 
genes. This may illustrate the importance of a data-driven approach when selecting 
reference genes for qRT-PCR analyses. However, it is important to note that due to 
limitations in cDNA availability of the SB samples, only a subset of samples were used 
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for the geNorm analysis. The geNorm software identifies the most stably-expressed 
genes across an entire sample set and for each developmental stage, gene expression 
in the subset of samples was unlikely to be representative of the entire sample set. It is 
possible that, had another subset of samples been used for geNorm analysis, the 
recommended reference genes might have differed. Nonetheless, it is likely that the 
findings obtained following normalisation to geNorm-recommended genes are more 
valid than those in the analysis performed by SB and FS in these samples, due to their 
use of a sub-optimal reference assay. 
 
As there was significant differential expression of Sortilin family members in the SB 
sample, an independent sample set was collected with an aim of replicating these 
findings. Little overlap was observed with regards to differential expression of Sortilin 
family members between the two sample sets. Only one result was consistent between 
these sample sets in terms of significance and direction of effect. It would not be 
unreasonable to expect this finding to occur by chance, however, as no multiple testing 
correction was implemented in this study.  
 
There are several possible reasons for the discordance between the findings from the 
two sets of samples. As mentioned before, the normalisation strategy taken during 
reanalysis of the SB samples may still have been sub-optimal. Genetic and 
environmental factors may also have played a role. The mice from which the SB RNA 
batch was prepared were housed in a facility in Toronto, while the mice from the 
second batch of samples were housed in Edinburgh. While there is no evidence 
available for a systematic environmental difference between the two facilities, it is 
unlikely that pregnant dams and postnatally-collected mice from the SB samples 
shared identical environments with those from the DM samples prior to culling. 
Although animal research facilities generally take measures to maintain a controlled 
environment, variables such as handlers and ambient noise may result in stress, and 
potential stress-related effects on gene expression (Reinhardt, 2004; Murata et al., 
2005). In addition, factors such as season and maternal stress are known to impact 
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upon gene expression in the developing brain, both in humans and mice (Talge et al., 
2007). 
 
Differences in genetic background may have also played a role in the different results 
obtained from the two sample sets. To generate the 100P mutation, C57/Bl6/J males 
were injected with ENU and crossed with females from a DBA/2J background. Males 
heterozygous for the 100P mutation were further backcrossed with C57/Bl6/J females 
for four generations to obtain a C57/Bl6/J background (Clapcote et al., 2007). There 
have been conflicting reports of behavioural phenotypes in the 100P mouse. Clapcote 
et al., (2007) previously reported schizophrenic-like behaviours in these mice 
including deficits in prepulse inhibition. However, Shoji et al. (2012) reported normal 
prepulse inhibition in 100P mice compared to wild-type. Furthermore, the mice in 
which Clapcote et al. (2007) initially reported the schizophrenic-like behaviours were 
assessed by Arime et al. (2014), who found residual genetic variation from the DBA/2J 
background. The authors of this study also raised the concern of confounding effects 
arising from any remaining ENU-induced mutations elsewhere in the genome. To this 
end, it is of possible note that exome sequencing of the male mouse from which the 
100P strain was derived identified 116 variants, including a missense mutation in 
SorCS3 (Arime et al.. 2014). The mice from the DM samples had undergone additional 
backcrosses to a C57/Bl6/J background (performed by Malgorzata Borkowska). This 
should have rendered these mice less likely to be confounded by residual ENU 
mutations and mixed genetic backgrounds than those from the SB samples. The SB 
samples were obtained from the same colony as the mice originally reported by 
Clapcote et al. (2007), and were bred approximately five years prior to the DM 
samples. This analyses of the DM samples might therefore be considered more valid 
than the analyses using the SB samples. 
 
Evidence of altered SORL1 expression and SORCS1 methylation was reported in 
human t(1;11) samples in Chapters 3 and 5, respectively. It is possible that, in addition 
to DISC1, other consequences of the t(1;11) translocation are responsible for the 
disrupted regulation of Sortilin gene expression and/or methylation in the t(1;11) 
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family. Factors such as DISC1FP1 on chromosome 11, fusion transcripts, or passive 
transmission of regulatory variants on the derived chromosomes might be responsible 
for the abnormalities observed in SORCS1 and SORL1. However, should a regulatory 
relationship exist between Disc1 and the Sortilin gene family, it may not be affected 
by the 100P mutation, but rather by disruptions to other regions of Disc1. The 100P 
mutation occurs at the N-terminal region of Disc1 within exon 2 (Clapcote et al., 
2007), whereas the DISC1 frameshift mutation associated with differential expression 
of SORCS1-3 is present in the gene’s C-terminal region (Sachs et al., 2005; Wen et 
al., 2014; Srikanth et al., 2015).  The 100P substitution has not been reported to affect 
Disc1 expression levels. It does, however, result in reduced binding of PDE4B to 
DISC1 (Clapcote et al., 2007). Perturbed PDE4B activity may result in altered cAMP 
signalling, presenting a mechanism through which the 100P mutation may lead to 
dysregulated gene expression in these mice. Although the L100P site is not conserved 
between humans and mice (Soares et al., 2011), similar functional consequences have  
may occur through reduced DISC1-PDE4B binding in the context of DISC1 
haploinsufficiency (Millar et al., 2005). Moreover, the frameshift mutation reported 
by Srikanth et al. (2015) results in nonsense-mediated decay of DISC1. Heterozygotes 
for this mutation showed decreased levels of SORCS2. Investigation of SORCS2 
expression in t(1;11) carrier iPSC-derived neurons is therefore warranted, as 
translocation carriers display half the normal levels of DISC1 (Millar et al., 2005) 
 
As described in Chapter 5, neuronal precursors generated from t(1;11) family iPSCs 
have recently become available. These are likely to be useful resources to further 
investigate the possible relationship between Sortilin genes and the impact of the 
translocation event upon DISC1 in a human neuronal model. This could be achieved 
through the analysis of gene and protein expression in these samples, as well as 
analyses of protein interactions. The 100P mouse model could also be improved upon 
using technologies developed since its original characterisation by Clapcote et al. 
(2007). Genome-editing methods such as CRISPR/Cas9 (Ran et al., 2014) may prove 
useful in introducing the 100P mutation whilst avoiding the generation of confounding 
background mutations. Furthermore, this method could be utilised for the generation 
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of additional mutations in Disc1. Such experiments should inform as to which regions 
of Disc1, if any, are responsible for regulating Sortilin family expression. 
 
Using an in-silico approach, the relationship between DISC1 and Sortilin family 
members was further investigated, with an aim to identify gene-gene interactions 
which may be related to depressive and/or cognitive phenotypes in humans. This work 
was performed based on previous associations identified between Sortilin family 
members and DISC1 in both cognitive and depressive phenotypes. This work is 
described in Chapter 7. 
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Chapter 7 
Investigating epistatic interactions 
between DISC1 and Sortilin family genes 
in cognition and depression 
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7 Investigating epistatic interactions between DISC1 and 
Sortilin family genes in cognition and depression 
7.1 Introduction 
Genome-wide association studies of complex traits have had some success in 
identifying associations at the level of individual SNPs, taking, for example, the most 
recent GWASs of MDD (Cai et al., 2015; Hyde et al., 2016). However, such 
associations go a limited way to explaining the heritability of psychiatric disorders 
(Crow, 2011), which has been estimated at approximately 37% for MDD (Sullivan et 
al., 2000). It has been argued that a proportion of this missing heritability could be 
accounted for by the interactions between already-identified risk loci (Zuk et al., 
2012). A statistical challenge presented by large-scale genomic datasets is a large 
number of observations among a comparatively small number of samples (otherwise 
known as the “large p small n” problem; Johnstone and Titterington, 2009). This has 
rendered the identification of epistatic interactions challenging in with regards to both 
the computational and statistical burdens involved: assuming a GWAS cohort in which 
500,000 SNPs have been genotyped, the number of tests required to assess all pairwise 
genetic interactions would be in the order of billions (Wei et al., 2014).  
 
Machine learning algorithms (MLAs) may go some way to address this challenge. One 
such algorithm, random forest analysis, is based on classification and regression trees 
(CARTs) first introduced by Breiman et al. (1984). CART analysis is a method 
whereby a decision tree is drawn, recursively partitioning data based on known 
variables (e.g. genotype), in order to predict an outcome (e.g. disease/trait status). This 
method has been shown to achieve high prediction accuracy, with the ability to provide 
measures relating to the impact of individual effects (e.g. a single SNP) as well as 
interactions between variables (e.g. epistatic interactions). Ensemble methods can 
improve upon CART analysis through the construction of multiple trees (i.e. random 
forests). Random forest analysis is an ensemble technique involving the construction 
a forest of multiple, uncorrelated trees, achieved by random sampling of population 
and predictors for each tree, thereby increasing classification accuracy. After 
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constructing a forest, each predictor within a given tree is permuted and run through 
that tree among the unsampled observations to determine that predictor’s classification 
accuracy. The average difference in classification accuracy between a permuted and 
real predictor is calculated across all trees, creating a variable importance measure for 
each SNP (VIM; Breiman, 2001). This VIM can then be used as a measure of a given 
SNP’s association with the phenotype of interest in the context of all other SNPs 
assessed. 
 
Random forest analysis has been suggested as a useful tool for epistatic analyses, by 
using a variant’s associated VIM to rank and select candidate SNPs to address the 
computational and statistical burden associated with a typical genome-wide approach 
(Schwarz et al., 2007). The underlying hypothesis of the work performed in this 
chapter was that DISC1 interacts genetically with members of the Sortilin gene family. 
The work below describes the use of random forests to select SNPs to investigate 
genetic interactions within members the Sortilin gene family and DISC1, which may 
be associated with cognitive phenotypes and/or MDD. These genes were selected 
based on evidence of a relationship between DISC1 and Sortilin family gene 
expression in iPSC-derived neurons containing DISC1 disruptions (Wen et al., 2014; 
Srikanth et al., 2015; section 1.7.1), as well as from findings described in this thesis. 
In Chapter 3, an association was observed between SORL1 gene expression and the 
t(1;11) translocation in lymphoblastoid cell lines while in Chapter 5, two differentially 
methylated regions were observed in SORCS1 in iPSC-derived neurons from t(1;11) 
carriers. DISC1 and Sortilin family genes have been implicated in psychiatric disorders 
including bipolar disorder and depression (Thomson et al., 2014; Hyde et al., 2016; 
Baum et al., 2008). Furthermore, DISC1 has been associated with working memory 
(Carless et al., 2011) while Sortilin family genes have been implicated in Alzheimer’s 
disease, both independently and through epistatic interactions (Reitz et al., 2013). 
Analyses were performed using genotype data from the Generation Scotland cohort 
(Smith et al., 2013).   
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7.2 Results 
7.2.1 Generation of an unrelated sample set prioritising depressed 
individuals 
The Generation Scotland sample is a family-based cohort. As sample relatedness can 
confound genetic data and increase a genetic bias through the over-representation of 
genotypes segregating within the families sampled, it is necessary to limit the number 
of closely related individuals in association studies. A genetic relationship matrix 
(GRM), was obtained from Dr. Mark Adams (Division of Psychiatry, Edinburgh). 
The GRM contained genetic relationship estimates based on genotype data from the 
Generation Scotland cohort (N = 19,994 genotyped for 561,125 SNPs). A total of 
40,871 pairs of individuals with a genetic relationship coefficient of ≥ 0.025 
(equivalent of an expected level of relatedness in between second and third cousins) 
were present in the sample. These 40,871 pairs comprised 18,659 different 
individuals. 
 
As MDD was one of the phenotypes to be tested for association, a method was 
devised to obtain the maximum number of unrelated individuals while prioritising 
the retention of depressed individuals. Starting with individuals without a diagnosis 
of MDD, the individual with the most relatives in the sample set, based on the GRM, 
was progressively discarded and relationships were recalculated until there were zero 
such individuals with a relative in the total sample. This was repeated for individuals 
diagnosed with MDD, resulting in a final sample containing of 7235 individuals. Of 
these, 2017 were diagnosed with MDD.  
 
7.2.2 Selection of markers for association analysis 
The five Sortilin family genes: SORT1, SORCS1, SORCS2, SORCS3 and SORL1 
were selected, along with DISC1, to investigate epistatic interactions associated with 
cognition and depression. Independent haplotype blocks (D’ < 0.8 between blocks), 
identified from 100 non-depressed unrelated individuals from the Generation 
Scotland cohort were generated across each gene using Haploview (50 males and 50 
females; section 2.13.2.2; Barrett et al., 2005). SNPs were considered for association 
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if they occurred within the haplotype blocks spanning the start and end coordinates 
of the each gene (Hg19), or any intermediate blocks. To reduce the multiple testing 
burden, Haploview’s tagger program was used to identify tagging SNPs that capture 
correlated SNPs (R2 ≥ 0.8; de Bakker et al., 2009). Table 7.1 summarises the number 







Table 7.1: Summary of markers selected for assessment of association with 
cognitive phenotypes and depression. 
Shown are the genes, the number of SNPs in each gene’s corresponding haplotype blocks 
defined by Haploview, and the number of tag SNPs identified by Tagger (R2 < 0.8 between tag 
SNPs). 
 
7.2.3 Investigating genetic interactions associated with cognition 
7.2.3.1 Cognitive phenotypes in Generation Scotland 
The Sortilin gene family, and DISC1 were assessed for association with cognition. The 
cognitive phenotypes available from the Generation Scotland cohort are vocabulary 
(Mill Hill test), verbal fluency, logical memory and digit symbol test performance. To 
reduce multiple testing, the latter three phenotypes were condensed to a single factor 
to represent general fluid intelligence, while the vocabulary phenotype was used as a 
measure of crystallised intelligence (Cattell, 1963). Of the 7235 unrelated individuals 
identified, 7122 had measurements for crystallised intelligence and 7192 had 
measurements for general fluid intelligence (i.e. non-missing values for all three of the 
verbal fluency, logical memory and digit symbol test scores).  
Gene Total SNPs in Haplotype Block(s) 
Tag 
SNPs 
SORT1 54 28 
SORL1 54 37 
SORCS1 203 100 
SORCS2 326 267 
SORCS3 132 66 
DISC1 129 87 
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7.2.3.2 Assessment of genetic interactions associated with general fluid 
intelligence 
Variants in the Sortilin gene family and DISC1 were assessed for association with 
cognition. This involved a two-stage process: random forest analysis was performed 
on 80% of the sample set, firstly using a real phenotype and secondly, on a dataset 
where the phenotype had been permuted. This created a VIM for each SNP in both the 
permuted and the real datasets. For each SNP, an empirical p-value was generated by 
comparing its corresponding VIM in the real data to the null distribution of VIMs in 
the permuted data. This permitted the prioritisation of SNPs for the second step: to test 
for association with general fluid intelligence by standard regression methods in the 
remaining 20% of the sample. In the case of general fluid intelligence, 15 SNPs had 
an empirical p–value of ≤ 0.05. These SNPs were within SORCS1, SORCS2 and DISC1 
(Table 7.2). In order to consider trans-interactions only to reduce the number of 
interactions under analysis, only combinations of SNPs within at least two genes were 
considered. Following the removal of within-gene combinations, 48 two-SNP 
combinations were assessed, and 291 three-SNP combinations. No significant two-
way interactions were observed following correction for multiple testing (Benjamini-
Hochberg FDR; q > 0.32). However, four interactions were nominally significantly 
associated with general fluid intelligence (p ≤ 0.05; Table 7.3). Twenty-eight three-
SNP interactions were nominally significantly associated with general fluid 















rs4689835 SORCS2 0.001 
rs6855453 SORCS2 0.001 
rs7695937 SORCS2 0.001 
rs821634 DISC1 0.001 
rs4689845 SORCS2 0.002 
rs4918274 SORCS1 0.007 
rs7440772 SORCS2 0.007 
rs821631 DISC1 0.021 
rs6816649 SORCS2 0.029 
rs2057723 SORCS2 0.037 
rs17828052 SORCS2 0.042 
rs7098468 SORCS1 0.043 
rs13126941 SORCS2 0.044 
rs17381732 SORCS2 0.044 
rs4689838 SORCS2 0.045 
Table 7.2: SNPs assessed for epistatic interactions associated with general 
fluid intelligence. 
Shown are SNP identifiers, their corresponding genes and empirical p-values calculated from 
the random forest analysis. 
 




rs4918274 rs7695937 SORCS1 SORCS2 0.006 0.111 0.323 
rs4918274 rs6816649 SORCS1 SORCS2 0.025 0.111 1 
rs17828052 rs4918274 SORCS2 SORCS1 0.034 0.111 1 
rs4918274 rs6855453 SORCS1 SORCS2 0.042 0.111 1 
Table 7.3: Two-SNP interactions nominally associated with general fluid 
intelligence. 
Shown is a summary of two-SNP interactions nominally significantly associated with general 
fluid intelligence (p < 0.05). From left to right, columns state the SNP identifiers and their 
corresponding genes, the likelihood ratio test p-value for the difference in goodness-of-fit of 
the interaction model versus the null model, omitting the interaction term; the proportion of 
variance explained by the model (R2), and the Benjamini-Hochberg FDR q-value for the SNP 
interaction following correction for 48 tests. 
 
Chapter 7        241 
 
SNP1 SNP2 SNP3 Gene1 Gene2 Gene3 
LRT         
p-value 
R2 q-value 
rs4689835 rs4918274 rs6855453 SORCS2 SORCS1 SORCS2 0.002 0.115 0.675 
rs2057723 rs4689838 rs821634 SORCS2 SORCS2 DISC1 0.002 0.110 0.749 
rs2057723 rs7098468 rs821634 SORCS2 SORCS1 DISC1 0.004 0.110 1 
rs17828052 rs4689845 rs821631 SORCS2 SORCS2 DISC1 0.004 0.112 1 
rs17381732 rs4689838 rs821634 SORCS2 SORCS2 DISC1 0.006 0.114 1 
rs4689835 rs4918274 rs7695937 SORCS2 SORCS1 SORCS2 0.009 0.110 1 
rs17381732 rs7098468 rs7440772 SORCS2 SORCS1 SORCS2 0.009 0.112 1 
rs13126941 rs4689835 rs4918274 SORCS2 SORCS2 SORCS1 0.010 0.111 1 
rs4689845 rs6855453 rs821631 SORCS2 SORCS2 DISC1 0.010 0.112 1 
rs2057723 rs4689845 rs821634 SORCS2 SORCS2 DISC1 0.011 0.110 1 
rs2057723 rs7098468 rs821631 SORCS2 SORCS1 DISC1 0.013 0.112 1 
rs2057723 rs7695937 rs821631 SORCS2 SORCS2 DISC1 0.020 0.112 1 
rs17381732 rs4689838 rs821631 SORCS2 SORCS2 DISC1 0.020 0.114 1 
rs17828052 rs4689845 rs821634 SORCS2 SORCS2 DISC1 0.022 0.112 1 
rs13126941 rs4689838 rs821634 SORCS2 SORCS2 DISC1 0.024 0.111 1 
rs2057723 rs4689838 rs821631 SORCS2 SORCS2 DISC1 0.024 0.110 1 
rs4689835 rs4689845 rs7098468 SORCS2 SORCS2 SORCS1 0.025 0.115 1 
rs4918274 rs7440772 rs821631 SORCS1 SORCS2 DISC1 0.027 0.111 1 
rs4918274 rs7440772 rs821634 SORCS1 SORCS2 DISC1 0.028 0.112 1 
rs4689835 rs4689838 rs821631 SORCS2 SORCS2 DISC1 0.028 0.112 1 
rs2057723 rs6855453 rs821631 SORCS2 SORCS2 DISC1 0.037 0.111 1 
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SNP1 SNP2 SNP3 Gene1 Gene2 Gene3 
LRT         
p-value 
R2 q-value 
rs4689838 rs6816649 rs821631 SORCS2 SORCS2 DISC1 0.039 0.112 1 
rs17828052 rs4689838 rs821631 SORCS2 SORCS2 DISC1 0.039 0.113 1 
rs6816649 rs6855453 rs821631 SORCS2 SORCS2 DISC1 0.039 0.112 1 
rs13126941 rs4918274 rs7695937 SORCS2 SORCS1 SORCS2 0.040 0.112 1 
rs4689845 rs7440772 rs821634 SORCS2 SORCS2 DISC1 0.041 0.111 1 
rs13126941 rs4689838 rs821631 SORCS2 SORCS2 DISC1 0.045 0.113 1 
rs4689845 rs821631 rs821634 SORCS2 DISC1 DISC1 0.047 0.115 1 
Table 7.4: Three-SNP interactions nominally associated with general fluid intelligence. 
Shown is a summary of nominally significant genetic interactions associated with general fluid intelligence (p ≤ 0.05). From left to right, columns show 
the SNP identifiers, their corresponding genes, the likelihood ratio test p-value for the difference in goodness-of-fit of the interaction model versus the 
null model, omitting the interaction term; the proportion of variance explained by the model (R2), and the FDR q-value for the SNP interaction following 
correction for 291 tests. 
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7.2.3.3 Genetic interactions associated with crystallised intelligence 
Vocabulary, measured using the Mill Hill Vocabulary scale (Raven, 1941), was used 
as a measure of crystallised intelligence.  
 
Random forest analysis identified 29 SNPs with an empirical p–value of ≤ 0.05 for 
association with crystallised intelligence (Table 7.5). These SNPs, which were located 
within DISC1, SORCS1, SORCS2 and SORCS3, were selected for analysis of epistatic 
interactions in the remaining 20% of the sample set. Following removal of within-gene 
combinations, 273 between-gene two-way combinations were assessed, along with 
3168 three-SNP combinations. No significant two-way interactions were observed 
following correction for multiple testing for either the two-SNP or three-SNP 
interactions (FDR q > 0.32). However, ten interactions were nominally significantly 
associated with crystallised intelligence (p < 0.05; Table 7.6). One hundred eighty-
seven three-SNP interactions were nominally significantly associated with crystallised 



















rs10032900 SORCS2 0.001 
rs4350297 SORCS3 0.001 
rs4613570 SORCS2 0.001 
rs610785 SORCS1 0.001 
rs6541281 DISC1 0.001 
rs665679 SORCS1 0.001 
rs756255 SORCS2 0.001 
rs7667970 SORCS2 0.002 
rs6835799 SORCS2 0.003 
rs12730369 DISC1 0.004 
rs2269850 SORCS2 0.004 
rs10937826 SORCS2 0.005 
rs1557816 SORCS2 0.005 
rs2269852 SORCS2 0.005 
rs1336979 SORCS1 0.007 
rs2295959 DISC1 0.008 
rs10884100 SORCS3 0.014 
rs1565415 SORCS3 0.014 
rs2107182 SORCS2 0.017 
rs11932646 SORCS2 0.02 
rs4637403 SORCS2 0.021 
rs17466832 SORCS2 0.023 
rs7897974 SORCS1 0.024 
rs4689869 SORCS2 0.028 
rs7440772 SORCS2 0.03 
rs823162 DISC1 0.031 
rs9432040 DISC1 0.032 
rs4918288 SORCS1 0.04 
rs1251753 SORCS1 0.043 
Table 7.5: SNPs assessed for epistatic interactions associated with crystallised 
intelligence. 
Shown are SNP identifiers, their corresponding genes and empirical p-values calculated from 
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SNP1 SNP2 Gene1 Gene2 
LRT     
p- value 
R2 q-value 
rs10032900 rs1565415 SORCS2 SORCS3 0.003 0.080 0.753 
rs10937826 rs1565415 SORCS2 SORCS3 0.015 0.079 1 
rs2269850 rs6541281 SORCS2 DISC1 0.016 0.077 1 
rs11932646 rs1565415 SORCS2 SORCS3 0.016 0.078 1 
rs11932646 rs4350297 SORCS2 SORCS3 0.017 0.078 1 
rs10884100 rs11932646 SORCS3 SORCS2 0.018 0.077 1 
rs1565415 rs4613570 SORCS3 SORCS2 0.029 0.078 1 
rs4637403 rs6541281 SORCS2 DISC1 0.031 0.078 1 
rs2269852 rs6541281 SORCS2 DISC1 0.034 0.079 1 
rs610785 rs7667970 SORCS1 SORCS2 0.043 0.077 1 
Table 7.6: Two-SNP interactions nominally associated with crystallised 
intelligence. 
Shown is a summary of two-SNP interactions nominally significantly associated with 
crystallised intelligence (p < 0.05). From left to right, columns state the SNP identifiers and 
their corresponding genes, the likelihood ratio test p-value for the difference in goodness-of-
fit of the interaction model versus the null model, omitting the interaction term; the proportion 
of variance explained by the model (R2), and the Benjamini-Hochberg FDR q-value for the 
SNP interaction following correction for 273 tests. 
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SNP1 SNP2 SNP3 Gene1 Gene2 Gene3 LRT     p-value R2 q-value 
rs12730369 rs1336979 rs6541281 DISC1 SORCS1 DISC1 0.0001 0.08 0.36 
rs1565415 rs2107182 rs823162 SORCS3 SORCS2 DISC1 0.0002 0.08 0.79 
rs17466832 rs6541281 rs823162 SORCS2 DISC1 DISC1 0.0003 0.08 0.98 
rs6835799 rs7440772 rs823162 SORCS2 SORCS2 DISC1 0.0003 0.08 1 
rs1565415 rs756255 rs823162 SORCS3 SORCS2 DISC1 0.0004 0.08 1 
rs1336979 rs2269852 rs4918288 SORCS1 SORCS2 SORCS1 0.0004 0.08 1 
rs1565415 rs2269852 rs823162 SORCS3 SORCS2 DISC1 0.0005 0.08 1 
rs2107182 rs6541281 rs823162 SORCS2 DISC1 DISC1 0.0006 0.08 1 
rs10937826 rs1557816 rs6541281 SORCS2 SORCS2 DISC1 0.0007 0.08 1 
rs6541281 rs756255 rs823162 DISC1 SORCS2 DISC1 0.0009 0.08 1 
Table 7.7: Three-SNP interactions nominally significantly associated with crystallised intelligence. 
Shown is a summary of nominally significant genetic interactions associated with crystallised intelligence (p ≤ 0.05). From left to right, columns show 
the SNP identifiers and their corresponding genes the likelihood ratio test p-value for the difference in goodness-of-fit of the interaction model versus the 
null model, omitting the interaction term; the proportion of variance explained by the model (R2), and the Benjamini-Hochberg FDR q-value for the SNP 
interaction following correction for 3168 tests. Shown are the top ten interactions ranked by p-value. A full list of three-SNP interactions and their 
associations with crystallised intelligence is presented in Appendix I (Table A8). 
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7.3 Genetic interactions associated with MDD 
Two- and three-SNP interactions between DISC1 and Sortilin family genes were tested 
for association with MDD. Following random forest analysis of the permuted and real 
data, a total of 11 SNPs had an empirical p –value of ≤ 0.05 for association with MDD 
(Table 7.8). These SNPs were located in SORCS2, SORCS3 and DISC1. Thirty-six 
two-SNP interactions were assessed for association with MDD. No significant 
interactions were identified following correction for multiple testing (FDR q ≥ 0.297). 
However, one nominally significant interaction was observed (p = 0.007; Table 7.9). 
In the analysis of three-SNP interactions, 144 SNP combinations were assessed. No 
interactions were significantly associated with MDD following correction for multiple 
testing (FDR q = 1). However, 11 interactions were nominally significantly associated 






















rs7692314 SORCS2 0.001 
rs11122324 DISC1 0.002 
rs12256390 SORCS3 0.002 
rs4689789 SORCS2 0.01 
rs10012347 SORCS2 0.012 
rs970054 SORCS3 0.013 
rs7679804 SORCS2 0.016 
rs12040259 DISC1 0.021 
rs4689682 SORCS2 0.034 
rs1174741 SORCS3 0.04 
rs10021084 SORCS2 0.049 
Table 7.8: SNPs assessed for epistatic interactions associated with MDD. 
Shown are SNP identifiers, their corresponding genes and empirical p-values calculated from 
the random forest analysis. 
 
 
SNP1 SNP2 Gene1 Gene2 
LRT     
p- value 
R2 q-value 
rs12256390 rs10012347 SORCS3 SORCS2 0.007 0.12 0.258 
Table 7.9: Two-SNP interactions nominally associated with MDD. 
Shown is a summary of two-SNP interactions nominally significantly associated with MDD (p 
< 0.05). From left to right, columns state the SNP identifiers and their corresponding genes 
the likelihood ratio test p-value for the difference in goodness-of-fit of the interaction model 
versus the null model, omitting the interaction term; the proportion of variance explained by 
the model (R2), and the Benjamini-Hochberg FDR q-value for the SNP interaction following 
correction for 36 tests. 
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SNP1 SNP2 SNP3 Gene1 Gene2 Gene3 
LRT   
p-value 
R2 q-value 
rs4689789 rs12040259 rs4689682 SORCS2 DISC1 SORCS2 0.009 0.11 1 
rs11122324 rs4689789 rs4689682 DISC1 SORCS2 SORCS2 0.009 0.11 1 
rs970054 rs12040259 rs4689682 SORCS3 DISC1 SORCS2 0.009 0.11 1 
rs12256390 rs970054 rs7679804 SORCS3 SORCS3 SORCS2 0.011 0.11 1 
rs11122324 rs970054 rs4689682 DISC1 SORCS3 SORCS2 0.012 0.11 1 
rs11122324 rs970054 rs7679804 DISC1 SORCS3 SORCS2 0.028 0.12 1 
rs10012347 rs970054 rs10021084 SORCS2 SORCS3 SORCS2 0.033 0.11 1 
rs7692314 rs1174741 rs10021084 SORCS2 SORCS3 SORCS2 0.030 0.12 1 
rs12256390 rs12040259 rs4689682 SORCS3 DISC1 SORCS2 0.039 0.11 1 
rs11122324 rs10012347 rs4689682 DISC1 SORCS2 SORCS2 0.046 0.11 1 
rs970054 rs7679804 rs12040259 SORCS3 SORCS2 DISC1 0.045 0.11 1 
Table 7.10: Three-SNP interactions nominally associated with MDD. 
Shown are the three-SNP interactions nominally significantly associated with MDD (p ≤ 0.05).From left to right, columns show the SNP identifiers and 
their corresponding genes the likelihood ratio test p-value for the difference in goodness-of-fit of the interaction model versus the null model, omitting 
the interaction term; the proportion of variance explained by the model (R2), and the Benjamini-Hochberg FDR q-value for the SNP interaction following 
correction for 144 tests. 
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7.4 Discussion 
The aim of this chapter was to investigate whether epistatic interactions between SNPs 
in Sortilin family genes and DISC1 contribute to variation in cognitive and depressive 
phenotypes. Variation in DISC1 has been associated with working memory and 
depression (Carless et al., 2011; Thomson et al., 2015) while others have reported both 
independent and epistatic associations between Sortilin family genes and Alzheimer’s 
disease (Reitz et al., 2013). Moreover, multiple lines of evidence suggest roles for 
DISC1 and the Sortilin genes in psychiatric illness, as described in Chapters 1.4 and 
1.5 while the work described in Chapter 3 and Chapter 5 reported nominally significant 
expression and methylation differences in SORL1 and SORCS1, respectively, in 
t(1;11) carriers. 
 
Prior to performing the analysis, a set of genetically unrelated individuals was 
generated from the total sample set, prioritising individuals with a diagnosis of MDD 
over those without. This was performed with an aim to maximise the number of cases, 
and therefore power to detect any significant genetic associations with MDD. This list 
of unrelated individuals was circulated to those studying MDD in the Generation 
Scotland cohort as a resource for subsequent analyses. 
 
Random forest analysis was performed to identify SNPs most likely to interact as 
determined by their permutation-based p-values for association with depressive and 
cognitive phenotypes. For each phenotype, two- and three-SNP interactions were 
assessed. No significant interactions were observed after correction for multiple 
testing. Several nominally significant two-way and three-way interactions were 
observed in all three of the phenotypes examined (p < 0.05). Testing the nominally 
significant interactions identified here in an independent and/or larger population may, 
however, provide support for these findings. 
 
In the case of depression, it is possible that disease heterogeneity and/or sample size 
had a role in the failure to detect significant epistatic interactions. Early large-scale 
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association studies of MDD had failed to detect variants significantly associated with 
MDD (Ripke et al., 2013). However, Cai et al. (2015) reported significant genetic 
associations with depression through reducing heterogeneity amongst cases by 
limiting their study to Chinese females with severe (hospitalised) depression. More 
recently, Hyde et al. (2016) reported 15 significant associations with MDD, including 
a SNP in SORCS3, in the largest GWAS of the disorder to date consisting of over 
300,000 individuals of European ancestry. The success of Cai et al. (2015) reflects the 
importance of phenotype homogeneity for the detection of genetic associations in 
MDD. It is likely, however, that due to the limited sample size of the Generation 
Scotland cohort, subdividing the depressed individuals to improve phenotypic 
homogeneity would render the current analysis underpowered. Conversely, Hyde et 
al. (2016) demonstrated the efficiency of using a large study cohort with less intensive 
phenotyping. It is possible that significant interactions may be observed in a larger 
cohort, such as UK Biobank.  
 
It is possible that significant interactions between variants in DISC1 and/or Sortilin 
family members might be detected when assessed in the presence of variants from 
other genes that are involved in common functions or pathways. An example of one 
such function common to DISC1, SORL1, SORT1 and SORCS1 is the proteolytic 
processing of APP (Reitz et al., 2011; Gustafsen et al., 2012; Shahani et al., 2015). 
APP processing can occur through the action of either α-secretases or β-secretases, 
both of which are followed by γ-secretase processing (Zhang et al., 2011). 
Dysregulated expression of SORL1 and an α-secretase gene, ADAM10, was observed 
in t(1;11) carrier lymphoblastoids (described in Chapter 3). It is possible that 
interactions exist between DISC1, Sortilin family members and key players in the APP 
processing pathway, such as APP and/or the α-, β-, and γ-secretase-encoding genes. 
Processing of APP by action of β-secretases results in the generation of neurotoxic 
amyloid-β plaques: a hallmark of Alzheimer’s disease pathology associated with 
cognitive deficits (Olsson et al., 2003). Conversely, processing via the α-secretases 
results in the release of the neurotrophic soluble APP-α, levels of which have been 
positively correlated with cognitive function in rats (Anderson et al., 1999). 
Assessment of interactions between DISC1, Sortilin family members and genes in the 
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APP processing pathway; and their association with cognition and Alzheimer’s disease 
may be worthy of further investigation. 
 
Interactions may also exist between DISC1 and the Sortilin family in other psychiatric 
phenotypes. In addition to depression, there is some evidence for involvement of these 
genes in susceptibility to bipolar disorder and schizophrenia (Hennah et al., 2003; 
Hennah et al., 2009; Baum et al., 2008; Montano et al., 2016). It was not possible to 
assess this hypothesis as Generation Scotland did not record information on 
schizophrenia diagnosis and only 70 individuals in the cohort have a diagnosis of 
bipolar disorder. Further investigation in alternative datasets, such as those used by the 
psychiatric genomics consortium (PGC), may inform as to whether the interactions 
observed in this study are associated with other psychiatric disorders. 
 
In summary, no genetic interactions were observed between variants in the Sortilin 
genes and DISC1 that were significantly associated with cognition or depression in the 
Generation Scotland cohort. However, nominally significant associations were 
observed for all phenotypes assessed. Investigation of these interactions in larger 
independent cohorts and/or other psychiatric phenotypes is warranted. Ultimately, the 
functional effects of any variants of interest should be assessed in a laboratory setting 
to determine whether there exists a biological basis for the observed interactions.  
 




























Chapter 8  254 
 
8 Discussion 
There were two aims to this thesis. The primary aim was to investigate the genome-
wide effects of a psychiatric illness-associated translocation, t(1;11), on gene 
expression and DNA methylation in patient-derived samples. A secondary aim was to 
investigate a potential relationship between DISC1, the protein-coding gene disrupted 
by the t(1;11) translocation, and the Sortilin family of genes. This aim was predicted 
on both evidence of a regulatory relationship between Disc1 and Sortilin gene family 
members observed in a Disc1 mutant mouse (Brown et al., unpublished data), and 
evidence for dysregulation of Sortilin family members in iPSC-derived neurons 
containing mutations disrupting DISC1 (Wen et al., 2014; Srikanth et al., 2015). 
 
To address the primary aim, transcriptomic and methylomic analyses were performed 
on three patient-derived sources: lymphoblastoid RNA, whole blood DNA, and iPSC-
derived neuronal DNA. The secondary aim was addressed using both in-vitro and in-
silico approaches, using brain tissue from the 100P Disc1 mutant mouse, and genetic 
data from the Generation Scotland cohort, respectively. 
 
This chapter will provide a summary of findings in this thesis, discuss how these might 
relate to the field of psychiatric genetics, highlight limitations to the work presented in 
this thesis, and recommend future work. 
 
8.1 Overall findings 
8.1.1 Analysis of gene expression in t(1;11) individuals 
Chapter 3 described a genome-wide analysis of gene expression in lymphoblastoid – 
derived RNA, comparing individuals with the t(1;11) translocation (n = 8) to their 
karyotypically normal relatives (n = 5). This work was based on the hypothesis that 
the t(1;11) translocation might affect gene expression, mediated via several possible 
routes. As discussed in section 3.1, potential causal mechanisms include DISC1 
haploinsufficiency (Millar et al., 2005), DISC2 disruption, DISC1FP1/Boymaw 
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disruption, generation of deleterious fusion transcripts (Eykelenboom et al., 2010), 
or through the passive transmission, due to linkage disequilibrium, of regulatory 
variants on the derived chromosomes. Genome-wide transcription was assessed in 
these samples using the Illumina HT-12 platform. No between-group differences 
were observed at a genome-wide significant level (FDR q ≤ 0.05). However, 
imposing a relaxed p-value cut-off (p ≤ 0.05) coupled with an absolute fold-change 
threshold of ≥ 1.25 revealed 303 differentially expressed genes as candidates for 
further follow-up. Among these genes was SORL1, a member of the Sortilin gene 
family. This finding was successfully validated in a targeted follow-up using qRT-
PCR.  
 
Previously, an analysis of gene expression was performed by Xu Tang on a separate 
growth of lymphoblastoids from the same individuals included in this study. Here, 
both microarray and qRT-PCR data supported dysregulation of DLGAP1, HIPK2 and 
SV2B, among others (Table 3.3). HIPK2 was among the genes meeting the criteria 
for nominally significant differential expression in the current study: a finding which 
was successfully validated by qRT-PCR. Furthermore, although SV2B and DLGAP1 
were not amongst the differentially expressed genes on the microarray, they were 
found to be differentially expressed by qRT-PCR analysis, with the same direction 
of effect as observed by Xu Tang. This study also supported a relationship between 
DISC1 and Sortilin genes: carriers of the translocation showed downregulation of 
SORL1. This was observed both on the microarray and by qRT-PCR.  
 
Other studies of gene expression in the context of DISC1-disrupting mutations have 
been performed on iPSC-derived neuronal samples (Wen et al., 2014; Srikanth et al., 
2015). These studies have reported increased Wnt signaling, altered neuronal fate 
and altered expression of synaptic genes. Dysregulation of the synaptic genes 
DLGAP1 and SV2B was confirmed by qRT-PCR in two separate growths of t(1;11) 
lymphoblastoid samples, further supporting the role of DISC1 in synaptic function. 
These findings would suggest that normal DISC1 function is required to regulate the 
neuronal expression of genes involved in processes such as neurodevelopment and 
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synaptic function. This is supported by neuroanatomical findings in individuals 
carrying certain DISC1 variants/genomic rearrangements, including the t(1;11) 
translocation. Doyle et al. (2015) reported reduced cortical thickness in t(1;11) 
carriers compared to their non-carrying relatives, while Whalley et al. (2015) 
reported an association between the t(1;11) translocation and reduced white matter 
integrity. Moreover, others have reported reduced grey matter volumes were 
associated with the DISC1 variant rs6675281, suggestive of synaptic and 
neurodevelopmental deficits (Cannon et al., 2005; Trost et al., 2013).  
 
Assessment of lymphoblastoid cell lines has revealed that individuals with the t(1;11) 
translocation display half the levels of DISC1 seen in their karyotypically normal 
relatives, both at the mRNA and protein level (Millar et al., 2005), presenting a 
possible mechanism through which its disruption might impact upon gene 
expression. Overlap was observed between dysregulated genes observed in t(1;11) 
carriers and those dysregulated in iPSC-derived neurons containing DISC1 mutations 
(Wen et al., 2014; Srikanth et al., 2015). Of these genes, HIPK2 may be of note as 
upregulation was observed in t(1;11) carriers using two separate growths of 
lymphoblastoid-derived samples: a finding confirmed by microarray and qRT-PCR 
analyses in both sets of samples. Although not implicated in psychiatric illness by 
GWAS, its function in promoting neuronal survival may be relevant to psychiatric 
illness (Zhang et al., 2007; Jarskog et al., 2005).  Srikanth et al. (2015) reported 
downregulation of HIPK2 in neurons with a DISC1 frameshift mutation in exon 2: a 
mutation which targets all known coding isoforms of DISC1. The difference 
observed with regards to HIPK2 expression could be attributed to independent effects 
of different mutations in DISC1. For example, upregulation of HIPK2 may be 
associated with DISC1 haploinsufficiency in t(1;11) carriers while downregulation 
may be associated with the effects of the DISC1 frameshift mutation. Srikanth et al. 
(2015) reported normal DISC1 expression levels in these cells. Alternatively, other 
consequences of the translocation (described in section 3.1) might impact upon 
HIPK2 expression in a DISC1-independent manner. Multiple PDE4B binding sites 
are present in exon 2 of DISC1 (Soares et al., 2011). Should these be affected by the 
mutation reported by Srikanth et al. (2015), it may present a mechanism through 
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which dysregulation of gene expression occurs through the cAMP signaling pathway 
(Millar et al., 2005; section 1.4.2). 
 
The work carried out in Chapter 3 also supported a previously-reported role for 
DISC1 in the APP processing pathway (Shahani et al., 2015). SORL1 has been 
shown by others to modulate levels of APP processing in which it inhibits both 
amyloidogenic and non-amyloidogenic processing (Gustafsen et al., 2013; section 
7.4). Shahani et al. (2015) reported a decrease in non-amyloidogenic processing and 
an increase in amyloidogenic processing following DISC1 knockdown. 
Downregulation of SORL1 was observed in t(1;11) carriers, which, along with DISC1 
haploinsufficiency, would be predicted to affect APP processing in t(1;11) carriers. 
This disruption to the APP processing pathway might occur independently, or 
through the joint effects of DISC1 and SORL1 misexpression. SORL1 is located on 
chromosome 11, approximately 30 Mb telomeric to the translocation breakpoint. A 
possible mechanism for its observed downregulation in t(1;11) carriers is the 
presence of linkage disequilibrium between alleles associated with SORL1 
expression, and the translocation. The same might also apply to other differentially 
expressed genes on chromosomes 1 and 11. In Chapter 4 of this thesis, a potential 
mechanism for differential methylation at the t(1;11) breakpoint was observed. This 
pertained to the transmission of meQTLs in LD with the translocation causing 
genome-wide significant difference in methylation at regions surrounding the t(1;11) 
breakpoints. However, no differences in methylation were observed in SORL1 in 
either blood or iPSC-derived neuronal DNA from the family. Experimental follow-
up to investigate the effects of the t(1;11) translocation on APP processing was not 
possible as not all of the constituent genes of the APP processing pathway are 
expressed (according to the expression array) in these cells. Should these genes be 
expressed in the t(1;11) family iPS-derived neurons, further investigation using these 
samples might determine whether the translocation is associated with altered APP 
processing. Such experiments could assess the levels of soluble products of APP 
processing in conditioned media (i.e. sAPP-α and sAPP-β), to determine whether the 
translocation is associated with abnormal levels of APP processing by either α- or β-
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secretase activity. Further experiments could assess whether DISC1 and SORL1 act 
together or independently in the APP processing pathway. 
 
8.1.2 DNA methylation in t(1;11) individuals 
Chapter 4 described the assessment of methylation in whole blood DNA samples 
from the t(1;11) family. There were two aims to this chapter. Firstly, to determine 
whether the t(1;11) translocation was associated with differential methylation in 
blood, and secondly, to assess whether t(1;11) carriers with a psychotic disorder show 
differences in methylation compared to t(1;11) carriers with a non-psychotic 
disorder. Thirteen sites were found to be significantly differentially methylated 
between translocation carriers and non-carriers (FDR q < 0.05). Of these, four sites 
were within DISC1. A comparison between translocation carriers with psychotic and 
non-psychotic diagnoses revealed three significantly differentially-methylated sites. 
Distribution of the methylation signal at these loci suggested that the findings at these 
three sites may be due to a technical artefact arising from impaired probe binding due 
to genetic variation. Analysis of differentially methylated regions revealed several 
loci with multiple nominally significant differentially methylated sites in both the 
carrier vs. non-carrier comparison, and the comparison of individuals with psychotic 
and non-psychotic diagnoses. 
 
The observation of differential methylation around the t(1;11) breakpoint regions 
may have been due to the passive transmission of meQTLs in linkage disequilibrium 
with the translocation.  In the comparison of t(1;11) carriers with a psychotic disorder 
to those with a non-psychotic disorder, three sites were significantly differentially 
methylated. At all three loci, genetic variation was discovered at the probe binding 
site, resulting in genotype-specific signal. In both comparisons, differentially 
methylated regions (DMRs) were identified in genes previously implicated in 
psychiatric illness by GWAS and candidate gene studies. 
 
All but one of the significantly differentially methylated loci between t(1;11) carriers 
and non-carriers occurred in the regions of the translocation breakpoints. These 
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findings are in agreement with a previous study of differential methylation in a 
leukaemia-associated t(11;14) translocation (Walker et al. 2011). Here, the top six 
ranked DMPs were hypomethylated and located within one of the genes directly 
disrupted by the translocation.  
 
A potential mechanism whereby differential methylation occurs at translocation 
breakpoint regions was identified in this study. Seven of the 13 t(1;11) associated 
DMPs were previously reported to be associated with variation at independent loci 
(meQTLs; Lemire et al., 2015). Of these seven DMPs, five were found to be 
influenced by cis-acting meQTLs, all on either chromosome 1 or 11. Furthermore, 
these meQTLs were significantly associated with t(1;11) carrier status. Linkage 
disequilibrium between the translocation and regulatory variants may be a pathogenic 
mechanism in t(1;11) carriers. It is likely that other variants in LD with the 
translocation affect gene expression in addition to methylation by acting as 
expression QTLs. In addition, differential methylation mediated by meQTLs may 
result in altered gene expression (Shin et al., 2015). It is possible that such 
consequences could affect downstream pathways relating to pathogenesis. 
 
Overlap was observed between findings from this analysis and a recent blood-based 
epigenome-wide study of schizophrenia performed by Montano et al. (2016). Among 
other genes, Montano et al. (2016) reported differential methylation in MAD1L1, 
RPTOR and DDR1. Differentially methylated regions were observed in each of these 
genes when comparing t(1;11) carriers with a psychotic disorder to those with a non-
psychotic disorder. MAD1L1 has also been implicated in schizophrenia and bipolar 
disorder by GWAS (Ruderfer et al., 2014; Ripke et al., 2014; Hou et al., 2016). 
RPTOR has previously been implicated in bipolar disorder, having been identified at 
the breakpoint of a chromosomal translocation found in a case with bipolar disorder 
(Rajkumar et al., 2015). Roig et al. (2007) proposed DDR1 as a susceptibility gene 
for schizophrenia based on evidence of its reduced expression in schizophrenic 
patients carrying a variant showing significant association with the disorder. 
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However, RPTOR and DDR1 have not been implicated in psychiatric illness by 
GWAS. 
 
Differential methylation of genes relating to immune function was common to both 
the comparison of t(1;11) carriers and non-carriers, and the comparison of psychotic 
and non-psychotic illness in t(1;11) carriers. This adds support to a long-standing 
observation of immune system dysfunction in psychiatric illness (reviewed in 
Upthegroves and Barnes, 2014). Recent evidence further implicating the immune 
system in psychiatric illness has come from GWAS and studies of gene expression 
and function (Ripke et al., 2014; Sekar et al., 2016).  
 
Two significantly differentially methylated sites were observed in t(1;11) carriers 
within EGLN1. EGLN1 plays a role in the transcriptional response to hypoxia through 
regulation of the hypoxia-inducible factor HIF-1α. Hypoxia is a known obstetric risk 
factor for schizophrenia. Methylation levels at both of these sites in EGLN1 were 
found to be associated with genotype at nearby meQTLs in linkage disequilibrium 
with the translocation. Should differential methylation of this gene affect 
transcription in response to oxygen levels, this finding might indicate a mechanism 
for increased risk of illness through a t(1;11)-associated gene-environment 
interaction. 
 
Chapter 5 described the assessment of DNA methylation in iPSC-derived neurons 
from six members of the t(1;11) family. There were two aims to this chapter. The 
first was to determine whether the t(1;11) translocation was associated with 
differential methylation in a cellular model more physiologically relevant to 
psychiatric illness. The second aim was to permit the comparison of DNA 
methylation levels in blood to those in neuron-like cells from t(1;11) family 
members. This work was performed using the Infinium HumanMethylationEPIC 
BeadChip. As this array has only recently been developed, prior to addressing the 
first two aims of this Chapter 5, it was necessary to identify probes on this array that 
(i) are affected by polymorphisms and/or (ii) have the potential to cross-hybridise. 
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Lists of these probes have been published in order to provide a resource for the 
research community (McCartney et al., 2016; Appendix 1). No significant 
differences in methylation were observed between translocation carriers and non-
carriers. Nine of the top ten loci ranked by p-value for differential methylation were 
found to be driven by a single individual, with consistently higher levels of DNA 
methylation compared to the remaining five samples. Differentially-methylated 
regions were identified containing multiple probes nominally significantly associated 
with t(1;11) carrier status. Of the regions identified, two were within SORCS1, a 
member of the Sortilin gene family. This, along with the finding of differential 
expression of SORL1 in Chapter 3, provided justification to further investigate a 
relationship between DISC1 and Sortilin family members. 
 
Analysis of DMRs identified a number of genes previously implicated in psychiatric 
illness including COMT, a long time candidate gene for schizophrenia described in 
section 1.3.2.1. This DMR was hypomethylated in iPSC-derived neurons from 
t(1;11) carriers. Others have reported hypomethylation in COMT in the frontal lobes 
of post-mortem brains of schizophrenia and bipolar disorder patients, accompanied 
with increased COMT expression (Abdolmaleky et al., 2006). Hypomethylation of 
COMT has also been observed in saliva-derived DNA of schizophrenia and bipolar 
disorder patients (Nohesara et al., 2011). Dempster et al. (2006) did not find a 
difference in COMT methylation in the cerebellum of post-mortem brains of patients 
with schizophrenia, bipolar disorder or depression. This is perhaps unsurprising, as 
Hannon et al. (2015) have reported distinct methylation profiles between the 
cerebellum and cortical regions. Egan et al. (2001) proposed a mechanism whereby 
COMT enzyme activity regulates synaptic dopamine levels (section 1.3.2.1). This 
could point to a COMT-mediated effect on the dopaminergic system in t(1;11) 
carriers, which may be associated with increased risk of illness. As this finding is one 
of 424 DMRs, validation by targeted methods such as pyrosequencing and qRT-PCR 
in the t(1;11) iPSC-derived neurons is recommended to first confirm the presence of 
differential methylation at COMT in these individuals, and secondly, determine 
whether this has an effect on gene expression. 
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Two DMRs were discovered in SORCS1, supporting a regulatory relationship 
between DISC1 and the Sortilin family. Both regions were hypomethylated in t(1;11) 
carriers. Although it was not possible to assess gene expression differences in these 
samples, others have reported downregulation of SORCS1 in iPSC-derived neurons 
containing a 4 bp DISC1 frameshift mutation (Wen et al., 2014). RNA-seq analysis 
is currently ongoing which will permit assessment of the relationship between 
SORCS1 expression and methylation, and whether differential expression of SORL1 
can be observed, as seen in t(1;11) family LCLs. 
 
Numerous GO terms relating to synaptic function and transmission were over-
represented by genes harbouring the most significantly differentially methylated loci. 
DISC1 localises to synapses where it regulates dendritic spine morphology and 
function, as well as levels of post-synaptic density proteins (Hayashi-Takagi et al., 
2010; Wang et al., 2011). Moreover, Wen et al. (2014) reported dysregulation of 
synaptic gene expression in iPSC-derived neurons with a 4 bp frameshift mutation in 
DISC1. Dysregulation of expression and methylation of synaptic genes was reported 
in the work performed in this thesis, including SV2B and DLGAP2. SV2B is a 
synaptic vesicle protein which functions in regulating presynaptic calcium levels 
(Wan et al., 2010). Calcium signaling is a key regulatory pathway in the brain and 
has been implicated in both schizophrenia and bipolar disorder (Berridge, 2014). 
SV2B had previously been found to be upregulated in t(1;11) lymphoblastoid samples 
by microarray expression and qRT-PCR. This finding was replicated in RNA from a 
separate growth of lymphoblastoid samples, as reported in Chapter 3. DLGAP2 is a 
postsynaptic density protein which has been implicated in neuropsychiatric disorders 
including autism and schizophrenia (Marshall et al., 2008; Li et al., 2014). DMRs 
were reported in DLGAP2 in iPSC-derived neurons and blood from the t(1;11) family 
in Chapter 4. Taken together, these findings might support a pathogenic mechanism 
via synaptic dysfunction in carriers of the translocation. Electrophysiological 
assessment of the iPSC-derived neurons from the t(1;11) family would aid in 
addressing this hypothesis. 
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In the blood-based analysis of DNA methylation in the t(1;11) family, significant 
differential methylation was reported at the translocation breakpoints. This was 
possibly due to the influence of meQTLs in LD with the translocation. There were 
no significant differences in DNA methylation at the breakpoint regions in iPSC-
derived neurons. Investigation of the blood-based meQTLs in iPSC-derived neurons 
showed no significant associations between genotype and methylation. This may 
have been due to limitations in sample size. Only one of the five meQTLs identified 
in 41 blood samples was also detected when subsetting the sample to the same six 
individuals profiled for DNA methylation in iPSC-derived neurons. This suggests 
that assessment of a larger sample would be required in order to identify meQTLs in 
the iPSC-derived neurons. 
 
8.1.3 Investigating a potential relationship between DISC1 and the 
Sortilin gene family 
Chapter 6 described an analysis of developmental gene expression of Sortilin family 
members in a mouse model containing a missense L100P mutation in exon 2 of 
Disc1. These mice had previously been reported to display schizophrenic-like 
behaviours (Clapcote et al., 2007) and transcriptional dysregulation (Lipina et al., 
2012), which were ameliorated following antipsychotic and anticonvulsant 
treatment, respectively. This work aimed to investigate a regulatory relationship 
between Disc1 and Sortilin family genes based on findings of dysregulated 
expression of SorCS1 and SorCS2 in the brains of 100P mice by others (Brown et al., 
unpublished). The samples assessed by Brown et al. were reanalysed using an 
optimised normalisation strategy revealing dysregulated Sortilin genes at several 
developmental stages in the mutant mice. However, attempts to validate these 
findings in an independently-collected batch of RNA were unsuccessful. 
 
There are several possible causes for the discordance of findings between the two 
batches of samples. One possible reason pertains to differences in the genetic 
backgrounds of the mice studied. Arime et al. (2014) reported residual ENU-
generated mutations in the mice assessed by Clapcote et al. (2007), including a 
missense mutation in SorCS3. The SB samples were more closely related to these 
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mice than the DM samples, as they were obtained from the same colony as those 
reported by Clapcote et al. (2007). This suggests they were more likely to be affected 
by a mixed genetic background.  Although the analysis performed on the DM 
samples is likely to be more valid due to reduced genetic heterogeneity, the degree 
of residual ENU mutations in these samples has not been ascertained. It is possible, 
should a regulatory relationship exist between Disc1 and the Sortilin genes in these 
mice, the potential confounder of a mixed genetic background would mask any 
effects attributable to this relationship. 
 
Additional analyses were performed to investigate a relationship between these genes 
in a human system, using an in-silico approach. Chapter 7 described an exploratory 
investigation of whether variants in DISC1 and Sortilin family genes interact 
epistatically to exert an effect on cognitive phenotypes and/or depression. Epistatic 
interactions have been hypothesised to partially account for the missing heritability 
of complex traits (Eichler et al., 2010). Machine learning algorithms are an attractive 
option to assess epistatic interactions in genomics data as they can efficiently address 
the computational and statistical burden associated with traditional association 
methods (Wei et al., 2014). Random forest analysis was selected because of its ability 
to score each variable on their predictive abilities, whilst considering the effects of 
other variables (Lunetta et al., 2004). Others have successfully identified genetic 
interactions associated with psychiatric illness using this method. Nicodemus et al., 
(2010) reported genetic interactions associated with schizophrenia risk using 
multiple machine learning algorithms, including random forests. DISC1 and the five 
members of the Sortilin gene family were assessed on the basis of evidence of 
dysregulation of Sortilin family genes in the context of DISC1 mutations, which 
might suggest a relationship between these genes (Wen et al., 2014; Srikanth et al., 
2015).  Depression and cognition were investigated as DISC1 and Sortilin family 
genes have been implicated in these phenotypes (Carless et al., 2011; Thomson et 
al., 2014; Hyde et al., 2016; Reitz et al., 2011). Random forest analysis was used to 
identify SNPs likely to interact in each phenotype. Interactions between these SNPs 
were then assessed for association with cognition and depression using likelihood 
ratio tests to compare the goodness-of-fit of a regression model containing an 
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interaction term; to a null model, omitting the interaction term. Although no 
significant interactions were observed following correction for multiple testing (all 
FDR q > 0.05). However, several two- and three- way interactions were nominally 
significantly associated with the phenotypes assessed (p ≤ 0.05). 
 
Although the absence of significant findings may suggest there are no epistatic 
interactions to be detected between DISC1 and Sortilin family members in the 
phenotypes tested, it is possible that phenotypic heterogeneity contributed to the 
failure to detect significant interactions. This is likely to be the reason for the failure 
to detect significant associations with MDD in early GWASs (Ripke et al., 2013). 
More recent studies have identified genome-wide significant associations with MDD 
through reducing phenotypic heterogeneity by considering only females with severe 
illness (Cai et al., 2015), or increasing sample size (Hyde et al., 2016).  However, 
due to the limited sample size involved in the current analysis, stratification of the 
phenotype would likely impede the power of this study to detect significant 
interactions associated with MDD. Moreover, in order to stratify by phenotype, 
detailed measures of illness, such as information regarding hospitalisation, would be 
required. Repeating the analysis in a larger sample of individuals would likely be a 
more accurate assessment of epistasis between these genes, and may support the 
nominally significant findings reported here.  
 
8.2 Limitations 
8.2.1 Potential confounders 
An important point to consider when interpreting the findings of the comparisons 
between t(1;11) carriers and non-carriers is the presence of factors which may be 
correlated with translocation carrier status. These factors (e.g. smoking status, 
alcohol intake) may, at least in part, be responsible for any differences observed in 
the above analyses. Although surrogate variable analysis was performed on the data 
to identify and remove latent sources of variation, this would not be sufficient to 
eliminate factors which are highly correlated with translocation carrier status. Further 
follow-up of t(1;11) family members is recommended, if possible, in order to attain 
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information pertaining to factors known to contribute to gene expression, DNA 
methylation, and increased risk of major mental illness. 
 
8.2.2 Multiple study tissues 
There are several limitations to consider when interpreting findings from the work 
presented in this thesis. The use of three different study tissues (i.e. LCLs, whole 
blood and iPSC-derived neurons) in the analysis of the t(1;11) family presents a 
challenge when drawing parallels between the results of Chapters 3-5. Moreover, 
each study tissue has its own drawbacks which must be acknowledged when 
considering the findings from the three t(1;11)-based studies.  
 
Whether the differences in DNA methylation translate to effects on gene expression 
remains to be ascertained. It was not possible to determine whether changes in 
methylation had an effect on gene expression in the individuals assessed in this 
chapter, as RNA was not available. Although RNA is available from LCLs and iPSC-
derived neurons from the t(1;11) family members, the overlap with the individuals 
for whom whole blood DNA was available is limited. Furthermore, inherent gene 
expression differences between blood, LCLs and neuronal cells would render 
findings from inter-tissue comparisons of DNA methylation and gene expression 
difficult to interpret.  
 
With regards to Chapter 3, it is unlikely that LCLs will faithfully recapitulate all gene 
expression differences present in the brains of t(1;11) carriers. In part, this is because 
several brain-expressed genes are not expressed in blood-derived cell lines (Sullivan 
et al., 2006). Moreover, cell passage numbers were not available for these samples. 
Long-term culture has been shown to result in the accumulation of random mutations, 
which, if present in these samples, might have confounded the results (Mohyuddin et 
al., 2004). Use of whole blood in this analysis would have been a more attractive 
option, as it would have allowed for a more direct comparison with the findings from 
Chapter 4, with the additional benefit of being free of possible confounders resulting 
from long-term culture. Whole-blood derived samples, however, are not without their 
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disadvantages – particularly when studying disorders of the brain, as in the 
methylation analysis described in Chapter 4. Peripheral blood is an attractive tissue 
for the analysis of DNA methylation, due to its accessibility.  However, differential 
methylation in blood may not always correlate with differential methylation in the 
brain (Walton et al., 2015; Hannon et al., 2015). Equally importantly, whether these 
differences in methylation are correlated with DNA methylation and gene expression 
in the brain cannot be determined with certainty. Smith et al. (2014) have reported a 
significant overlap of meQTLs between blood and brain. Should differences in 
methylation observed in this study be influenced by such meQTLs, this may suggest 
similar differences in methylation occur in the brains of these individuals. This 
represents a limitation of blood-based studies of psychiatric illness. Should 
meaningful conclusions be drawn from such studies, supporting evidence from a 
more physiologically-relevant tissue would be necessary. An attempt to address this 
limitation is presented in Chapter 5, in which DNA methylation was profiled in iPSC-
derived neurons from six t(1;11) family members who were profiled for DNA 
methylation in the blood-based analysis. However, no overlap was evident between 
the findings of Chapter 4 and Chapter 5. This may be due to limitations in the ability 
of iPSC-derived neurons to model the brain. Although more physiologically relevant 
to psychiatric illness than whole blood, iPSC-derived neurons cannot faithfully 
model a human brain, in which different cell subtypes interact in a three-dimensional 
environment. Furthermore, iPSC-derived neurons are not representative of adult 
neurons: Mariani et al. (2012) reported significant similarities between the 
transcriptomes of human iPSC-derived neurons and foetal neurons between 8 and 10 
weeks post-conception while no correlation was observed between patient age and 
DNA methylation age in the iPSC-derived neurons in this analysis.  
 
8.2.3 Sample size 
Although the use of a closely-related pedigree should go some way to reduce genetic 
variation between samples, thereby increasing power; the work presented in Chapters 
3 and 5 was further hindered by the small sample size, which may have rendered 
these studies underpowered to detect genome-wide significant differences in gene 
expression and methylation, should any exist in these samples. Moreover, within the 
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six individuals profiled for DNA methylation in iPSC-derived neurons, gender was 
confounded with translocation carrier status. This may have resulted in sex-specific 
effects on DNA methylation being misinterpreted as t(1;11)-associated effects. It is 
also possible that t(1;11) effects were inadvertently removed after covarying for 
gender in the regression model.  Although sex chromosome-targeting probes were 
removed from this analysis in an attempt to address the relationship between t(1;11) 
status and gender, it is known that autosomal sites also display sex-associated 
differences in DNA methylation (Liu et al., 2010). Furthermore, a single sample 
appeared to drive the most differentially-methylated sites in t(1;11) samples in 
Chapter 5. It is difficult to conclude whether this outlier sample was artefactual, 
however, considering such a small sample. Generation of iPSC-derived neurons from 
additional members, followed by further methylation profiling and appropriate batch 
effect corrections may go some way to clarify the distribution of DNA methylation 
levels in the family. Optimally, these samples should be matched to those profiled in 
blood, to permit a direct comparison between the two tissues.  
 
With regards to the work perfomed in Chapter 7, a cohort of approximately 20,000 
individuals was used. However, to remove potentially confounding effects of shared 
genetic sequences amongst related individuals, only 7000 unrelated individuals were 
included in this analysis. The sample size was further reduced when splitting the 
cohort, with 80% included in the random forest analysis and the remaining 20% 
included for the validation stage. It is possible that, should interactions between 
DISC1 and Sortilin family genes contribute to small effects in cognition and/or 
depression, such effects may not be detected due to a low sample number.  
 
8.2.4 DNA hydroxymethylation 
An additional limitation to this study concerns DNA hydroxymethylation. It is not 
possible to distinguish between DNA methylation and hydroxymethylation using the 
bisulphite-based method of detection used by the Infinium HumanMethylation450 
BeadChip (Nestor et al., 2013). Any methylation differences reported in this thesis 
therefore might also reflect changes in hydroxymethylation. 
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DNA hydroxymethylation is abundant in neurons, where it is thought to play a 
regulatory role (Mellén et al., 2012). Moreover, Hahn et al. (2013) reported increased 
DNA hydroxymethylation during neurogenesis in embryonic mouse brains. Should 
the t(1;11) family iPSC-derived samples be representative of embryonic neurons, it 
is possible that increased DNA hydroxymethylation levels are present. A further 
possibility is that changes DNA methylation and hydroxymethylation might have 
cancelled each other out at some loci, resulting in a failure to identify any differences 
in DNA methylation. Dissection of these individual effects by methods such as 
oxidative bisulphite conversion is therefore warranted. 
 
8.2.5 The L100P mouse 
The 100P mouse was an attractive option to investigate a relationship between DISC1 
and Sortilin family members in Chapter 6, due to previous findings of differential 
expression by Brown et al. (unpublished), and reports of behaviours reminiscent of 
psychiatric disorders and their amelioration by antipsychotic and antidepressant 
medications (Clapcote et al., 2007). As it has since emerged that these mice were 
genetically heterogeneous due to residual ENU-derived mutations, the original 
findings of differentially-expressed Sortilin family members may be compromised. 
Differences in expression of Sortilin family genes have been reported in the context 
of DISC1 mutations in human iPSC-derived neurons (Wen et al., 2014; Srikanth et 
al., 2015). This might suggest that a regulatory relationship does indeed exist 
between DISC1 and these genes, but is either human-specific or not modeled by the 
100P mutation. Due to the differences in complexity between the brains of mice and 
humans, the former is a strong possibility. 
 
Tissue heterogeneity from the use of whole brains is a confounding factor as murine 
SorCS1-3 have shown region-specific expression patterns in the brain (Hermey et al., 
2001; Hermey et al., 2004). It is therefore possible that the 100P mutation exerts 
different effects on Sortilin family expression in different brain regions. This may 
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render 100P-associated expression differences difficult to detect in whole-brain 
samples, through the dilution of small effects in individual brain regions.  
 
8.3 Future work 
8.3.1 Recommended future work on t(1;11) samples 
It is likely that the limited sample sizes in Chapters 3 and 5 have contributed to 
increase in both type I and type II errors. Therefore, follow-up of findings in 
additional individuals is warranted. Moreover, differences in study tissue are also 
likely to be obstructive in permitting a direct assessment in the relationship between 
gene expression and DNA methylation in the t(1;11) family. To this end, the iPSC-
derived neurons may prove a valuable resource for future analyses. Fibroblasts from 
additional family members are available which will provide an increased sample size 
upon differentiation to iPSC-derived neurons. Others are currently carrying out 
RNA-seq analysis in the iPSC-derived neurons from the t(1;11) family described in 
Chapter 5 of this thesis. Protein is also available from these cells which will permit 
investigation of the relationship between gene expression, DNA methylation and 
protein expression in t(1;11) individuals. Furthermore, genetic data is available from 
all individuals profiled for DNA methylation in the iPSC-derived neurons. This data 
could be applied to the gene expression data, when available, to investigate whether 
illness- or translocation-associated eQTLs are present in these samples. This should 
also be utilised in combination with the methylation data to identify iPSC-derived 
neuronal meQTLs for comparison with those present in blood. However, sample size 
may pose an issue in the identification of such sites, and power analysis would be 
recommended before performing an association analysis in order to generate robust 
results. Such studies might be informative as to which sites in blood are likely to be 
affected by differential methylation in the brain, permitting the selection of candidate 
loci to examine their possible roles in psychiatric illness.  
 
As the findings from Chapter 4 and Chapter 5 may, at least in part, be due to 
differences in DNA hydroxymethylation, oxidative bisulphite treatment of the DNA 
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is recommended to dissect any effects of DNA hydroxymethylation from those of 
DNA methylation (Booth et al., 2013).  
 
Brain imaging data from the family is also now available from which t(1;11)-
associated deficits in white matter integrity and cortical thinning have been reported 
(Whalley et al., 2015; Doyle et al., 2015). Future experiments could also assess the 
relationship between DNA methylation, gene expression and imaging data in order 
to identify possible effects of differential DNA methylation and gene expression on 
neurodevelopment in the family, which might be associated with illness or the 
translocation. 
 
8.3.2 Recommended future work to investigate the DISC1-Sortilin 
relationship 
Since the generation of the 100P mouse, more efficient means of mutagenesis have 
been developed, such as CRISPR-Cas9 gene editing (Ran et al., 2013). Mutant 
animal models derived using this method are less likely to be confounded by residual 
mutations (Arime et al., 2014). A possible future experiment could involve the 
introduction of the 100P mutation by means of gene editing, coupled with screening 
for additional, off-target mutations using high-throughput sequencing methods. Any 
findings of differential gene expression observed in such a model would be more 
robustly associated with the 100P mutation than the findings in the ENU model, due 
to the reduced heterogeneity of its genetic background. Furthermore, investigation of 
other Disc1 mouse models (Johnstone et al., 2011) might also be warranted to 
determine whether expression differences in Sortilin genes vary according to the type 
of disruption to Disc1. The 100P mutation involves a single amino acid change in 
exon 2 Disc1 (Clapcote et al., 2007). It is possible, however, that other disruptions to 
Disc1 might affect Sortilin family expression. To this end, a CRISPR-Cas9 
mutagenised model might be of use to induce mutations in candidate regions of Disc1 
to dissect this potential regulatory relationship. Additionally, in-vitro knock-out and 
knock-down studies might inform of such a relationship. 
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Assessing the relationship between DISC1 and Sortilin family genes in a human 
system should also be informative. In Chapter 3, t(1;11)-associated downregulation 
of SORL1 was reported in LCLs; while in Chapter 5, two hypomethylated SORCS1 
DMRs were identified in t(1;11) iPSC-derived neurons. Investigation of the 
expression and/or functions of these genes in the iPSC-derived samples from the 
t(1;11) family, or iPSC-derived neurons carrying CRISPR-Cas9-induced DISC1 
variants; may go some way to support or refute the hypothesis of a regulatory 
relationship between DISC1 and Sortilin family genes. 
 
Although no genome-wide significant interactions were identified in the analysis in 
Chapter 7, future analysis in a larger cohort might be informative as to whether 
significant interactions are associated with depression or cognition when increasing 
the sample size and/or reducing phenotypic heterogeneity. This could be addressed 
through the inclusion of additional cohorts, such as UK Biobank: a cohort over 
500,000 genotyped individuals (Sudlow et al., 2015). Furthermore, inclusion of 
additional genes which may interact with DISC1 and Sortilin family genes may be 
necessary to detect genetic interactions. Should any interactions be observed by these 
methods, investigation of their role in a biological system would be warranted in 
order to identify mechanisms through which they contribute to the phenotype of 
interest. This could be through gene expression analyses to determine the co-
expression patterns of interacting genes. Further investigation involving co-
immunoprecipitation or mass spectrometry analyses could also be performed to 
assess whether such genetic interactions translate to a relationship at the protein level. 
The availability of t(1;11) neuronal precursors and iPSC-derived neurons may be a 
useful resource for such experiments.  
 
Restricting the genes studied to DISC1 and Sortilin family genes may have posed a 
limitation in identifying significant interactions. The study was limited to these genes 
to reduce the statistical and computational burden involved with investigating 
combinations of a large set of genes. However, it is possible that DISC1 and Sortilin 
family members interact in the context of other genes that were not included in this 
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analysis. Selection of additional candidates that might occur in an interaction 




Although the work presented here has provided suggestive evidence for t(1;11) 
associated differential methylation and gene expression, caution should be exerted 
when drawing links studies described in this thesis, due to the use of three different 
study tissues and low sample sizes, particularly in Chapters 3 and 5. The recent 
generation of iPSC derivatives from the family may address this due to the availability 
of concurrently-harvested DNA, RNA and protein. At the time of writing this thesis, 
gene expression, proteomic and morphological analyses are ongoing for t(1;11) family 
iPSC-derived neurons. There is also scope to generate iPSC-derived neurons from 
additional family members, permitting improvements in sample size. In addition, 
whole-genome sequence data is now available from the family. This is likely to be a 
key resource for the identification of additional risk factors pertaining to illness in the 
t(1;11) family. Future work should aim to integrate findings from gene expression, 
protein expression and DNA methylation studies of these samples, whilst also 
considering the available genetic data, in order to identify mechanisms through which 
increased risk of illness is conferred in these individuals. Such mechanisms may relate 
both functional and regulatory variants associated with the translocation, and their 
effects on gene expression, DNA methylation and protein function in t(1;11) carriers. 
 
This work presented in this thesis has involved the use of a pedigree with a highly 
penetrant disease-associated mutation to identify genes and processes which might 
relate to a psychiatric phenotype. It is clear that the t(1;11) translocation has complex 
and far-reaching effects beyond the disruption of the breakpoint genes as illustrated by 
the expression and methylation analyses presented in this thesis. Furthering our 
knowledge of the genes and pathways disrupted by the translocation should lead to 
identification of mechanisms conferring increased risk of illness in the family, which 
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may extend to the general population. Ultimately, such findings should improve our 
understanding of psychiatric disorders, permitting the development of more effective 
treatments.
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ILMN_1767523 3 IL17RB -2.58 -9.89 3.52 x 10-6 
ILMN_2098446 18 PMAIP1 -1.46 -7.10 5.27 x 10-5 
ILMN_1675797 7 EPDR1 -2.63 -6.94 6.32 x 10-5 
ILMN_2046470 14 DAAM1* -1.43 -6.21 0.0001 
ILMN_1659270 5 OTP -1.72 -5.73 0.0003 
ILMN_1709484 15 BLM 1.32 5.26 0.0005 
ILMN_1708936 9 EXOSC3 1.23 5.22 0.0005 
ILMN_1724181 4 IL15 -1.25 -5.13 0.0006 
ILMN_1789106 1 IPP -1.21 -5.10 0.0006 
ILMN_3251423 3 CHDH -1.50 -5.05 0.0007 
ILMN_3178258 13 FABP5L2* 1.34 5.04 0.0007 
ILMN_1763129 16 DCTPP1 1.21 5.02 0.0007 
ILMN_1659365 4 LOC653071 -1.47 -4.99 0.0007 
ILMN_1733515 2 LOXL3 1.53 4.98 0.0007 
ILMN_1668092 11 ESAM -1.74 -4.80 0.0009 
ILMN_2121068 2 ADAM17 -1.22 -4.77 0.0010 
ILMN_1729749 4 HERC5 -1.63 -4.76 0.0010 
ILMN_2089175 X SYAP1 -1.24 -4.73 0.0010 
ILMN_1803995 12 TM7SF3 -1.32 -4.73 0.0010 
ILMN_1788283 16 COTL1 1.46 4.70 0.0011 
ILMN_1665219 19 LTBP4 -1.22 -4.68 0.0011 
ILMN_1725387 6 TMEM200A 1.47 4.67 0.0011 
ILMN_1680037 16 FAM65A -1.41 -4.66 0.0011 
ILMN_1763198 12 STAT6 -1.22 -4.57 0.0013 
ILMN_1708906 2 C2orf29 -1.21 -4.54 0.0014 
ILMN_1758731 1 CYP2J2 -1.29 -4.51 0.0014 
ILMN_1694711 6 MAD2L1BP 1.21 4.48 0.0015 
ILMN_2289593 11 FXYD2 -1.47 -4.45 0.0015 
ILMN_1708427 13 KPNA3 1.23 4.40 0.0017 
ILMN_2364062 17 THOC4* 1.26 4.38 0.0017 
ILMN_2324056 3 GNL3 1.25 4.31 0.0019 
ILMN_1678086 2 CCDC74A 1.33 4.31 0.0019 
ILMN_1812721 12 LOC728014 1.29 4.30 0.0019 
ILMN_2080080 X MAP7D2 -1.36 -4.29 0.0019 
ILMN_1761069 11 UVRAG 1.30 4.26 0.0020 
ILMN_1803194 17 GALK1 1.21 4.25 0.0021 
ILMN_1776181 11 BIRC3* -1.75 -4.24 0.0021 
ILMN_1656274 1 PRPF38A 1.22 4.22 0.0022 
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ILMN_2076463 12 SLC15A4 -1.25 -4.19 0.0023 
ILMN_1799069 15 LOC440280 1.35 4.17 0.0023 
ILMN_1702279 20 KIF3B 1.21 4.16 0.0024 
ILMN_1713636 1 S100A6 -1.51 -4.14 0.0024 
ILMN_1767320 22 MAPK1* 1.21 4.13 0.0025 
ILMN_2198878 4 INPP4B -1.54 -4.12 0.0025 
ILMN_1759991 22 MGC3731 1.28 4.12 0.0025 
ILMN_1706959 17 TIMM22 1.25 4.04 0.0028 
ILMN_1787251 14 DAAM1* -1.36 -4.02 0.0029 
ILMN_2341254 13 STARD13 -1.30 -4.02 0.0030 
ILMN_1717886 8 PKHD1L1 -1.21 -4.00 0.0030 
ILMN_1787265 10 ZNF503 -1.37 -3.98 0.0031 
ILMN_2372413 22 BID 1.25 3.98 0.0031 
ILMN_3249216 13 PDX1 -1.34 -3.97 0.0032 
ILMN_1733256 19 PSMD8 1.26 3.95 0.0033 
ILMN_2235851 2 LINCR -1.53 -3.92 0.0034 
ILMN_2146761 8 FABP5 1.35 3.89 0.0036 
ILMN_1741406 1 HOOK1 -1.50 -3.87 0.0037 
ILMN_1759326 12 P2RX7 -1.30 -3.85 0.0038 
ILMN_2301083 20 UBE2C* 1.21 3.84 0.0039 
ILMN_1714730 20 UBE2C* 1.23 3.84 0.0039 
ILMN_1748844 6 CNKSR3 -1.39 -3.82 0.0040 
ILMN_1663042 20 SDC4 -1.22 -3.73 0.0046 
ILMN_1696485 5 HNRNPAB 1.24 3.73 0.0046 
ILMN_2073307 1 IL10 -1.32 -3.72 0.0046 
ILMN_1682368 7 LRWD1 1.34 3.72 0.0046 
ILMN_1745420 9 PHF19 1.21 3.71 0.0047 
ILMN_3273229 16 LOC100129781 -1.22 -3.70 0.0048 
ILMN_1808783 9 STRBP 1.29 3.68 0.0050 
ILMN_2329429 7 GIMAP6 1.71 3.67 0.0050 
ILMN_1729180 15 GATM -1.24 -3.67 0.0050 
ILMN_2231928 21 MX2 -1.37 -3.67 0.0051 
ILMN_2089329 13 SPRY2 -1.37 -3.66 0.0051 
ILMN_1765578 3 TIPARP 1.21 3.64 0.0053 
ILMN_1756942 2 SP3 1.25 3.63 0.0054 
ILMN_1720829 19 ZFP36 -1.34 -3.62 0.0054 
ILMN_1732296 1 ID3 1.51 3.55 0.0061 
ILMN_1721457 22 RANBP1* 1.43 3.55 0.0061 
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ILMN_1794825 17 ALDH3A2 1.23 3.54 0.0062 
ILMN_3236036 15 LOC283663 -1.25 -3.54 0.0062 
ILMN_1740466 6 FAM46A -1.84 -3.49 0.0067 
ILMN_1687440 7 HIPK2 1.25 3.48 0.0068 
ILMN_2192072 11 MMP7* -2.08 -3.46 0.0070 
ILMN_1800225 3 PPARG -1.28 -3.46 0.0071 
ILMN_1719696 3 PLD1 -1.66 -3.45 0.0071 
ILMN_3212373 12 LOC727803 1.34 3.44 0.0073 
ILMN_2357361 11 THYN1 1.20 3.43 0.0073 
ILMN_3251383 2 CCDC74B 1.24 3.43 0.0074 
ILMN_1764577 22 MFNG 1.22 3.42 0.0074 
ILMN_2060115 11 SORL1 -1.29 -3.42 0.0074 
ILMN_2357855 9 NTRK2 -1.24 -3.42 0.0075 
ILMN_2173451 19 GPI 1.20 3.41 0.0076 
ILMN_1685124 12 TCTN1 -1.21 -3.41 0.0076 
ILMN_2347068 19 MKNK2* -1.41 -3.39 0.0078 
ILMN_2157277 7 AKR1D1 -1.25 -3.37 0.0081 
ILMN_1724497 2 ABI2 1.22 3.36 0.0083 
ILMN_1697363 20 C20orf27 1.25 3.34 0.0085 
ILMN_1772359 1 LAPTM5 -1.21 -3.33 0.0086 
ILMN_1811433 8 RPL8 1.31 3.33 0.0087 
ILMN_1814465 17 UBE2G1 1.30 3.32 0.0088 
ILMN_1658464 13 GTF3A 1.23 3.30 0.0090 
ILMN_1871233 14  1.20 3.29 0.0092 
ILMN_1738491 9 SNX30 1.23 3.28 0.0094 
ILMN_1752668 6 DAAM2 -1.26 -3.27 0.0094 
ILMN_3276990 3 LOC389141 1.26 3.27 0.0095 
ILMN_1685403 11 MMP7* -1.78 -3.26 0.0096 
ILMN_1797332 11 NARS2 1.20 3.26 0.0097 
ILMN_2070044 4 PPM1K -1.32 -3.25 0.0098 
ILMN_2320330 2 MAL* -1.45 -3.25 0.0099 
ILMN_1748923 9 SMC2 1.26 3.24 0.0099 
ILMN_1728710 19 ZNF816A -1.21 -3.23 0.0101 
ILMN_1757723 6 C6orf106 1.20 3.23 0.0101 
ILMN_1737517 3 RPL29 1.30 3.23 0.0101 
ILMN_1660462 1 MCOLN2 -1.37 -3.22 0.0103 
ILMN_1815527 11 HBD 1.22 3.22 0.0104 
ILMN_1709233 1 F5 -1.26 -3.21 0.0105 
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ILMN_2072296 9 CKS2* 1.32 3.19 0.0108 
ILMN_1719695 3 NFKBIZ -1.38 -3.17 0.0111 
ILMN_1724422 1 SELL -1.94 -3.17 0.0112 
ILMN_1811933 17 SHMT1 1.39 3.15 0.0115 
ILMN_1700182 19 LOC400721 -1.21 -3.15 0.0116 
ILMN_1695157 17 CA4 -1.32 -3.13 0.0120 
ILMN_1794707 11 ATHL1 -1.25 -3.11 0.0124 
ILMN_1654060 19 MKNK2* -1.47 -3.11 0.0124 
ILMN_1781536 15 FAH 1.42 3.09 0.0126 
ILMN_1689908 12 ANKRD13A 1.31 3.09 0.0127 
ILMN_2115862 2 ESPNL -1.22 -3.09 0.0127 
ILMN_1720513 18 SETBP1 1.37 3.08 0.0130 
ILMN_3235709 17 HNF1B -1.35 -3.07 0.0130 
ILMN_1726064 6 PAK1IP1 1.21 3.07 0.0131 
ILMN_2405684 11 BIRC3* -1.53 -3.07 0.0131 
ILMN_2413015 2 EMX1 -1.24 -3.07 0.0132 
ILMN_1721580 1 TBX15 -1.39 -3.06 0.0134 
ILMN_2100209 17 CCL4L1 -1.73 -3.06 0.0134 
ILMN_3266944 7 LOC100129599 -1.27 -3.04 0.0138 
ILMN_1700967 3 C3orf59 -1.88 -3.04 0.0139 
ILMN_2094360 15 NR2F2 -1.26 -3.01 0.0145 
ILMN_1775734 9 SH2D3C -1.26 -3.00 0.0146 
ILMN_1808584 1 FAM36A 1.22 3.00 0.0147 
ILMN_2109156 22 RANBP1* 1.26 2.98 0.0152 
ILMN_1781752 16 CLEC16A -1.25 -2.97 0.0154 
ILMN_2140799 10 FAM24B -1.29 -2.97 0.0154 
ILMN_1721713 4 EXOSC9 1.21 2.97 0.0155 
ILMN_1763638 1 BCAR3 1.37 2.97 0.0156 
ILMN_1662846 3 GPR160 1.32 2.95 0.0159 
ILMN_1771987 19 SLC44A2 -1.51 -2.95 0.0161 
ILMN_3300797 5 LOC729090 -1.35 -2.95 0.0161 
ILMN_1760509 3 EOMES -1.45 -2.93 0.0165 
ILMN_1756326 9 CKS2* 1.28 2.93 0.0166 
ILMN_1672389 1 CRYZ -1.49 -2.92 0.0167 
ILMN_1773963 19 GNA15 -1.48 -2.91 0.0170 
ILMN_1724139 11 TMEM123 1.20 2.91 0.0171 
ILMN_2338785 5 RPS14 -1.21 -2.91 0.0171 
ILMN_2318011 14 PSMA3 -1.22 -2.89 0.0175 
 
Appendix I  324 
 






ILMN_2235283 22 MAPK1* 1.26 2.89 0.0176 
ILMN_1807825 6 LY86 -1.31 -2.89 0.0177 
ILMN_1803254 14 KIAA2010 1.21 2.89 0.0178 
ILMN_2307455 X UBE2A 1.21 2.88 0.0178 
ILMN_2220187 2 GFPT1 -1.20 -2.87 0.0183 
ILMN_2344373 16 MVP* -1.22 -2.86 0.0185 
ILMN_1742382 1 RIMS3 -1.57 -2.86 0.0185 
ILMN_1654685 5 MCTP1 -1.50 -2.84 0.0190 
ILMN_1661717 13 TFDP1 1.27 2.82 0.0198 
ILMN_2048700 8 ATAD2 1.27 2.82 0.0198 
ILMN_1795811 14 ASB2 1.39 2.81 0.0199 
ILMN_1698213 X RBM3 1.21 2.81 0.0201 
ILMN_1787628 20 NOP56* 1.24 2.81 0.0202 
ILMN_1713156 X MSL3L1 -1.21 -2.80 0.0203 
ILMN_2120982 13 ALG11 -1.21 -2.80 0.0205 
ILMN_2367113 4 CASP6 1.23 2.79 0.0206 
ILMN_2124769 1 YBX1 1.26 2.79 0.0209 
ILMN_1807372 22 ADORA2A -1.31 -2.77 0.0214 
ILMN_1842582 18  1.36 2.76 0.0218 
ILMN_1750518 17 THOC4* 1.24 2.76 0.0218 
ILMN_1680738 5 C5orf13 -1.30 -2.76 0.0219 
ILMN_2407824 1 ATP1B1* -1.56 -2.75 0.0220 
ILMN_1658494 13 C13orf15 1.59 2.75 0.0220 
ILMN_2373791 8 ENPP2* -1.44 -2.75 0.0223 
ILMN_1800390 10 ZNF511 1.21 2.74 0.0226 
ILMN_3266606 13 FABP5L2* 1.27 2.74 0.0227 
ILMN_1775708 12 SLC2A3 -1.27 -2.73 0.0228 
ILMN_1776678 7 GIMAP7 1.51 2.73 0.0231 
ILMN_1776653 X SCML1 -1.22 -2.72 0.0232 
ILMN_1750409 X RAB9A -1.28 -2.72 0.0235 
ILMN_1658071 1 ATP1B1* -1.49 -2.71 0.0238 
ILMN_1740170 22 CHCHD10 1.27 2.70 0.0239 
ILMN_2374692 10 WAC 1.21 2.70 0.0240 
ILMN_1761820 1 EDARADD -1.25 -2.69 0.0245 
ILMN_1731070 16 ORC6L 1.24 2.69 0.0246 
ILMN_1752947 17 C17orf79 1.23 2.69 0.0247 
ILMN_1685580 3 CBLB 1.31 2.68 0.0247 
ILMN_1796417 7 ASNS -1.24 -2.68 0.0249 
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ILMN_2058251 10 VIM* -1.69 -2.68 0.0249 
ILMN_1707763 7 ST7 1.25 2.67 0.0255 
ILMN_1745112 9 FAM102A 1.30 2.66 0.0257 
ILMN_3235593 19 ZNF841 -1.23 -2.65 0.0260 
ILMN_1738578 3 FILIP1L -1.21 -2.64 0.0267 
ILMN_1663035 17 SREBF1 -1.21 -2.64 0.0267 
ILMN_1760779 1 ENSA 1.22 2.64 0.0268 
ILMN_2044471 6 NCR3 1.28 2.64 0.0268 
ILMN_1734596 14 TC2N -1.33 -2.63 0.0268 
ILMN_1781373 2 IFIH1 -1.30 -2.63 0.0271 
ILMN_1803277 16 MVP* -1.33 -2.62 0.0273 
ILMN_1694780 15 GCHFR 1.20 2.62 0.0274 
ILMN_1781472 1 CDC42BPA -1.24 -2.62 0.0275 
ILMN_1653466 1 HES4 -1.36 -2.62 0.0276 
ILMN_1811426 12 TMTC1 -1.26 -2.61 0.0277 
ILMN_1778337 17 TCF2 -1.27 -2.61 0.0278 
ILMN_1730612 20 DBNDD2 -1.42 -2.60 0.0283 
ILMN_1733937 17 MMD -1.32 -2.60 0.0285 
ILMN_1653871 7 NAMPT -1.23 -2.60 0.0285 
ILMN_2066858 13 TNFSF13B -1.22 -2.60 0.0286 
ILMN_2352090 17 GPRC5C -1.27 -2.60 0.0286 
ILMN_1712312 15 RAB11A -1.22 -2.59 0.0287 
ILMN_3248443 8 SNHG6 -1.22 -2.59 0.0290 
ILMN_1810962 6 PTPRK -1.32 -2.58 0.0292 
ILMN_3251467 3 LRRC58 -1.27 -2.58 0.0292 
ILMN_1739576 11 CYB5R2 1.49 2.58 0.0296 
ILMN_1808238 15 RBPMS2 -1.71 -2.57 0.0298 
ILMN_1783247 10 C10orf11 -1.21 -2.56 0.0302 
ILMN_2047885 5 PCDHB9 -1.24 -2.56 0.0303 
ILMN_1684929 3 TOPBP1 1.22 2.56 0.0304 
ILMN_1712985 17 C17orf58 1.27 2.55 0.0307 
ILMN_1782538 10 VIM* -1.60 -2.55 0.0309 
ILMN_1700515 17 C17orf58 1.22 2.55 0.0311 
ILMN_1739805 16 NDE1 -1.23 -2.55 0.0311 
ILMN_1692295 7 MYO1G -1.23 -2.54 0.0312 
ILMN_1770922 3 TMEM45A -1.29 -2.53 0.0320 
ILMN_1763036 1 CLCN6 -1.22 -2.52 0.0322 
ILMN_1798181 11 IRF7 -1.31 -2.52 0.0324 
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ILMN_3265365 9 CEP78 1.22 2.51 0.0327 
ILMN_1730291 1 ATP1B1* -1.63 -2.51 0.0328 
ILMN_1679438 4 MLF1IP 1.30 2.51 0.0331 
ILMN_2112402 22 PHF5A 1.34 2.51 0.0331 
ILMN_1709634 5 CMBL -1.47 -2.50 0.0334 
ILMN_1789999 1 SLC30A7 -1.29 -2.50 0.0337 
ILMN_1661599 10 DDIT4 -1.42 -2.50 0.0338 
ILMN_1718629 21 NRIP1 1.30 2.49 0.0342 
ILMN_1780799 8 ENPP2* -1.41 -2.48 0.0344 
ILMN_1714364 8 PTK2 1.46 2.48 0.0344 
ILMN_3243644 12 LOC100132564 1.45 2.48 0.0344 
ILMN_1771051 3 RPL29 1.24 2.48 0.0347 
ILMN_3235326  LOC388796 1.51 2.48 0.0347 
ILMN_1806754 9 GLDC 1.50 2.48 0.0347 
ILMN_1746408 19 MIDN -1.21 -2.47 0.0350 
ILMN_1796497 6 PIP3-E -1.28 -2.47 0.0351 
ILMN_1707551 17 AFMID 1.20 2.47 0.0353 
ILMN_1882512 5  -1.24 -2.46 0.0358 
ILMN_2362549 10 ZWINT 1.27 2.46 0.0361 
ILMN_1745256 5 CXXC5 -1.28 -2.45 0.0364 
ILMN_2341815 3 TFG 1.56 2.45 0.0365 
ILMN_1761138 9 C9orf142 1.20 2.45 0.0367 
ILMN_1796063 11 TRIM44 -1.23 -2.44 0.0370 
ILMN_1780533 14 RNASE6 1.23 2.43 0.0374 
ILMN_2044832 20 NOP56* 1.21 2.42 0.0380 
ILMN_2201533 17 C17orf61 -1.25 -2.42 0.0386 
ILMN_2138801 3 TP73L 1.69 2.41 0.0386 
ILMN_1665877 2 RNF149 -1.29 -2.41 0.0388 
ILMN_1771084 16 ACSM3 -1.28 -2.41 0.0391 
ILMN_2235785 17 KCNH6 -1.38 -2.41 0.0392 
ILMN_2327860 2 MAL* -1.79 -2.40 0.0394 
ILMN_2073604 X EBP 1.25 2.40 0.0396 
ILMN_3247139 17 C17orf96 -1.20 -2.40 0.0396 
ILMN_3277365 1 LOC100133233 -1.22 -2.39 0.0400 
ILMN_2308582 22 CYB5R3 -1.24 -2.39 0.0401 
ILMN_2367743 17 TUBG1 1.20 2.38 0.0405 
ILMN_1678766 6 DYNLT1 -1.34 -2.38 0.0408 
ILMN_1774604 2 PNKD -1.27 -2.38 0.0411 
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ILMN_3210741 15 FABP5L9 1.26 2.38 0.0412 
ILMN_1785198 9 POLE3 1.23 2.37 0.0413 
ILMN_1801118 16 C16orf33 1.33 2.37 0.0413 
ILMN_1702177 6 GLO1 1.21 2.37 0.0416 
ILMN_1812666 13 DNAJC15 1.24 2.36 0.0421 
ILMN_1652371 7 KIAA1324L 1.34 2.36 0.0424 
ILMN_1723043 19 NAPSB 1.42 2.36 0.0426 
ILMN_1712678 15 RPS27L -1.26 -2.35 0.0426 
ILMN_1656011 1 RGS1 -1.89 -2.35 0.0428 
ILMN_2338038 1 AK3L1 1.45 2.35 0.0431 
ILMN_2373515 14 HSP90AA1 1.21 2.35 0.0432 
ILMN_3274929 2 LOC653924 1.40 2.34 0.0434 
ILMN_2143795 2 MGC4677 1.30 2.34 0.0435 
ILMN_1778991 9 NFIB -1.32 -2.34 0.0438 
ILMN_1676629 2 INSIG2 -1.21 -2.33 0.0445 
ILMN_1742577 10 GTPBP4 -1.48 -2.33 0.0447 
ILMN_1699695 6 TNFRSF21 -1.49 -2.32 0.0453 
ILMN_1784602 6 CDKN1A -1.38 -2.32 0.0453 
ILMN_1723274 2 GPR55 1.30 2.32 0.0455 
ILMN_1714197 20 ACSS2 1.32 2.31 0.0457 
ILMN_1829845 13  -1.35 -2.31 0.0458 
ILMN_1794782 21 ABCG1 -1.34 -2.31 0.0460 
ILMN_1787509 20 PRIC285 -1.30 -2.30 0.0466 
ILMN_1798886 16 NUDT21 1.20 2.30 0.0467 
ILMN_1704369 12 LIMA1 1.23 2.30 0.0467 
ILMN_2396672 10 ABLIM1 1.40 2.30 0.0468 
ILMN_3219764 16 LOC441506 1.21 2.29 0.0474 
ILMN_2155719 1 NBPF10 1.33 2.29 0.0478 
ILMN_1682038 11 SNORA25 1.21 2.28 0.0480 
ILMN_1695420 9 CLTA 1.20 2.28 0.0482 
ILMN_1711073 2 LOC653489 -1.24 -2.28 0.0484 
ILMN_1707503 1 C1orf144 1.27 2.28 0.0484 
ILMN_1813295 12 LMO3 -1.42 -2.28 0.0485 
ILMN_1742981 12 TUBA1A 1.21 2.27 0.0487 
ILMN_1752802 5 CLPTM1L 1.21 2.27 0.0490 
ILMN_2364700 1 ENSA 1.20 2.27 0.0494 
ILMN_1769810 3 ARL6IP5 -1.22 -2.26 0.0496 
 
 
Appendix I  328 
 
Table A1: Differentially expressed genes in t(1;11) carrier LCL RNA. 
Summary of genes meeting an absolute expression fold-change ≥ 1.2 in t(1;11) carriers with 
an associated p-value ≤ 0.05 for differential expression. In order of column appearance are 
the HT12 array probe’s associated Illumina ID, the probe’s target chromosome, gene name, 
fold-change in t(1;11) carriers, differential expression t-statistic, and unadjusted p-value for 
differential expression between t(1;11) carriers and non-carriers. Genes flagged with a red 
asterisk (*) are those with multiple non-overlapping probes meeting the criteria for differential 
expression in t(1;11) carriers. Shown are the top 10 differentially expressed genes ranked by 
p-value. 
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GO Term Description Class Enrichment p-value q-value 
GO:0043005 neuron projection Component 1.73 2.29 X 10-9 3.72 X 10-6 
GO:0042995 cell projection Component 1.44 3.63 X 10-7 0.0003 




Process 1.5 6.49 X 10-8 0.0009 
GO:0097458 neuron part Component 1.96 1.93 X 10-6 0.001 
GO:0009987 cellular process Process 1.33 5.98 X 10-7 0.002 
GO:0048562 embryonic organ morphogenesis Process 4.36 4.93 X 10-7 0.0022 
GO:0048856 anatomical structure development Process 1.07 4.14 X 10-7 0.0028 
GO:0048731 system development Process 1.72 1.04 X 10-6 0.0028 
GO:0030424 axon Component 1.12 3.05 X 10-5 0.0083 
GO:0044444 cytoplasmic part Component 4.26 2.75 X 10-5 0.0089 
GO:0032502 developmental process Process 1.3 6.12 X 10-6 0.0093 
GO:0010646 regulation of cell communication Process 1.25 4.91 X 10-6 0.0096 
GO:0044763 single-organism cellular process Process 1.1 5.69 X 10-6 0.0097 
GO:0050793 
regulation of developmental 
process 
Process 1.21 4.54 X 10-6 0.01 
GO:0048812 neuron projection morphogenesis Process 2.26 8.99 X 10-6 0.012 
GO:0009887 organ morphogenesis Process 2.15 8.55 X 10-6 0.017 
GO:0051960 
regulation of nervous system 
development 
Process 1.25 1.29 X 10-5 0.014 
GO:0023051 regulation of signaling Process 1.54 1.52 X 10-5 0.014 
GO:0051094 
positive regulation of 
developmental process 
Process 1.41 1.43 X 10-5 0.014 
GO:0048583 regulation of response to stimulus Process 1.25 1.24 X 10-5 0.014 
GO:0050807 regulation of synapse organisation Process 6.99 2.31 X 10-5 0.02 
GO:0044424 intracellular part Component 1.07 8.74 X 10-5 0.02 
GO:0070588 
calcium ion transmembrane 
transport 
Process 1.21 4.33 X 10-5 0.021 
GO:0051962 
positive regulation of nervous 
system development 
Process 1.93 2.97 X 10-5 0.021 
GO:0044708 single-organism behavior Process 1.68 4.57 X 10-5 0.022 
GO:2000026 
regulation of multicellular 
organismal development 
Process 1.38 3.19 X 10-5 0.022 
GO:0045595 regulation of cell differentiation Process 1.56 3.52 X 10-5 0.022 
GO:2001030 
negative regulation of cellular 
glucuronidation 
Process 1.34 4.33 X 10-5 0.022 
GO:0048858 cell projection morphogenesis Process 1.98 2.90 X 10-5 0.022 
GO:0009888 tissue development Process 1.63 3.75 X 10-5 0.022 
GO:0050767 regulation of neurogenesis Process 25.57 3.46 X 10-5 0.023 
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GO:0031344 
regulation of cell projection 
organisation 
Process 25.57 3.98 X 10-5 0.023 
GO:1904224 
negative regulation of 
glucuronosyltransferase activity 








Process 1.79 4.33 X 10-5 0.024 
GO:0021852 pyramidal neuron migration Process 17,640 5.67 X 10-5 0.026 
GO:0051239 
regulation of multicellular 
organismal process 
Process 1.29 6.25 X 10-5 0.028 
GO:0032990 cell part morphogenesis Process 1.84 6.46 X 10-5 0.028 
GO:0003197 endocardial cushion development Process 1.45 7.97 X 10-5 0.028 
GO:2001029 
regulation of cellular 
glucuronidation 
Process 2.01 7.94 X 10-5 0.029 
GO:0045597 
positive regulation of cell 
differentiation 
Process 1.75 7.08 X 10-5 0.029 
GO:0052697 xenobiotic glucuronidation Process 46.22 7.94 X 10-5 0.029 
GO:2000467 
positive regulation of glycogen 
(starch) synthase activity 
Process 22.72 7.90 X 10-5 0.03 
GO:0046578 
regulation of Ras protein signal 
transduction 
Process 22.72 7.55 X 10-5 0.03 
GO:0048598 embryonic morphogenesis Process 21.83 7.86 X 10-5 0.031 
GO:0051240 
positive regulation of multicellular 
organismal process 
Process 1.35 9.01 X 10-5 0.031 
GO:0048513 organ development Process 1.43 0.0001 0.034 
GO:0034702 ion channel complex Component 1.81 0.0002 0.035 
GO:0072300 
positive regulation of metanephric 
glomerulus development 
Process 213.82 0.0001 0.037 
GO:0005783 endoplasmic reticulum Component 5.76 0.0003 0.041 
GO:0005768 endosome Component 1.64 0.0003 0.042 
GO:0014069 postsynaptic density Component 35.18 0.0003 0.043 
GO:0048167 regulation of synaptic plasticity Process 1.79 0.0001 0.044 
GO:0044699 single-organism process Process 1.07 0.0001 0.044 
GO:0044216 other organism cell Component 5.29 0.0003 0.044 
GO:0044297 cell body Component 1.43 0.0002 0.045 
GO:0050804 
modulation of synaptic 
transmission 
Process 2.5 0.0001 0.045 
GO:0043524 
negative regulation of neuron 
apoptotic process 
Process 2.63 0.0002 0.046 
GO:0033387 
putrescine biosynthetic process 
from ornithine 
Process 22.88 0.0002 0.047 
GO:0031225 anchored component of membrane Component 1.38 0.0004 0.048 
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GO:0044463 cell projection part Component 4.34 0.0004 0.049 
Table A2: Summary of GO terms enriched amongst differentially methylated 
genes in t(1;11) carriers. 
For each GO term, table summarises the GO identifier, the GO description, the GO class, 
enrichment, the enrichment p-values, and enrichment FDR q-values for genes showing the 
most differential methylation in t(1,11) carriers compared to non-carriers. Enrichment is 
defined as (b/n) / (B/N), where b = the number of genes at the top of the p-value ranked list 
that is associated with a given GO term, n = the number of genes at the top of the p-value-
ranked gene list, B = the total number of genes associated with a given GO term, and N = the 
total number of genes.  
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Gene(s) Feature(s) Region Probes DMR p-value 
TNXB Body Chr6:32063516-32065113 51 2.46 x 10-13 
NA IGR Chr3:196704439-196707088 5 7.89 x 10-10 
C11orf75 TSS1500 Chr11:93277097-93277255 3 1.67 x 10-9 
NA;PRRT1 IGR, 3'UTR Chr6:32115866-32116728 14 2.60 x 10-9 
RNF5P1;AGPAT1 TSS1500, TSS200 Chr6:32145233-32145902 20 6.26 x 10-9 
GABRG1 TSS1500, TSS200, 5'UTR Chr4:46125801-46126455 7 7.27 x 10-9 
KRTAP5-9 TSS1500, TSS200, 5'UTR Chr11:71259142-71259846 5 3.17 x 10-8 
CYP2E1 Body Chr10:135343047-135343426 3 5.93 x 10-8 
XRRA1 TSS200 Chr11:74660246-74660274 4 6.07 x 10-8 
RHOD 3'UTR Chr11:66839183-66839543 3 8.99 x 10-8 
TUBGCP5 TSS1500, TSS200 Chr15:22833108-22833236 3 1.58 x 10-7 
TRAK1 TSS1500, Body, 1stExon Chr3:42201087-42202130 6 1.64 x 10-7 
PSMB8 3'UTR, Body Chr6:32807898-32810304 22 3.32 x 10-7 
NA IGR Chr1:209526301-209528771 3 3.46 x 10-7 
NA IGR Chr6:159359910-159360236 3 1.48 x 10-6 
RTKN TSS1500 Chr2:74669347-74669415 4 1.94 x 10-6 
NA; KLHL30 IGR, TSS1500, TSS200 Chr2:239043942-239047460 9 2.67 x 10-6 
PCSK6 Body Chr15:101991031-101992367 5 2.8 x 10-6 
MIR663 TSS1500 Chr20:26190290-26190418 3 3.66 x 10-6 
ZNF385D Body, 1stExon Chr3:21791767-21792729 4 3.82 x 10-6 
TNF 1stExon Chr6:31543557-31543767 6 4.05 x 10-6 
BNIP3 Body Chr10:133793398-133793556 3 9.21 x 10-6 
TMEM131 Body Chr2:98377310-98378420 3 9.58 x 10-6 
LTA TSS200, 5'UTR, 1stExon Chr6:31540040-31540705 11 9.59 x 10-6 
NA IGR Chr17:41380728-41383399 5 9.98 x 10-6 
MIXL1 TSS1500 Chr1:226411005-226411085 4 1.06 x 10-5 
C17orf98 Body, 1stExon Chr17:36997274-36997566 3 1.3 x 10-5 
FAM83A Body Chr8:124217614-124217906 3 1.42 x 10-5 
SP140 TSS200, 5'UTR, Body Chr2:231090159-231091121 5 1.56 x 10-5 
MEST 5'UTR Chr7:130131819-130131937 8 3 x 10-5 
MOV10L1 TSS200, Body Chr22:50584735-50585710 7 3.02 x 10-5 
NA IGR Chr5:101117938-101120956 5 3.37 x 10-5 
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NA IGR Chr2:54934730-54938012 4 3.42 x 10-5 
LOC399815 TSS200 Chr10:124638974-124638992 3 3.43 x 10-5 
STX6 TSS200 Chr1:180992101-180992126 3 3.44 x 10-5 
NA IGR Chr7:156888064-156890971 5 3.65 x 10-5 
NA IGR Chr14:54814555-54817362 4 5.68 x 10-5 
NA IGR Chr7:73001195-73003686 3 6.35 x 10-5 
NA IGR Chr4:77341749-77342075 3 6.66 x 10-5 
TDH Body Chr8:11203736-11204163 4 7.48 x 10-5 
SMYD2 Body Chr1:214476582-214477761 3 9.03 x 10-5 
IGSF9B Body Chr11:133820356-133821733 4 9.05 x 10-5 
TAP1 Body Chr6:32819956-32820360 7 9.06 x 10-5 
NA IGR Chr1:39281563-39282050 4 9.11 x 10-5 
NA IGR Chr10:134898718-134899190 3 9.24 x 10-5 
NA IGR Chr11:123939376-123941869 3 0.0001 
NA IGR Chr1:147799913-147804738 9 0.0001 
HLA-DPA1 Body, 3'UTR Chr6:33033283-33037541 16 0.0001 
MIR548N Body Chr2:179387372-179388545 3 0.0001 
LIME1 Body Chr20:62369366-62369583 3 0.0001 
NA IGR Chr7:1208305-1210932 3 0.0001 
VSTM1 TSS200, Body, 1stExon Chr19:54566357-54567319 3 0.0001 
NA IGR Chr5:61027075-61030044 6 0.0001 
ZNF677 TSS200 Chr19:53758279-53758315 3 0.0001 
NA IGR Chr11:8290652-8290978 3 0.0002 
ACP5 TSS1500 Chr19:11689791-11689944 5 0.0002 
PSKH2 TSS1500, TSS200 Chr8:87082001-87082129 5 0.0002 
ATP8A2 Body Chr13:26586108-26586400 3 0.0002 
VAX2 TSS1500 Chr2:71126945-71127001 3 0.0002 
LRP1B TSS200 Chr2:142889366-142889402 3 0.0003 
C2orf54 TSS1500 Chr2:241836300-241836518 3 0.0003 
KCNIP1; KCNMB1 TSS200, Body Chr5:169815897-169816859 4 0.0003 
NA IGR Chr8:832849-833211 4 0.0003 
C6orf48 5'UTR Chr6:31802972-31803220 9 0.0004 
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NHEDC1 TSS200, 1stExon Chr4:103940811-103940897 3 0.0004 
HEATR2 Body, 3'UTR Chr7:824351-826059 6 0.0004 
NA IGR Chr10:115860117-115860473 3 0.0004 
OR2L13 1stExon Chr1:248100542-248100657 4 0.0005 
RPTOR Body Chr17:78809217-78810354 3 0.0005 
ADARB2 Body Chr10:1452489-1453586 3 0.0005 
KLHL29 Body Chr2:23885619-23886838 3 0.0005 
NA IGR Chr6:33870717-33874881 16 0.0006 
C2CD4D Body Chr1:151810808-151810978 4 0.0006 
KATNAL2 5'UTR Chr18:44561939-44562173 5 0.0006 
NA IGR Chr1:46632418-46632744 4 0.0007 
NA IGR Chr1:117316713-117319422 6 0.0007 
RHOU Body Chr1:228872106-228872264 3 0.0007 
ADAMTS2 Body Chr5:178594504-178594662 3 0.0007 
NFE2L1 TSS1500 Chr17:46124661-46124789 3 0.0007 
TBCD Body Chr17:80759197-80760159 3 0.0007 
RP1 Body Chr8:55533808-55534034 4 0.0007 
DPYSL3 Body Chr5:146832152-146832444 5 0.0008 
DZIP1L TSS1500 Chr3:137834643-137834771 3 0.0009 
NA IGR Chr12:29302148-29302314 3 0.0009 
NA IGR Chr12:114916775-114919883 6 0.0010 
MSX1 Body Chr4:4864284-4864576 6 0.0010 
NA IGR Chr6:32848233-32852184 3 0.0011 
MAPT 1stExon Chr17:43971863-43971971 4 0.0011 
ERMAP 5'UTR, Body Chr1:43295986-43296972 4 0.0012 
TRIM10 3'UTR, Body Chr6:30118914-30123074 24 0.0012 
NA; RPRM IGR, 3'UTR Chr2:154333734-154334094 5 0.0013 
NA IGR Chr1:160950485-160953893 5 0.0013 
NA IGR Chr10:133528532-133530912 4 0.0016 
HOXC11 3'UTR Chr12:54369487-54373005 6 0.0017 
TSPAN19;LRRIQ1 TSS200, 5'UTR Chr12:85430071-85430601 8 0.0018 
TRIM15 3'UTR Chr6:30140125-30140546 8 0.0019 
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PRICKLE1 Body, 3'UTR Chr12:42850912-42854914 7 0.0019 
STAT3 Body Chr17:40489088-40490266 5 0.0021 
NA; COX19 IGR, 3'UTR Chr7:1001886-1005509 9 0.0022 
NA IGR Chr8:53325115-53327858 8 0.0023 
S100A13; S100A14 TSS1500, 3'UTR Chr1:153589312-153593314 5 0.0036 
MICB Body Chr6:31466095-31466266 4 0.0039 
NA IGR Chr6:30094973-30095632 25 0.0040 
SLC6A12 TSS200, 5'UTR Chr12:322249-322914 9 0.0044 
TNXB Body Chr6:32054900-32055225 8 0.0063 
NA IGR Chr5:3102528-3106063 4 0.0064 
TMCO3 Body Chr13:114192835-114194543 11 0.0064 
ASCL2 TSS1500 Chr11:2293053-2293275 9 0.0064 
VARS2 Body Chr6:30883736-30885444 14 0.0074 
B3GALT4 1stExon Chr6:33245445-33245846 20 0.0090 
NOM1 Body Chr7:156755232-156756616 6 0.0092 
ALPL 5'UTR Chr1:21877057-21877844 6 0.0105 
HLA-DPA1 Body Chr6:33040054-33041250 8 0.0121 
EHMT2 Body Chr6:31858853-31861146 20 0.0124 
NA IGR Chr12:131700432-131703053 5 0.0166 
KLC2 3'UTR Chr11:66034892-66035327 14 0.0169 
CNTN4 Body Chr3:3079716-3080819 4 0.0224 
GNL1 3'UTR Chr6:30507466-30511643 15 0.0289 
PRDM16 Body Chr1:3209038-3210391 5 0.0380 
HCP5 
TSS1500, TSS200, 1stExon, 
Body, 3'UTR 
Chr6:31429311-31433970 18 0.0392 
NA IGR Chr5:170762452-170765146 9 0.0408 
ARHGAP25 TSS1500, 5'UTR, Body Chr2:69001334-69002335 10 0.0428 
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Table A3: Summary of t(1;11)-associated DMRs identified by the probe lasso 
algorithm.                                       
Summary of the genes (if applicable), genomic features, hg19 genomic coordinates, number 
of probes and p-value associated with each DMR. “NA” in the “Gene” column represents 
intergenic regions (i.e. regions not annotated to a RefSeq gene). Genomic features are coded 
“IGR” for intergenic regions, “TSS200” and “TSS1500” for probes occurring within 200 and 
1500 of a gene’s transcription start site, respectively; “5’UTR” and “3’UTR” for probes 
occurring within a gene’s 5’ and 3’ untranslated region, respectively, “1stExon” for probes 
occurring within the first exon of a gene, and “Body” for probes occurring within the gene 
body. 
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GO Term Description Class Enrichment p-value q-value 
GO:0071556 
integral component of lumenal 
side of endoplasmic reticulum 
membrane 
Component 82.96 3.55 x 10-8 5.89 x 10-5 
GO:0042611 MHC protein complex Component 140.38 1.45 x 10-7 0.0001 
GO:0030658 transport vesicle membrane Component 30.85 5.56 x 10-7 0.0003 
GO:0048518 
positive regulation of 
biological process 
Process 1.19 8.43 x 10-8 0.0012 
GO:0012507 
ER to Golgi transport vesicle 
membrane 
Component 68.76 3.41 x 10-6 0.0014 
GO:0048522 
positive regulation of cellular 
process 
Process 1.2 5.73 x 10-7 0.0020 
GO:0042605 peptide antigen binding Function 4.97 2.29 x 10-6 0.0024 
GO:0042995 cell projection Component 1.38 7.47 x 10-6 0.0025 
GO:0051960 
regulation of nervous system 
development 




Process 1.28 4.57 x 10-7 0.0032 
GO:0005150 
interleukin-1, Type I receptor 
binding 
Function 655.11 2.24 x 10-6 0.0032 
GO:0002486 
antigen processing and 
presentation of endogenous 
peptide antigen via MHC class 
I via ER pathway, TAP-
independent 
Process 1,310.22 1.22 x 10-6 0.0034 
GO:0008092 cytoskeletal protein binding Function 1.51 4.26 x 10-6 0.0036 





Function 9.54 5.54 x 10-6 0.0039 
GO:0046977 TAP binding Function 184.89 1.86 x 10-6 0.0040 
GO:0030054 cell junction Component 1.43 1.54 x 10-5 0.0043 
GO:0048869 cellular developmental process Process 1.28 2.15 x 10-6 0.0050 




Function 6.81 1.05 x 10-5 0.0064 
GO:0030534 adult behavior Process 2.32 3.34 x 10-6 0.0066 
GO:0035315 hair cell differentiation Process 12.41 4.34 x 10-6 0.0067 
GO:0060284 regulation of cell development Process 1.52 4.83 x 10-6 0.0067 
GO:0050767 regulation of neurogenesis Process 1.59 5.39 x 10-6 0.0068 




Process 1.39 4.03 x 10-6 0.0070 
GO:0005856 cytoskeleton Component 1.51 4.09 x 10-5 0.0075 
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GO:0032502 developmental process Process 1.18 6.69 x 10-6 0.0077 
GO:0019885 
antigen processing and 
presentation of endogenous 
peptide antigen via MHC class 
I 
Process 129.42 7.84 x 10-6 0.0077 
GO:0002484 
antigen processing and 
presentation of endogenous 
peptide antigen via MHC class 
I via ER pathway 




Process 4.05 7.84 x 10-6 0.0083 
GO:0030662 coated vesicle membrane Component 32.71 7.63 x 10-5 0.0091 
GO:0030176 
integral component of 
endoplasmic reticulum 
membrane 
Component 20.35 6.04 x 10-5 0.0091 
GO:0042612 MHC class I protein complex Component 393.07 5.53 x 10-5 0.0092 
GO:0032395 MHC class II receptor activity Function 8.19 1.74 x 10-5 0.0093 
GO:0002483 
antigen processing and 
presentation of endogenous 
peptide antigen 
Process 117.66 1.09 x 10-5 0.0094 
GO:0030666 endocytic vesicle membrane Component 24.96 6.86 x 10-5 0.0095 
GO:0031227 
intrinsic component of 
endoplasmic reticulum 
membrane 
Component 19.43 7.50 x 10-5 0.0096 
GO:0042270 
protection from natural killer 
cell mediated cytotoxicity 
Process 655.11 1.51 x 10-5 0.0123 
GO:0048708 astrocyte differentiation Process 5.88 1.72 x 10-5 0.0132 
GO:0019883 
antigen processing and 
presentation of endogenous 
antigen 




Process 1.18 2.30 x 10-5 0.0152 
GO:0048731 system development Process 1.55 2.29 x 10-5 0.0158 
GO:0002711 
positive regulation of T cell 
mediated immunity 
Process 103.64 2.52 x 10-5 0.0158 
GO:0097458 neuron part Component 1.34 0.0002 0.0182 
GO:0043005 neuron projection Component 1.45 0.0002 0.0183 
GO:0009893 
positive regulation of 
metabolic process 
Process 1.2 3.85 x 10-5 0.0231 
GO:0031344 
regulation of cell projection 
organisation 
Process 1.61 4.16 x 10-5 0.0239 
GO:0002480 
antigen processing and 
presentation of exogenous 
peptide antigen via MHC class 
I, TAP-independent 
Process 436.74 4.40 x 10-5 0.0243 
GO:0045936 
negative regulation of 
phosphate metabolic process 
Process 1.57 5.95 x 10-5 0.0249 
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GO:0010563 
negative regulation of 
phosphorus metabolic process 
Process 1.57 5.95 x 10-5 0.0257 
GO:1903403 
negative regulation of renal 
phosphate excretion 
Process 17,688.00 5.65 x 10-5 0.0260 
GO:0051130 
positive regulation of cellular 
component organisation 
Process 1.4 5.84 x 10-5 0.0260 
GO:1903402 
regulation of renal phosphate 
excretion 
Process 17,688.00 5.65 x 10-5 0.0269 
GO:0003421 
growth plate cartilage axis 
specification 
Process 17,688.00 5.65 x 10-5 0.0279 
GO:0045953 
negative regulation of natural 
killer cell mediated 
cytotoxicity 
Process 393.07 5.53 x 10-5 0.0283 
GO:0002716 
negative regulation of natural 
killer cell mediated immunity 
Process 393.07 5.53 x 10-5 0.0294 
GO:0042491 
auditory receptor cell 
differentiation 




Process 1.59 7.86 x 10-5 0.0319 
GO:0005883 neurofilament Component 6.48 0.0003 0.0323 
GO:0051961 
negative regulation of nervous 
system development 
Process 1.84 8.91 x 10-5 0.0342 
GO:0002709 
regulation of T cell mediated 
immunity 
Process 69.09 0.0001 0.0350 
GO:0016045 detection of bacterium Process 302.36 0.0001 0.0353 
GO:0001911 
negative regulation of 
leukocyte mediated 
cytotoxicity 
Process 302.36 0.0001 0.0362 
GO:0007411 axon guidance Process 1.53 9.99 x 10-5 0.0363 




Process 1.09 0.0001 0.0389 
GO:0045665 
negative regulation of neuron 
differentiation 
Process 3.03 0.0001 0.0392 
GO:0007166 
cell surface receptor signaling 
pathway 
Process 1.25 0.0001 0.0395 
GO:0003382 epithelial cell morphogenesis Process 3.17 0.0001 0.0396 
GO:0000902 cell morphogenesis Process 1.89 0.0001 0.0399 
GO:0031342 
negative regulation of cell 
killing 
Process 262.04 0.0001 0.0399 
GO:0031225 
anchored component of 
membrane 
Component 2.48 0.0004 0.0400 
GO:0007156 
homophilic cell adhesion via 
plasma membrane adhesion 
molecules 
Process 44.82 0.0001 0.0404 
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GO:0098543 detection of other organism Process 262.04 0.0001 0.0407 
GO:0050768 
negative regulation of 
neurogenesis 
Process 2.75 0.0001 0.0413 
GO:0045664 
regulation of neuron 
differentiation 
Process 1.55 0.0001 0.0419 
GO:0007010 cytoskeleton organisation Process 1.47 0.0002 0.0427 
GO:0002478 
antigen processing and 
presentation of exogenous 
peptide antigen 
Process 12.99 0.0002 0.0433 
GO:0031061 
negative regulation of histone 
methylation 
Process 20.69 0.0002 0.0433 
GO:0010721 
negative regulation of cell 
development 
Process 1.75 0.0002 0.0436 
GO:0005737 cytoplasm Component 1.14 0.0006 0.0465 
GO:0019884 
antigen processing and 
presentation of exogenous 
antigen 
Process 19.47 0.0002 0.0465 
GO:0015629 actin cytoskeleton Component 1.79 0.0005 0.0474 
GO:0001916 
positive regulation of T cell 
mediated cytotoxicity 
Process 231.22 0.0002 0.0485 
GO:0048002 
antigen processing and 
presentation of peptide antigen 
Process 18.93 0.0002 0.0494 
GO:0043197 dendritic spine Component 2.82 0.0006 0.0496 
Table A4: Summary of GO terms enriched for differentially methylated genes 
in t(1;11) carriers with a psychotic disorder. 
For each GO term, table summarises the GO identifier, the GO description, the GO class, 
enrichment, the enrichment p-values, and enrichment FDR q-values for genes showing the 
most differential methylation in t(1,11) carriers with psychotic disorders compared to carriers 
with a non-psychotic disorder. Enrichment is defined as (b/n) / (B/N), where b = the number 
of genes at the top of the p-value ranked list that is associated with a given GO term, n = the 
number of genes at the top of the p-value-ranked gene list, B = the total number of genes 
associated with a given GO term, and N = the total number of genes. 
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RPTOR Body Chr17:78865119-78867431 8 1.55 x 10-21 
NA, MIR886 IGR, TSS200, Body Chr5:135415531-135416414 13 1.18 x 10-19 
PTPRN2 Body Chr7:158045532-158046806 6 2.13 x 10-15 
TNXB Body Chr6:32064430-32064738 13 1.49 x 10-13 
NA IGR Chr6:29721548-29725160 4 1.6 x 10-13 
NA IGR Chr13:113295067-113297572 4 4.17 x 10-13 
SLC38A4 TSS200, 5'UTR, 1stExon Chr12:47219385-47219867 6 4.95 x 10-12 
HCG27 TSS1500 Chr6:31164851-31165031 8 3.24 x 10-11 
NA IGR Chr6:29520536-29521310 15 4.37 x 10-11 
NA IGR Chr6:25882428-25882752 3 7.78 x 10-11 
NA IGR Chr3:196704504-196707023 5 1.4 x 10-9 
C1orf173 TSS200, 1stExon, Body Chr1:75138516-75139587 9 2.29 x 10-9 
TAGLN TSS1500, TSS200, 5'UTR Chr11:117069672-117070287 6 2.33 x 10-9 
TNNT1 TSS200, 5'UTR, 1stExon Chr19:55660273-55660755 5 2.82 x 10-9 
C11orf21, TSPAN32 Body, 1stExon Chr11:2321881-2324344 29 3.68 x 10-9 
PKNOX2 5'UTR Chr11:125105815-125106376 3 6.05 x 10-9 
TRIM31 Body Chr6:30071309-30071756 13 1.18 x 10-8 
NA IGR Chr12:10094777-10097919 6 1.91 x 10-8 
NA IGR Chr6:31275481-31276043 11 3.37 x 10-8 
NA IGR Chr2:730996-731756 6 4.95 x 10-8 
SLC23A1 Body Chr5:138714244-138714417 3 5.16 x 10-8 
NA IGR Chr2:54934795-54937947 4 5.33 x 10-8 
JARID2 Body Chr6:15504475-15505793 6 1.37 x 10-7 
KIAA1875 Body Chr8:145162890-145163180 4 1.43 x 10-7 
NA IGR Chr6:28956177-28956469 13 1.8 x 10-7 
NA IGR Chr4:187421843-187422201 5 1.85 x 10-7 
NA IGR Chr1:117316713-117319357 6 2.96 x 10-7 
NA IGR Chr1:28573735-28573959 4 3.87 x 10-7 
ANGPT2 
TSS1500, TSS200, 5'UTR, 
1stExon, Body 
Chr8:6418918-6422358 11 3.87 x 10-7 
CRISP2 TSS200, 5'UTR Chr6:49680937-49681474 7 3.93 x 10-7 
NA IGR Chr6:170337585-170338059 3 3.95 x 10-7 
NA IGR Chr12:68880247-68882552 3 3.97 x 10-7 
NA IGR Chr13:110385027-110387392 3 5.14 x 10-7 
ATP6V1C1 TSS1500 Chr8:104032756-104032939 3 5.24 x 10-7 
B3GNT3 TSS1500 Chr19:17905578-17905634 3 5.49 x 10-7 
VWA5B2 Body Chr3:183958890-183959196 7 6.92 x 10-7 
NA IGR Chr1:149168848-149171477 5 7.77 x 10-7 
ZNF528 TSS1500,TSS200 Chr19:52900819-52900977 6 9.28 x 10-7 
DDR1 TSS1500 Chr6:30850988-30851701 9 9.63 x 10-7 
CRB2 Body Chr9:126135156-126135444 3 1.26 x 10-6 
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NA IGR Chr10:125032645-125035943 10 1.66 x 10-6 
VPS16 Body Chr20:2844211-2845161 6 1.75 x 10-6 
PAX8 Body Chr2:113992699-113993196 6 1.76 x 10-6 
NA IGR Chr17:41438248-41438484 3 1.87 x 10-6 
NA IGR Chr1:35586487-35586811 3 1.87 x 10-6 
TOP1MT Body Chr8:144403361-144403517 3 1.88 x 10-6 
NA IGR Chr6:19804549-19804946 3 1.91 x 10-6 
BLCAP 5'UTR Chr20:36148593-36148721 7 2.29 x 10-6 
NA IGR Chr6:164028178-164030681 3 2.29 x 10-6 
C6orf138 TSS200 Chr6:48036584-48036634 6 2.34 x 10-6 
TBC1D16 Body Chr17:77924521-77924809 3 2.39 x 10-6 
PRTN3 TSS1500, TSS200, 1stExon, Body Chr19:840230-841934 6 3.09 x 10-6 
TNNT3 Body Chr11:1948954-1949191 4 3.2 x 10-6 
NA IGR Chr4:6689577-6692218 4 3.21 x 10-6 
NA IGR Chr7:27137097-27140727 7 3.59 x 10-6 
ITGAE 1stExon Chr17:3704392-3704573 4 3.95 x 10-6 
NA IGR Chr7:73155464-73159136 4 3.99 x 10-6 
WFIKKN2 TSS200, 1stExon, Body Chr17:48912518-48912700 5 4.04 x 10-6 
HLCS TSS1500, TSS200 Chr21:38362714-38362782 4 4.42 x 10-6 
NA IGR Chr7:155149556-155152552 5 5.02 x 10-6 
NA IGR Chr13:22613924-22616459 5 5.3 x 10-6 
SFTA2 3'UTR, Body Chr6:30898957-30900097 7 5.32 x 10-6 
NA IGR Chr8:67454513-67454749 4 5.32 x 10-6 
LRRC17 TSS200, 5'UTR Chr7:102553128-102553698 5 6.92 x 10-6 
NA IGR Chr16:53407596-53407970 4 7.22 x 10-6 
STK19 TSS1500 Chr6:31939217-31939385 4 7.64 x 10-6 
C10orf11 Body Chr10:77871474-77871819 3 7.67 x 10-6 
NA IGR Chr16:3210063-3210387 3 8.02 x 10-6 
HLA-DQB1 Body Chr6:32632883-32633301 10 8.11 x 10-6 
NA IGR Chr11:41480233-41482703 5 9.04 x 10-6 
NA IGR Chr3:42977807-42978035 5 9.76 x 10-6 
DLGAP2 Body Chr8:1616237-1616594 3 9.82 x 10-6 
TPM4 Body Chr19:16186762-16186951 3 1.01 x 10-5 
NA IGR Chr2:121775189-121777729 3 1.02 x 10-5 
RNU5E Body Chr5:80690127-80690303 3 1.21 x 10-5 
NA IGR Chr3:195576915-195579384 6 1.31 x 10-5 
NA IGR Chr7:20818495-20819006 6 1.31 x 10-5 
HLA-DQB2 Body Chr6:32728986-32729418 8 1.65 x 10-5 
NA IGR Chr1:19110816-19111140 3 1.8 x 10-5 
SLC36A3 Body Chr5:150677714-150678610 3 1.91 x 10-5 
NMUR1 Body Chr2:232393052-232393340 3 1.92 x 10-5 
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SGK1 TSS1500, Body Chr6:134497031-134497391 6 2.08 x 10-5 
ZBTB47 Body Chr3:42700441-42700822 3 2.2 x 10-5 
NA IGR Chr5:149866606-149870608 5 2.24 x 10-5 
ENOSF1 TSS200 Chr18:712722-712746 3 2.54 x 10-5 
C22orf9 Body Chr22:45607980-45609161 10 2.61 x 10-5 
C6orf47 1stExon Chr6:31627549-31627782 6 2.64 x 10-5 
NA IGR Chr13:106062013-106064297 3 2.8 x 10-5 
NA IGR Chr6:28602381-28602829 12 2.9 x 10-5 
NA IGR Chr6:29768148-29768332 6 2.94 x 10-5 
NA IGR Chr13:29327854-29330351 3 3.13 x 10-5 
NA IGR Chr15:98446452-98448821 3 3.29 x 10-5 
ARHGEF10 5'UTR Chr8:1788928-1789704 6 3.41 x 10-5 
VSTM1 TSS200, 1stExon, Body Chr19:54566390-54567286 3 3.54 x 10-5 
WBSCR17 TSS1500 Chr7:70597037-70597093 3 3.62 x 10-5 
SPRED3 Body, 3'UTR Chr19:38886514-38886811 4 3.65 x 10-5 
ASB16 TSS200, 5'UTR Chr17:42247858-42248340 4 3.66 x 10-5 
AOAH Body Chr7:36700468-36701464 4 3.98 x 10-5 
SLC9A3R2 Body Chr16:2081837-2084020 5 4.41 x 10-5 
NA IGR Chr4:187985370-187985534 3 4.43 x 10-5 
ECM1 1stExon, Body Chr1:150480408-150481304 3 4.61 x 10-5 
TMTC4 Body Chr13:101314806-101315848 3 4.68 x 10-5 
NA IGR Chr4:174429164-174429536 5 5.19 x 10-5 
RARA TSS200, 5'UTR Chr17:38465269-38465751 6 5.58 x 10-5 
NA IGR Chr16:53542860-53545446 4 5.63 x 10-5 
RASA3 Body Chr13:114875026-114875314 3 5.64 x 10-5 
NA IGR Chr2:66656160-66659666 5 6.68 x 10-5 
ZMAT2 TSS1500, TSS200, 1stExon, Body Chr5:140079646-140080693 11 6.85 x 10-5 
HTR2A TSS1500 Chr13:47472142-47472468 8 6.9 x 10-5 
NA IGR Chr3:87138478-87138802 3 7.34 x 10-5 
NA IGR Chr12:7781126-7781450 3 7.36 x 10-5 
NA IGR Chr2:3485268-3488537 10 7.71 x 10-5 
NA IGR Chr8:48675485-48675933 4 7.77 x 10-5 
NA IGR Chr10:134331152-134333567 3 7.93 x 10-5 
NA IGR Chr1:9222878-9225501 3 8.11 x 10-5 
PTPRN2 Body Chr7:157955906-157956305 4 8.12 x 10-5 
NA IGR Chr7:148662823-148665257 3 8.14 x 10-5 
RADIL Body Chr7:4885073-4886091 3 8.2 x 10-5 
TET1 5'UTR Chr10:70321759-70322074 4 8.69 x 10-5 
NA IGR Chr19:14444105-14444479 4 8.7 x 10-5 
KIAA1614 Body Chr1:180882511-180882825 3 8.79 x 10-5 
ZMYND15 Body, 3'UTR Chr17:4648132-4649524 7 9.21 x 10-5 
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NA IGR Chr14:97058702-97059026 4 9.55 x 10-5 
NA IGR Chr2:89158063-89160390 3 0.0001 
LOC84931 TSS1500, TSS200, Body Chr2:121223086-121224357 8 0.0001 
GRM2 TSS1500, TSS200 Chr3:51740847-51740903 3 0.0001 
TNF 1stExon Chr6:31543559-31543734 5 0.0001 
NA IGR Chr12:19935352-19937788 3 0.0001 
NA IGR Chr10:7516090-7518958 4 0.0002 
AHNAK Body Chr11:62272524-62273866 3 0.0002 
CRY2 TSS1500 Chr11:45868386-45868512 4 0.0002 
EPB49 1stExon Chr8:21916725-21916930 3 0.0002 
NA IGR Chr13:114907148-114911086 3 0.0002 
NA IGR Chr7:155831867-155834117 4 0.0002 
NA IGR Chr1:247802541-247802865 4 0.0002 
LTB4R2, LTB4R 5'UTR, Body Chr14:24780604-24780769 3 0.0002 
TRIM69 TSS1500 Chr15:45027975-45028269 3 0.0002 
NA IGR Chr5:4229421-4231997 6 0.0002 
PRSSL1 TSS200, 5'UTR, Body Chr19:693985-695689 6 0.0002 
C19orf77 TSS200, 5'UTR Chr19:3480393-3480623 3 0.0002 
LDHC TSS1500 Chr11:18433392-18433672 3 0.0002 
ITFG3 5'UTR Chr16:302924-303433 3 0.0002 
KIF13A Body Chr6:17984556-17986260 3 0.0003 
NA IGR Chr6:106441279-106441668 5 0.0003 
TRAPPC9 Body Chr8:140945334-140946291 3 0.0003 
NA IGR Chr6:31037468-31039838 6 0.0003 
NA IGR Chr11:69259291-69262797 7 0.0003 
NA IGR Chr2:8421111-8424247 5 0.0003 
NA IGR Chr19:13949415-13952921 3 0.0004 
FAM83A Body Chr8:124217616-124217904 3 0.0004 
NA IGR Chr13:114060687-114066289 13 0.0004 
GAS7 TSS1500, Body Chr17:9939556-9940675 4 0.0004 
MAD1L1 Body Chr7:2060038-2060194 4 0.0005 
SFRP2 TSS1500 Chr4:154711557-154711738 5 0.0005 
C19orf57 5'UTR Chr19:14016712-14016810 4 0.0005 
NA IGR Chr10:135040088-135040412 3 0.0006 
RASA3 Body Chr13:114809779-114811646 4 0.0006 
NA IGR Chr15:89156690-89159521 5 0.0006 
TXNDC11 Body Chr16:11835324-11835612 3 0.0006 
LTBP1 TSS200, Body Chr2:33358750-33359646 5 0.0006 
DIO2 1stExon Chr14:80677579-80677737 3 0.0006 
NA IGR Chr12:89748564-89749094 8 0.0007 
NA IGR Chr8:53325249-53328204 8 0.0007 
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NA IGR Chr5:71851339-71853987 4 0.0008 
BEND7 Body Chr10:13481398-13482392 3 0.0008 
CD8A TSS200 Chr2:87018941-87018975 3 0.0008 
NA IGR Chr10:96989418-96992630 7 0.0009 
NA IGR Chr10:112290169-112290493 3 0.0010 
NA IGR Chr6:170555977-170559101 7 0.0010 
NOP56 1stExon, Body Chr20:2633246-2633402 4 0.0010 
NA IGR Chr13:113273357-113275660 3 0.0010 
NA IGR Chr6:27724063-27726533 3 0.0011 
EYA4 TSS1500 Chr6:133562239-133562295 5 0.0011 
NA IGR Chr6:170552720-170554970 7 0.0011 
TNXB Body Chr6:32014062-32016684 45 0.0011 
NA IGR Chr4:572257-575763 3 0.0012 
POU2AF1 TSS1500, TSS200 Chr11:111250323-111250539 4 0.0013 
NA IGR Chr10:81967374-81967828 3 0.0013 
NA IGR Chr15:97320021-97323629 11 0.0015 
NA IGR Chr15:31514986-31517606 9 0.0017 
ZG16B TSS1500, TSS200, 1stExon, Body Chr16:2879911-2880879 6 0.0020 
SLC29A1 TSS1500, TSS200 Chr6:44186968-44187094 5 0.0022 
PTPRN2 Body Chr7:157811395-157812366 4 0.0022 
C17orf90, CCDC137 TSS1500, TSS200, 1stExon Chr17:79633717-79633844 6 0.0022 
SCHIP1 Body Chr3:159557104-159558245 4 0.0022 
NA IGR Chr16:85599110-85601764 4 0.0026 
GPX5 Body Chr6:28498931-28500273 6 0.0026 
VARS2 Body Chr6:30882497-30882852 4 0.0026 
WDFY4 Body Chr10:50142889-50143931 5 0.0028 
PSORS1C1, CDSN 
TSS1500, TSS200, 5'UTR, 
1stExon, Body, 3'UTR 
Chr6:31080938-31085323 16 0.0038 
RPH3AL Body Chr17:153647-155523 5 0.0041 
CNKSR1 TSS1500, TSS200, Body Chr1:26503543-26504467 10 0.0044 
PPAP2C TSS1500 Chr19:292208-292334 4 0.0046 
UBE2I, NA IGR, Body, 3'UTR Chr16:1372915-1376938 10 0.0048 
NA IGR Chr14:76733243-76735730 6 0.0048 
C6orf136 Body Chr6:30615599-30615887 7 0.0051 
BTNL2 TSS200, Body Chr6:32374306-32375202 4 0.0063 




TSS200, Body Chr19:49993013-49994725 12 0.0064 
EXPH5 TSS1500, Body Chr11:108408514-108409429 6 0.0065 
TNFRSF9 TSS1500, TSS200, 5'UTR, Body Chr1:7998726-8001902 6 0.0073 
PPT2 Body Chr6:32122609-32123110 10 0.0074 
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TSS200, 5'UTR, Body Chr11:2919203-2921289 21 0.0074 
NUP188 Body Chr9:131710373-131710529 4 0.0084 
HLA-DPB2 Body Chr6:33095685-33096760 6 0.0087 
PURG, WRN TSS1500, TSS200 Chr8:30890445-30890661 8 0.0098 
HLA-DPB2 Body Chr6:33091164-33092578 16 0.0101 
KLHL29 Body Chr2:23839834-23841003 7 0.0110 
WIPI2 3'UTR Chr7:5270698-5275408 14 0.0112 
NA IGR Chr11:1364021-1366533 8 0.0112 
P2RX7 TSS200, 5'UTR, 1stExon Chr12:121570436-121570993 4 0.0112 
NA, MC1R IGR, TSS1500 Chr16:89980515-89984172 8 0.0143 
TNXB Body Chr6:32048325-32050029 23 0.0147 
DIP2C Body Chr10:670554-672258 7 0.0155 
SLAMF8 TSS200, 5'UTR Chr1:159796376-159796899 4 0.0160 
PHYHIP Body Chr8:22084825-22088001 7 0.0160 
MCF2L Body Chr13:113689103-113690807 6 0.0160 
FXYD1 TSS1500, TSS200, 5'UTR Chr19:35628518-35631893 14 0.0162 
NA IGR Chr6:170751560-170755066 6 0.0197 
KRT222 TSS200, 5'UTR, 1stExon, Body Chr17:38821149-38821631 7 0.0197 
NA IGR Chr6:31408342-31410882 13 0.0219 
NA IGR Chr10:33293233-33295902 5 0.0228 
RPTOR Body Chr17:78853114-78855125 4 0.0255 
NA IGR Chr6:29895013-29895349 7 0.0266 
TBCD Body Chr17:80832541-80834245 8 0.0277 
NA IGR Chr12:115131136-115135488 43 0.0298 
OSBPL5, NA IGR, TSS1500 Chr11:3187454-3192429 24 0.0304 
NA IGR Chr11:133445060-133447540 4 0.0330 
SNCA 5'UTR Chr4:90757337-90757567 5 0.0350 
COL11A2 3'UTR, Body Chr6:33131041-33133848 41 0.0354 
PCGF3 5'UTR Chr4:717423-722458 15 0.0365 
TNXB Body Chr6:32037729-32038989 21 0.0391 
PROCR TSS1500, SS200, 5'UTR, 1stExon Chr20:33758333-33761509 10 0.0446 
NA IGR Chr6:31461666-31461903 6 0.0465 
NXN Body Chr17:800064-801197 8 0.0478 
TRIM31 Body, 5'UTR Chr6:30079782-30080943 10 0.0486 
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Table A5: Psychosis-associated DMRs identified by the probe lasso algorithm.  
Table summarises the genes (if applicable), genomic features, hg19 genomic coordinates, 
number of probes and p-value associated with each DMR. “NA” in the “Gene” column 
represents intergenic regions (i.e. regions not annotated to a RefSeq gene). Genomic features 
are coded “IGR” for intergenic regions, “TSS200” and “TSS1500” for probes occurring 
within 200 and 1500 of a gene’s transcription start site, respectively; “5’UTR” and “3’UTR” 
for probes occurring within a gene’s 5’ and 3’ untranslated region, respectively, “1stExon” 
for probes occurring within the first exon of a gene, and “Body” for probes occurring within 
the gene body. 
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GO Term Description Class Enrichment P-value FDR q-value 
GO:0044459 Plasma membrane part Component 433/2385 2.09 x 10-15 3.57 x 10-12 
GO:0009887 Organ morphogenesis Process 114/424 3.32 x 10-15 4.72 x 10-11 
GO:0048856 Anatomical structure development Process 516/2969 3.81 x 10-14 2.70 x 10-10 
GO:0032502 Developmental process Process 654/3896 3.86 x 10-13 1.82 x 10-9 
GO:0005886 Plasma membrane Component 596/3766 2.49 x 10-11 2.12 x 10-8 
GO:0048731 System development Process 141/629 7.86 x 10-12 2.79 x 10-8 
GO:0009653 Anatomical structure morphogenesis Process 245/1229 1.61 x 10-11 4.58 x 10-8 




Process 567/3416 2.31 x 10-10 4.69 x 10-7 
GO:0048562 Embryonic organ morphogenesis Process 41/115 3.37 x 10-10 5.99 x 10-7 
GO:0050804 Modulation of synaptic transmission Process 68/269 5.94 x 10-10 9.36 x 10-7 




Process 354/2319 1.72 x 10-9 2.44 x 10-6 
GO:0031226 
Intrinsic component of plasma 
membrane 
Component 240/1334 7.32 x 10-9 3.13 x 10-6 
GO:0098797 Plasma membrane protein complex Component 99/485 9.34 x 10-9 3.19 x 10-6 
GO:0048869 Cellular developmental process Process 398/2379 3.48 x 10-9 4.49 x 10-6 
GO:0097458 Neuron part Component 226/1215 2.50 x 10-8 7.11 x 10-6 
GO:0044425 Membrane part Component 920/6105 3.33 x 10-8 8.12 x 10-6 
GO:0044456 Synapse part Component 120/554 5.58 x 10-8 1.19 x 10-5 
GO:0005887 
Integral component of plasma 
membrane 
Component 223/1278 6.75 x 10-8 1.28 x 10-5 
GO:0051239 
Regulation of multicellular 
organismal process 
Process 414/2453 1.46 x 10-8 1.73 x 10-5 




Process 43/133 2.62 x 10-8 2.86 x 10-5 
GO:0044763 Single-organism cellular process Process 1232/8467 5.81 x 10-8 5.90 x 10-5 
GO:0034702 Ion channel complex Component 59/260 4.09 x 10-7 6.35 x 10-5 
GO:0043565 Sequence-specific DNA binding Function 187/978 2.09 x 10-8 9.02 x 10-5 
GO:0051094 
Positive regulation of developmental 
process 
Process 185/994 1.04 x 10-7 9.86 x 10-5 
GO:0008066 Glutamate receptor activity Function 15/26 4.66 x 10-8 1.01E-04 
GO:0030054 Cell junction Component 197/1085 1.05 x 10-6 1.49E-04 
GO:0043005 Neuron projection Component 120/703 1.25 x 10-6 1.64E-04 
GO:0045202 Synapse Component 58/231 1.50 x 10-6 1.83E-04 
GO:0098802 Plasma membrane receptor complex Component 25/161 1.71 x 10-6 1.94E-04 
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GO Term Description Class Enrichment P-value FDR q-value 
GO:0007389 Pattern specification process Process 82/357 2.49 x 10-7 2.21E-04 
GO:0048704 
Embryonic skeletal system 
morphogenesis 
Process 28/78 3.23 x 10-7 2.55E-04 
GO:0048705 Skeletal system morphogenesis Process 34/106 3.14 x 10-7 2.62E-04 
GO:0098878 Neurotransmitter receptor complex Component 17/41 2.65 x 10-6 2.66E-04 
GO:0008328 
Ionotropic glutamate receptor 
complex 
Component 17/41 2.65 x 10-6 2.83E-04 
GO:0030154 Cell differentiation Process 274/1605 4.70 x 10-7 3.51E-04 
GO:0051240 
Positive regulation of multicellular 
organismal process 
Process 231/1325 5.35 x 10-7 3.80E-04 
GO:0000977 
RNA polymerase II regulatory 
region sequence-specific DNA 
binding 
Function 115/556 4.00 x 10-7 4.33E-04 
GO:0048167 Regulation of synaptic plasticity Process 36/135 6.44 x 10-7 4.35E-04 
GO:0001012 
RNA polymerase II regulatory 
region DNA binding 
Function 115/559 5.04 x 10-7 4.36E-04 
GO:0015267 Channel activity Function 84/435 7.12 x 10-7 4.40E-04 
GO:0045597 
Positive regulation of cell 
differentiation 
Process 154/784 7.25 x 10-7 4.68E-04 
GO:0044699 Single-organism process Process 1341/9882 7.79 x 10-7 4.81E-04 
GO:0005216 Ion channel activity Function 80/395 7.00 x 10-7 5.05E-04 
GO:0022803 
Passive transmembrane transporter 
activity 
Function 85/436 3.68 x 10-7 5.31E-04 
GO:0050803 
Regulation of synapse structure or 
activity 
Process 36/137 9.02 x 10-7 5.33E-04 
GO:0003002 Regionalisation Process 57/221 1.03 x 10-6 5.83E-04 
GO:0023052 Signaling Process 124/608 1.16 x 10-6 6.31E-04 
GO:0044700 Single organism signaling Process 123/605 1.55 x 10-6 6.65E-04 
GO:2000026 
Regulation of multicellular 
organismal development 
Process 266/1584 1.60 x 10-6 6.70E-04 
GO:0007268 Chemical synaptic transmission Process 68/283 1.53 x 10-6 6.81E-04 
GO:0048598 Embryonic morphogenesis Process 85/384 1.30 x 10-6 6.82E-04 
GO:0098916 Anterograde trans-synaptic signaling Process 68/283 1.53 x 10-6 7.03E-04 
GO:0022838 Substrate-specific channel activity Function 81/407 1.34 x 10-6 7.22E-04 
GO:0099537 Trans-synaptic signaling Process 68/283 1.53 x 10-6 7.26E-04 
GO:0097060 Synaptic membrane Component 54/245 8.68 x 10-6 7.41E-04 
GO:0099536 Synaptic signaling Process 68/283 1.53 x 10-6 7.51E-04 
GO:0031224 Intrinsic component of membrane Component 722/4796 7.97 x 10-6 7.56E-04 
GO:0045211 Postsynaptic membrane Component 32/190 8.51 x 10-6 7.64E-04 
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GO Term Description Class Enrichment P-value FDR q-value 
GO:0003008 System process Process 228/1269 1.52 x 10-6 7.69E-04 
GO:0015291 
Secondary active transmembrane 
transporter activity 




Function 165/872 2.43 x 10-6 0.0012 
GO:0010646 Regulation of cell communication Process 432/2788 2.91 x 10-6 0.0012 
GO:0002009 Morphogenesis of an epithelium Process 61/270 3.01 x 10-6 0.0012 
GO:0022836 Gated channel activity Function 64/304 2.77 x 10-6 0.0012 
GO:0048732 Gland development Process 51/235 3.22 x 10-6 0.0012 
GO:0000976 
Transcription regulatory region 
sequence-specific DNA binding 
Function 123/631 3.63 x 10-6 0.0013 
GO:0022610 Biological adhesion Process 177/953 3.75 x 10-6 0.0014 
GO:0048468 Cell development Process 106/554 4.01 x 10-6 0.0015 
GO:0098796 Membrane protein complex Component 154/968 1.81 x 10-5 0.0015 
GO:1902495 Transmembrane transporter complex Component 59/292 2.01 x 10-5 0.0015 
GO:1990351 Transporter complex Component 59/298 1.94 x 10-5 0.0015 




Function 127/660 4.97 x 10-6 0.0017 
GO:0001228 
Transcriptional activator activity, 
RNA polymerase II transcription 
regulatory region sequence-specific 
binding 
Function 69/306 5.61 x 10-6 0.0017 
GO:0016324 Apical plasma membrane Component 51/272 3.03 x 10-5 0.0022 
GO:0007215 
Glutamate receptor signaling 
pathway 
Process 16/39 6.65 x 10-6 0.0023 
GO:0023051 Regulation of signaling Process 435/2830 6.64 x 10-6 0.0023 
GO:0001501 Skeletal system development Process 41/155 7.14 x 10-6 0.0024 
GO:0050877 Neurological system process Process 154/815 7.92 x 10-6 0.0026 
GO:0034703 Cation channel complex Component 42/164 4.37 x 10-5 0.0030 
GO:0015293 Symporter activity Function 35/137 1.05 x 10-5 0.0030 




Process 26/81 1.03 x 10-5 0.0032 
GO:0030326 Embryonic limb morphogenesis Process 26/81 1.03 x 10-5 0.0033 
GO:0004970 
Ionotropic glutamate receptor 
activity 
Function 10/18 1.32 x 10-5 0.0036 
GO:0015075 
Ion transmembrane transporter 
activity 
Function 140/754 1.67 x 10-5 0.0038 
GO:0022857 Transmembrane transporter activity Function 172/943 1.50 x 10-5 0.0038 
GO:0005516 Calmodulin binding Function 37/171 1.60 x 10-5 0.0038 
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GO:0097485 Neuron projection guidance Process 45/188 1.27 x 10-5 0.0038 
GO:0098609 Cell-cell adhesion Process 112/560 1.36 x 10-5 0.0040 




Process 4/4 1.46 x 10-5 0.0042 
GO:0005230 
Extracellular ligand-gated ion 
channel activity 
Function 21/69 1.96 x 10-5 0.0042 
GO:0099572 Postsynaptic specialisation Component 20/132 6.71 x 10-5 0.0043 
GO:0007154 Cell communication Process 126/746 1.52 x 10-5 0.0043 




Function 10/19 2.42 x 10-5 0.0050 
GO:0000975 Regulatory region DNA binding Function 142/780 2.57 x 10-5 0.0050 
GO:0031012 Extracellular matrix Component 72/353 8.64 x 10-5 0.0051 
GO:0044449 Contractile fiber part Component 42/190 9.03 x 10-5 0.0051 
GO:0008092 Cytoskeletal protein binding Function 138/779 2.96 x 10-5 0.0053 
GO:0001067 
Regulatory region nucleic acid 
binding 
Function 142/781 2.86 x 10-5 0.0054 
GO:0032879 Regulation of localisation Process 369/2284 2.08 x 10-5 0.0057 
GO:0048729 Tissue morphogenesis Process 69/336 2.16 x 10-5 0.0057 
GO:0007411 Axon guidance Process 44/186 2.22 x 10-5 0.0057 
GO:0007187 
G-protein coupled receptor signaling 
pathway, coupled to cyclic 
nucleotide second messenger 
Process 33/162 2.14 x 10-5 0.0057 
GO:0003690 Double-stranded DNA binding Function 128/730 3.45 x 10-5 0.0060 
GO:0044212 
Transcription regulatory region 
DNA binding 
Function 141/777 3.62 x 10-5 0.0060 
GO:0007267 Cell-cell signaling Process 87/545 2.67 x 10-5 0.0068 
GO:0015276 Ligand-gated ion channel activity Function 19/133 5.34 x 10-5 0.0070 
GO:0007188 
Adenylate cyclase-modulating G-
protein coupled receptor signaling 
pathway 
Process 29/136 2.84 x 10-5 0.0071 
GO:0035108 Limb morphogenesis Process 29/95 2.94 x 10-5 0.0071 
GO:0035107 Appendage morphogenesis Process 29/95 2.94 x 10-5 0.0072 
GO:0022834 Ligand-gated channel activity Function 19/133 5.34 x 10-5 0.0072 
GO:0022835 Transmitter-gated channel activity Function 11/24 4.91 x 10-5 0.0073 
GO:0046873 
Metal ion transmembrane transporter 
activity 
Function 75/397 5.11 x 10-5 0.0074 
GO:0004972 NMDA glutamate receptor activity Function 5/8 5.28 x 10-5 0.0074 
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GO:0022824 
Transmitter-gated ion channel 
activity 
Function 11/24 4.91 x 10-5 0.0076 
GO:0000981 
RNA polymerase II transcription 
factor activity, sequence-specific 
DNA binding 
Function 113/599 4.76 x 10-5 0.0076 
GO:0051046 Regulation of secretion Process 118/634 3.32 x 10-5 0.0079 
GO:0061138 
Morphogenesis of a branching 
epithelium 
Process 37/137 3.65 x 10-5 0.0085 
GO:0031852 Mu-type opioid receptor binding Function 3/3 7.45 x 10-5 0.0095 
GO:0044420 Extracellular matrix component Component 29/120 1.83 x 10-4 0.0101 
GO:0051049 Regulation of transport Process 280/1685 4.52 x 10-5 0.0104 
GO:0016020 Membrane Component 999/6965 1.97 x 10-4 0.0105 
GO:0030425 Dendrite Component 60/301 2.26 x 10-4 0.0117 
GO:0015081 
Sodium ion transmembrane 
transporter activity 
Function 31/128 9.59 x 10-5 0.0118 
GO:0045666 
Positive regulation of neuron 
differentiation 
Process 63/295 5.24 x 10-5 0.0118 
GO:0051410 Detoxification of nitrogen compound Process 2/5 5.70 x 10-5 0.0126 
GO:0098742 
Cell-cell adhesion via plasma-
membrane adhesion molecules 
Process 24/197 5.80 x 10-5 0.0127 




Function 182/1043 0.0001 0.0138 
GO:0050793 Regulation of developmental process Process 315/1930 6.51 x 10-5 0.0140 
GO:0008514 
Organic anion transmembrane 
transporter activity 
Function 23/84 0.0001 0.0141 
GO:0007156 
Homophilic cell adhesion via plasma 
membrane adhesion molecules 
Process 20/149 0.0001 0.0141 
GO:0051962 
Positive regulation of nervous 
system development 
Process 83/418 0.0001 0.0143 
GO:2000667 
Positive regulation of interleukin-13 
secretion 
Process 5/6 0.0001 0.0149 
GO:0048583 Regulation of response to stimulus Process 480/3366 0.0001 0.0154 
GO:0005578 Proteinaceous extracellular matrix Component 38/251 0.0003 0.0160 
GO:0016021 Integral component of membrane Component 690/4674 0.0004 0.0175 
GO:0071837 HMG box domain binding Function 10/18 0.0002 0.0177 
GO:0009581 Detection of external stimulus Process 27/107 9.05 x 10-5 0.0181 
GO:0017146 
NMDA selective glutamate receptor 
complex 
Component 5/11 0.0004 0.0186 
GO:0008509 
Anion transmembrane transporter 
activity 
Function 39/192 0.0002 0.0195 
GO:0035239 Tube morphogenesis Process 34/207 0.0001 0.0197 
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GO:0042221 Response to chemical Process 322/2164 0.0001 0.0197 
GO:0090596 Sensory organ morphogenesis Process 18/48 0.0001 0.0198 
GO:0005509 Calcium ion binding Function 122/667 0.0002 0.0201 
GO:0051960 
Regulation of nervous system 
development 
Process 129/717 0.0001 0.0204 
GO:0048592 Eye morphogenesis Process 16/40 0.0001 0.0205 
GO:2000664 
Positive regulation of interleukin-5 
secretion 
Process 4/4 0.0001 0.0221 
GO:0051047 Positive regulation of secretion Process 60/346 0.0001 0.0226 
GO:0021707 
Cerebellar granule cell 
differentiation 
Process 3/7 0.0001 0.0227 
GO:0007417 Central nervous system development Process 19/111 0.0001 0.0250 
GO:0001763 
Morphogenesis of a branching 
structure 
Process 36/146 0.0002 0.0250 
GO:0048168 
Regulation of neuronal synaptic 
plasticity 
Process 16/47 0.0001 0.0251 
GO:0008631 
Intrinsic apoptotic signaling pathway 
in response to oxidative stress 
Process 9/17 0.0002 0.0251 
GO:0019369 Arachidonic acid metabolic process Process 11/48 0.0001 0.0252 
GO:0055085 Transmembrane transport Process 160/1036 0.0001 0.0252 
GO:0009582 Detection of abiotic stimulus Process 27/110 0.0002 0.0253 
GO:0001505 Regulation of neurotransmitter levels Process 34/130 0.0001 0.0254 
GO:0048646 
Anatomical structure formation 
involved in morphogenesis 
Process 141/776 0.0002 0.0259 
GO:0043194 Axon initial segment Component 7/12 0.0006 0.0264 
GO:0045664 Regulation of neuron differentiation Process 98/531 0.0002 0.0288 
GO:0010720 
Positive regulation of cell 
development 
Process 86/452 0.0002 0.0288 
GO:0031430 M band Component 8/19 0.0007 0.0307 
GO:0031235 
Intrinsic component of the 
cytoplasmic side of the plasma 
membrane 
Component 7/13 0.0007 0.0312 
GO:0048522 
Positive regulation of cellular 
process 
Process 582/4317 0.0002 0.0318 
GO:0035235 
Ionotropic glutamate receptor 
signaling pathway 
Process 10/23 0.0002 0.0320 
GO:0008285 
Negative regulation of cell 
proliferation 
Process 110/613 0.0002 0.0335 
GO:0001642 
Group III metabotropic glutamate 
receptor activity 




Function 2/2 0.0003 0.0338 
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GO Term Description Class Enrichment P-value FDR q-value 
GO:0044463 Cell projection part Component 148/867 0.0008 0.0344 
GO:1902710 GABA receptor complex Component 4/15 0.0009 0.0356 
GO:0051430 
Corticotropin-releasing hormone 
receptor 1 binding 
Function 2/4 0.0004 0.0359 
GO:1902711 GABA-A receptor complex Component 4/15 0.0009 0.0364 
GO:0071625 Vocalisation behavior Process 7/10 0.0002 0.0365 
GO:0000987 
Core promoter proximal region 
sequence-specific DNA binding 
Function 72/354 0.0004 0.0366 
GO:0060078 
Regulation of postsynaptic 
membrane potential 
Process 17/53 0.0002 0.0367 
GO:0048518 
Positive regulation of biological 
process 
Process 635/4755 0.0003 0.0370 
GO:0010575 
Positive regulation of vascular 
endothelial growth factor production 
Process 11/25 0.0003 0.0372 
GO:0005581 Collagen trimer Component 24/85 0.0010 0.0382 
GO:0001503 Ossification Process 31/111 0.0003 0.0409 
GO:1903793 Positive regulation of anion transport Process 12/33 0.0003 0.0410 
GO:0001159 
Core promoter proximal region DNA 
binding 
Function 72/357 0.0004 0.0430 
GO:0006836 Neurotransmitter transport Process 27/93 0.0003 0.0430 
GO:0021602 Cranial nerve morphogenesis Process 7/11 0.0003 0.0431 
GO:0044708 Single-organism behavior Process 64/360 0.0003 0.0432 
GO:0005272 Sodium channel activity Function 13/36 0.0005 0.0433 
GO:0050806 
Positive regulation of synaptic 
transmission 
Process 28/102 0.0003 0.0433 
GO:0007605 Sensory perception of sound Process 32/127 0.0003 0.0441 
GO:0006811 Ion transport Process 179/1091 0.0003 0.0443 
GO:0060575 
Intestinal epithelial cell 
differentiation 
Process 5/6 0.0003 0.0443 
GO:0045785 Positive regulation of cell adhesion Process 55/353 0.0003 0.0445 
GO:0045595 Regulation of cell differentiation Process 217/1407 0.0004 0.0478 
GO:0048251 Elastic fiber assembly Process 4/6 0.0004 0.0479 
GO:0045582 
Positive regulation of T cell 
differentiation 
Process 17/65 0.0004 0.0492 
GO:1902578 Single-organism localisation Process 383/2459 0.0004 0.0494 
Table A6: Summary of GO terms found to be enriched amongst the most 
differentially methylated genes in iPSC-derived neurons of t(1;11) carriers. 
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For each GO term, table summarises the GO identifier, the GO description, the GO class, 
enrichment, the enrichment p-values, and enrichment FDR q-values for genes showing the 
most differential methylation in t(1,11) carriers compared to non-carriers. Enrichment is 
defined as (b/n) / (B/N), where b = the number of genes at the top of the p-value ranked list 
that is associated with a given GO term, n = the number of genes at the top of the p-value-
ranked gene list, B = the total number of genes associated with a given GO term, and N = the 
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FLOT1, IER3 TSS1500, 3'UTR, Body Chr6:30710912-30711968 26 7.72 x 10-29 
GNASAS, GNAS 3'UTR, TSS1500 Chr20:57425870-57427652 51 1.96 x 10-20 
CCDC130 TSS1500, TSS200 Chr19:13858480-13858585 5 1.46 x 10-15 
SNORD116-15 - SNORD116-19 TSS1500, TSS200, Body Chr15:25325510-25330514 16 1.46 x 10-15 
C22orf32, SMDT1 TSS200, 1stExon Chr22:42475680-42475844 6 4.10 x 10-15 
MIR4458HG, LOC729506 Body Chr5:8457127-8457933 7 1.89 x 10-14 




Chr13:36871465-36872189 10 6.16 x 10-13 
GDNF Body, 5'UTR Chr5:37834742-37835348 9 1.18 x 10-12 
RFPL2 TSS1500 Chr22:32601040-32601418 4 2.08 x 10-12 
SNORD116-3, SNORD116-8 - 
SNORD116-12 
TSS1500, TSS200, Body Chr15:25314660-25322096 25 5.52 x 10-12 
LOC286083 TSS1500, TSS200 Chr8:1247657-1254583 9 5.75 x 10-12 
LRRIQ3, TNNI3K, FPGT, 
FPGT-TNNI3K 
TSS200, 1stExon, Body Chr1:74663818-74664684 13 5.75 x 10-12 
DYX1C1 Body, 5'UTR Chr15:55790403-55790649 4 7.20 x 10-12 
SUCLG2 TSS200, Body, TSS1500 Chr3:67704958-67705415 5 1.26 x 10-11 
LYNX1 5'UTR Chr8:143858411-143858899 10 2.99 x 10-11 
GABRB3 5'UTR, Body Chr15:26874257-26875242 10 5.50 x 10-11 
OPCML 1stExon, TSS200 Chr11:133402081-133402540 7 9.69 x 10-11 
SLC25A4 1stExon, Body Chr4:186064419-186064876 4 2.01 x 10-10 
FAM115A, TCAF1 5'UTR Chr7:143582420-143582830 7 2.59 x 10-10 
ATPBD4, DPH6-AS1, DPH6 Body, TSS200, TSS1500 Chr15:35837611-35838829 11 3.10 x 10-10 
TRIM58 1stExon Chr1:248020638-248020745 3 4.74 x 10-10 
NA IGR, TSS200 Chr1:24740123-24740365 5 6.18 x 10-10 
NA IGR Chr16:86230282-86235475 8 1.34 x 10-9 
SYCP1 TSS200, 1stExon Chr1:115397370-115397669 8 1.85 x 10-9 
AK2 TSS200, TSS1500 Chr1:33502644-33502906 7 2.45 x 10-9 
SNCA 5'UTR Chr4:90757170-90757809 6 2.76 x 10-9 
C4orf39, TRIM61 Body, 1stExon Chr4:165877646-165878196 6 2.76 x 10-9 
RAG2, C11orf74 TSS1500, Body, 5'UTR Chr11:36614033-36617183 15 2.76 x 10-9 
NBR1, TMEM106A 3'UTR, TSS1500 Chr17:41363234-41363894 9 2.89 x 10-9 
IFT74 5'UTR, TSS200 Chr9:26955771-26956380 8 3.58 x 10-9 
SNORD116-2, SNORD116-6, 
SNORD116-5 
TSS1500, TSS200 Chr15:25308804-25311885 6 3.89 x 10-9 




Chr12:12848796-12849157 5 8.48 x 10-9 
NPY TSS200, 1stExon Chr7:24323786-24323893 3 9.22 x 10-9 
DYNLRB2, LOC102724084 Body, 1stExon Chr16:80574806-80575123 5 
1.24 x 10-8 
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NA IGR Chr3:138658825-138659056 3 1.40 x 10-8 
TXNRD2, COMT 
Body, 1stExon, 5'UTR, 
TSS200 
Chr22:19929008-19929737 10 2.34 x 10-8 
NA IGR Chr3:64253489-64253933 6 2.58 x 10-8 
ZNF267 TSS200, 1stExon Chr16:31885037-31885144 3 3.96 x 10-8 
MIR3663HG, MIR3663 Body, TSS200 Chr10:118928281-118928738 3 3.96 x 10-8 
NR2F1, MIR548AO Body, 3'UTR Chr5:92929213-92929839 5 4.25 x 10-8 
NA IGR Chr15:56297839-56301176 4 4.49 x 10-8 
LOC151174, LOC643387 Body Chr2:239139682-239140295 6 4.68 x 10-8 
ACAA1, MYD88 1stExon, TSS1500 Chr3:38180042-38180158 3 5.02 x 10-8 
SVOPL Body Chr7:138349032-138349263 3 7.46 x 10-8 
NKD1 Body Chr16:50586910-50589287 6 9.75 x 10-8 
NBEAL1 TSS1500 Chr2:203879114-203879307 3 9.75 x 10-8 
NSMCE1, FLJ21408 5'UTR Chr16:27279315-27279964 5 1.24 x 10-7 
NA IGR Chr8:33862743-33869095 8 1.56 x 10-7 
SNORD116-1 TSS1500, TSS200, Body Chr15:25295628-25297627 7 1.58 x 10-7 
GABPB2 TSS200, TSS1500 Chr1:151042707-151042918 5 1.82 x 10-7 
LOC153684 Body Chr5:43044255-43046853 6 2.12 x 10-7 
OR2L13* 1stExon Chr1:248100531-248100667 4 3.26 x 10-7 
PRDM16* Body Chr1:3301199-3304640 11 3.60 x 10-7 
TSNARE1 5'UTR Chr8:143473719-143476331 8 4.17 x 10-7 
NA IGR Chr10:131216295-131219549 3 9.77 x 10-7 
TNFSF11 5'UTR Chr13:43147443-43148394 8 1.13 x 10-6 
PAR5, SNORD64 TSS1500, Body Chr15:25229200-25231867 7 1.24 x 10-6 
MPZL3, MPZL2 
Body, 1stExon, TSS200, 
TSS1500, 3'UTR 
Chr11:118121715-118125529 16 1.45 x 10-6 
KCNQ1DN TSS1500 Chr11:2890586-2890752 12 1.47 x 10-6 
KIAA1462 TSS200 , TSS1500 Chr10:30348608-30348805 4 1.47 x 10-6 
NA IGR Chr8:74279957-74284471 5 1.58 x 10-6 
LOC399815*, FAM24B 1stExon, Body Chr10:124639051-124639365 8 1.81 x 10-6 
SNORD116-28 TSS1500, Body Chr15:25348817-25350835 4 2.54 x 10-6 
NRROS, LRRC33 1stExon, TSS200 Chr3:196366527-196366658 3 2.65 x 10-6 
NA IGR Chr4:12797269-12801122 6 2.69 x 10-6 
TXNRD1, EID3 5'UTR Chr12:104697435-104697623 5 2.69 x 10-6 




Chr15:25336103-25340250 10 3.94 x 10-6 
LOC646405 Body Chr13:25506129-25506611 4 4.13 x 10-6 
C3orf67 TSS1500 Chr3:59035879-59036089 5 5.65 x 10-6 
KIF17 TSS200, TSS1500 Chr1:21044642-21044733 4 6.08 x 10-6 
NA IGR Chr13:45490318-45494868 8 6.11 x 10-6 
PAX6 Body Chr11:31821192-31821680 5 7.34 x 10-6 
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HOXA5 TSS1500 Chr7:27183907-27184072 6 7.41 x 10-6 
KHDC1 1stExon Chr6:73972688-73972873 4 8.81 x 10-6 
FOXG1-AS1, FOXG1 TSS1500, TSS200 Chr14:29234379-29234962 5 9.08 x 10-6 
WDR72 1stExon, Body, TSS200 Chr15:54051767-54051999 5 9.88 x 10-6 




Chr17:7757665-7758368 10 1.17 x 10-5 
C1orf87 TSS200, TSS1500 Chr1:60539574-60539771 3 1.22 x 10-5 
PWWP2B Body Chr10:134211628-134212136 3 1.35 x 10-5 
LOC648987 Body Chr5:43037295-43037957 5 1.44 x 10-5 
MGMT Body Chr10:131498562-131507260 18 1.54 x 10-5 
C6orf174 Body Chr6:127835947-127836264 4 1.54 x 10-5 
SHF 3'UTR Chr15:45459463-45459997 3 1.54 x 10-5 
SLC35E3 TSS1500, TSS200 Chr12:69139606-69139841 8 1.54 x 10-5 
CLNK Body Chr4:10599367-10602421 5 1.59 x 10-5 




Chr4:135121591-135123536 6 2.09 x 10-5 
MARVELD3 Body Chr16:71660679-71661136 4 2.42 x 10-5 
GAL3ST3 TSS1500 Chr11:65816838-65817081 3 2.45 x 10-5 
NA IGR Chr5:175558908-175562712 3 2.45 x 10-5 
SBK2 TSS1500, TSS200 Chr19:56048356-56048614 5 2.45 x 10-5 
RUNDC3A Body Chr17:42392562-42392802 3 2.61 x 10-5 
NA IGR Chr1:165086860-165087091 3 2.84 x 10-5 
SORCS1 Body Chr10:108728446-108730917 4 2.85 x 10-5 
KIAA0556 Body Chr16:27728635-27731609 8 2.96 x 10-5 
UNC5D Body Chr8:35400059-35402907 5 3.01 x 10-5 
NA IGR Chr4:138464719-138468410 6 3.29 x 10-5 
PRR15 Body, 3'UTR Chr7:29606081-29606615 3 3.29 x 10-5 
LINC00887, LOC100131551 Body, TSS200, TSS1500 Chr3:194029837-194031210 6 3.31 x 10-5 
SYNPO2L Body Chr10:75407143-75407600 3 3.42 x 10-5 
NA IGR Chr6:27511308-27515019 6 3.57 x 10-5 
DIABLO, LOC101593348 TSS200, 5'UTR Chr12:122711109-122711266 5 3.68 x 10-5 
SPDL1, CCDC99 TSS1500, TSS200 Chr5:169010192-169010471 6 3.68 x 10-5 
NA IGR Chr8:103818745-103819034 3 3.70 x 10-5 
37681 Body Chr5:126210060-126212351 3 3.91 x 10-5 
NA IGR Chr8:72470408-72471273 5 4.00 x 10-5 
PACS2, TEX22 3'UTR Chr14:105864044-105864696 4 4.05 x 10-5 
URI1 Body Chr19:30493289-30496076 6 4.06 x 10-5 
MAP3K13 TSS200 Chr3:185000532-185000875 6 4.26 x 10-5 
DLGAP2-AS1, DLGAP2 Body Chr8:1568905-1570904 5 4.26 x 10-5 
CLNK Body Chr4:10657763-10660447 5 4.52 x 10-5 
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IFIH1 TSS200, TSS1500 Chr2:163175190-163175547 7 4.59 x 10-5 
GATA4 TSS1500 Chr8:11531474-11535523 4 4.91 x 10-5 
RAD50 1stExon, 5'UTR Chr5:131893120-131893481 3 4.91 x 10-5 
MGMT Body Chr10:131423627-131426281 5 5.01 x 10-5 
BBS4, HIGD2B TSS1500, Body Chr15:72977622-72978268 6 5.53 x 10-5 
ZNF486 TSS200, 1stExon, Body Chr19:20277423-20279422 6 5.56 x 10-5 
KCNC3 TSS200 Chr19:50836794-50837025 3 5.68 x 10-5 
C1orf101 TSS1500, TSS200 Chr1:244624348-244624541 4 5.69 x 10-5 
ZNF528 TSS1500, TSS200 Chr19:52900804-52901010 7 5.77 x 10-5 
NA IGR Chr18:76266256-76266487 3 5.81 x 10-5 
LBXCOR1 Body Chr15:68126062-68126293 3 6.07 x 10-5 
MGMT Body Chr10:131459030-131461633 3 6.11 x 10-5 
KIAA1324, C1orf194 1stExon Chr1:109656628-109656856 4 6.20 x 10-5 
BRCA1, NBR2 TSS1500 Chr17:41278098-41278221 4 6.20 x 10-5 
NA IGR Chr2:47499600-47499831 3 6.30 x 10-5 
HLCS TSS200, TSS1500 Chr21:38362699-38362796 4 6.43 x 10-5 
NA IGR Chr8:1198261-1202123 12 6.50 x 10-5 
NA IGR Chr5:2684024-2688626 4 6.75 x 10-5 
NA IGR Chr10:43913915-43918051 9 6.96 x 10-5 
NA IGR Chr6:166711265-166711603 3 7.10 x 10-5 
QPCT Body Chr2:37572194-37572651 3 7.14 x 10-5 
HIST1H3G, HIST1H2BI TSS1500 Chr6:26271651-26271844 5 7.54 x 10-5 
TMEM246 TSS200, TSS1500 Chr9:104249644-104249855 4 7.59 x 10-5 
NFE2 TSS200, TSS1500 Chr12:54694871-54695160 6 7.70 x 10-5 
FN3K, TBCD* Body, 3'UTR Chr17:80708364-80708898 3 8.15 x 10-5 
COL5A2 
Body, 1stExon, TSS200, 
TSS1500 
Chr2:190043091-190045109 9 8.16 x 10-5 
MFNG TSS200 Chr22:37882512-37882593 3 9.01 x 10-5 
LINC01007 Body Chr7:101206410-101209723 4 9.19 x 10-5 
NA IGR Chr6:10883574-10884431 5 9.36 x 10-5 
PLD6 1stExon, TSS200 Chr17:17109586-17109693 4 0.0001 
CHDH, IL17RB Body Chr3:53880624-53881100 4 0.0001 
P3H4, FKBP10, SC65 1stExon Chr17:39969159-39969376 5 0.0001 
RCCD1 5'UTR Chr15:91498772-91499203 3 0.0001 
VTRNA1-3 TSS1500, TSS200 Chr5:140104488-140108652 10 0.0001 
TSSC1 Body Chr2:3286306-3286517 3 0.0001 
ASPSCR1 Body Chr17:79952299-79952756 3 0.0001 
ZIC4 3'UTR, Body Chr3:147105152-147107234 8 0.0001 
NA IGR Chr1:2765178-2768849 5 0.0001 
AURKC TSS200, 1stExon Chr19:57742340-57742497 5 0.0001 
SNRPN TSS1500, TSS200 Chr15:25068557-25070194 8 0.0001 
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MDK TSS1500 Chr11:46402504-46402697 4 0.0001 
WDR90 Body Chr16:710804-711261 4 0.0001 
HIST1H2BI TSS200 Chr6:26272999-26273192 5 0.0001 
C17orf49, RNASEK-C17orf49, 
MIR497HG 
Body Chr17:6918723-6919180 3 0.0001 
L3MBTL1 Body Chr20:42165996-42167995 3 0.0002 
NELL1 Body Chr11:20692638-20693112 6 0.0002 
NA IGR Chr12:132168689-132169421 4 0.0002 
EVX1, EVX1-AS 3'UTR Chr7:27286392-27287285 5 0.0002 
FAAP20 1stExon; TSS200 Chr1:2143710-2144293 6 0.0002 
RARA Body Chr17:38501385-38501596 4 0.0002 
RFWD3 TSS1500 Chr16:74701311-74701583 3 0.0002 
SERHL2 TSS1500 Chr22:42949429-42949622 4 0.0002 
NA IGR Chr2:11529070-11532247 5 0.0002 
WDR27 Body Chr6:170068156-170068686 3 0.0002 
NA IGR Chr1:244393574-244396892 3 0.0002 
RGS22 Body Chr8:101117673-101118130 6 0.0002 
NA IGR Chr22:35387324-35391041 3 0.0002 
NA IGR Chr18:76476379-76480717 4 0.0002 
NA IGR Chr12:131215610-131218928 3 0.0002 
NA IGR Chr2:127653621-127657985 4 0.0002 
ESYT3 TSS1500 Chr3:138153030-138153266 3 0.0002 
HLA-G Body Chr6:29795909-29796210 6 0.0002 
NA IGR Chr11:69286177-69286467 5 0.0002 
CWH43 Body Chr4:48988400-48988707 5 0.0002 
GCM2 TSS200, TSS1500 Chr6:10882229-10882422 3 0.0002 
ANGPTL2, RALGPS1 5'UTR, 1stExon, Body Chr9:129883494-129886937 12 0.0002 
MCM5 TSS1500 Chr22:35795207-35795400 5 0.0002 
FBXL16 Body Chr16:745819-746360 4 0.0002 
CACNB3 TSS1500, 1stExon Chr12:49207818-49208401 5 0.0002 
NA IGR Chr8:143119205-143125208 7 0.0002 
KLHL8 TSS1500 Chr4:88142178-88142383 3 0.0002 
FAM19A3 TSS1500 Chr1:113261680-113261765 3 0.0002 
RAI1 5'UTR Chr17:17694446-17696389 6 0.0002 
NA IGR Chr2:21616546-21620941 6 0.0002 
HERC5 TSS1500 , TSS200 Chr4:89377875-89378148 5 0.0002 
CACNA2D2 Body Chr3:50491746-50493882 3 0.0002 
RUNX1 Body Chr21:36399120-36399331 3 0.0003 
L3MBTL1 TSS200 Chr20:42136013-42136244 4 0.0003 
SFRP1 Body Chr8:41164377-41165032 4 0.0003 
CR1L Body Chr1:207842497-207843032 4 0.0003 
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TNFRSF11A 3'UTR Chr18:60052196-60052730 3 0.0003 
USP3 Body Chr15:63847612-63849744 4 0.0003 
TMED7-TICAM2, TICAM2, 
LOC101927100 
Body, TSS1500 Chr5:114937768-114938107 5 0.0003 
WFIKKN2 TSS1500 Chr17:48911036-48911325 4 0.0003 
NA IGR Chr7:127911851-127912082 3 0.0003 
MGMT Body Chr10:131333690-131335865 3 0.0003 
RASA3 TSS1500 Chr13:114898366-114898451 3 0.0003 
FAM107B 5'UTR, Body Chr10:14643903-14644416 3 0.0003 
SYNGR3 Body Chr16:2041573-2042030 3 0.0003 
KIFC3 TSS200, TSS1500 Chr16:57836613-57836734 7 0.0003 
C21orf119, URB1 1stExon, Body Chr21:33765223-33765680 8 0.0003 
NA IGR Chr4:11635992-11639073 3 0.0003 
MAS1L 1stExon Chr6:29454770-29455056 3 0.0003 
CPN1 Body Chr10:101825012-101825223 4 0.0004 
UNC5D Body Chr8:35233678-35236593 3 0.0004 
OR2T11 TSS200 Chr1:248790418-248790499 3 0.0004 
NA IGR Chr2:22752740-22756406 3 0.0004 
ACCN1 TSS200, TSS1500 Chr17:32483984-32484077 4 0.0004 
NA IGR Chr14:106345374-106348606 3 0.0004 
GPX1 TSS1500 Chr3:49396096-49396328 3 0.0004 
NA IGR Chr7:45298075-45301306 3 0.0005 
PCSK2 TSS1500 Chr20:17206677-17206786 3 0.0005 
CA3 TSS1500 Chr8:86350471-86350688 3 0.0005 
LOC100188947, HECTD2-AS1 Body Chr10:93333974-93336676 5 0.0005 
TSNARE1 TSS200, TSS1500 Chr8:143484773-143484880 4 0.0005 
MGMT Body Chr10:131405583-131408553 3 0.0005 
NA IGR Chr8:711621-714723 4 0.0005 
NA IGR Chr6:100914986-100915217 3 0.0005 
DLX3 3'UTR Chr17:48064472-48067553 3 0.0005 
CST6 1stExon, Body Chr11:65779618-65780075 3 0.0006 
FABP3 TSS1500 Chr1:31846346-31846686 3 0.0006 
LOC100129550 TSS200 Chr3:122605307-122605388 3 0.0006 
CAMTA1 Body Chr1:7740137-7740391 4 0.0006 
HOXC12 Body Chr12:54349924-54350522 3 0.0006 
TTC7B Body Chr14:91021269-91023407 3 0.0006 
RTN2 Body Chr19:45996231-45996812 5 0.0006 
NA IGR Chr2:177003443-177004306 4 0.0006 
HLA-L Body Chr6:30228137-30228659 4 0.0006 
NA IGR Chr17:53509189-53512861 3 0.0006 
PRKCD TSS1500 Chr3:53194601-53194794 3 0.0006 
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MBD6, DDIT3 TSS1500 Chr12:57915458-57915732 4 0.0006 
NA IGR Chr2:241289146-241292368 6 0.0006 
DPP10 Body Chr2:115920596-115921053 3 0.0007 
NA IGR Chr17:41446167-41446398 4 0.0007 
KCNQ4 1stExon , Body Chr1:41250011-41250222 3 0.0007 
LOC101928414 TSS1500, TSS200 Chr15:45569676-45573176 8 0.0007 
AMICA 1stExon, Body, 5'UTR Chr11:118083920-118086554 10 0.0007 
NA IGR Chr20:48535779-48539395 4 0.0007 
WNT10A Body Chr2:219746625-219747307 3 0.0007 
NA IGR Chr11:2884002-2884260 3 0.0007 
RCAN3 Body , 3'UTR Chr1:24861708-24861926 4 0.0007 
EPB42 Body Chr15:43509478-43512449 4 0.0007 
ACTN4 Body Chr19:39218124-39218639 3 0.0007 
TSNARE1 Body Chr8:143327572-143330725 7 0.0007 
SORCS1 Body Chr10:108459467-108461516 3 0.0008 
NA IGR Chr17:75524797-75525119 3 0.0008 
ERICH1-AS1 Body Chr8:819402-822386 3 0.0008 
NA IGR Chr12:120835662-120835893 3 0.0008 
NA IGR Chr7:142420271-142423352 5 0.0009 
HOXA11AS, HOXA11 Body Chr7:27225116-27225501 9 0.0009 
MGMT Body Chr10:131353782-131356301 7 0.0009 
SLC6A3 Body Chr5:1408937-1411155 4 0.0010 
ZC3H12D Body Chr6:149772663-149773120 4 0.0010 
TPO Body Chr2:1486895-1489637 5 0.0010 
NKX6-2 TSS1500 Chr10:134600608-134600743 5 0.0010 
NA IGR Chr10:130757981-130761062 5 0.0010 
FOLH1 1stExon Chr11:49230020-49230179 5 0.0010 
FOXL2 1stExon Chr3:138662648-138663231 4 0.0011 
TBC1D16 Body Chr17:77982111-77982705 3 0.0011 
NA IGR Chr10:133206945-133211351 7 0.0011 
WDR52 5'UTR, 1stExon Chr3:113160002-113160363 3 0.0011 
BPIL2, BPIFC Body, TSS1500 Chr22:32852147-32854146 4 0.0012 
NA IGR Chr6:29413214-29417635 5 0.0012 
ZNF385A, LOC102724050 Body Chr12:54779066-54781194 8 0.0012 
PAOX Body Chr10:135192881-135193105 3 0.0012 
ALKBH3 TSS1500 Chr11:43898530-43901398 4 0.0012 
ZNF729 TSS200, 1stExon Chr19:22468931-22469514 5 0.0012 
MGMT 3'UTR, Body Chr10:131563371-131572287 33 0.0013 
HTR3D 5'UTR, 1stExon Chr3:183749242-183751251 6 0.0013 
MGC2752, CENPBD1P1 Body Chr19:59092383-59092840 3 0.0013 
DUSP22 TSS200, TSS1500 Chr6:291785-291978 3 0.0014 
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CABIN1 Body Chr22:24551449-24551957 4 0.0014 
ARL6IP1 TSS1500 Chr16:18813216-18813320 3 0.0014 
PAQR8 TSS1500, TSS200 Chr6:52226601-52226803 4 0.0014 
NA IGR Chr8:47117778-47120859 4 0.0016 
BEND7 3'UTR, Body Chr10:13479534-13484810 11 0.0016 
SH3GL3 5'UTR, Body Chr15:84158516-84160969 4 0.0017 
NFE2L1* Body Chr17:46130332-46133017 5 0.0017 
PLA2G16 TSS200, TSS1500 Chr11:63382046-63382239 6 0.0017 
GRM7 1stExon Chr3:6902965-6903072 3 0.0017 
NA IGR Chr10:130828104-130833933 20 0.0017 
IL1F10 5'UTR Chr2:113828621-113830684 5 0.0017 
SOX9, SOX9-AS1 Body Chr17:70115602-70116059 4 0.0018 
KCNQ5 TSS1500 Chr6:73330200-73330393 3 0.0018 
LINC01449 Body Chr7:41146516-41149597 3 0.0018 
RUFY4 Body Chr2:218936172-218939005 10 0.0019 
SLC16A7 5'UTR Chr12:59990383-59991085 4 0.0019 




Chr8:1448815-1450849 9 0.0021 
NA IGR Chr3:13323451-13323757 3 0.0022 
RAPGEFL1 Body Chr17:38347587-38348044 5 0.0022 
ZNF354A TSS1500 Chr5:178157859-178158141 5 0.0022 
TRIM10* 3'UTR, Body Chr6:30117358-30122147 15 0.0023 
NA IGR Chr8:1136005-1136829 8 0.0026 
SYNGAP1 Body Chr6:33393493-33394012 11 0.0028 
NMRAL1, HMOX2 TSS200 Chr16:4526196-4526263 3 0.0028 
NA IGR Chr1:179696392-179699641 7 0.0029 
DDX54 Body Chr12:113598306-113601158 6 0.0030 
NA IGR Chr2:97134967-97138795 4 0.0030 
ZNF790, ZNF345 5'UTR Chr19:37342251-37342765 7 0.0031 




Chr4:82125889-82127526 5 0.0032 
CASZ1 Body Chr1:10731063-10734510 13 0.0032 
SNRPN 5'UTR Chr15:25100155-25101792 7 0.0033 
SV2B 5'UTR Chr15:91767439-91769754 5 0.0036 
LINC01574 TSS1500, TSS200 Chr5:176169846-176170429 6 0.0036 
LOC646999 Body Chr7:39648995-39649464 5 0.0038 
NA IGR Chr6:3051955-3056424 12 0.0040 
MGMT Body Chr10:131558596-131561420 9 0.0040 
C15orf29 TSS1500, TSS200 Chr15:34502428-34502676 6 0.0040 
LOC101927274, LOC4404466 Body, TSS1500 Chr17:49411301-49415610 6 0.0041 
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NA IGR Chr6:8341845-8346144 5 0.0041 
NA IGR Chr16:86669407-86673086 4 0.0043 
C22orf26, LOC150381 Body, 1stExon Chr22:46449201-46449778 5 0.0043 




Chr3:118863646-118865447 17 0.0044 
IGFBP7-AS1, IGFBP7 Body Chr4:57975509-57976139 6 0.0045 




Chr5:102897404-102899041 11 0.0050 
NA IGV Chr10:133483051-133486730 7 0.0052 
SPRED2 1stExon, Body Chr2:65592933-65595889 10 0.0053 
HRH2 TSS1500 Chr5:175084555-175084839 4 0.0053 
CAPN14 TSS1500 Chr2:31441134-31444215 6 0.0057 




Chr11:114429466-114431103 4 0.0062 
LOC100506406, CAPSL 5'UTR, TSS1500 Chr5:35937856-35939510 4 0.0064 
CCL24 
Body, 1stExon, TSS200, 
TSS1500 
Chr7:75441678-75443677 10 0.0064 
VASN, CORO7, CORO7-PAM16 Body Chr16:4421216-4421831 6 0.0065 
NA IGV Chr2:89156388-89161703 13 0.0069 
NPBWR1 TSS1500 Chr8:53850517-53851224 4 0.0069 
WDR72 5'UTR Chr15:54024598-54026992 4 0.0069 
ZNF257 TSS1500, TSS200, Body Chr19:22234850-22236849 8 0.0070 




Chr3:25830824-25832767 15 0.0078 
NA IGV Chr6:170410016-170413493 6 0.0086 
CYP51A1-AS1 Body Chr7:91808513-91809345 9 0.0091 
LOC100506272 Body Chr4:188512911-188515758 5 0.0094 
NA IGV Chr8:1271087-1276226 12 0.0094 
NA IGV Chr12:131269782-131274762 8 0.0096 
COASY Body Chr17:40715116-40715386 5 0.0098 
C2, CFB Body, 3'UTR, 1stExon Chr6:31912016-31916531 22 0.0098 
OR2H1 5'UTR, Body Chr6:29429272-29432460 10 0.0100 
SNRPN, SNURF 5'UTR Chr15:25198847-25199344 4 0.0103 
MYOM2, MIR7160 Body Chr8:2022251-2025299 8 0.0103 
MGMT Body Chr10:131449224-131451999 5 0.0103 
HLA-DQB2 TSS1500 Chr6:32731678-32734276 6 0.0104 




Chr5:35229347-35231161 11 0.0110 
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NA IGV Chr5:43006091-43011083 9 0.0110 
MGMT Body Chr10:131360165-131362539 6 0.0111 
ACOX3 Body Chr4:8394941-8397813 7 0.0113 
NA IGV Chr6:68597160-68601633 11 0.0113 
DLGAP2 5'UTR Chr8:1462084-1463943 4 0.0113 
LEMD3 TSS1500 Chr12:65562806-65563059 5 0.0115 
TRIM40 Body Chr6:30112074-30115801 20 0.0116 
GPR116, ADGRF5 5'UTR Chr6:46889401-46891760 8 0.0117 
DLGAP2 Body Chr8:1623580-1627554 11 0.0118 
SULT2B1 Body, 1stExon Chr19:49076983-49079118 4 0.0118 
ZDHHC8P Body, TSS1500 Chr22:23743094-23745724 5 0.0123 
PSMB9 Body Chr6:32824677-32826383 13 0.0128 
IRF8 5'UTR, Body Chr16:85934624-85937410 10 0.0128 
TBX5 5'UTR Chr12:114843806-114844343 9 0.0131 
MAP2K5 Body Chr15:67839376-67842406 6 0.0137 
NT5C TSS1500, TSS200 Chr17:73127982-73128175 6 0.0138 
NME2, NME1-NME2 Body Chr17:49244488-49245025 4 0.0138 
TAP1*, PSMB9 Body, TSS1500 Chr6:32820192-32820649 11 0.0140 
DPP10-AS1 Body Chr2:115918369-115919118 7 0.0141 




Chr19:51529932-51531941 8 0.0158 
NA IGV Chr1:2819124-2823189 11 0.0171 
VAX1 3'UTR Chr10:118890822-118891356 4 0.0172 
NA IGV Chr8:808950-812979 10 0.0174 
IRX4, CTD-2194D22.4 TSS1500 Chr5:1887741-1888324 4 0.0174 
SEMA3G 
Body, 1stExon, TSS200, 
TSS1500 
Chr3:52477874-52479873 9 0.0174 
NA IGV Chr10:131073007-131076843 9 0.0178 
NA IGV Chr6:27634837-27638057 11 0.0180 
NA IGV Chr7:156294950-156298855 7 0.0192 
ZBTB20 5'UTR Chr3:114789424-114792059 6 0.0194 
URAHP, LOC100130015 Body, TSS200, TSS1500 Chr16:90112696-90115172 11 0.0198 
WHSC1L1 3'UTR, Body Chr8:38130862-38134370 6 0.0216 
DLX6AS, DLX6-AS1 Body Chr7:96625788-96628252 11 0.0231 
NAF1 TSS1500 Chr4:164088381-164088661 4 0.0238 
HOXB5, LOC404266 Body Chr17:46669349-46669671 6 0.0239 
GABBR1 Body Chr6:29598931-29599618 9 0.0242 
MEIS1 Body Chr2:66672008-66672565 5 0.0245 
GOLT1A 
Body, 1stExon, TSS200, 
TSS1500 
Chr1:204181957-204183956 13 0.0259 
CDH22 Body Chr20:44848207-44851180 7 0.0268 
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MKRN3 TSS1500, TSS200 Chr15:23810093-23810382 5 0.0269 
ST8SIA6, ST8SIA6-AS1 Body Chr10:17439426-17442047 4 0.0271 
NA IGV Chr19:7411023-7415602 8 0.0276 
CPSF3L Body Chr1:1249982-1252004 6 0.0278 
NA IGV Chr10:130694531-130698677 4 0.0291 
ADCY1 TSS1500 Chr7:45613667-45613752 4 0.0295 
EGFR Body Chr7:55144727-55148426 9 0.0297 
ERICH1-AS1 Body Chr8:858574-862612 9 0.0297 
NA IGV Chr1:2730034-2734601 8 0.0319 
NA IGV Chr8:47013884-47018323 7 0.0327 




Chr7:142959778-142961868 9 0.0354 
NA IGV Chr4:11372499-11375675 4 0.0361 
BTNL2 Body Chr6:32369520-32372505 15 0.0366 
SMIM5, RECQL5, LOC643008 TSS1500, Body Chr17:73629012-73629691 7 0.0387 
CTD-3080P12.3 Body, TSS200 Chr5:1177618-1180699 6 0.0388 
NA IGV Chr15:77374694-77379194 8 0.0401 
TREX1, ATRIP Body, TSS200, 1stExon Chr3:48505717-48507912 15 0.0414 
LOC149837, LINC00654 Body, TSS200, TSS1500 Chr20:5484144-5486143 9 0.0425 
NA IGV Chr2:18010334-18013922 5 0.0428 




Chr21:37536104-37538122 5 0.0433 
NA IGV Chr11:64653573-64657364 4 0.0446 
ABHD12B 5'UTR Chr14:51338993-51339396 4 0.0446 
NA IGV Chr20:42098438-42103116 5 0.0449 
LOC100130357 TSS1500, TSS200 Chr6:13294608-13297689 10 0.0453 
GNA12 Body Chr7:2846477-2848922 6 0.0455 
VANGL1 5'UTR, Body Chr1:116192821-116195193 5 0.0462 
LINC01346 TSS1500, TSS200, Body Chr1:3998584-4002140 8 0.0462 




Chr20:30406329-30408300 12 0.0468 
NA IGV Chr8:1281291-1285648 7 0.0497 
Table A7: DMRs identified between t(1;11) carriers and non-carriers in iPSC-
derived neurons. 
From left to right, columns summarise the DMR-containing genes, the DMR’s underlying 
genomic features, the Hg19 genomic coordinates of each DMR, the number of probes within 
each DMR, and the p-value for differential methylation in t(1;11) carriers. Genes highlighted 
with a red asterisk (*) indicate those that also contained t(1;11)-associated DMRs identified 
in blood. 
 




SNP1 SNP2 SNP3 Gene1 Gene2 Gene3 
LRT        
p-value 
R2 q-value 
rs12730369 rs1336979 rs6541281 DISC1 SORCS1 DISC1 0.0001 0.08 0.36 
rs1565415 rs2107182 rs823162 SORCS3 SORCS2 DISC1 0.0002 0.08 0.79 
rs17466832 rs6541281 rs823162 SORCS2 DISC1 DISC1 0.0003 0.08 0.98 
rs6835799 rs7440772 rs823162 SORCS2 SORCS2 DISC1 0.0003 0.08 1 
rs1565415 rs756255 rs823162 SORCS3 SORCS2 DISC1 0.0004 0.08 1 
rs1336979 rs2269852 rs4918288 SORCS1 SORCS2 SORCS1 0.0004 0.08 1 
rs1565415 rs2269852 rs823162 SORCS3 SORCS2 DISC1 0.0005 0.08 1 
rs2107182 rs6541281 rs823162 SORCS2 DISC1 DISC1 0.0006 0.08 1 
rs10937826 rs1557816 rs6541281 SORCS2 SORCS2 DISC1 0.0007 0.08 1 
rs6541281 rs756255 rs823162 DISC1 SORCS2 DISC1 0.0009 0.08 1 
rs10884100 rs1251753 rs1336979 SORCS3 SORCS1 SORCS1 0.0010 0.08 1 
rs2269852 rs6541281 rs823162 SORCS2 DISC1 DISC1 0.0016 0.08 1 
rs1336979 rs610785 rs756255 SORCS1 SORCS1 SORCS2 0.0017 0.08 1 
rs11932646 rs2107182 rs4350297 SORCS2 SORCS2 SORCS3 0.0017 0.08 1 
rs610785 rs665679 rs756255 SORCS1 SORCS1 SORCS2 0.0017 0.08 1 
rs10937826 rs7667970 rs9432040 SORCS2 SORCS2 DISC1 0.0020 0.08 1 
rs1557816 rs2269852 rs2295959 SORCS2 SORCS2 DISC1 0.0021 0.08 1 
rs11932646 rs4350297 rs756255 SORCS2 SORCS3 SORCS2 0.0021 0.08 1 
rs1336979 rs1557816 rs4918288 SORCS1 SORCS2 SORCS1 0.0025 0.08 1 
rs2107182 rs610785 rs6541281 SORCS2 SORCS1 DISC1 0.0029 0.08 1 
rs2269850 rs4918288 rs665679 SORCS2 SORCS1 SORCS1 0.0029 0.08 1 
rs4350297 rs6835799 rs823162 SORCS3 SORCS2 DISC1 0.0036 0.08 1 
rs12730369 rs1557816 rs9432040 DISC1 SORCS2 DISC1 0.0036 0.08 1 
 




SNP1 SNP2 SNP3 Gene1 Gene2 Gene3 
LRT        
p-value 
R2 q-value 
rs4689869 rs4918288 rs756255 SORCS2 SORCS1 SORCS2 0.0037 0.08 1 
rs1565415 rs2269850 rs823162 SORCS3 SORCS2 DISC1 0.0039 0.08 1 
rs1251753 rs1557816 rs6835799 SORCS1 SORCS2 SORCS2 0.0043 0.08 1 
rs10884100 rs12730369 rs17466832 SORCS3 DISC1 SORCS2 0.0045 0.08 1 
rs10032900 rs2269850 rs7897974 SORCS2 SORCS2 SORCS1 0.0045 0.08 1 
rs1565415 rs2269852 rs610785 SORCS3 SORCS2 SORCS1 0.0052 0.08 1 
rs1557816 rs4918288 rs665679 SORCS2 SORCS1 SORCS1 0.0054 0.08 1 
rs11932646 rs6541281 rs7897974 SORCS2 DISC1 SORCS1 0.0054 0.08 1 
rs10884100 rs1565415 rs2269852 SORCS3 SORCS3 SORCS2 0.0056 0.08 1 
rs2269852 rs4689869 rs665679 SORCS2 SORCS2 SORCS1 0.0059 0.08 1 
rs1557816 rs2269850 rs4918288 SORCS2 SORCS2 SORCS1 0.0060 0.08 1 
rs10937826 rs4613570 rs6541281 SORCS2 SORCS2 DISC1 0.0061 0.08 1 
rs2269852 rs4918288 rs665679 SORCS2 SORCS1 SORCS1 0.0063 0.08 1 
rs10884100 rs2269852 rs7667970 SORCS3 SORCS2 SORCS2 0.0068 0.08 1 
rs1557816 rs7440772 rs823162 SORCS2 SORCS2 DISC1 0.0070 0.08 1 
rs4350297 rs6835799 rs7667970 SORCS3 SORCS2 SORCS2 0.0073 0.08 1 
rs4918288 rs7440772 rs9432040 SORCS1 SORCS2 DISC1 0.0074 0.08 1 
rs1557816 rs4613570 rs6541281 SORCS2 SORCS2 DISC1 0.0080 0.08 1 
rs1565415 rs2269850 rs610785 SORCS3 SORCS2 SORCS1 0.0086 0.08 1 
rs10884100 rs17466832 rs2269850 SORCS3 SORCS2 SORCS2 0.0088 0.08 1 
rs4350297 rs4689869 rs7897974 SORCS3 SORCS2 SORCS1 0.0093 0.08 1 
rs1336979 rs6541281 rs7440772 SORCS1 DISC1 SORCS2 0.0105 0.08 1 
rs10937826 rs12730369 rs9432040 SORCS2 DISC1 DISC1 0.0106 0.08 1 
 




SNP1 SNP2 SNP3 Gene1 Gene2 Gene3 
LRT        
p-value 
R2 q-value 
rs1251753 rs4918288 rs7440772 SORCS1 SORCS1 SORCS2 0.0107 0.08 1 
rs1557816 rs17466832 rs610785 SORCS2 SORCS2 SORCS1 0.0109 0.08 1 
rs10884100 rs12730369 rs756255 SORCS3 DISC1 SORCS2 0.0110 0.08 1 
rs10884100 rs7440772 rs756255 SORCS3 SORCS2 SORCS2 0.0117 0.08 1 
rs10937826 rs6541281 rs9432040 SORCS2 DISC1 DISC1 0.0117 0.08 1 
rs1557816 rs2269850 rs2295959 SORCS2 SORCS2 DISC1 0.0117 0.08 1 
rs610785 rs6541281 rs756255 SORCS1 DISC1 SORCS2 0.0120 0.08 1 
rs4613570 rs7440772 rs823162 SORCS2 SORCS2 DISC1 0.0122 0.09 1 
rs10884100 rs1565415 rs823162 SORCS3 SORCS3 DISC1 0.0125 0.08 1 
rs11932646 rs2269850 rs4350297 SORCS2 SORCS2 SORCS3 0.0127 0.08 1 
rs1336979 rs17466832 rs7440772 SORCS1 SORCS2 SORCS2 0.0127 0.08 1 
rs6541281 rs665679 rs6835799 DISC1 SORCS1 SORCS2 0.0127 0.08 1 
rs10937826 rs2269850 rs7897974 SORCS2 SORCS2 SORCS1 0.0128 0.08 1 
rs1251753 rs1557816 rs2295959 SORCS1 SORCS2 DISC1 0.0130 0.08 1 
rs10884100 rs1557816 rs2107182 SORCS3 SORCS2 SORCS2 0.0132 0.08 1 
rs12730369 rs17466832 rs2269850 DISC1 SORCS2 SORCS2 0.0132 0.08 1 
rs10032900 rs2269852 rs7897974 SORCS2 SORCS2 SORCS1 0.0135 0.08 1 
rs11932646 rs1565415 rs665679 SORCS2 SORCS3 SORCS1 0.0136 0.08 1 
rs2269850 rs6541281 rs823162 SORCS2 DISC1 DISC1 0.0137 0.08 1 
rs2107182 rs610785 rs665679 SORCS2 SORCS1 SORCS1 0.0138 0.08 1 
rs1336979 rs4689869 rs7440772 SORCS1 SORCS2 SORCS2 0.0138 0.08 1 
rs1565415 rs4689869 rs823162 SORCS3 SORCS2 DISC1 0.0140 0.08 1 
rs1251753 rs2269852 rs9432040 SORCS1 SORCS2 DISC1 0.0143 0.08 1 
 




SNP1 SNP2 SNP3 Gene1 Gene2 Gene3 
LRT        
p-value 
R2 q-value 
rs1251753 rs7440772 rs9432040 SORCS1 SORCS2 DISC1 0.0143 0.08 1 
rs610785 rs665679 rs823162 SORCS1 SORCS1 DISC1 0.0146 0.08 1 
rs1565415 rs17466832 rs4689869 SORCS3 SORCS2 SORCS2 0.0147 0.08 1 
rs1565415 rs6541281 rs9432040 SORCS3 DISC1 DISC1 0.0147 0.08 1 
rs10032900 rs7667970 rs9432040 SORCS2 SORCS2 DISC1 0.0156 0.08 1 
rs2269852 rs4350297 rs665679 SORCS2 SORCS3 SORCS1 0.0158 0.08 1 
rs10032900 rs12730369 rs1565415 SORCS2 DISC1 SORCS3 0.0164 0.08 1 
rs1557816 rs4689869 rs665679 SORCS2 SORCS2 SORCS1 0.0166 0.08 1 
rs4637403 rs610785 rs9432040 SORCS2 SORCS1 DISC1 0.0166 0.08 1 
rs11932646 rs756255 rs7897974 SORCS2 SORCS2 SORCS1 0.0168 0.08 1 
rs4918288 rs823162 rs9432040 SORCS1 DISC1 DISC1 0.0171 0.08 1 
rs10937826 rs1251753 rs12730369 SORCS2 SORCS1 DISC1 0.0178 0.08 1 
rs4350297 rs4637403 rs9432040 SORCS3 SORCS2 DISC1 0.0180 0.08 1 
rs1557816 rs4613570 rs665679 SORCS2 SORCS2 SORCS1 0.0184 0.08 1 
rs17466832 rs7667970 rs823162 SORCS2 SORCS2 DISC1 0.0192 0.08 1 
rs12730369 rs1565415 rs6541281 DISC1 SORCS3 DISC1 0.0195 0.08 1 
rs610785 rs6541281 rs9432040 SORCS1 DISC1 DISC1 0.0195 0.08 1 
rs6541281 rs665679 rs7440772 DISC1 SORCS1 SORCS2 0.0196 0.08 1 
rs1251753 rs1557816 rs4689869 SORCS1 SORCS2 SORCS2 0.0198 0.08 1 
rs665679 rs7440772 rs823162 SORCS1 SORCS2 DISC1 0.0199 0.08 1 
rs4350297 rs7440772 rs823162 SORCS3 SORCS2 DISC1 0.0201 0.08 1 
rs4613570 rs610785 rs823162 SORCS2 SORCS1 DISC1 0.0201 0.09 1 
rs11932646 rs4350297 rs4689869 SORCS2 SORCS3 SORCS2 0.0206 0.08 1 
 




SNP1 SNP2 SNP3 Gene1 Gene2 Gene3 
LRT        
p-value 
R2 q-value 
rs4350297 rs756255 rs823162 SORCS3 SORCS2 DISC1 0.0213 0.08 1 
rs10884100 rs17466832 rs2295959 SORCS3 SORCS2 DISC1 0.0222 0.08 1 
rs1251753 rs1336979 rs9432040 SORCS1 SORCS1 DISC1 0.0226 0.08 1 
rs12730369 rs1565415 rs4918288 DISC1 SORCS3 SORCS1 0.0228 0.08 1 
rs1336979 rs2107182 rs610785 SORCS1 SORCS2 SORCS1 0.0230 0.08 1 
rs1336979 rs2269850 rs4918288 SORCS1 SORCS2 SORCS1 0.0234 0.08 1 
rs2269850 rs6835799 rs823162 SORCS2 SORCS2 DISC1 0.0243 0.08 1 
rs2295959 rs610785 rs7440772 DISC1 SORCS1 SORCS2 0.0246 0.08 1 
rs1251753 rs610785 rs6541281 SORCS1 SORCS1 DISC1 0.0251 0.08 1 
rs2269852 rs6541281 rs665679 SORCS2 DISC1 SORCS1 0.0259 0.08 1 
rs4918288 rs6835799 rs823162 SORCS1 SORCS2 DISC1 0.0262 0.08 1 
rs10032900 rs1251753 rs12730369 SORCS2 SORCS1 DISC1 0.0263 0.08 1 
rs1557816 rs4613570 rs7897974 SORCS2 SORCS2 SORCS1 0.0264 0.08 1 
rs10937826 rs12730369 rs1565415 SORCS2 DISC1 SORCS3 0.0264 0.08 1 
rs1251753 rs1557816 rs7440772 SORCS1 SORCS2 SORCS2 0.0264 0.08 1 
rs1251753 rs6835799 rs9432040 SORCS1 SORCS2 DISC1 0.0272 0.08 1 
rs12730369 rs4918288 rs6541281 DISC1 SORCS1 DISC1 0.0274 0.08 1 
rs17466832 rs4637403 rs7897974 SORCS2 SORCS2 SORCS1 0.0278 0.08 1 
rs12730369 rs1336979 rs1565415 DISC1 SORCS1 SORCS3 0.0286 0.08 1 
rs1557816 rs2269850 rs823162 SORCS2 SORCS2 DISC1 0.0288 0.08 1 
rs4637403 rs7667970 rs7897974 SORCS2 SORCS2 SORCS1 0.0294 0.08 1 
rs2269850 rs2269852 rs2295959 SORCS2 SORCS2 DISC1 0.0296 0.08 1 
rs1557816 rs4918288 rs7897974 SORCS2 SORCS1 SORCS1 0.0298 0.08 1 
 




SNP1 SNP2 SNP3 Gene1 Gene2 Gene3 
LRT        
p-value 
R2 q-value 
rs10884100 rs11932646 rs2107182 SORCS3 SORCS2 SORCS2 0.0300 0.08 1 
rs10884100 rs2269852 rs4613570 SORCS3 SORCS2 SORCS2 0.0301 0.08 1 
rs2295959 rs4918288 rs610785 DISC1 SORCS1 SORCS1 0.0306 0.08 1 
rs10937826 rs12730369 rs6541281 SORCS2 DISC1 DISC1 0.0309 0.08 1 
rs1557816 rs2269852 rs4918288 SORCS2 SORCS2 SORCS1 0.0309 0.08 1 
rs10884100 rs2107182 rs7440772 SORCS3 SORCS2 SORCS2 0.0313 0.08 1 
rs10032900 rs12730369 rs4613570 SORCS2 DISC1 SORCS2 0.0315 0.08 1 
rs10937826 rs12730369 rs4637403 SORCS2 DISC1 SORCS2 0.0318 0.08 1 
rs6835799 rs7897974 rs9432040 SORCS2 SORCS1 DISC1 0.0319 0.08 1 
rs4637403 rs665679 rs9432040 SORCS2 SORCS1 DISC1 0.0326 0.08 1 
rs10884100 rs17466832 rs2107182 SORCS3 SORCS2 SORCS2 0.0330 0.08 1 
rs10884100 rs756255 rs7667970 SORCS3 SORCS2 SORCS2 0.0332 0.08 1 
rs2107182 rs6541281 rs665679 SORCS2 DISC1 SORCS1 0.0333 0.08 1 
rs1557816 rs17466832 rs665679 SORCS2 SORCS2 SORCS1 0.0334 0.08 1 
rs17466832 rs4918288 rs823162 SORCS2 SORCS1 DISC1 0.0337 0.08 1 
rs10032900 rs4918288 rs7440772 SORCS2 SORCS1 SORCS2 0.0341 0.08 1 
rs12730369 rs610785 rs6541281 DISC1 SORCS1 DISC1 0.0342 0.08 1 
rs1336979 rs4918288 rs9432040 SORCS1 SORCS1 DISC1 0.0343 0.08 1 
rs1557816 rs6541281 rs7440772 SORCS2 DISC1 SORCS2 0.0343 0.08 1 
rs10032900 rs1557816 rs6541281 SORCS2 SORCS2 DISC1 0.0344 0.08 1 
rs2107182 rs7440772 rs823162 SORCS2 SORCS2 DISC1 0.0347 0.08 1 
rs1251753 rs1565415 rs6835799 SORCS1 SORCS3 SORCS2 0.0352 0.08 1 
rs11932646 rs610785 rs665679 SORCS2 SORCS1 SORCS1 0.0354 0.08 1 
 




SNP1 SNP2 SNP3 Gene1 Gene2 Gene3 
LRT        
p-value 
R2 q-value 
rs1565415 rs4350297 rs9432040 SORCS3 SORCS3 DISC1 0.0354 0.08 1 
rs10937826 rs1565415 rs7667970 SORCS2 SORCS3 SORCS2 0.0359 0.08 1 
rs4613570 rs823162 rs9432040 SORCS2 DISC1 DISC1 0.0363 0.08 1 
rs1251753 rs1565415 rs7897974 SORCS1 SORCS3 SORCS1 0.0365 0.08 1 
rs10884100 rs10937826 rs6835799 SORCS3 SORCS2 SORCS2 0.0366 0.08 1 
rs2269852 rs6541281 rs7667970 SORCS2 DISC1 SORCS2 0.0368 0.08 1 
rs10937826 rs12730369 rs4613570 SORCS2 DISC1 SORCS2 0.0370 0.08 1 
rs2107182 rs665679 rs6835799 SORCS2 SORCS1 SORCS2 0.0371 0.08 1 
rs17466832 rs4637403 rs823162 SORCS2 SORCS2 DISC1 0.0374 0.08 1 
rs2269852 rs4350297 rs9432040 SORCS2 SORCS3 DISC1 0.0374 0.08 1 
rs1251753 rs2107182 rs756255 SORCS1 SORCS2 SORCS2 0.0375 0.08 1 
rs10884100 rs11932646 rs756255 SORCS3 SORCS2 SORCS2 0.0378 0.08 1 
rs10937826 rs2269852 rs7897974 SORCS2 SORCS2 SORCS1 0.0379 0.08 1 
rs10032900 rs12730369 rs9432040 SORCS2 DISC1 DISC1 0.0382 0.08 1 
rs1565415 rs4637403 rs4689869 SORCS3 SORCS2 SORCS2 0.0382 0.08 1 
rs2107182 rs665679 rs823162 SORCS2 SORCS1 DISC1 0.0382 0.08 1 
rs4613570 rs6541281 rs7897974 SORCS2 DISC1 SORCS1 0.0383 0.08 1 
rs10884100 rs17466832 rs756255 SORCS3 SORCS2 SORCS2 0.0392 0.08 1 
rs1565415 rs2295959 rs756255 SORCS3 DISC1 SORCS2 0.0394 0.08 1 
rs10937826 rs11932646 rs6541281 SORCS2 SORCS2 DISC1 0.0396 0.08 1 
rs2269852 rs2295959 rs7667970 SORCS2 DISC1 SORCS2 0.0400 0.08 1 
rs10032900 rs4637403 rs9432040 SORCS2 SORCS2 DISC1 0.0401 0.08 1 
rs12730369 rs4637403 rs7897974 DISC1 SORCS2 SORCS1 0.0405 0.08 1 
 




SNP1 SNP2 SNP3 Gene1 Gene2 Gene3 
LRT        
p-value 
R2 q-value 
rs10884100 rs11932646 rs2269850 SORCS3 SORCS2 SORCS2 0.0409 0.08 1 
rs12730369 rs6835799 rs823162 DISC1 SORCS2 DISC1 0.0410 0.08 1 
rs610785 rs7667970 rs823162 SORCS1 SORCS2 DISC1 0.0416 0.08 1 
rs2269850 rs610785 rs6541281 SORCS2 SORCS1 DISC1 0.0418 0.08 1 
rs10032900 rs2107182 rs7897974 SORCS2 SORCS2 SORCS1 0.0423 0.08 1 
rs665679 rs6835799 rs756255 SORCS1 SORCS2 SORCS2 0.0426 0.08 1 
rs1336979 rs2269852 rs6541281 SORCS1 SORCS2 DISC1 0.0426 0.08 1 
rs7440772 rs756255 rs823162 SORCS2 SORCS2 DISC1 0.0428 0.09 1 
rs10884100 rs1557816 rs1565415 SORCS3 SORCS2 SORCS3 0.0432 0.08 1 
rs1336979 rs2269852 rs4350297 SORCS1 SORCS2 SORCS3 0.0435 0.08 1 
rs10937826 rs1336979 rs7897974 SORCS2 SORCS1 SORCS1 0.0436 0.08 1 
rs1251753 rs1557816 rs4918288 SORCS1 SORCS2 SORCS1 0.0438 0.08 1 
rs1251753 rs2295959 rs4613570 SORCS1 DISC1 SORCS2 0.0439 0.08 1 
rs1251753 rs17466832 rs2295959 SORCS1 SORCS2 DISC1 0.0441 0.08 1 
rs12730369 rs4918288 rs7440772 DISC1 SORCS1 SORCS2 0.0444 0.08 1 
rs10884100 rs1336979 rs4613570 SORCS3 SORCS1 SORCS2 0.0446 0.08 1 
rs1336979 rs2107182 rs6541281 SORCS1 SORCS2 DISC1 0.0448 0.08 1 
rs2295959 rs756255 rs7667970 DISC1 SORCS2 SORCS2 0.0453 0.08 1 
rs2107182 rs610785 rs823162 SORCS2 SORCS1 DISC1 0.0454 0.08 1 
rs10937826 rs4613570 rs610785 SORCS2 SORCS2 SORCS1 0.0457 0.08 1 
rs10884100 rs1565415 rs6835799 SORCS3 SORCS3 SORCS2 0.0464 0.08 1 
rs2269850 rs610785 rs665679 SORCS2 SORCS1 SORCS1 0.0464 0.08 1 
rs11932646 rs1565415 rs4637403 SORCS2 SORCS3 SORCS2 0.0466 0.08 1 
 




rs12730369 rs1336979 rs4689869 DISC1 SORCS1 SORCS2 0.0472 0.09 1 
rs12730369 rs17466832 rs2269852 DISC1 SORCS2 SORCS2 0.0473 0.08 1 
rs12730369 rs1565415 rs4613570 DISC1 SORCS3 SORCS2 0.0475 0.08 1 
Table A8: Three-SNP interactions nominally significantly associated with crystallised intelligence. 
Shown is a summary of nominally significant genetic interactions associated with crystallised intelligence (p ≤ 0.05). From left to 
right, columns show the SNP identifiers and their corresponding genes the likelihood ratio test p-value for the difference in goodness-
of-fit of the interaction model versus the null model, omitting the interaction term; the proportion of variance explained by the model 
(R2), and the Benjamini-Hochberg FDR q-value for the SNP interaction following correction for 3168 tests. 
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Genome-wide analysis of DNAmethylation has now become a relatively inexpensive technique thanks to array-
based methylation profiling technologies. The recently developed Illumina Infinium MethylationEPIC BeadChip
interrogates methylation at over 850,000 sites across the human genome, covering 99% of RefSeq genes. This
array supersedes the widely used Infinium HumanMethylation450 BeadChip, which has permitted insights
into the relationship between DNA methylation and a wide range of conditions and traits. Previous research
has identified issues with certain probes on both the HumanMethylation450 BeadChip and its predecessor, the
Infinium HumanMethylation27 BeadChip, which were predicted to affect array performance. These issues con-
cerned probe-binding specificity and the presence of polymorphisms at target sites. Using in silico methods,
we have identified probes on the InfiniumMethylationEPIC BeadChip that are predicted to (i) measure methyl-
ation at polymorphic sites and (ii) hybridise to multiple genomic regions. We intend these resources to be used
for quality control procedures when analysing data derived from this platform.
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Specifications [standardized info for the reader]
Organism/cell line/tissue Homo sapiens genome sequence (Hg19)
Sex n/a
Sequencer or array type Illumina Infinium MethylationEPIC Array
Data format Analysed: Table of polymorphic targets and lists
of crosshybridising probes
Experimental factors Infinium MethylationEPIC probe data, 1000 genomes
phase 3 data, UCSC genome browser human reference
genome sequence
Experimental features In silico alignment of Infinium MethylationEPIC probe
sequences to bisulfite converted genome sequences
(Hg19) and cross-referencing of probe target
coordinates to 1000 genomes project phase 3 data.
Consent Raw data available from Illumina, UCSC genome
browser and 1000 genomes project
Sample source location n/a
2. Introduction
DNA methylation is an epigenetic mark typically occurring at cyto-
sine-guanine dinucleotides (CpGs). Changes in DNA methylation are
observed in normal development, in response to environmental stimuli,
and in certain disease states [1]. DNAmethylation is linked to transcrip-
tional activity, rendering it a key regulatory motif [2]. Recent years have
seen the development of high-throughput DNA methylation profiling
techniques including whole-genome bisulphite sequencing (WGBS),
methylated DNA immunoprecipitation (meDIP) and microarray-based
technologies [3]. The InfiniumHumanMethylation450 BeadChip, devel-
oped by Illumina, has offered an attractive array-based option to re-
searchers, as it interrogates methylation at over 485,000 sites across
the genome at single-base resolution at a relatively low cost (Bibikova
et al., 2011 [4]). However, issues with probe-binding specificity and
polymorphic targets have been identified which may compromise
data integrity if not adequately addressed (Chen et al., 2013 [5]).
The Infinium HumanMethylation450 BeadChip has recently been
superseded by the InfiniumMethylationEPIC BeadChip. This array inter-
rogates DNA methylation at over 850,000 sites, including N90% of the
HumanMethylation450 array's targets. This substantial increase in
coverage, coupled with a continuing trend for interest in the role of
DNA methylation, is likely to result in wide-spread use of this array.
http://dx.doi.org/10.1016/j.gdata.2016.05.012
2213-5960/© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Contents lists available at ScienceDirect
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As such, it is essential that its potential shortcomings are thoroughly
understood. In order to generate a resource that will be of use to re-
searchers using the MethylationEPIC BeadChip we have identified
probes that may perform sub-optimally. This work, therefore, repre-
sents an update of Chen et al.'s [5] previous characterisation of the
Infinium HumanMethylation450 BeadChip.
Like its predecessor, the MethylationEPIC BeadChip uses two types
of probe chemistry (Type I and Type II) to interrogate methylation.
The differences between the two chemistries and the situations in
which they are used have been described fully in previous publications
[6]. Briefly, Type I assays use separate probes for unmethylated and
methylated target sites while Type II assays use a single probe. Both
assay types differentiate methylation state via single base extension of
a fluorescent-labelled nucleotide.
Taking the differences between Type I and Type II assays into consid-
eration, we have performed in silico analyses to identify probes on the
Infinium MethylationEPIC BeadChip that are predicted to hybridise to
multiple genomic regions, as well as probes where signal may be affect-
ed by polymorphisms at the target site, which could alter probe binding.
Both of these factors should be taken into account when performing
quality control of data produced using this technology.
3. Methods
3.1. Identification of probes with a polymorphic target
Probes potentially affected by polymorphisms at the target site were
identified following methods described previously [5].
The signal-generating process of single-base extension requires end-
nucleotide matching for both Type I and Type II probes. Therefore, we
limited our query to target CpGs and sites of single-base extension, as
polymorphisms at these sites are most likely to generate spurious
signals.
Using information from the Infinium MethylationEPIC BeadChip
manifest file (MethylationEPIC_v-1-0_B1.csv; date of download: 8 Feb-
ruary 2016), we generated a list of genomic coordinates (hg19,
GRCh37) of the target cytosine base (C) and guanine base (G) for all
probes on the array. For Infinium Type I probes we also included the
base before the target CpG, as this is the site of single base extension
for these probes.We cross-referenced these coordinates to those of var-
iants listed by the 1000 Genomes Project (phase 3) [7] to generate a list
of probes affected by polymorphisms at the target CpG and/or site of
single-base extension.
3.2. Identification of probes with non-specific hybridisation potential
Probes with the potential to cross-hybridise were identified follow-
ing methods described previously [5].
3.2.1. Generation of probe sequences for in silico analyses
Many Infinium Type II probe sequences contain an “R” nucleotide
representing either an adenine (A) or guanine (G) base, depending on
whether the underlying target cytosine is methylated or unmethylated.
All possible combinations of Type II probe sequences were generated,
and combined with a list of the Type I probe sequences.
3.2.2. Generation of genomic comparison sequences for in silico analyses
The GRCh37 release of the human genome sequence was
downloaded from the University of California, Santa Cruz (UCSC)
Genome Browser website (https://genome.ucsc.edu/) as a reference,
excluding alternative assemblies (e.g. chr17_ctg5_hap1) to avoid
duplicated results (date of download: 11 January 2016). From this, we
generated four modified reference genome sequences. A bisulphite-
converted methylated forward genome sequence was generated in
silico by converting all non-CpG cytosine bases to thymine (T) bases in
the reference sequence. The same process was performed for the
reverse complement of the reference sequence to generate a
bisulphite-converted methylated reverse sequence of the human
genome. Bisulphite-converted unmethylated forward and reverse
sequences were generated by converting all C bases to T in the forward
reference sequence and its reverse complement.
Using the BLAST-like alignment tool (BLAT) [8], we aligned the
probe sequences described above to the four modified reference ge-
nome sequences, as well as their reverse complements. The BLAT pa-
rameters used were: stepSize = 5, minScore = 0, minIdentity = 0 and
repMatch = 1,000,000,000. Probes were defined as being at high-risk
of non-specific binding if there was a gap-free match of 47 or more
nucleotides, which had to include the end base of the query sequence,
at an off-target locus.
4. Results
4.1. Infinium MethylationEPIC BeadChip probes with polymorphic targets
Coordinates for 866,836 probes were obtained from the Infinium
MethylationEPIC BeadChip manifest downloaded on 8th February
2016. Excluding control probes, the manifest file contained 142,262
Type I probes (426,786 potential signal-affecting positions), and
724,574 Type II probes (1,449,148 potential signal-affecting positions),
giving a total of 1,875,934 sites which were interrogated for genetic
variation.
We identified 340,327 sites with either single nucleotide polymor-
phisms (SNPs), insertions or deletions (indels), or structural variation.
These sites were targeted by 297,744 unique probes: 34% of the
total probe content of the Infinium MethylationEPIC BeadChip. Of
these, 23,399 probes (2.7%) targeted polymorphic sites with a minor
allele frequency (MAF) of ≥5% in at least one population studied.
A table of probes affected by polymorphisms, with minor allele
frequencies corresponding to African, admixed American, European,
South Asian, and East Asian populations (AFR, AMR, EUR, SAS, EAS;
respectively) is available in the supplementary information of this
paper (Supplementary Table 1).
4.2. Infinium MethylationEPIC BeadChip probes with cross-hybridisation
potential
A total of 1,752,932 potential probe sequences, each 50 bases in
length, were aligned to in silico bisulphite-converted forward and re-
verse methylated and unmethylated reference genomes, and their cor-
responding complementary strands in BLAT (i.e. eight single-stranded
genomes in total). We identified 44,210 probes (11,772 Type I probes
and 32,438 Type II probes) with ≥47 nucleotide off-target matches
including the end base, which were defined as potentially cross-
hybridising. A list of these probes is available in the supplementary in-
formation of this paper (Supplementary Tables 2–3).
Consistent with findings on the Infinium HumanMethylation450
BeadChip [5], a larger proportion of non-CpG-targeting probes (Probe
ID prefix = “ch”) were identified as potentially cross-hybridising com-
pared to CpG-targeting probes (Probe ID prefix = “cg”). Of 863,904
CpG-targeting probes present on the array, 42,558 (4.9% of total CpG-
targeting probes) were identified as potentially cross-hybridising
(Supplementary Table 2). In contrast, of 2932 non-CpG targeting
probes, we found only 1280 to bind specifically to their targets while
the remaining 1652 were potentially cross-hybridising (56% of total
non-CpG targeting probes; Supplementary Table 3), based on the infor-
mation provided in the Illumina manifest.
5. Discussion
In order to identify probes that might compromise the performance
of the Illumina InfiniumMethylationEPIC BeadChip, we have generated
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lists of probes thatmay be affected by non-specific binding and/or poly-
morphisms at the target site.
Our in silico analyses identified 44,210 probes (5.1% total probe con-
tent) with potential off-target binding sites and 23,399 probes (2.7%
total probe content) whose target site contains a polymorphism with
a MAF ≥ 0.05 in at least one population studied, which may lead to
artefactual signal due to impaired probe-binding. We recommend that
users take these probes into consideration when analysing data on
this platform, applying the appropriate filtering criteria in a popula-
tion-specific manner, where possible. We recognise that there may be
some situationswhere retaining probesmapping to polymorphic target
sites will be desirable. For example, a difference in methylation due to a
SNP that creates or destroys a CpG at a target site may be informative if
it confers a change in disease risk.
Chen et al. (2013) [5] demonstrated that autosomal probes defined
as potentially cross-hybridising according to their criterion of an off-tar-
get match of 47/50 bases, including the end nucleotide, showed an en-
richment for off-target binding sites on the sex chromosomes. Failure
to exclude these probes could, therefore, result in the spurious conclu-
sion that these loci are differentially methylated between males and fe-
males. Following their methods, we have identified probes on the
Infinium MethylationEPIC BeadChip with the potential to hybridise to
multiple genomic regions, thus generating off-target signal. We suggest
the exclusion of these probes prior to data analysis. Although the exclu-
sion of potentially cross-hybridisingprobes defined using thismethod is
likely to result in an improvement in the validity of the results obtained
from the array, it is likely that the actual extent of off-target bindingwill
vary by locus. Factors such as local sequence composition, including the
presence of polymorphismsunderlying the probe sequence, are likely to
play a role in determining the likelihood of cross-hybridisation. It is,
therefore, recommended that any results of interest that may have
been generateddue to cross-hybridisation are checked using an alterna-
tive technique, such as pyrosequencing of bisulphite-converted DNA.
In summary, we have produced lists of probes on the new Illumina
Infinium MethylationEPIC BeadChip that measure methylation at sites
affected by polymorphisms and/or have thepotential to cross-hybridise.
Based on the wide-spread use of the HumanMethylation450 BeadChip,
we predict that the Illumina Infinium MethylationEPIC BeadChip will
play a central role in epigenome-wide association studies (EWAS)
over the next few years. As such, it is essential that factors affecting
the performance of the array, such as probe specificity and sequence
polymorphisms, which we have demonstrated to potentially affect a
substantial proportion of probes, are taken into consideration. We rec-
ommend that the resources supplied with this paper be used in
conjunction with additional standard quality control measures, such
as excluding probes with low signal-to-background ratios, omission of
samples with a high proportion of such probes, and appropriate data
normalisation strategies (for review see Wilhelm-Benartzi et al., 2013
[9]), in order to maximise the likelihood of producing meaningful
results.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.gdata.2016.05.012.
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